<SEC-DOCUMENT>0001193125-20-136311.txt : 20200507
<SEC-HEADER>0001193125-20-136311.hdr.sgml : 20200507
<ACCEPTANCE-DATETIME>20200507162611
ACCESSION NUMBER:		0001193125-20-136311
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		59
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200507
DATE AS OF CHANGE:		20200507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDNAX, INC.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				263667538
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12111
		FILM NUMBER:		20856868

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d888266d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:md="http://www.mednax.com/20200331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>10-Q</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="">
 <div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2020To03_31_2020">false </ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="hidden12788133" contextRef="PAsOn03_31_2020" unitRef="Unit_USD_per_Share" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="hidden12788135" contextRef="PAsOn03_31_2020" unitRef="Unit_USD_per_Share" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF">0.01</ix:nonFraction><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2020To03_31_2020">2020</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P01_01_2020To03_31_2020">Q1</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2020To03_31_2020">0000893949</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P01_01_2020To03_31_2020">--12-31</ix:nonNumeric><ix:footnote id="FN_48780" xml:lang="en-US">Due to a loss from continuing operations for the three months ended March 31, 2020, no incremental shares are included because the effect would be antidilutive.</ix:footnote ><ix:footnote id="FN_49229" xml:lang="en-US">Presented within retained earnings on the consolidated balance sheet as the balance is immaterial. </ix:footnote ></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="md-20200331.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="md-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="md-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="md-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="md-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P01_01_2020To03_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_01_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >md:UnnamedCorporateJointVentureOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_UnnamedCorporateJointVentureTwoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >md:UnnamedCorporateJointVentureTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:CashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:TwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:TwoThousandTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:CashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:TwoThousandTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:TwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_HospitalsContractsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:HospitalsContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_TwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >md:ContractedManagedCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:GovernmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:SelfPayMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ExecutiveOfficerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:Seniorunsecurdnotes2023Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_Seniorunsecurdnotes2027MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:Seniorunsecurdnotes2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019_HospitalsContractsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:HospitalsContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >md:ContractedManagedCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:GovernmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:SelfPayMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForSecondQuarterOf2021Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-27</xbrli:startDate> <xbrli:endDate>2020-03-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_01_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_RuralAreaMemberusgaapGeographicDistributionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis" >md:RuralAreaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-04-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_01_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_UrbanAreaMemberusgaapGeographicDistributionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis" >md:UrbanAreaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-04-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_01_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-04-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForFourthQuarterOf2020Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForFirstQuarterOf2021Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-05-06</xbrli:startDate> <xbrli:endDate>2020-05-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_06_2020To05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-05-06</xbrli:startDate> <xbrli:endDate>2020-05-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_06_2020To05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-05-06</xbrli:startDate> <xbrli:endDate>2020-05-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><ix:relationship fromRefs="Fact_12788386" toRefs="FN_48780"/><ix:relationship fromRefs="Fact_12788387" toRefs="FN_48780"/><ix:relationship fromRefs="Fact_12788440" toRefs="FN_49229"/><ix:relationship fromRefs="Fact_12788442" toRefs="FN_49229"/><ix:relationship fromRefs="Fact_12788507" toRefs="FN_49229"/><ix:relationship fromRefs="Fact_12788508" toRefs="FN_49229"/></ix:resources></ix:header></div><div style="font-size: 13.28px;margin-top: 0em;margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"><div style="text-align: center;"><div style="width: 100%; line-height: 0.5pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;"><div style="width: 100%; line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="margin-top: 4pt; margin-bottom: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div><div style="text-align: center;"><div style="margin: 12pt auto 0px; width: 21.05%; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2020To03_31_2020">10-Q</ix:nonNumeric> </div></div></div><div style="text-align: center;"><div style="margin: 12pt auto 0px; width: 21.05%; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="margin-top: 12pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="P01_01_2020To03_31_2020" format="ixt:booleantrue">&#9746;</ix:nonNumeric></div> </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P01_01_2020To03_31_2020" format="ixt:datemonthdayyearen">March 31, 2020</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OR </div></div></div><div style="margin-top: 12pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P01_01_2020To03_31_2020" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></div> </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the transition period from ______ to ______ </div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;">Commission File Number: <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P01_01_2020To03_31_2020">001-12111</ix:nonNumeric></div></div></div><div style="text-align: center;"><div style="margin: 12pt auto 0px; width: 21.05%; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 24pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2020To03_31_2020">MEDNAX, INC.</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of registrant as specified in its charter) </div></div></div><div style="text-align: center;"><div style="margin: 12pt auto 0px; width: 21.05%; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 8pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 50%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 1%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 48%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2020To03_31_2020" format="ixt-sec:stateprovnameen">Florida</ix:nonNumeric> </div></div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2020To03_31_2020">26-3667538</ix:nonNumeric> </div> </div></div></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(State or other jurisdiction of </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Incorporation or organization) </div></div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(I.R.S. Employer </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Identification No.) </div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2020To03_31_2020">1301 Concord Terrace</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2020To03_31_2020">Sunrise</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P01_01_2020To03_31_2020" format="ixt-sec:stateprovnameen">Florida</ix:nonNumeric> </div></div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2020To03_31_2020">33323</ix:nonNumeric> </div></div></div></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Address of principal executive offices) </div></div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Zip Code) </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2020To03_31_2020">954</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2020To03_31_2020">384-0175</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Registrant&#8217;s telephone number, including area code) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not Applicable </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Former name, former address and former fiscal year, if changed since last report) </div></div></div><div style="text-align: center;"><div style="margin: 12pt auto 0px; width: 21.05%; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(b) of the Act: </div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 8pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 34%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 33%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 1%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 33%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap; font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title of each class </div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Trading </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Symbol </div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name of each exchange </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">on which registered </div></div></div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2020To03_31_2020">Common Stock</ix:nonNumeric>, par value $.01 per share </div></div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2020To03_31_2020">MD</ix:nonNumeric> </div></div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2020To03_31_2020" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric> </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;</div></div><ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P01_01_2020To03_31_2020">Yes</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; &#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9745;</div>&#160;&#160; No&#160;&#160;&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div> (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P01_01_2020To03_31_2020">Yes</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; &#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9745;</div>&#160;&#160;No&#160;&#160;&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></div></div><div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 20%; padding: 0px;"></td>
<td style="width: 1%; padding: 0px;"></td>
<td style="width: 56%; padding: 0px;"></td>
<td style="width: 1%; padding: 0px;"></td>
<td style="width: 20%; padding: 0px;"></td>
<td style="width: 1%; padding: 0px;"></td>
<td style="width: 1%; padding: 0px;"></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accelerated&#160;filer </div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div> </div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2020To03_31_2020" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric> </div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9745;</div> </div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div>&#160;filer </div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 8px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="height: 8px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Smaller&#160;reporting&#160;company </div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2020To03_31_2020" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></div> </div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-size: 10pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emerging&#160;growth&#160;company </div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2020To03_31_2020" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"></div></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#160;&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></div></div><div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant is a shell company (as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act). Yes&#160;&#160;&#160;&#160;<div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div>&#160;&#160;No&#160;&#160;&#160;&#160;</div><div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityShellCompany" contextRef="P01_01_2020To03_31_2020" format="ixt:booleanfalse">&#9745;</ix:nonNumeric></div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On <div style="letter-spacing: 0px; top: 0px;;display:inline;">May</div>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div>, 2020, the registrant had outstanding <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn05_01_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">85,409,248</ix:nonFraction>&#160;shares of Common Stock, par value $.01 per share. </div></div><div style="margin-top: 10pt; margin-bottom: 0px;"></div><div style="text-align: center;"><div style="width: 100%; line-height: 0.5pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;"><div style="width: 100%; line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div></div><div style="margin-top: 1em; margin-bottom: 0em;"></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div> <div id="toc" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX </div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 6%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 89%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Page </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART I - FINANCIAL INFORMATION </div></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1. </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Statements </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx888266_2">Consolidated Balance Sheets as of March&#160;31, 2020 and December&#160;31, 2019 (Unaudited)</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx888266_3">Consolidated Statements of Income for the Three Months Ended March&#160;31, 2020 and 2019 (Unaudited)</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx888266_4">Consolidated Statements of Equity for the Three Months Ended March&#160;31, 2020 and 2019 (Unaudited)</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx888266_5">Consolidated Statements of Cash Flows for the Three Months Ended March&#160;31, 2020 and 2019 (Unaudited)</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx888266_6">Notes to Consolidated Financial Statements (Unaudited)</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;2. </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx888266_7">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;3. </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx888266_8">Quantitative and Qualitative Disclosures About Market Risk</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;4. </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx888266_9">Controls and Procedures</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II - OTHER INFORMATION </div></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1. </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx888266_10">Legal Proceedings</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1A. </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx888266_11">Risk Factors</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;2. </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx888266_12">Unregistered Sales of Equity Securities and Use of Proceeds</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;6. </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx888266_13">Exhibits</a> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx888266_14">SIGNATURES </a> </div></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2</div></div> </div> </div> </div> <div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div id="tx888266_1" style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC.</div></div></div></div> <div id="tx888266_2" style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED BALANCE SHEETS</div></div></div></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands)</div></div></div></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited)</div></div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 76%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 5%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;"> <div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; text-align: center; font-size: 8pt; margin-bottom: 0pt; margin-top: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;">&#160;</td>
<td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;;width:;"> <div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; text-align: center; font-size: 8pt; margin-bottom: 0pt; margin-top: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div> </td>
<td style="vertical-align: bottom; font-weight: normal; padding-right: 2pt; margin-bottom: 0pt; margin-top: 0pt; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;;width:;">&#160;</td>
<td colspan="2" style="border-bottom:1pt solid #000000;vertical-align:bottom;;width:;"> <div style="font-family: &quot;Times New Roman&quot;; font-weight: normal; text-align: center; font-size: 8pt; margin-bottom: 0pt; margin-top: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div> </td>
<td style="vertical-align: bottom; font-weight: normal; padding-right: 2pt; margin-bottom: 0pt; margin-top: 0pt; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASSETS </div></div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="padding: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="padding: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="padding: 0px; text-align: center; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets: </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">312,155</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">112,767</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">85,041</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,510</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">476,991</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">498,869</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,409</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,919</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr>
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes receivable </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,449</ix:nonFraction></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> <div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,851</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,442</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 76%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">940,896</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">731,507</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">100,227</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">94,492</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,710,292</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,710,292</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">263,308</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">274,407</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div> assets</div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">79,810</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">82,824</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax assets </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">132,783</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">162,385</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">92,346</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">89,994</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 76%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,319,662</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,145,901</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 76%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align: top; padding: 0px; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY </div></div></div> </td>
<td style="vertical-align: top; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-right: 2pt; margin-bottom: 0pt; margin-top: 0pt; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: top; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-right: 2pt; margin-bottom: 0pt; margin-top: 0pt; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities: </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">323,363</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">511,866</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of finance lease liabilities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">697</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">130</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of operating lease liabilities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,340</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,317</ix:nonFraction></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes payable </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; font-size: 10pt; background-color: rgba(255, 255, 255, 0); height: 16px; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,505</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 76%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);"> <div style="font-family:Times New Roman;margin-left:7.00em;text-align:left;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">346,400</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">541,818</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Line of credit </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LongTermLineOfCredit" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">368,500</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; font-size: 10pt; height: 17px; padding: 0pt 5pt 0pt 0pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:LongTermLineOfCredit" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt and finance lease liabilities, net </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,733,469</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,730,295</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term operating lease liabilities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">62,238</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">67,005</ix:nonFraction></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term professional liabilities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">238,347</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">226,892</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax liabilities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesNoncurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">61,975</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">57,995</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,337</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,900</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 76%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="font-family:Times New Roman;margin-left:7.00em;text-align:left;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,832,266</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,646,905</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 76%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; equity: </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock; $<span style="-sec-ix-hidden:hidden12788133">.01</span> par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction> issued </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; font-size: 10pt; height: 17px; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; font-size: 10pt; height: 17px; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock; $<span style="-sec-ix-hidden:hidden12788135">.01</span> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal">200,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal">85,150</ix:nonFraction></ix:nonFraction>&#160;and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal">84,248</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">852</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">842</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">995,257</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">987,942</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Retained earnings </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">491,287</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">510,212</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 76%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);"> <div style="font-family:Times New Roman;margin-left:7.00em;text-align:left;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shareholders&#8217; equity </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,487,396</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,498,996</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 76%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="font-family:Times New Roman;margin-left:7.00em;text-align:left;text-indent:-1.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and shareholders&#8217; equity </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,319,662</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,145,901</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 76%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 5%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></div> <div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC.</div></div></div></div> <div id="tx888266_3" style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF INCOME</div></div></div></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except per share data)</div></div></div></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited)</div></div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">845,918</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">851,183</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses: </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice salaries and benefits </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">652,721</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">621,539</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice supplies and other operating expenses </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,264</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,791</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">105,235</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">101,821</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,673</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,033</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,907</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,544</ix:nonFraction></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">832,800</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">772,728</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from operations </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,118</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">78,455</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment and other (expense) income </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">679</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,647</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,608</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,723</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in earnings of unconsolidated affiliates </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,345</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,236</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses</div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">26,942</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">27,840</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations before income taxes </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">13,824</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50,615</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,286</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,962</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,110</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">41,653</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; font-size: 10pt; width: 5%; height: 16px; padding: 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,602</ix:nonFraction></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">284,525</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,712</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">242,872</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Per common and common equivalent share data: </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations: </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.20</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.48</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.20</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.48</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations: </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.03</ix:nonFraction></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.31</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.03</ix:nonFraction></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.29</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss: </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.23</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.82</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.23</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.81</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common shares: </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">82,799</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">86,073</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">82,799</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">86,545</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></div> <div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC.</div></div></div></div><div id="tx888266_4" style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF EQUITY</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands)</div></div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number&#160;of<br/>Shares </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Amount </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in </div><br/>Capital </div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Retained<br/>Earnings </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; text-decoration: none; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="text-decoration:underline;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January&#160;1, 2020 </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">84,248</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">842</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">987,942</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">510,212</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,498,996</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,712</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,712</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized holding loss on investments, net of tax</div><div style="font-size: 7.4pt; line-height: 5.476pt;;display:inline;vertical-align: top;">(1) </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal" id="Fact_12788507">213</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal" id="Fact_12788440">213</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">78</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,831</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,832</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of restricted stock </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">968</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures of restricted stock </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,035</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,035</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased common stock </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">125</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,541</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; font-size: 10pt; width: 6%; height: 16px; padding: 0pt 5pt 0pt 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,542</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2020 </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">85,150</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">852</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">995,257</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">491,287</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,487,396</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; text-decoration: none; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="text-decoration:underline;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January&#160;1, 2019 </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">87,820</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">878</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">992,647</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,094,359</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,087,884</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">242,872</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">242,872</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized holding loss on investments, net of tax</div><div style="font-size: 7.4pt; line-height: 5.476pt;;display:inline;vertical-align: top;">(1) </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal" id="Fact_12788508">194</ix:nonFraction></div></div></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal" id="Fact_12788442">194</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">140</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,541</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,542</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of restricted stock </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">978</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures of restricted stock </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock swaps </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="md:StockIssuedDuringPeriodSharesStockSwaps" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">20</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="md:StockIssuedDuringPeriodValueStockSwaps" contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">666</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="md:StockIssuedDuringPeriodValueStockSwaps" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">666</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,100</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,100</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased common stock </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">2,525</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,740</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50,217</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">78,982</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2019 </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">86,387</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">864</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">977,872</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,801,076</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,779,812</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="margin-top: 12pt; margin-bottom: 0px;"></div><div style="margin: 0px auto; width: 8.5in; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="display:inline;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">(1)</div> </div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">Presented within retained earnings on the consolidated balance sheet as the balance is immaterial.</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div></div><div></div><div style="margin-top: 1em; margin-bottom: 0em;"></div><div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5</div></div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></div> <div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC.</div></div></div></div> <div id="tx888266_5" style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS</div></div></div></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands)</div></div></div></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited)</div></div></div></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;">&#160;</div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt auto 0px;width: 100%;font-size: 10pt;border-collapse: separate;border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 1%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 1%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months&#160;Ended&#160;March&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from operating activities: </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; line-height: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Net income (loss) </div></div></div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; line-height: 10pt; font-size: 10pt; width: 1%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; white-space: nowrap; text-align: right; padding: 0pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,712</ix:nonFraction></div></div></td>
<td style="text-align: right; font-size: 10pt; padding: 0pt; line-height: 10pt;"> <div style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; line-height: 10pt; font-size: 10pt; width: 1%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: &quot;Times New Roman&quot;; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="text-align: right; font-size: 10pt; padding: 0pt; line-height: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap; line-height: 10pt;;display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">242,872</ix:nonFraction></div></div></div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; font-size: 10pt; width: 7%; height: 18px; padding: 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,602</ix:nonFraction></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">284,525</ix:nonFraction></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net income to net cash from operating activities: </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.55in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,673</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,033</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.55in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of premiums, discounts and issuance costs </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,458</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,520</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.55in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,035</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,989</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.55in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">33,582</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,108</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.55in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,883</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,767</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.55in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in assets and liabilities: </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.85in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">25,904</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,915</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.85in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,101</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,790</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.85in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term assets </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,189</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,580</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.85in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">198,452</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132,559</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.85in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes payable </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">32,883</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,373</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.85in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments of contingent consideration liabilities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">102</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">42</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.85in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term professional liabilities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,969</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">496</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.85in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,912</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,993</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities &#8211; continuing operations </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">146,431</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">60,408</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by operating activities <div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div>&#160;discontinued operations </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction> &#160;&#160;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,591</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">146,431</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">56,817</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from investing activities: </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition payments, net of cash acquired </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">75</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,250</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of investments </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,042</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">)&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from maturities or sales of investments </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,860</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,800</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of property and equipment </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,713</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,821</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of business </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,750</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities &#8211; continuing operations </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">20,220</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,271</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities <div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div>&#160;discontinued operations </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction> &#160;&#160;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,420</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">20,220</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,691</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from financing activities: </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings on credit agreement </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">515,000</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">518,500</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments on credit agreement </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">146,500</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">866,000</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of senior notes </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; font-size: 10pt; height: 16px; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">500,000</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Payments for credit facility amendment and financing costs </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">500</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,380</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments of contingent consideration liabilities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,248</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,308</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments on finance lease obligations </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">42</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of common stock </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,832</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,876</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchases of common stock </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,542</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">78,982</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided from financing activities &#8211; continuing operations </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">366,039</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">66,664</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided from financing activities <div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div>&#160;discontinued operations </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; font-size: 10pt; height: 16px; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; font-size: 10pt; width: 8%; height: 16px; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided from financing activities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">366,039</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">66,664</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net increase in cash and cash equivalents </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">199,388</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,156</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents at beginning of period </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">112,767</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,745</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less cash and cash equivalents of discontinued operations at end of period </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction> &#160;&#160;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,425</ix:nonFraction></div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 84%;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents of continuing operations at end of period </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">312,155</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,476</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></div> <div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC.</div></div></div></div><div id="tx888266_6" style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, 2020</div></div></div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: normal; text-align: center; margin-bottom: 0pt; margin-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited)</div></div></div></div><div style="margin-top: 12pt; margin-bottom: 0px;"></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">1. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Basis of Presentation and New Accounting Pronouncements:</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;">The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of MEDNAX, Inc. and its consolidated subsidiaries (collectively, &#8220;MDX&#8221;) together with the accounts of MDX&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#8220;affiliated professional contractors&#8221;). Certain subsidiaries of MDX have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The terms &#8220;MEDNAX&#8221; and the &#8220;Company&#8221; refer collectively to MEDNAX, Inc., its subsidiaries and the affiliated professional contractors.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is a party to a joint venture in which it owns a <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn03_31_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">37.5</ix:nonFraction>% economic interest and a second joint venture in which it owns a <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn03_31_2020_UnnamedCorporateJointVentureTwoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">49.0</ix:nonFraction>% economic interest. The Company accounts for these joint ventures under the equity method of accounting because the Company exercises significant influence over, but does not control, these entities. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;">The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#8217;s most recent Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> (the &#8220;Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K&#8221;). </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2019, the Company divested its management services organization, which operated as MedData, to allow the Company to focus on its core physician services business. The operating results of MedData were reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the three months ended March&#160;31, 2019. See note 6 for more information. </div></div><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New Accounting Pronouncements </div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div> loss limitations. The guidance becomes effective for the Company on January&#160;1, 2021, including interim periods therein, with early adoption permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company does not believe the adoption of this new guidance will have a material impact on its Consolidated Financial Statements and related disclosures. </div></div></ix:nonNumeric> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0px;"></div><ix:nonNumeric name="md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true" continuedAt="TextSelection_12938446">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2. </div></div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Coronavirus Pandemic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;COVID-19&#8221;): </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and related &#8220;stay at home&#8221; and social distancing measures implemented across the country has significantly impacted demand for medical services provided by the Company&#8217;s affiliated clinicians. Beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020, the Company experienced a significant decline in the number of elective surgeries at the facilities where&#160;the Company&#8217;s affiliated clinicians provided anesthesia services. See Note 12 - Subsequent Events for information regarding the divestment of the Company&#8217;s anesthesia medical group on May 6, 2020. Much of this decline has been due to the closure of operating suites or facilities following federal advisories to cancel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> procedures and the prohibition of such procedures by several states. Within the Company&#8217;s radiology service line, orders for radiological studies have declined by a meaningful amount from historically normal levels, with much of this reduction focused in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> studies. The Company&#8217;s affiliated office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, have seen a significant elevation of appointment cancellations compared to historical normal levels. At this time, the Company has not experienced, nor does it currently anticipate, any significant impact to neonatal intensive care unit (NICU) patient volumes as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19. </div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has implemented a number of actions to preserve financial flexibility and partially mitigate the significant anticipated impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> These steps included a suspension of most activities related to the Company&#8217;s transformational and restructuring programs, limiting these expenditures to those that <div style="letter-spacing: 0px; top: 0px;;display:inline;">provide</div>&#160;essential support for the Company&#8217;s response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> In addition, (i)&#160;the Company temporarily reduced executive and key management base salaries, including <ix:nonFraction name="md:PercentageIncreaseDecreaseInSalaryAndWage" contextRef="P01_01_2020To03_31_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% reductions in salaries for its named executive officers through at least June&#160;30, 2020; (ii) the Board of Directors agreed to forego their annual cash retainer and cash meeting payments, until further notice; (iii)&#160;the Company enacted a combination of salary reductions and furloughs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> employees; and (iv)&#160;the Company enacted significant operational and practice-specific expense reduction plans across its clinical operations. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In response to the anticipated impact of COVID-19 on the Company&#8217;s results of operations, on </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;25, 2020, the Company amended and restated its Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $<ix:nonFraction name="md:EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">139.2</ix:nonFraction>&#160;million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the </div></div></div></ix:nonNumeric> <div style="margin-top: 12pt;margin-bottom: 0px;"></div><div style="margin-top: 1em; margin-bottom: 0em;"></div><div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">7</div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"><ix:continuation id="TextSelection_12938446" continuedAt="TextSelectionAppend_12938446_1"><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by the Company from <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis">4.50:1:00</ix:nonNumeric> to <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis">5.00:1:00</ix:nonNumeric> for the second and third quarters of 2020 and <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis">4.75:1:00</ix:nonNumeric> for the fourth quarter of <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis">2020</ix:nonNumeric>, before returning to <div style="letter-spacing: 0px; top: 0px;;display:inline;">4.50:1:00</div> for the first quarter of 2021 and beyond, (iii)&#160;require that the Company maintains minimum availability under the Credit Agreement of $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction>&#160;million through the third quarter of 2021, (iv) provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction>&#160;million, plus a reserve for certain payables, and (v)&#160;temporarily restrict the Company&#8217;s ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">exceptions. At March 31, 2020, the Company believes it was in compliance, in all material respects, with the financial covenants and other restrictions applicable to the Company under its Credit Agreement, its <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P01_01_2020To03_31_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">5.25</ix:nonFraction>% senior unsecured notes due 2023 and its <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P01_01_2020To03_31_2020_Seniorunsecurdnotes2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">6.25</ix:nonFraction>% senior unsecured notes due 2027. The Company believes it will be in compliance with these covenants for the next twelve months.</div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CARES Act </div></div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $<ix:nonFraction name="md:ContributionsInAidOfReimbursementOfLostRevenue" contextRef="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction>&#160;billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The Department of Health and Human Services (&#8220;HHS&#8221;) is administering this program and began disbursing funds from the initial $<ix:nonFraction name="md:ContributionsInAidOfReimbursementOfLostRevenue" contextRef="PAsOn04_01_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_UrbanAreaMemberusgaapGeographicDistributionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction>&#160;billion in early April 2020, of which the Company&#8217;s affiliated physician practices received an aggregate of $<ix:nonFraction name="md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue" contextRef="PAsOn04_01_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">12.2</ix:nonFraction>&#160;million based on their respective share of Medicare fee for service reimbursements in 2019. The remaining $<ix:nonFraction name="md:ContributionsInAidOfReimbursementOfLostRevenue" contextRef="PAsOn04_01_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_RuralAreaMemberusgaapGeographicDistributionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction>&#160;billion in aid is intended to focus on providers in areas particularly impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act the Company and its affiliated physician practices will qualify for and receive. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with <ix:nonFraction name="md:PercentageOfDeferredPaymentOfSocialSecurityTaxes" contextRef="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% of the deferred amount due December&#160;31, 2021 and the remaining <ix:nonFraction name="md:PercentageOfDeferredPaymentOfSocialSecurityTaxes" contextRef="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% due December&#160;31, 2022. The Company intends to utilize this deferral option throughout 2020. </div></div></div></ix:continuation><ix:continuation id="TextSelectionAppend_12938446_1"><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company currently expects that the COVID-19 situation will materially impact its financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from COVID-19, the Company is unable to predict the ultimate impact on its business, financial condition, results of operations and cash flows. The Company, however, believes it will be able to generate sufficient liquidity to satisfy its obligations for the next twelve months.</div></div></div><div style="margin-top: 18pt; margin-bottom: 0px;"></div></ix:continuation><div style="margin-top: 1em; margin-bottom: 0em;"></div><div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">8</div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"><ix:nonNumeric name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3. </div></div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash Equivalents and Investments:</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2020 and December&#160;31, 2019, the Company&#8217;s cash equivalents consisted entirely of money market funds totaling $<ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="PAsOn03_31_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">6.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="PAsOn12_31_2019_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">16.8</ix:nonFraction>&#160;million, respectively. Investments consisted of corporate securities, municipal debt securities, federal home loan securities and certificates of deposit. All investments are classified as current. </div></div><ix:nonNumeric name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true"><div style="font-family:Times New Roman;margin-left:4%;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:6pt"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held at March&#160;31, 2020 and December&#160;31, 2019 are summarized as follows (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 11%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 11%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,&#160;2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,&#160;2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate securities </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn03_31_2020_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,883</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,962</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Municipal debt securities </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn03_31_2020_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,327</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,066</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal home loan securities </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn03_31_2020_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,052</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,013</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of deposit </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn03_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,779</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,469</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">85,041</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,510</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor;width: 100%;text-align: left;font-family: &quot;Times New Roman&quot;;font-size: 10pt;font-weight: normal;margin-top: 18pt;margin-bottom: 0pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">4. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Fair Value Measurements:</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.&#160;Each fair value measurement is reported in one of three levels: </div></div><div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 8%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 &#8211; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. </div></div><div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 8%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 &#8211; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </div></div><div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 8%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 &#8211; inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. </div></div><ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at March&#160;31, 2020 and December&#160;31, 2019 (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 60%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 9%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 9%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 9%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair&#160;Value<br/>Category </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,&#160;2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,&#160;2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets: </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:MoneyMarketFundsFairValueDisclosure" contextRef="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,357</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:MoneyMarketFundsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,775</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">85,041</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,510</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mutual Funds </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:MutualFundsFairValueDisclosure" contextRef="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,640</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:MutualFundsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,264</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities: </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" contextRef="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,288</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,696</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric> <ix:nonNumeric name="md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true"><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at March&#160;31, 2020 and December&#160;31, 2019 (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 92%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 62%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, 2020 </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2019 </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying<br/>Amount </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Value </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying<br/>Amount </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Value </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities: </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 Notes </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="PAsOn03_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">750,000</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn03_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">611,250</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">750,000</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">766,875</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027 Notes </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="PAsOn03_31_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn03_31_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">801,200</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,025,600</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the Company&#8217;s line of credit approximates fair value. If the line of credit was measured at fair value, it would be </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">categorized as Level&#160;2 in the fair value hierarchy. </div></div></ix:nonNumeric> <div style="margin-top: 6pt;margin-bottom: 0px;"></div><div style="margin-top: 1em; margin-bottom: 0em;"></div><div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">9</div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"><ix:nonNumeric name="md:AccountsReceivableAndNetRevenueDisclosureTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Accounts Receivable and Net Revenue:</div></td></tr></table><ix:nonNumeric name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net consists of the following (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 7%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 7%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,&#160;2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,&#160;2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross accounts receivable </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,840,118</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,943,664</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for contractual adjustments and uncollectibles </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,363,127</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,444,795</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">476,991</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">498,869</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient service revenue is recognized at the time services are provided by the Company&#8217;s affiliated physicians. The Company&#8217;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#8217;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) and third-party insurance payors. Payments for services rendered to the Company&#8217;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#8220;DSO&#8221;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within&#160;30&#160;to&#160;60&#160;days of billing. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital. </div></div> <ix:nonNumeric name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s net revenue by category (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style=" font-size: 0pt; ">
<td style="width:76%;">&#160;</td>
<td style="width:4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width:4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months&#160;Ended </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net patient service revenue </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To03_31_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">734,387</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To03_31_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">749,585</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hospital contract administrative fees </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To03_31_2020_HospitalsContractsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">104,595</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To03_31_2019_HospitalsContractsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">94,721</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenue </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To03_31_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,936</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To03_31_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,877</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">845,918</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">851,183</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The approximate percentage of net patient service revenue by type of payor was as follows: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style=" font-size: 0pt; ">
<td style="width:82%;">&#160;</td>
<td style="width:7%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width:7%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months&#160;Ended </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contracted managed care </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To03_31_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">68</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">%</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To03_31_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">69</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To03_31_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To03_31_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">24</ix:nonFraction></div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other third-parties </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To03_31_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To03_31_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 82%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Private-pay</div> patients</div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To03_31_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To03_31_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">%</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">%</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0px;"></div><ix:nonNumeric name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true" continuedAt="TextSelection_12938096">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div>. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Discontinued Operations:</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;10, 2019, the Company entered into a securities purchase agreement with an affiliate of Frazier Healthcare Partners to divest its management services organization, which operated as MedData, and the transaction closed on October&#160;31, 2019. The operating results of the management services service line were reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the three months ended March&#160;31, 2019. Loss from discontinued operations, net of income taxes, as reported in the Company&#8217;s Consolidated Statements of Income for the three months ended March&#160;31, 2019<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> was $<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">284.5</ix:nonFraction>&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> which included a loss on classification as held for sale of $<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To03_31_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">321.2</ix:nonFraction>&#160;million. </div></div></div></ix:nonNumeric> <div style="margin-top: 1em; margin-bottom: 0em;"></div><div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">10</div><div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"><ix:continuation id="TextSelection_12938096"><div style="text-align: left;text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 0pt;margin-bottom: 0px;margin-left: 4%;">During the three months ended March&#160;31, 2020, <div style="letter-spacing: 0px; top: 0px;;display:inline;">the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company recorded an incremental loss on the sale of MedData </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">of $<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To03_31_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.6</ix:nonFraction>&#160;million, primarily related to the finalization of certain transaction related expenses of $<ix:nonFraction name="md:TransactionRelatedExpenses" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">5.1</ix:nonFraction>&#160;million and a working capital <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">true-up</div> of $<ix:nonFraction name="md:WorkingCapitalTrueUp" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction>&#160;million, partially offset by the completion of its preliminary valuation for the contingent economic consideration<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> which decreased the loss on sale by $<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>&#160;million. </div></div><div style="margin-top: 18pt; margin-bottom: 0px;"></div></ix:continuation><ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">7. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Accounts Payable and Accrued Expenses:</div></td></tr></table><ix:nonNumeric name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses consist of the following (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 10%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="width: 10%; font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"></td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,&#160;2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,&#160;2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">47,519</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,610</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued salaries and bonuses </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">108,079</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">268,619</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll taxes and benefits </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:AccruedPayrollTaxesAndBenefitsCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">47,791</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:AccruedPayrollTaxesAndBenefitsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">67,268</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional liabilities </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,149</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">44,869</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued contingent consideration </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:AccruedContingentConsiderationLiabilityCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,288</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:AccruedContingentConsiderationLiabilityCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,696</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,422</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,910</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,115</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">55,894</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">323,363</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">511,866</ix:nonFraction> </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The net decrease in accrued salaries and bonuses of $<ix:nonFraction name="md:IncreaseDecreaseInAccruedSalariesAndBonuses" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">160.5</ix:nonFraction>&#160;million, from December&#160;31, 2019 to March&#160;31, 2020, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#8217;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the three months ended March&#160;31, 2020. A majority of the Company&#8217;s payments for performance-based incentive compensation is paid annually during the first quarter. </div></div></ix:nonNumeric> </div> <div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true" continuedAt="TextSelection_12788494">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div>. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Common and Common Equivalent Shares:</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock, deferred stock and stock options and is calculated using the treasury stock method. </div></div></ix:nonNumeric><ix:continuation id="TextSelection_12788494"><ix:nonNumeric name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of shares used in the basic and diluted net income per common share calculation for the three months ended March&#160;31, 2020 and 2019 is as follows (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months&#160;Ended </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common shares outstanding </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">82,799</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">86,073</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of dilutive common share equivalents </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; font-size: 10pt; width: 6%; height: 17px; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">472</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common and common<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>equivalent shares outstanding<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;(a)</div> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_12788386">82,799</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_12788387">86,545</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.13in; line-height: normal; text-indent: -0.13in;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Antidilutive securities not included in the diluted<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>net income per common share<br/> calculation </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">849</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">504</ix:nonFraction> </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(a) </div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Due to a loss from continuing operations for the three months ended March&#160;31, 2020, no incremental shares are included because the effect would be antidilutive.</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div></ix:nonNumeric></ix:continuation> <div style="margin-top: 18pt; margin-bottom: 0px;"></div> <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true" continuedAt="TextSelection_12938105">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></div>. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Stock Incentive Plans and Stock Purchase Plans:</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Amended and Restated 2008 Incentive Compensation Plan (the &#8220;Amended and Restated 2008 Incentive Plan&#8221;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;">Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2020To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years from the date of grant and generally become exercisable on a pro rata basis over a three-year period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2020To03_31_2020_RestrictedStockMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">three years</ix:nonNumeric> upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the three months ended March&#160;31, 2020, the Company granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2020To03_31_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">894,718</ix:nonFraction> shares of restricted stock to its employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors under the Amended and Restated 2008 Incentive Plan. At March&#160;31, 2020, the Company had <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn03_31_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">million </div>shares available for future grants and awards under <div style="letter-spacing: 0px; top: 0px;;display:inline;">the</div> Amended and Restated 2008 Incentive Plan.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;">Under the Company&#8217;s 1996 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</div> Employee Stock Purchase Plan, as amended (the &#8220;ESPP&#8221;), employees are permitted to purchase the Company&#8217;s common stock at <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P01_01_2020To03_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">85</ix:nonFraction>% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#8217;s 2015 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</div> Stock Purchase Plan (the &#8220;SPP&#8221;), certain eligible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> service providers are permitted to purchase the Company&#8217;s common stock at <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P01_01_2020To03_31_2020_TwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">90</ix:nonFraction>% of market value on January 1st, April 1st, July 1st and October 1st of each year.</div> <div style="margin-top: 1em; margin-bottom: 0em;"></div></ix:nonNumeric> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"><ix:continuation id="TextSelection_12938105"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0px; margin-left: 4%;">Each of the ESPP and the SPP provide for the issuance of an aggregate of <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">2.6</ix:nonFraction>&#160;million shares of the Company&#8217;s common stock less the number of shares of common stock purchased under the other plan. The Company recognizes stock-based compensation expense for the discount received by participating employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> service providers. During the three months ended March&#160;31, 2020, approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2020To03_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">78,300</ix:nonFraction> shares in aggregate were issued under the ESPP and SPP. At March&#160;31, 2020, the Company had approximately <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>&#160;million shares in aggregate reserved for issuance under the ESPP and SPP.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended March&#160;31, 2020 and 2019, the Company recognized stock-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction>&#160;million, respectively. </div></div> </ix:continuation> <div style="margin-top: 18pt; margin-bottom: 0px;"></div> <ix:nonNumeric name="md:CommonStockRepurchasesTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true" continuedAt="TextSelection_12788513">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div></div>. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Common Stock Repurchase Programs:</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;">In July 2013, the Company&#8217;s Board of Directors authorized the repurchase of shares of the Company&#8217;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#8217;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">time-to-time</div> based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#8217;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#8217;s acquisition program. No shares were purchased under this program during the three months ended March&#160;31, 2020.</div></ix:nonNumeric><ix:continuation id="TextSelection_12788513"> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $<ix:nonFraction name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="PAsOn08_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">500.0</ix:nonFraction>&#160;million of the Company&#8217;s common stock in addition to its existing share repurchase program, of which $<ix:nonFraction name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">107.2</ix:nonFraction>&#160;million remained available&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for repurchase as of December&#160;31, 2019. Under this share repurchase program, during the three months ended March&#160;31, 2020, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company withheld </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="P01_01_2020To03_31_2020_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">125,100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of <div style="letter-spacing: 0px; top: 0px;;display:inline;">its</div> common stock to satisfy minimum statutory withholding obligations of $</div><ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="P01_01_2020To03_31_2020_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in connection with the vesting of restricted stock.</div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions. </div></div></div> </ix:continuation> <div style="margin-top: 18pt; margin-bottom: 0px;"></div> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11</div>. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Commitments and Contingencies:</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of March&#160;31, 2020 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company&#8217;s affiliated physicians. The Company&#8217;s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company&#8217;s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company&#8217;s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. </div></div></ix:nonNumeric> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2020To03_31_2020" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12. </div></div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subsequent Event:</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;6, 2020, the Company entered into a securities purchase agreement with an affiliate of North American Partners in Anesthesia (&#8220;NAPA&#8221;) to divest of the Company&#8217;s anesthesiology medical group, and the transaction closed on May&#160;6, 2020. Pursuant to the terms and conditions of the agreement, at the closing of the transaction, the Company received a cash payment<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of $</div><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, subject to certain customary adjustments, as well as a contingent economic interest in NAPA with a value ranging from $<ix:nonFraction name="md:MaximumConsiderationReceivable" contextRef="PAsOn05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">0</ix:nonFraction> to $<ix:nonFraction name="md:MaximumConsiderationReceivable" contextRef="PAsOn05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction> million based upon the multiple of invested capital returned to NAPA&#8217;s owners upon exit of the investment. The Company will begin to receive a payment on its economic interest at an exit multiple of 2.0, with such payment reaching&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div><ix:nonFraction name="md:MaximumConsiderationReceivable" contextRef="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million at an exit multiple of 5.0. In addition, the Company retained the accounts receivable of the anesthesiology medical group, which net of various other working capital items, approximated<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div><ix:nonFraction name="md:AccountsReceivableRetained" contextRef="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">110.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million at March 31, 2020. Upon completion of a valuation to determine the final net proceeds, the Company anticipates recording a loss on disposal in the range of approximately </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div><ix:nonFraction name="us-gaap:GainLossOnSaleOfBusiness" contextRef="P05_06_2020To05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">500.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to $</div><ix:nonFraction name="us-gaap:GainLossOnSaleOfBusiness" contextRef="P05_06_2020To05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">600.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" contextRef="P01_01_2020To03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" escape="true"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents the major classes of assets and liabilities of the anesthesiology medical group that are included in the accompanying Consolidated Balance Sheets as of March&#160;31, 2020 (in thousands): </div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 68%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 87%; padding: 0px;">&#160;</td>
<td style="width: 5%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,<br/> 2020 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets </div></div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">147,717</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other assets </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,519</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">900</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">545,272</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">60,034</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">768,461</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities </div></div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54,311</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional liabilities </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities" contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,627</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,174</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">80,112</ix:nonFraction></div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div></ix:nonNumeric></ix:nonNumeric> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13</div></div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div id="tx888266_7" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </div></div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="display:inline;">The following discussion highlights the principal factors that have affected our financial condition and results of operations, as well as our liquidity and capital resources, for the periods described. This discussion should be read in conjunction with the unaudited Consolidated Financial Statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the fiscal year ended December&#160;31, 2019, filed with the Securities and Exchange Commission on February&#160;20, 2020 (the &#8220;2019 Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K&#8221;).</div> As used in this Quarterly Report, the terms &#8220;MEDNAX&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to the parent company, MEDNAX, Inc., a Florida corporation, and the consolidated subsidiaries through which its businesses are actually conducted (collectively, &#8220;MDX&#8221;), together with MDX&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (&#8220;affiliated professional contractors&#8221;). Certain subsidiaries of MDX have contracts with our affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The following discussion contains forward-looking statements. Please see the Company&#8217;s 2019 Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> including Item 1A, Risk Factors, for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements. In addition, please see &#8220;Caution Concerning Forward-Looking Statements&#8221; below. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX is a leading provider of physician services including newborn, maternal-fetal, radiology and teleradiology, pediatric cardiology and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in all 50 states, the District of Columbia and Puerto Rico. Our affiliated physicians provide neonatal clinical care, primarily within hospital-based neonatal intensive care units, to babies born prematurely or with medical complications; radiology services including diagnostic imaging and interventional radiology; and maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where our affiliated neonatal physicians practice. Our network also includes other pediatric subspecialists, including those who provide pediatric intensive care, pediatric cardiology care, hospital-based pediatric care, pediatric surgical care, pediatric ear, nose and throat, pediatric ophthalmology and pediatric urology services. MEDNAX also provides radiology services including diagnostic imaging and interventional radiology, through a network of affiliated physicians, as well as teleradiology services through a network of affiliated radiologists. In addition to our national physician network, we provide services nationwide to healthcare facilities and physicians, including ours, through a consulting services company. MEDNAX divested its anesthesia medical group on May 6, 2020.</div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Coronavirus Pandemic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19) </div></div></div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and related &#8220;stay at home&#8221; and social distancing measures implemented across the country have significantly impacted demand for medical services provided by our affiliated clinicians. Beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020, we experienced a significant decline in the number of elective surgeries at the facilities where&#160;our affiliated clinicians provided anesthesia services. Much of this decline was due to the closure of operating suites or facilities following federal advisories to cancel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent </div> procedures and the prohibition of such procedures by several states. Within our radiology service line, orders for radiological studies have declined by a meaningful amount from historically normal levels, with much of this reduction focused in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> studies. Our affiliated office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, have seen a significant elevation of appointment cancellations compared to historical normal levels. At this time, we have not experienced, nor do we currently anticipate, any significant impact to neonatal intensive care unit (NICU) patient volumes as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19. </div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="display:inline;">We have implemented a number of actions to preserve financial flexibility and partially mitigate the significant anticipated impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> These steps included a suspension of most activities related to our transformational and restructuring programs, limiting these expenditures to those that provide essential support for our response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> In addition, (i)&#160;we temporarily reduced executive and key management base salaries, including 50% reductions in salaries for our named executive officers through at least June&#160;30, 2020; (ii) our Board of Directors agreed to forego their annual cash retainer and cash meeting payments, until further notice; (iii)&#160;we enacted a combination of salary reductions and furloughs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> employees; and (iv)&#160;we enacted significant operational and practice-specific expense reduction plans across our clinical operations. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have also implemented a variety of solutions across specialties to support clinicians and patients during this pandemic, including </div></div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;"><div style="display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;"><div style="display:inline;">&#8226;</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">Clinician Shortage Support</div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 8%;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pediatric clinicians are lending their expertise to help fulfill the need for added adult care. </div></div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;"><div style="display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;"><div style="display:inline;">&#8226;</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">Strengthening of Supply Chain</div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 8%;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX is helping to address the shortage of personal protective equipment (PPE) by partnering with vendors across industries to source high filtration respirators, surgical masks and other forms of PPE for protective use. </div></div></div> </div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14</div></div></div> </div> </div> </div> </div> <div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Expanded Virtual Care Offerings</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Utilizing VSee, an internationally recognized telehealth platform, MEDNAX has deployed a national multi-specialty virtual clinic to expand its telehealth offerings and make virtual care available to its clinical workforce, enabling continued patient consults and clinician collaboration while minimizing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> exposure. </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Early Virus Detection Using Cutting-Edge Imaging Diagnostic Tools</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX Radiology Solutions is leading early detection efforts through chest imaging. vRad, a MEDNAX company, diagnosed one of the first <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients in the United States via chest computed tomography (&#8220;CT&#8221;), which showed findings consistent with a severe acute respiratory viral infection. In the absence of laboratory testing kits, chest CT can serve as a diagnostic tool. In addition, MEDNAX Radiology Solutions is refining natural language processing (&#8220;NLP&#8221;) to identify the incidence of viral pneumonia and typical findings of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> virus in the lungs via chest CT across the proprietary MEDNAX Imaging Platform and inference engine, which is connected to more than 2,000 partner facilities across the country. The NLP is run retrospectively to monitor the amount and rate of increase of suspected chest CT findings for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and viral pneumonia, supporting faster treatment. If successful, this cutting-edge diagnostic tool could serve as an effective tracker of the disease&#8217;s progression throughout the country and provide new insights for imaging findings for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients. </div></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Virtual Forum to Provide Clinician Support</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">To support frontline clinicians while abiding by social distancing recommendations, MEDNAX has created a virtual doctors&#8217; lounge for clinicians across specialties to connect and socialize in the absence of typical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> lounges, helping to boost morale and preserve a sense of normalcy. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We currently expect that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will materially impact our financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> we are unable to predict the ultimate impact on our business, financial condition, results of operations, cash flows and the trading price of our securities at this time. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CARES Act </div></div></div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $100&#160;billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The Department of Health and Human Services (&#8220;HHS&#8221;) is administering this program and began disbursing funds from the initial $30&#160;billion in early April 2020, of which our affiliated physician practices received an aggregate of $12.2&#160;million based on their respective share of Medicare fee for service reimbursements in 2019. The remaining $70&#160;billion in aid is intended to focus on providers in areas particularly impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act we and our affiliated physician practices will qualify for and receive. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due December&#160;31, 2021 and the remaining 50% due December&#160;31, 2022. We intend to utilize this deferral option throughout 2020. </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General Economic Conditions and Other Factors </div></div></div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Our operations and performance depend significantly on economic conditions. During the three months ended March&#160;31, 2020, the percentage of our patient service revenue being reimbursed under government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) remained relatively consistent as compared to the three months ended March&#160;31, 2019. Economic conditions in the United States (&#8220;U.S.&#8221;) have deteriorated, primarily as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> and patient volumes have declined. We could also experience additional shifts toward GHC Programs if changes occur in population demographics within geographic locations in which we provide services, including an increase in unemployment and underemployment as well as losses of commercial health insurance. Payments received from GHC Programs are substantially less for equivalent services than payments received from commercial insurance payors. In addition, due to the rising costs of managed care premiums and patient responsibility amounts, we may experience lower net revenue resulting from increased bad debt due to patients&#8217; inability to pay for certain services. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformation and Restructuring Initiatives </div></div></div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have developed a number of strategic initiatives across our organization, in both our shared services functions and our operational infrastructure, with a goal of generating improvements in our general and administrative expenses and our operational infrastructure. We have broadly classified these workstreams in four broad categories including practice operations, revenue cycle management, information technology and human resources. We have included the expenses, which in certain cases represent estimates, related to such activity on a separate line item in our consolidated statements. In our shared services departments, we were focused on improving processes, using our resources more efficiently and utilizing our scale more effectively to improve cost and service performance across our operations. Within our operational infrastructure, we developed specific operational plans within each of our service lines and affiliated physician practices, with specific milestones and regular reporting, with the goal of generating long-term operational improvements and fostering even greater collaboration across our national medical group. We intended to make a series of information-technology and other investments to improve processes and performance across our enterprise, using both internal and external resources. We believed these strategic initiatives, together with our </div></div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">continued plans to invest in focused, targeted and strategic organic and acquisitive growth, positioned us well to deliver a differentiated value proposition to our stakeholders while continuing to provide the highest quality care for our patients. </div></div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15</div></div></div> </div> </div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></div> <div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We originally expected these activities to continue through at least 2020. However, as discussed above, beginning in April 2020, we reduced the scope of our transformation and restructuring related initiatives unless they are initiatives that provide essential support for our response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Healthcare Reform </div></div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;) contains a number of provisions that have affected us and, absent amendment or repeal, may continue to affect us over the next several years. These provisions include the establishment of health insurance exchanges to facilitate the purchase of qualified health plans, expanded Medicaid eligibility, subsidized insurance premiums and additional requirements and incentives for businesses to provide healthcare benefits. Other provisions have expanded the scope and reach of the Federal Civil False Claims Act and other healthcare fraud and abuse laws. Moreover, we could be affected by potential changes to various aspects of the ACA, including changes to subsidies, healthcare insurance marketplaces and Medicaid expansion. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ACA remains subject to continuing legislative and administrative flux and uncertainty. In 2017, Congress unsuccessfully sought to replace substantial parts of the ACA with different mechanisms for facilitating insurance coverage in the commercial and Medicaid markets. Congress may again attempt to enact substantial or target changes to the ACA in the future. Additionally, Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;) has administratively revised a number of provisions and may seek to advance additional significant changes through regulation, guidance and enforcement in the future. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the end of 2017, Congress repealed the part of the ACA that required most individuals to purchase and maintain health insurance or face a tax penalty, known as the individual mandate. In light of these changes, in December 2018, a federal district court in Texas declared that key portions of the ACA were inconsistent with the U.S. Constitution and that the entire ACA is invalid as a result. Several states appealed this decision, and in December 2019, a federal court of appeals upheld the district court&#8217;s conclusion that part of the ACA is unconstitutional but remanded for further evaluation whether in light of this defect the entire ACA must be invalidated. These legal proceedings are likely to continue for several years, and the fate of the ACA will be unresolved and uncertain during this period. Actions by the court of appeals or eventually the Supreme Court of the United States could invalidate portions or all of the ACA. Changes resulting from these proceedings could have a material impact on our business. In the meantime, it also is possible that as a result of these actions, enrollment in healthcare exchanges could decline. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, there will be federal and state elections that could affect which persons and parties occupy the Office of the President of the United States, control one or both chambers of Congress and many states&#8217; governors and legislatures. Some candidates running for President of the United States are proposing sweeping changes to the U.S. healthcare system, including expanding government-funded healthcare insurance options. Any legislative or administrative change to the current healthcare financing system could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the ACA is repealed or further substantially modified by judicial, legislative or administrative action, or if implementation of certain aspects of the ACA are diluted, delayed or replaced with a &#8220;Medicare for All&#8221; or single payor system, such repeal, modification or delay may impact our business, financial condition, results of operations, cash flows and the trading price of our securities. We are unable to predict the impact of any repeal, modification or delay in the implementation of the ACA, including the repeal of the individual mandate or implementation of a single payor system, on us at this time. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the potential impacts to the ACA, there could be changes to other GHC Programs, such as a change to the structure of Medicaid. Congress and the Administration have sought to convert Medicaid into a block grant or to institute &#8220;per capita spending caps&#8221;, among other things. These changes, if implemented could eliminate the guarantee that everyone who is eligible and applies for benefits would receive them and could potentially give states new authority to restrict eligibility, cut benefits and make it more difficult for people to enroll. Additionally, several states are considering and pursuing changes to their Medicaid programs, such as requiring recipients to engage in employment or education activities as a condition of eligibility for most adults, disenrolling recipients for failure to pay a premium, or adjusting premium amounts based on income. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result, we cannot predict with any assurance the ultimate effect of these laws and resulting changes to payments under GHC Programs, nor can we provide any assurance that they will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Further, any fiscal tightening impacting GHC Programs or changes to the structure of any GHC Programs could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Medicare Access and CHIP Reauthorization Act </div></div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Medicare Access and CHIP Reauthorization Act (&#8220;MACRA&#8221;) requires physicians to choose to participate in one of two payment formulas, Merit-Based Incentive Payment System (&#8220;MIPS&#8221;) or Alternative Payment Models (&#8220;APMs&#8221;). Beginning in 2020, MIPS allows eligible physicians to receive incentive payments based on the achievement of certain quality and cost metrics, among other measures, and be reduced for those who are underperforming against those same metrics and measures. As an alternative, physicians can choose to participate in an advanced APM, and physicians who are meaningful participants in APMs will receive bonus payments from Medicare pursuant to the law. MACRA also remains subject to review and potential modification by Congress, as well as shifting regulatory requirements established by CMS. We currently anticipate that our affiliated physicians will continue to be eligible to receive bonus payments in 2020 through participation in the MIPS, although the amounts of such bonus payments are not expected to be material. We will continue to operationalize the provisions of MACRA and assess any further changes to the law or additional regulations enacted pursuant to the law. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16</div></div> </div> </div> </div> </div> <div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> </div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot predict the ultimate effect that these changes will have on us, nor can we provide any assurance that its provisions will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicaid Expansion </div></div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The ACA also allows states to expand their Medicaid programs through federal payments that fund most of the cost of increasing the Medicaid eligibility income limit from a state&#8217;s historic eligibility levels to 133% of the federal poverty level. To date, 36 states and the District of Columbia have expanded Medicaid eligibility to cover this additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-income</div> patient population, and other states are considering expansion. All of the states in which we operate, however, already cover children in the first year of life and pregnant women if their household income is at or below 133% of the federal poverty level.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Surprise&#8221; Billing Legislation </div></div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">&#8220;Surprise&#8221; medical bills arise when an insured patient receives care from an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div> provider resulting in costs that were not expected by the patient. The bill is a &#8220;surprise&#8221; either because the patient did not expect to receive care from an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div> provider, or because their cost-sharing responsibility is higher than the patient expected. For the past several years, state legislatures have been enacting laws that are intended to address the problems associated with surprise billing or balance billing.</div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">More recently, Congress and President Trump have proposed bipartisan solutions to address this circumstance, either by working in tandem with, or in the absence of, applicable state laws. Several committees of jurisdiction in the U.S. House of Representatives and in the U.S. Senate have proposed solutions to address surprise medical bills, but it is unclear whether any of the proposed solutions will become law. In addition, state legislatures and regulatory bodies continue to address and modify existing laws on the same issue. Any state or federal legislation on the topic of surprise billing may have an unfavorable impact on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network </div> reimbursement that we receive. In addition, actual or prospective legislative changes in this area may impact, and may have impacted, our ability to contract with private payors at favorable reimbursement rates or remain in contract with such payors.</div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Although our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div> revenue is currently not material, we cannot predict the ultimate effect that these changes will have on us, nor can we provide any assurance that future legislation or regulations will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicare Sequestration </div></div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012, required <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">across-the-board</div> cuts (&#8220;sequestrations&#8221;) to Medicare reimbursement rates. These annual reductions of 2%, on average, apply to mandatory and discretionary spending through 2025. Unless Congress acts in the future to modify these sequestrations, Medicare reimbursements will be reduced by 2%, on average, annually. In connection with the CARES Act, the Medicare sequestrations will be suspended beginning on May&#160;1, 2020 through December&#160;31, 2020. Aside from the suspension, the reduction in Medicare reimbursement rates is not expected to have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our securities.</div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> Measures </div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">In our analysis of our results of operations, we use certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures. We have incurred and anticipate we will continue to incur certain expenses related to transformational and restructuring related expenses that are expected to be project-based and periodic in nature. In addition, beginning with the first quarter of 2019, we reported MedData as assets held for sale and discontinued operations. Accordingly, beginning with the first quarter of 2019, we began reporting Adjusted earnings before interest, taxes and depreciation and amortization (&#8220;EBITDA&#8221;) from continuing operations, defined as income (loss) from continuing operations before interest, taxes, depreciation and amortization, and transformational and restructuring related expenses. Adjusted earnings per share (&#8220;Adjusted EPS&#8221;) from continuing operations has also been further adjusted for these items and beginning with the first quarter of 2019 consists of diluted income (loss) from continuing operations per common and common equivalent share adjusted for amortization expense, stock-based compensation expense and transformational and restructuring related expenses. Adjusted EPS from continuing operations is being further adjusted to reflect the impacts from discrete tax events. Adjusted EBITDA and Adjusted EPS have also been adjusted for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> goodwill impairment charge recorded during the third quarter of 2019. Historical periods do not include any material items that meet the current definition of transformational and restructuring related expenses or goodwill impairment, so although we are retrospectively presenting historical periods for the new definitions, we do not reflect any adjustments for these items.</div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We believe these measures, in addition to income (loss) from continuing operations, net income (loss) and diluted net income (loss) from continuing operations per common and common equivalent share, provide investors with useful supplemental information to compare and understand our underlying business trends and performance across reporting periods on a consistent basis. These measures should be considered a supplement to, and not a substitute for, financial performance measures determined in accordance with GAAP. In addition, since these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measures are not determined in accordance with GAAP, they are susceptible to varying calculations and may not be comparable to other similarly titled measures of other companies.</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17</div></div> </div> </div> </div> </div> <div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a reconciliation of each of Adjusted EBITDA from continuing operations and Adjusted EPS from continuing operations to the most directly comparable GAAP measures for the three months ended March&#160;31, 2020 and 2019, refer to the tables below (in thousands, except per share data). </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 78%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 0.5pt;"> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(16,110</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41,653 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27,608 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30,723 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2,286 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8,962 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18,673 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20,033 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30,907 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3,544 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBITDA from continuing operations </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63,364 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">104,915 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 92%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 69%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt; padding-bottom: 0.5pt;"> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average diluted shares outstanding </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82,799 </div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">86,545 </div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations and diluted income from continuing operations per share </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">(1)</div>: </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(16,110</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(0.20</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41,653 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.48 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization (net of tax of $2,740 and $3,449) </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8,220 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.10 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9,325 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.11 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation (net of tax of $1,962 and $2,967) </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5,885 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.07 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8,022 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.09 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring expenses (net of tax of $7,727 and $957) </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23,180 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.28 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2,587 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.03 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net impact from discrete tax events </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5,077 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.07 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(4,791</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(0.06</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted income and diluted EPS from continuing operations </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26,252 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.32 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">56,796 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.65 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">(1)</div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effective tax rates of 25.0% and 27.0% were used to calculate the tax effects of the adjustments in March&#160;31, 2020 and 2019, respectively. The effective tax rates used for the three months ended March&#160;31, 2020 and 2019 exclude the impacts from discrete tax events.</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Results of Operations </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended March&#160;31, 2020 as Compared to Three Months Ended March&#160;31, 2019 </div></div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Our net revenue attributable to continuing operations was $845.9&#160;million for the three months ended March&#160;31, 2020, as compared to $851.2&#160;million for the same period in 2019. The decrease in revenue of $5.3&#160;million, or 0.6%, was primarily attributable to the unfavorable impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on same-unit revenue. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue declined by $8.1&#160;million, or 1.0%. The decline in same-unit net revenue was comprised of a decrease of $16.3&#160;million, or 2.0%, related to patient service volumes, partially offset by a net increase of $8.2&#160;million, or 1.0%, from net reimbursement-related factors. The decrease in revenue from patient service volumes was primarily related to a decline in our anesthesia and office-based women&#8217;s and children&#8217;s services, primarily as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19. </div> The net increase in revenue related to net reimbursement-related factors was primarily due to increases in administrative fees from our hospital partners and modest improvements in managed care contracting.</div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice salaries and benefits attributable to continuing operations increased $31.2&#160;million, or 5.0%, to $652.7&#160;million for the three months ended March&#160;31, 2020, as compared to $621.5&#160;million for the same period in 2019. This increase was primarily attributable to increased costs associated with physicians and other staff to support organic-growth initiatives and growth at our existing units, as well as increases in malpractice expense due to unfavorable trends in claims experience. Of the $31.2&#160;million increase, $20.0&#160;million was related to salaries and $11.2&#160;million was related to benefits and incentive compensation. We anticipate that we will continue to experience a higher rate of growth in clinician compensation expense and malpractice expense at our existing units over historic averages, which could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice supplies and other operating expenses attributable to continuing operations decreased $0.5&#160;million, or 2.0%, to $25.3&#160;million for the three months ended March&#160;31, 2020, as compared to $25.8&#160;million for the same period in 2019. The decrease was primarily attributable to decreases in other practice operating expenses as compared to the prior year. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">General and administrative expenses attributable to continuing operations primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div> operations of our physician practices and services. General and administrative expenses were $105.2&#160;million for the three months ended March&#160;31, 2020, as compared to $101.8&#160;million for the same period in 2019. General and administrative expenses as a percentage of net revenue was 12.4% for the three months ended March&#160;31, 2020, as compared to 12.0% for the same period in 2019.</div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses attributable to continuing operations were $30.9&#160;million for the three months ended March&#160;31, 2020, as compared to $3.5&#160;million for the same period in 2019. The expenses were primarily for external consulting costs for various process improvement and restructuring initiatives. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18</div></div> </div> </div> </div> </div> <div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></div> <div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization expense attributable to continuing operations was $18.7&#160;million for the three months ended March&#160;31, 2020, as compared to $20.0&#160;million for the same period in 2019. The decrease of $1.3&#160;million was primarily related to a decrease in amortization expense underlying various finite lived intangible assets due to the expiration of amortization periods. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from operations attributable to continuing operations decreased $65.4&#160;million, or 83.3%, to $13.1&#160;million for the three months ended March&#160;31, 2020, as compared to $78.5&#160;million for the same period in 2019. Our operating margin was 1.6% for the three months ended March&#160;31, 2020, as compared to 9.2% for the same period in 2019. The decrease in our operating margin was primarily due to higher operating expense growth, including transformation and restructuring related expenses, and the decrease in revenue. Excluding the transformation and restructuring expenses, our income from operations attributable to continuing operations was $44.0&#160;million, and our operating margin was 5.2%. We believe excluding the impacts from the transformational and restructuring related activity provides a more comparable view of our operating income and operating margin from continuing operations. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses attributable to continuing operations were $26.9&#160;million for the three months ended March&#160;31, 2020, as compared to $27.8&#160;million for the same period in 2019. The decrease in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses was primarily related to a decrease in interest expense, primarily due to lower average borrowings under our credit agreement (the &#8220;Credit Agreement&#8221;), partially offset by the settlement of a litigation matter.</div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Our effective income tax rate attributable to continuing operations was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-16.5%</div> and 17.7% for the three months ended March&#160;31, 2020 and 2019, respectively. Income taxes for the first quarter of 2020 were calculated by applying the actual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date </div> effective rate to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss. After excluding discrete tax impacts, during the three months ended March&#160;31, 2020 and 2019, our effective income tax rate was 20.0% and 27.0%, respectively. We believe excluding discrete tax impacts on our effective income tax rate provides a more comparable view of our effective income tax rate. The decrease in the effective tax rate during the three months ended March&#160;31, 2020 is primarily due to the reduction in income before taxes due to the impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from continuing operations was $16.1&#160;million for the three months ended March&#160;31, 2020, as compared to income from continuing operations of $41.7&#160;million for the same period in 2019. Adjusted EBITDA from continuing operations was $63.4&#160;million for the three months ended March&#160;31, 2020, as compared to $104.9&#160;million for the same period in 2019. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted loss from continuing operations per common and common equivalent share was $0.20 on weighted average shares outstanding of 82.8&#160;million for the three months ended March&#160;31, 2020, as compared to diluted income of $0.48 on weighted average shares outstanding of 86.5&#160;million for the same period in 2019. Adjusted EPS from continuing operations was $0.32 for the three months ended March&#160;31, 2020, as compared to $0.65 for the same period in 2019. The decrease of 3.7&#160;million in our weighted average shares outstanding is primarily due to the impact of shares repurchased in 2019 through open market repurchase activity and the exclusion of common stock equivalents from the weighted average shares calculation for the three months ended March&#160;31, 2020 as the effect would have been antidilutive. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax, was $2.6&#160;million for the three months ended March&#160;31, 2020, as compared to loss of $284.5&#160;million for the same period in 2019. Diluted loss from discontinued operations per common and common equivalent share was $0.03 for the three months ended March&#160;31, 2020, as compared to $3.29 for the same period in 2019. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss was $18.7&#160;million for the three months ended March&#160;31, 2020, as compared to $242.9&#160;million for the same period in 2019. Diluted net loss per common and common equivalent share was $0.23 for the three months ended March&#160;31, 2020, as compared to $2.81 for the same period in 2019. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Capital Resources </div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2020, we had $312.2&#160;million of cash and cash equivalents attributable to continuing operations as compared to $112.8&#160;million at December&#160;31, 2019. Additionally, we had working capital attributable to continuing operations of $594.5&#160;million at March&#160;31, 2020, an increase of $404.8&#160;million from working capital of $189.7&#160;million at December&#160;31, 2019. The net increase in working capital is primarily due to net borrowings on our Credit Agreement, partially offset by a decline in operating results. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Continuing Operations </div></div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash (used in) provided by operating, investing and financing activities from continuing operations is summarized as follows (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(146,431</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(60,408</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing activities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(20,220</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(5,271</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">366,039 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66,664 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Activities from Continuing Operations </div></div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended March&#160;31, 2020, our net cash used in operating activities for continuing operations was $146.4&#160;million, compared to $60.4&#160;million for the same period in 2019. The net increase in cash used of $86.0&#160;million was primarily due to a decrease in cash flow from lower earnings, a decrease in cash flow from changes in accounts payable and accrued expenses, primarily incentive compensation payments, and a decrease in cash flow from income taxes payable, partially offset by an increase in cash flow from accounts receivable and deferred income taxes. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19</div></div> </div> </div> <div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended March&#160;31, 2020, cash flow from accounts receivable for continuing operations increased by $25.9&#160;million, as compared to a decrease of $15.9&#160;million for the same period in 2019. The increase in cash flow from accounts receivable for the three months ended March&#160;31, 2020 was primarily due to decreases in ending accounts receivable balances at existing units due to lower revenue. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Days sales outstanding (&#8220;DSO&#8221;) is one of the key factors that we use to evaluate the condition of our accounts receivable and the related allowances for contractual adjustments and uncollectibles. DSO reflects the timeliness of cash collections on billed revenue and the level of reserves on outstanding accounts receivable. Our DSO for continuing operations was 51.3 days at March&#160;31, 2020 as compared to 50.7 days at December&#160;31, 2019. The increase in our DSO primarily related to the increases in our accounts receivable balances at existing units due to timing of cash collections. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing Activities from Continuing Operations </div></div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended March&#160;31, 2020, our net cash used in investing activities for continuing operations of $20.2&#160;million consisted of capital expenditures of $13.7&#160;million and net purchases of investments of $11.2&#160;million, partially offset by proceeds from the sale of assets of $4.8&#160;million. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing Activities from Continuing Operations </div></div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended March&#160;31, 2020, our net cash provided from financing activities for continuing operations of $366.0&#160;million consisted of net borrowings on our Credit Agreement of $368.5&#160;million, partially offset by the repurchase of $2.5&#160;million of our common stock. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity </div></div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;25, 2020, we amended and restated our Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $139.2&#160;million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by us from 4.50:1:00 to 5.00:1:00 for the second and third quarters of 2020 and 4.75:1:00 for the fourth quarter of 2020, before returning to 4.50:1:00 for the first quarter of 2021 and beyond, (iii)&#160;require that we maintain minimum availability under the Credit Agreement of $300.0&#160;million through the third quarter of 2021, (iv) provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $300.0&#160;million, plus a reserve for certain payables, and (v)&#160;temporarily restrict our ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain exceptions. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">The Credit Agreement provides for a $1.2&#160;billion unsecured revolving credit facility, subject to the limitations discussed above, and includes a $37.5&#160;million <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-facility</div> for the issuance of letters of credit. The Credit Agreement matures on March&#160;28, 2024 and is guaranteed by substantially all of our subsidiaries and affiliated professional associations and corporations. At our option, borrowings under the Credit Agreement will bear interest at (i)&#160;the alternate base rate (defined as the higher of (a)&#160;the prime rate, (b)&#160;the Federal Funds Rate plus 1/2 of 1.00% and (c)&#160;LIBOR for an interest period of one month plus 1.00%) plus an applicable margin rate ranging from 0.125% to 0.750% based on our consolidated leverage ratio or (ii)&#160;the LIBOR rate plus an applicable margin rate ranging from 1.125% to 1.750% based on our consolidated leverage ratio. The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee ranging from 0.150% to 0.200% of the unused lending commitments, based on our consolidated leverage ratio. The Credit Agreement contains customary covenants and restrictions, including covenants that require us to maintain a minimum interest charge ratio, not to exceed a specified consolidated leverage ratio and to comply with laws, and restrictions on the ability to pay dividends and make certain other distributions, as specified therein. Failure to comply with these covenants would constitute an event of default under the Credit Agreement, notwithstanding the ability of the company to meet its debt service obligations. The Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Credit Agreement.</div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2020, we had an outstanding principal balance of $368.5&#160;million on our Credit Agreement, of which approximately $300.0&#160;million is included in cash on the Consolidated Balance Sheet. We also had outstanding letters of credit of $0.2&#160;million which reduced the amount available on our Credit Agreement to $531.3&#160;million at March&#160;31, 2020, after giving effect to the temporary reduction of the capacity of our Credit Agreement described above through September&#160;30, 2021. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2020, we had an outstanding principal balance of $750.0&#160;million on our 5.25% senior unsecured notes due 2023 (the &#8220;2023 Notes&#8221;) and an outstanding principal balance of $1.0&#160;billion on our 6.25% senior unsecured notes due 2027 (the &#8220;2027 Notes&#8221;). Our obligations under the 2023 Notes and the 2027 Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee our Credit Agreement. Interest on the 2023 Notes accrues at the rate of 5.25% per annum, or $39.4&#160;million, and is payable semi-annually in arrears on June&#160;1 and December 1. Interest on the 2027 Notes accrues at the rate of 6.25% per annum, or $62.5&#160;million, and is payable semi-annually in arrears on January&#160;15 and July 15. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The indenture under which the 2023 Notes and the 2027 Notes are issued, among other things, limits our ability to (1)&#160;incur liens and (2)&#160;enter into sale and lease-back transactions, and also limits our ability to merge or dispose of all or substantially all of our assets, in all cases, subject to a number of customary exceptions. Although we are not required to make mandatory redemption or sinking fund payments with respect to the 2023 Notes or the 2027 Notes, upon the occurrence of a change in control of MEDNAX, we may be required to repurchase the 2023 Notes and the 2027 Notes at a purchase price equal to 101% of the aggregate principal amount of the 2023 Notes and the 2027 Notes repurchased plus accrued and unpaid interest. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20</div></div> </div> </div> <div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2020, we believe we were in compliance, in all material respects, with the financial covenants and other restrictions applicable to us under the Credit Agreement and the 2023 Notes and the 2027 Notes. We believe we will be in compliance with these covenants throughout 2020. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We maintain professional liability insurance policies with third-party insurers, subject to self-insured retention, exclusions and other restrictions. We self-insure our liabilities to pay self-insured retention amounts under our professional liability insurance coverage through a wholly owned captive insurance subsidiary. We record liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Our total liability related to professional liability risks at March&#160;31, 2020 was $286.5&#160;million, of which $48.1&#160;million is classified as a current liability within accounts payable and accrued expenses in the Consolidated Balance Sheet. In addition, there is a corresponding insurance receivable of $35.6&#160;million recorded as a component of other assets for certain professional liability claims that are covered by insurance policies. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Credit Agreement, will be sufficient to finance our working capital requirements, fund anticipated acquisitions and capital expenditures, fund expenses related to our transformational and restructuring activities, fund our share repurchase programs and meet our contractual obligations for at least the next 12 months from the date of issuance of this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Caution Concerning Forward-Looking Statements </div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Certain information included or incorporated by reference in this Quarterly Report may be deemed to be &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as &#8220;believe,&#8221; &#8220;hope,&#8221; &#8220;may,&#8221; &#8220;anticipate,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;positioned,&#8221; &#8220;strategy&#8221; and similar expressions, and are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this Quarterly Report are made as of the date hereof, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the 2019 Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> including the section entitled &#8220;Risk Factors.&#8221;</div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21</div></div> </div> </div> <div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div id="tx888266_8" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk </div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities. We intend to manage interest rate risk through the use of a combination of fixed rate and variable rate debt. We borrow under our Credit Agreement at various interest rate options based on the Alternate Base Rate or LIBOR rate depending on certain financial ratios. At March&#160;31, 2020, the outstanding principal balance on our Credit Agreement was $368.5&#160;million, and considering this outstanding balance, a 1% change in interest rates would result in an impact to income before income taxes of approximately $3.7&#160;million per year. </div></div> <div id="tx888266_9" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;4. Controls and Procedures </div></div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Evaluation of Disclosure Controls and Procedures </div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">We maintain disclosure controls and procedures (as defined in Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(e)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(e)</div> under the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by the Company in reports it files or submits under the Exchange Act is (i)&#160;recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii)&#160;accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March&#160;31, 2020. </div></div> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in Internal Controls Over Financial Reporting </div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No changes in our internal control over financial reporting occurred during the three months ended March&#160;31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22</div></div> </div> </div> </div> <div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II - OTHER INFORMATION </div></div></div> <div id="tx888266_10" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1. Legal Proceedings </div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated physicians. Our contracts with hospitals generally require us to indemnify them and their affiliates for losses resulting from the negligence of our affiliated physicians and other clinicians. We may also become subject to other lawsuits that could involve large claims and significant defense costs. We believe, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we currently maintain liability insurance coverage intended to cover professional liability and certain other claims, we cannot assure that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us in the future where the outcomes of such claims are unfavorable to us. With respect to professional liability risk, we self-insure a significant portion of this risk through our wholly owned captive insurance subsidiary. Liabilities in excess of our insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">On July&#160;10, 2018, a securities class action lawsuit was filed against our company and certain of our officers and a director in the U.S. District Court for the Southern District of Florida (Case No. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0:18-cv-61572-WPD)</div> that purports to state a claim for alleged violations of Sections 10(b) and 20(a) of the Exchange Act, and Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10b-5</div> thereunder, based on statements made by the defendants primarily concerning our former anesthesiology business. The complaint was seeking unspecified damages, interest, attorneys&#8217; fees and other costs. We filed a motion to dismiss in April 2019, which was granted in October 2019; however, the plaintiff filed a second amended complaint on October&#160;25, 2019. On November&#160;25, 2019, we filed a motion to dismiss the second amended complaint, and on February&#160;7, 2020 a final order granting our motion to dismiss the second amended complaint with prejudice was issued.</div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">On March&#160;20, 2019, a separate derivative action was filed by plaintiff Beverly Jackson on behalf of MEDNAX, Inc. against MEDNAX, Inc. and certain of its officers and directors in the Seventeenth Judicial Circuit in and for Broward County, Florida (Case Number <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CACE-19-006253).</div> The plaintiff purported to bring suit derivatively on behalf of our company against certain of our officers and directors for breach of fiduciary duties and unjust enrichment. The derivative complaint repeated many of the allegations in the securities class action described above. We filed a motion to dismiss in December 2019, and on March&#160;16, 2020, an order granting our motion to dismiss without prejudice was issued. On April 6, 2020, the plaintiff filed an amended complaint, and on April 30, 2020, we filed a motion to dismiss the amended complaint.</div> <div id="tx888266_11" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1A. Risk Factors </div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">Item 1A. Risk Factors in our most recent Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> includes a discussion of our risk factors. The information presented below updates, and should be read in conjunction with, the risk factors disclosed in our most recent Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> Except as presented below, there have been no material changes to the risk factors disclosed in our most recent Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K. </div></div> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 12pt; margin-bottom: 0px;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Our financial condition and results of operations for fiscal year 2020 and beyond may be materially adversely affected by the ongoing coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19)</div> outbreak. </div></div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;">The outbreak of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div>&#160;has evolved into a global pandemic. The coronavirus has spread to many regions of the world, including the United States and Europe. The full extent to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> outbreak will impact our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and the actions to contain it or treat its impact.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;">Our anesthesiology medical group, which we divested on May 6, 2020, experienced a significant decline in the number of elective surgeries at a number of the facilities where its affiliated clinicians provide anesthesia services as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> A significant portion of this decline was due to the closure of operating suites or facilities following federal advisories to cancel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> procedures and the prohibition of such procedures by several states. Within our radiology medical group, orders for radiological studies have declined by a meaningful amount from historically normal levels as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> with much of this reduction focused in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> studies.&#160;Additionally, our office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, have seen a significant elevation of appointment cancellations compared to historical normal levels as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div>&#160;To date, we have not experienced, nor do we currently anticipate, any significant impact to our neonatal intensive care unit (&#8220;NICU&#8221;) patient volumes as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> however, there is no assurance that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will not adversely affect our NICU patient volumes or otherwise adversely affect our NICU and related neonatology business.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Across our medical groups, we believe that these patient volume declines primarily reflect a deferral of healthcare services utilization to a later period, rather than a permanent reduction in demand for our services. Given the general necessity of the services our affiliated clinicians provide, we anticipate that this deferral of services may create a backlog of demand in the future, in addition to the resumption of historically normal activity, however, there is no assurance that either will occur.&#160;We may also require an increased level of working capital if we </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23</div></div> </div> </div> </div> </div> <div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">experience extended billing and collection cycles as a result of displaced employees, payors, revenue cycle management contractors, or otherwise.&#160;The foregoing and other continued disruptions to our business as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> could result in a material adverse effect on our business, results of operations, financial condition, prospects and the trading prices of our securities in the near-term and beyond 2020.</div> <div id="tx888266_12" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds </div></div></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended March&#160;31, 2020, we repurchased 125,100 shares of our common stock that were withheld to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock and deferred stock. </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 92%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 46%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 10%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 10%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 10%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 10%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Period </div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total&#160;Number&#160;of<br/> Shares<br/> Repurchased </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Average<br/> Price&#160;Paid<br/> per Share </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total&#160;Number&#160;of<br/> Shares Purchased as<br/> part of the<br/> Repurchase&#160;Program </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Approximate&#160;Dollar Value of Shares that May&#160;Yet&#160;Be&#160;Purchased Under the Repurchase Programs </div></div> <div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;">(a)</div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">January&#160;1 &#8211; January&#160;31, 2020 </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">40,150</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">(b)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;27.17 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">February&#160;1 &#8211; February&#160;29, 2020 </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;1 &#8211; March&#160;31, 2020 </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">84,950</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">(b)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17.09 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">125,100 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20.33 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a</div></div> </td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="margin-top: 6pt; margin-bottom: 0px;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;">(a)</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We have two active repurchase programs. Our July 2013 program allows us to repurchase shares of our common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under our equity compensation programs, which is estimated to be approximately 1.4&#160;million shares for 2020. Our August 2018 repurchase program allows us to repurchase up to an additional $500.0&#160;million of shares of our common stock, of which we repurchased $395.3&#160;million as of March&#160;31, 2020.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;">(b)</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Represents shares withheld to satisfy minimum statutory withholding obligations of an aggregate of $2.5&#160;million in connection with the vesting of restricted stock.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: left; text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount and timing of any future repurchases will depend upon several factors, including general economic and market conditions and trading restrictions. </div></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24</div></div> </div> </div> </div> <div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div id="tx888266_13" style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;6. Exhibits </div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 100%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 89%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td colspan="2" style="text-align: left; vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit No. </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; display: inline-block; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description </div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="padding: 0px; text-align: left; vertical-align: top; white-space: nowrap; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10.1+ </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="d888266dex101.htm">Amendment No.3, dated as of March&#160;25, 2020, to the Credit Agreement, dated as of October&#160;30, 2017, among MEDNAX, Inc., certain of its domestic subsidiaries from time to time party thereto as Guarantors, the Lenders party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent. </a> </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="padding: 0px; text-align: left; vertical-align: top; white-space: nowrap; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31.1+ </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="d888266dex311.htm">Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002. </a> </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="padding: 0px; text-align: left; vertical-align: top; white-space: nowrap; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31.2+ </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="d888266dex312.htm">Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002. </a> </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="padding: 0px; text-align: left; vertical-align: top; white-space: nowrap; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32.1* </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="d888266dex321.htm">Certification pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002. </a> </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="padding: 0px; text-align: left; vertical-align: top; white-space: nowrap; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.1+ </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interactive Data File </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="padding: 0px; text-align: left; vertical-align: top; white-space: nowrap; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.INS+ </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="padding: 0px; text-align: left; vertical-align: top; white-space: nowrap; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.SCH+ </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">XBRL Schema Document. </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="padding: 0px; text-align: left; vertical-align: top; white-space: nowrap; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.CAL+ </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">XBRL Calculation Linkbase Document. </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="padding: 0px; text-align: left; vertical-align: top; white-space: nowrap; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.DEF+ </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">XBRL Definition Linkbase Document. </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="padding: 0px; text-align: left; vertical-align: top; white-space: nowrap; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.LAB+ </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">XBRL Label Linkbase Document. </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="padding: 0px; text-align: left; vertical-align: top; white-space: nowrap; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101.PRE+ </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">XBRL Presentation Linkbase Document. </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 8px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="padding: 0px; text-align: left; vertical-align: top; white-space: nowrap; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">104+ </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: top; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 10.53%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.5px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; vertical-align: top; white-space: nowrap;">+</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Filed herewith.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; vertical-align: top; white-space: nowrap;">*</td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Furnished herewith.</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25</div></div> <div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div style="margin: 0px auto; width: 8.5in; font-size: 10pt;"> <div id="tx888266_14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURES </div></div></div> <div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px 0px; width: 100%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 46%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 1%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 4%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 1%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 45%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="3" style="padding: 0px; vertical-align: top;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-style: normal; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">MEDNAX, INC.</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px 0px 0.25pt; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Date: May&#160;7, 2020 </div></div> </td>
<td style="vertical-align: top; padding-bottom: 0.25pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px 0px 0.25pt; vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.25pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px 0px 0.25pt; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">By: </div></div> </td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Roger J. Medel, M.D. </div></div> </td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roger J. Medel, M.D. </div></div> </td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Executive Officer </div></div> </td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Principal Executive Officer) </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px 0px 0.25pt; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Date: May&#160;7, 2020 </div></div> </td>
<td style="vertical-align: top; padding-bottom: 0.25pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px 0px 0.25pt; vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.25pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px 0px 0.25pt; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">By: </div></div> </td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Stephen D. Farber </div></div> </td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stephen D. Farber </div></div> </td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Financial Officer </div></div> </td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Principal Financial Officer) </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="height: 16px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px 0px 0.25pt; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Date: May&#160;7, 2020 </div></div> </td>
<td style="vertical-align: top; padding-bottom: 0.25pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px 0px 0.25pt; vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; padding-bottom: 0.25pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px 0px 0.25pt; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">By: </div></div> </td>
<td style="vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; border-bottom: 0.5pt solid rgb(0, 0, 0); font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ John C. Pepia </div></div> </td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">John C. Pepia </div></div> </td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Accounting Officer </div></div> </td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: left; text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Principal Accounting Officer) </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div></div> <div style="margin-top: 1em; margin-bottom: 0em;"></div> <div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26</div></div> </div> </div> </div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d888266dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>

 <body style="font-family: &quot;Times New Roman&quot;, Times, serif; cursor: auto;">

<div style="width:8.5in; margin:0 auto"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Exhibit 10.1</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Execution Version</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&nbsp;</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><u>AMENDMENT&nbsp;NO.&nbsp;3&nbsp;TO CREDIT AGREEMENT</u></b></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 72pt;">AMENDMENT
NO. 3 dated as of March 25, 2020 (this &#8220;<u>Amendment</u>&#8221;), to the Credit Agreement, dated as of October 30, 2017 (as amended, modified, extended, restated, replaced, or supplemented from time to time in accordance with its terms prior
to the date hereof, the &#8220;<u>Credit Agreement</u>&#8221;), among <b>MEDNAX, INC.</b>, a Florida corporation (the &#8220;<u>Borrower</u>&#8221;), the Guarantors party thereto, the Lenders and <b>JPMORGAN CHASE BANK, N.A.</b>, as administrative
agent (the &#8220;<u>Administrative Agent</u>&#8221;), by and among the Borrower, the Guarantors, the Lenders party hereto and the Administrative Agent. Terms defined in the Amended Credit Agreement (as defined below) and used herein shall have the
meanings given to them in the Amended Credit Agreement unless otherwise defined herein.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">W I T N E S S E T H:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 72pt;">WHEREAS, the Borrower has requested certain amendments to the Credit Agreement;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 72pt;">WHEREAS,
the Administrative Agent, the Borrower and the Lenders party hereto, constituting at least the Required Lenders, are willing to so agree pursuant to <u>Section 9.1</u> of the Credit Agreement, subject to the terms and conditions set forth in this
Amendment; and</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 72pt;">WHEREAS, JPMorgan Chase Bank, N.A. is acting as the lead &#8220;left&#8221; arranger and bookrunner of this Amendment (in such
capacity, the &#8220;<u>Amendment No. 3 Lead Arranger</u>&#8221;).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 72pt;">NOW, THEREFORE, the parties hereto hereby agree as follows:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE I<br> <u>Required
Lender </u><u>Amendments to Credit Agreement</u></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 6pt; text-indent: 72pt;">Section 1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Credit Agreement is, effective as of the Amendment No. 3 Effective Date,
hereby amended to delete the stricken text (indicated textually in the same manner as the following example: <font style="color:#ff0000;"><strike>stricken text</strike></font>) and to add the double-underlined text (indicated textually in the same
manner as the following example: <font style="color:#0000ff;"><u style="border-bottom:1px solid #000000;">double-underlined text</u></font>) as set forth in the pages attached as <u>Exhibit A</u> hereto (as amended, the &#8220;<u>Amended Credit
Agreement</u>&#8221;).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE II&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br> <u>Conditions to Effectiveness</u></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 6pt; text-indent: 72pt;">Section 2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Effective Date</u>. This Amendment shall become effective on the date (the
&#8220;<u>Amendment No. </u><u>3</u><u> </u><u>Effective Date</u>&#8221;) on which:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Administrative Agent shall have received counterparts to this Amendment duly
executed and delivered by the Borrower, each Guarantor, the Administrative Agent and the Required Lenders.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Borrower shall have paid all reasonable and documented out-of-pocket fees and
expenses incurred by the Administrative Agent and the Amendment No. 3 Lead Arranger payable pursuant to Section 9.5(a) (including the reasonable and documented expenses of Cahill Gordon &amp; Reindel LLP, counsel to the Administrative Agent and the
Amendment No. 3 Lead Arranger) for which invoices have been presented at least two (2) Business Days prior to the Amendment No. 3 Effective Date.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Administrative Agent shall have received customary evidence of authorization of the
transactions described herein, valid organization and good standing (or applicable equivalent) in the jurisdiction of incorporation with respect to the Borrower, and an officer&#8217;s certificate related thereto (which shall include an incumbency
certificate), substantially in the form delivered on the Closing Date pursuant to <u>Section 4.1(b)</u> of the Credit Agreement.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Administrative Agent shall have received the opinion or opinions (including, if
requested by the Administrative Agent, local counsel opinions) of counsel for the Borrower dated as of the Closing Date and addressed to the Administrative Agent and the Lenders in form and substance reasonably satisfactory to the Administrative
Agent.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 45pt; text-indent: 27pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The representations and warranties of each Credit Party set forth in <u>Section
3</u> below are true and correct on and as of the Amendment No. 3 Effective Date and (ii) as of the date hereof, no Default or Event of Default has occurred and is continuing.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Administrative Agent shall have received a certificate signed by the President, a
Vice President or a Financial Officer of the Borrower certifying as to the satisfaction of the condition set forth in paragraph (e) of this <u>Section </u><u>2</u><u>.1</u> as of the Amendment No. 3 Effective Date.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent reasonably requested by the Administrative Agent, and in such case
reasonably satisfactory to the Administrative Agent, either (i) such affidavits relative to the execution and delivery of any Credit Document as required to support the determination that no Florida documentary stamp taxes are required to be paid or
(ii) evidence of payment by the Borrower of any Florida documentary stamp taxes applicable to the execution and delivery of the Credit Documents.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At least three (3) Business Days prior to the Amendment No. 3 Effective Date, to the
extent reasonably requested in writing by the Administrative Agent at least ten (10) Business Days prior to the Amendment No. 3 Effective Date, the Administrative Agent shall have received such information reasonably requested by the Lenders in
connection with applicable &#8220;know your customer&#8221; rules and regulations, including the PATRIOT Act.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE III</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><u>Representation and
Warranties</u>&nbsp;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 6pt; text-indent: 72pt;">Section 3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Borrower hereby represents and warrants as of the Amendment No. 3 Effective
Date that this Amendment has been, or when executed and delivered will be, duly executed and delivered by the Borrower. Neither the execution and delivery of this Amendment, nor the consummation of the transactions herein contemplated, nor
performance of and compliance with the terms and provisions herein and thereof, by the Borrower will (a) violate in any material respect any Requirement of Law (except those as to which waivers or consents have been obtained), (b)&nbsp;conflict
with, result in a breach of or constitute a default under (i) the articles of incorporation, bylaws, articles of organization, operating agreement or other organization documents of the Credit Parties or (ii) any Material Contract to which such
Person is a party or by which any of its properties may be bound or any material approval or material consent from any Governmental Authority relating to such Person (except those as to which waivers or consents have been obtained) which conflict,
breach or default in any such case in this clause (ii) could reasonably be expected to have a Material Adverse Effect, or (c) result in, or require, the creation or imposition of any Lien on any Credit Party&#8217;s properties or revenues pursuant
to any Requirement of Law, the articles of incorporation, bylaws, articles of organization, operating agreement or other organization documents of such Credit Party or Contractual Obligation other than the Liens arising under or contemplated in
connection with the Credit Documents or Permitted Liens.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-2-</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 6pt; text-indent: 72pt;">Section 3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The representations and warranties contained in Article III of the Amended
Credit Agreement (A) with respect to representations and warranties that contain a materiality qualification, are true and correct and (B) with respect to representations and warranties that do not contain a materiality qualification, are true and
correct in all material respects, in each case as of the Amendment No. 3 Effective Date as if made on and as of such date except for any representation or warranty made as of an earlier date, which representation and warranty shall remain true and
correct (subject to the applicable materiality threshold in the preceding clauses (A) or (B)) as of such earlier date.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE IV<br> <u>Miscellaneous</u></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 6pt; text-indent: 72pt;">Section 4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Counterparts</u>. This Amendment may be executed in any number of
counterparts and by different parties hereto on separate counterparts, each of which when so executed and delivered shall be deemed to be an original, but all of which when taken together shall constitute a single instrument. Delivery of an executed
counterpart of a signature page of this Amendment by facsimile or other electronic transmission shall be effective as delivery of a manually executed counterpart hereof.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 6pt; text-indent: 72pt;">Section 4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reaffirmation</u>. Each of the undersigned Guarantors (each, a
&#8220;<u>Reaffirming Party</u>&#8221;) hereby acknowledges the Amendment and the transactions contemplated thereby. Each Reaffirming Party hereby reaffirms all obligations and liabilities of such Reaffirming Party under the Credit Documents to
which it is a party, as such obligations and liabilities have been amended by this Amendment, and confirms that such obligations and liabilities shall continue to be in full force and effect and shall continue to apply to the Amended Credit
Agreement and each other Credit Document.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 78pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 6pt; text-indent: 72pt;">Section 4.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Applicable Law</u>. THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE
PARTIES HEREUNDER SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO ITS CONFLICTS OF LAW PRINCIPLES THAT WOULD CAUSE THE LAW OF ANOTHER JURISDICTION TO APPLY (OTHER THAN SECTIONS 5-1401 AND
5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 6pt; text-indent: 72pt; text-transform: uppercase;">Section 4.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Jury Waiver</u>. EACH PARTY TO THIS AMENDMENT
HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER THIS AMENDMENT OR IN ANY WAY CONNECTED WITH OR RELATED TO THIS AMENDMENT, OR THE TRANSACTIONS RELATED THERETO, IN EACH CASE WHETHER NOW
EXISTING OR HEREAFTER ARISING, AND WHETHER FOUNDED IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY, AND THAT ANY PARTY
TO THIS AMENDMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION 4.4 WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE SIGNATORIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 6pt; text-indent: 72pt;">Section 4.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The headings of this Amendment are for purposes of reference
only and shall not limit or otherwise affect the meaning hereof.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-3-</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 6pt; text-indent: 72pt;">Section 4.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Effect of Amendment</u>. On and after the Amendment No. 3 Effective Date,
each reference to the Credit Agreement in any Credit Document (including to any Exhibit or Schedule attached thereto) shall be deemed to be a reference to the Credit Agreement as amended by this Amendment. Except as expressly set forth in this
Amendment, nothing herein shall be deemed to entitle any Credit Party to a consent to, or a waiver, amendment, modification or other change of, any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement as
in effect immediately prior to the Amendment No. 3 Effective Date or any other Credit Document in similar or different circumstances. This Amendment shall constitute a &#8220;Credit Document&#8221; for all purposes of the Credit Agreement and the
other Credit Documents.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6pt;margin-right:0pt;margin-top:0pt;text-align:center;"><i>&nbsp;</i><i>[Remainder of this page intentionally left blank]</i></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-4-</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 72pt;">IN
WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed and delivered by their respective duly authorized officers as of the date first above written.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%; vertical-align: top;"><u><b>BORROWER</b></u><b>:&nbsp;&nbsp;</b></td>
<td style="width: 50%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>MEDNAX, INC.</b>,</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">a
Florida Corporation</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:<u><i>/s/ Dominic J. Andreano</i></u><u><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name: Dominic J. Andreano</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title:&nbsp;
&nbsp;Executive Vice President, General Counsel and</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&nbsp;Secretary</p> </td> </tr>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td> </tr>
<tr>
<td style="vertical-align: top;"><u><b>GUARANTORS</b></u><b>:&nbsp;&nbsp;</b></td>
<td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;"><b>1500 CONCORD TERRACE, LLC</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;"><b>ALASKA NEONATOLOGY ASSOCIATES, INC.</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;"><b>AMERICAN ANESTHESIOLOGY ASSOCIATES OF FLORIDA, INC. </b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;"><b>AMERICAN ANESTHESIOLOGY ASSOCIATES OF GEORGIA, LLC</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;"><b>AMERICAN ANESTHESIOLOGY ASSOCIATES OF ILLINOIS, S.C.</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;"><b>AMERICAN ANESTHESIOLOGY ASSOCIATES OF MICHIGAN, P.C.</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;"><b>AMERICAN ANESTHESIOLOGY ASSOCIATES OF VIRGINIA, INC.</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;"><b>AMERICAN ANESTHESIOLOGY GROUP OF MICHIGAN, P.C.</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;"><b>AMERICAN ANESTHESIOLOGY GROUP OF TENNESSEE, P.C.</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;"><b>AMERICAN ANESTHESIOLOGY, INC.</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;"><b>AMERICAN ANESTHESIOLOGY OF FLORIDA, INC.</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;"><b>AMERICAN ANESTHESIOLOGY OF GEORGIA, LLC</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">By: <u><i>/s/ Dominic J.
Andreano&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">Name: Dominic J. Andreano</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">Title: Attorney-in-Fact</p> </td> </tr> </table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to Mednax Amendment No. 3]</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>&nbsp;</b></p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%;">&nbsp;</td>
<td style="width: 50%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AMERICAN ANESTHESIOLOGY OF ILLINOIS, LLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AMERICAN ANESTHESIOLOGY OF MARYLAND, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AMERICAN ANESTHESIOLOGY OF MICHIGAN,&nbsp;P.C.</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AMERICAN
ANESTHESIOLOGY OF MINNESOTA, P.A.</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AMERICAN ANESTHESIOLOGY OF NAPLES, INC.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AMERICAN ANESTHESIOLOGY OF NEW JERSEY, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AMERICAN ANESTHESIOLOGY OF NEW YORK, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AMERICAN ANESTHESIOLOGY OF NORTH CAROLINA, PLLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AMERICAN ANESTHESIOLOGY OF SOUTH CAROLINA, LLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AMERICAN ANESTHESIOLOGY OF SYRACUSE, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AMERICAN ANESTHESIOLOGY OF TENNESSEE, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AMERICAN ANESTHESIOLOGY OF TEXAS, INC.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AMERICAN ANESTHESIOLOGY OF THE SOUTHEAST, PLLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AMERICAN ANESTHESIOLOGY OF VIRGINIA, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AMERICAN ANESTHESIOLOGY SERVICES OF FLORIDA, INC.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AMERICAN RADIOLOGY, LLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>ANESTHESIA AND PAIN MANAGEMENT GROUP, LLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">By: <u><i>/s/ Dominic J.
Andreano&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">Name: Dominic J. Andreano</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">Title: Attorney-in-Fact</p> </td> </tr> </table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to Amendment No. 3]</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:0pt;margin-top:0pt;text-align:left;"><b>&nbsp;</b></p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%;">&nbsp;</td>
<td style="width: 50%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>ANESTHESIOLOGY CONSULTANTS OF SOUTH CAROLINA, PLLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AUGUSTA NEONATOLOGY ASSOCIATES, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>AUSTIN ANESTHESIOLOGY GROUP, PLLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>BURLINGTON ANESTHESIA ASSOCIATES, P.A.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>CENTRAL OKLAHOMA NEONATOLOGY ASSOCIATES, INC.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>COMMUNITY RADIOLOGY PROVIDERS, LLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>CRITICAL CARE AND ANESTHESIA CONSULTANTS OF NEW JERSEY, LLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>CRITICAL HEALTH SYSTEMS, INC.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>GEORGIA PERIOPERATIVE CONSULTANTS, L.L.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>HEALTH NETWORK MANAGEMENT, L.L.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>HORIZON ANESTHESIA, PLLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>INFINITY MANAGEMENT, LLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>JEFFERSON RADIOLOGY, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>KEYSTONE GROUP, LLC</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>MAGELLA MEDICAL
ASSOCIATES BILLING, INC.</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>MAGELLA MEDICAL ASSOCIATES MIDWEST, P.C. </b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>MAGELLA MEDICAL ASSOCIATES OF GEORGIA, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">By: <u><i>/s/ Dominic J.
Andreano&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">Name: Dominic J. Andreano</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">Title: Attorney-in-Fact</p> </td> </tr> </table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:0pt;margin-top:0pt;text-align:left;"><b>&nbsp;</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to Amendment No. 3]</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%;">&nbsp;</td>
<td style="width: 50%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>MAGELLA MEDICAL GROUP, INC.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>MEDNAX RADIOLOGY OF TEXAS, INC.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>MEDNAX SERVICES, INC.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>MOUNTAIN STATES NEONATOLOGY, INC.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>MSI CONSULTING SERVICES, LLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>NEONATAL SPECIALISTS, LTD.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>NEONATOLOGY ASSOCIATES OF ATLANTA, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>NIGHTHAWK RADIOLOGY SERVICES, LLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>NORTHWEST NEWBORN SPECIALISTS, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>OBSTETRICS AND PEDIATRICS SUBSPECIALTY GROUP OF KANSAS AND MISSOURI, P.A. </b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>OBSTETRIX MEDICAL GROUP OF ARIZONA, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>OBSTETRIX MEDICAL GROUP OF ATLANTA, LLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>OBSTETRIX MEDICAL GROUP OF CALIFORNIA, A PROFESSIONAL CORPORATION</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>OBSTETRIX
MEDICAL GROUP OF COASTAL CAROLINA, PLLC</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>OBSTETRIX MEDICAL GROUP OF COLORADO, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>OBSTETRIX MEDICAL GROUP OF INDIANA, P.C.</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>OBSTETRIX
MEDICAL GROUP OF NEW JERSEY, P.C.</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">By: <u><i>/s/ Dominic J.
Andreano&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">Name: Dominic J. Andreano</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">Title: Attorney-in-Fact</p> </td> </tr> </table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to Amendment No. 3]</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%;">&nbsp;</td>
<td style="width: 50%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>OBSTETRIX MEDICAL GROUP OF PHOENIX, P.C.</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>OBSTETRIX MEDICAL
GROUP OF SACRAMENTO, P.C.</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>OBSTETRIX MEDICAL GROUP OF TEXAS BILLING, INC.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>OBSTETRIX MEDICAL GROUP OF THE CENTRAL COAST, PROFESSIONAL CORPORATION</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>OBSTETRIX MEDICAL GROUP OF UTAH, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>OBSTETRIX MEDICAL GROUP OF WASHINGTON, INC., P.S.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>OZARK NEONATAL ASSOCIATES, INC.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PAIN CENTERS OF CHICAGO, LLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX CARDIOLOGY OF NEW MEXICO, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX CARDIOLOGY OF ORANGE COUNTY, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX CARDIOLOGY OF SPRINGFIELD, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX CARDIOLOGY OF WASHINGTON, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX EMERGENT AND CRITICAL CARE SERVICES, LLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX INTERNATIONAL, INC.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP, INC. (FL)</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP, INC. (UT)</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP NEONATOLOGY AND PEDIATRIC INTENSIVE CARE SPECIALISTS OF NEW YORK, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF ARKANSAS, P.A.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">By: <u><i>/s/ Dominic J.
Andreano&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">Name: Dominic J. Andreano</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">Title: Attorney-in-Fact</p> </td> </tr> </table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to Amendment No. 3]</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%;">&nbsp;</td>
<td style="width: 50%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF CALIFORNIA, A PROFESSIONAL CORPORATION</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF COLORADO, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF FLORIDA, INC.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF GEORGIA, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF ILLINOIS, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF INDIANA, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF KANSAS, P.A.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF KENTUCKY, P.S.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF LOUISIANA, L.L.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF MICHIGAN, P.C.</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX
MEDICAL GROUP OF MISSISSIPPI, INC.</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF MISSOURI, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF MONTANA, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF NEW MEXICO, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF NORTH CAROLINA, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF OHIO CORP.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF OKLAHOMA, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF PENNSYLVANIA, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF SOUTH CAROLINA, P.A.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">By: <u><i>/s/ Dominic J.
Andreano&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">Name: Dominic J. Andreano</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">Title: Attorney-in-Fact</p> </td> </tr> </table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to Amendment No. 3]</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%;">&nbsp;</td>
<td style="width: 50%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF TENNESSEE, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF TEXAS BILLING, INC.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP OF THE MID-ATLANTIC, P.C.</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL
GROUP OF WASHINGTON, INC., P.S.</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP, P.A.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP, P.C. (VA)</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL GROUP, P.C. (WV)</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX MEDICAL
SERVICES, INC.</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX NEWBORN HEARING SCREEN, LLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PEDIATRIX OF MARYLAND,
P.A.</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PICKERT
MEDICAL GROUP, P.C. </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PIEDMONT ANESTHESIA ASSOCIATES, L.L.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PMG CARDIOLOGY,
INC.</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>PMGSC,
P.A.</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>POKROY
MEDICAL GROUP OF NEVADA, LTD.</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>QUANTUM CLINICAL NAVIGATION SYSTEM, LLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>RADIOLOGY ALLIANCE,
P.C. </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>RADIOLOGY
ASSOCIATES OF SOUTH FLORIDA, LLC</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>RADIOLOGY SPECIALISTS, LTD. (MARASSO/MILLER)</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>SOUTHEAST
ANESTHESIOLOGY CONSULTANTS, PLLC</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">By: <u><i>/s/ Dominic J.
Andreano&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">Name: Dominic J. Andreano</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">Title: Attorney-in-Fact</p> </td> </tr> </table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to Amendment No. 3]</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%;">&nbsp;</td>
<td style="width: 50%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>SOUTHEAST ANESTHESIOLOGY CONSULTANTS OF VIRGINIA, PLLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>SPECIALTY MRI,
LLC</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>SUMMIT
ANESTHESIA ASSOCIATES, P.A.</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>SYNERGY RADIOLOGY ASSOCIATES, PLLC</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>SYNTHESIS HEALTHCARE
MANAGEMENT, LLC</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>TEXAS NEWBORN SERVICES, INC.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>THE SURGICAL GROUP OF
MIAMI, LLC </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>VIRTUAL RADIOLOGIC CORPORATION</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>VIRTUAL RADIOLOGIC
PROFESSIONALS, LLC</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>VIRTUAL RADIOLOGIC PROFESSIONALS OF CALIFORNIA, P.A</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>VIRTUAL RADIOLOGIC PROFESSIONALS OF ILLINOIS, S.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>VIRTUAL RADIOLOGIC PROFESSIONALS OF MICHIGAN, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>VIRTUAL RADIOLOGIC PROFESSIONALS OF MINNESOTA, P.A.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>VIRTUAL RADIOLOGIC PROFESSIONALS OF NEW JERSEY, P.A.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>VIRTUAL RADIOLOGIC PROFESSIONALS OF NEW YORK, P.A.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>VIRTUAL RADIOLOGIC PROFESSIONALS OF TEXAS, P.A.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>WESTCHESTER ANESTHESIOLOGISTS, P.C.</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>&nbsp;</b></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">By: <u><i>/s/ Dominic J.
Andreano&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">Name: Dominic J. Andreano</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 43.2pt 0pt 0pt; text-align: left; text-indent: 9pt;">Title: Attorney-in-Fact</p> </td> </tr> </table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.7pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;"><b>&nbsp;</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;"><b>&nbsp;</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to Amendment No. 3]</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:193.5pt;margin-right:43.2pt;margin-top:0pt;text-align:left;"><b>&nbsp;</b></p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%;">&nbsp;</td>
<td style="width: 50%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">JPMORGAN CHASE BANK, N.A.,<br> &nbsp;&nbsp;&nbsp;&nbsp;as a Lender, an Issuing Lender and as Administrative
Agent</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>/s/ </i></u><u><i>Philip VanFossan</i></u><u><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Name: Philip VanFossan</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Title: Executive Director&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> </td> </tr> </table>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to Amendment No. 3]</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%;">&nbsp;</td>
<td style="width: 50%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Bank of America, N.A.,<br> &nbsp;&nbsp;&nbsp;as a Lender</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>/s/ </i></u><u><i>Joseph L. Corah</i></u><u><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Name: Joseph L. Corah</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Title: Director</p> </td> </tr> </table>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to Amendment No. 3]</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div> <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div> </div> </div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%;">&nbsp;</td>
<td style="width: 50%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">BBVA USA, an Alabama banking corporation,<br> &nbsp;&nbsp;&nbsp;as a Lender</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i><u>/s/ Heather
Allen&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;</u></i><br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Heather Allen<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:&nbsp; Senior Vice President&nbsp;&nbsp;</p> </td> </tr> </table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to Amendment No. 3]</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div> <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div> </div> </div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%;">&nbsp;</td>
<td style="width: 50%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Fifth Third Bank, National Association,<br> &nbsp;&nbsp;&nbsp;as a Lender</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>/s/ </i></u><u><i>Tamara M.
Dowd&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u><u><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Name: Tamara M. Dowd</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Title: Director</p> </td> </tr> </table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to
Amendment No. 3]</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%;">&nbsp;</td>
<td style="width: 50%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">MUFG BANK, LTD.,<br> &nbsp;&nbsp;&nbsp;as a Lender</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>/s/ </i></u><u><i>Kevin
Wood</i></u><u><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u><u><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Name:
Kevin Wood</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Title: Director</p> </td> </tr> </table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to
Amendment No. 3]</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%;">&nbsp;</td>
<td style="width: 50%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">PNC Bank,<br> &nbsp;&nbsp;&nbsp;as a Lender</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>/s/ </i></u><u><i>Rebekah Herman</i></u><u><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Name: Rebekah Herman</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Title: Senior Vice President</p> </td> </tr> </table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to
Amendment No. 3]</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%;">&nbsp;</td>
<td style="width: 50%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Truist Bank, formerly known as Branch Banking and Trust Company,<br> &nbsp;&nbsp;&nbsp;as a Lender</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>/s/ </i></u><u><i>Max N.Greer
III</i></u><u><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u><u><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Name: Max
N. Greer</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Title: Senior Vice President</p> </td> </tr> </table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to
Amendment No. 3]</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%;">&nbsp;</td>
<td style="width: 50%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Truist Bank, formerly known as SunTrust Bank,<br> &nbsp;&nbsp;&nbsp;as a Lender</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>/s/ </i></u><u><i>Max N.Greer
III</i></u><u><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u><u><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Name: Max
N. Greer</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Title: Senior Vice President</p> </td> </tr> </table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to Amendment No. 3]</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%;">&nbsp;</td>
<td style="width: 50%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Regions Bank,<br> &nbsp;&nbsp;&nbsp;as a Lender</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>/s/ </i></u><u><i>Ned
Spitzer</i></u><u><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u><u><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Name: Ned Spitzer</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Title: Managing Director</p> </td> </tr> </table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to
Amendment No. 3]</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
<tr>
<td style="width: 50%;">&nbsp;</td>
<td style="width: 50%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">SYNOVUS,<br> &nbsp;&nbsp;&nbsp;as a Lender</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><i>/s/ </i></u><u><i>Michael
Sawicki&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></u></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Name: Michael Sawicki</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Title: Director</p> </td> </tr> </table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:216pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[Signature Page to
Amendment No. 3]</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:right;"><u><b>EXHIBIT A
TO AMENDMENT NO. 3</b></u></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">$1,200,000,000<br> <br> CREDIT AGREEMENT<br> Dated as of October 30, 2017,</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">as amended by Amendment No. 1 to Credit Agreement, dated as of November 21, <font style="color:#ff0000;"><strike>2018 and</strike></font><font
style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">2018</u></font>, as <strike><font style="color:#ff0000;">further</font></strike> amended by Amendment No. 2 to Credit Agreement, dated as of March 28, 2019<font
style="color:#0000ff;"><u style="border-bottom:#000000 thin double;"> and as further amended by Amendment No. 3 to Credit Agreement, dated as of March 25, 2020</u></font></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><br> among<br> <br> MEDNAX, INC.,<br> as Borrower,<br> <br> CERTAIN DOMESTIC SUBSIDIARIES OF THE BORROWER<br> FROM TIME TO TIME PARTY HERETO,<br> as
Guarantors,<br> <br> THE LENDERS PARTY HERETO,<br> <br> JPMORGAN CHASE BANK, N.A.,<br> as Administrative Agent,</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">JPMORGAN CHASE BANK, N.A.,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">BANK OF AMERICA,
N.A.,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">BBVA COMPASS,</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;">FIFTH THIRD BANK,</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">MIZUHO BANK, LTD.,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">MUFG BANK, LTD.,</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">PNC BANK, NATIONAL ASSOCIATION</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">SUNTRUST
BANK&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">and</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">WELLS FARGO BANK, NATIONAL
ASSOCIATION,<br> as Syndication Agents,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">BB&amp;T,</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">REGIONS BANK</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">and</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">U.S. BANK NATIONAL ASSOCIATION,<br> as Senior Documentation Agents,<br> <br> and</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">JPMORGAN CHASE BANK, N.A.,<br> MERRILL
LYNCH, PIERCE, FENNER &amp; SMITH INCORPORATED,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">BBVA COMPASS,</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">FIFTH THIRD BANK,<br> MIZUHO BANK, LTD.,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">MUFG
BANK, LTD.,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">PNC BANK, NATIONAL ASSOCIATION<br> SUNTRUST ROBINSON HUMPHREY, INC.</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">and<br> WELLS FARGO SECURITIES, LLC,<br> as Joint Lead Arrangers and Joint Bookrunners</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p> <hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div> </div> <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div> </div> </div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><u>TABLE OF CONTENTS</u></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><u>Page</u></p> </td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE I</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">DEFINITIONS</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: middle; width: 70%;">&nbsp;</td>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 1.1</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Defined Terms</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">1</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 1.2</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Other Definitional Provisions</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">29</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 1.3</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Accounting Terms</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>29</strike></font><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">30</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 1.4</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Time References</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">30</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 1.5</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Execution of Documents</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">30</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 1.6</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Letter of Credit Amounts</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">30</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">31</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 1.7</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">LIBOR Notification</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">30</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">31</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: middle; width: 70%;">&nbsp;</td>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE II</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">THE LOANS; AMOUNT AND TERMS</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: middle; width: 70%;">&nbsp;</td>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.1</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Revolving Loans</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>30</strike></font><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">31</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.2</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">[Reserved]</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">32</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">33</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.3</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Letter of Credit Subfacility</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>32</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">33</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.4</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">[Reserved]</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">35</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">36</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.5</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Fees</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>35</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">36</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.6</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Revolving Commitment Reductions</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">35</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">36</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.7</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Repayments</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">36</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">37</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.8</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Default Rate and Payment Dates</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">37</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.9</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Conversion Options</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>37</strike></font><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">38</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.10</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Computation of Interest and Fees; Usury</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>37</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">38</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.11</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Pro Rata Treatment and Payments</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>38</strike></font><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">39</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.12</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Non-Receipt of Funds by the Administrative Agent</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">40</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.13</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Alternate Rate of Interest</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">41</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.14</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Yield Protection</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>41</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">42</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.15</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Indemnity</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">43</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.16</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Taxes</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>43</strike></font><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">44</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.17</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Indemnification; Nature of Issuing Lenders&#8217; Duties</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>45</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">46</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.18</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Illegality</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>46</strike></font><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">47</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.19</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Replacement of Lenders</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">47</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.20</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Cash Collateral</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>47</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">48</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.21</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Defaulting Lenders</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">48</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">49</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 2.22</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Incremental Facilities</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>50</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">51</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE III</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">REPRESENTATIONS AND WARRANTIES</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: middle; width: 70%;">&nbsp;</td>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.1</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial Condition</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">52</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.2</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">No Material Adverse Effect</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">52</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">53</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.3</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Corporate Existence; Compliance with Law</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>52</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">53</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.4</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Corporate Power; Authorization; Enforceable Obligations</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">53</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.5</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">No Legal Bar; No Default</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>53</strike></font><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">54</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.6</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">No Material Litigation</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">53</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">54</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.7</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Investment Company Act; etc.</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">53</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">54</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.8</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Margin Regulations</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">54</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.9</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ERISA</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">54</p> </td> </tr> </table> <p style="margin: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-i-</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.10</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Environmental Matters</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>54</strike></font><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">55</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.11</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Use of Proceeds</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>55</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">56</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.12</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Subsidiaries; Joint Ventures; Partnerships</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">55</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">56</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.13</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Ownership</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>55</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">56</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.14</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Taxes</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">56</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.15</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Solvency</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>56</strike></font><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">57</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.16</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">No Burdensome Restrictions</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">56</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">57</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.17</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Brokers&#8217; Fees</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>56</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">57</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.18</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Labor Matters</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">56</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">57</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.19</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Accuracy and Completeness of Information</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">57</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.20</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Material Contracts</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>57</strike></font><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">58</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.21</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Insurance</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">57</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">58</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.22</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Intellectual Property Matters</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>57</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">58</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.23</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Classification of Senior Indebtedness</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">57</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">58</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.24</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Anti-Corruption Laws and Sanctions</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">58</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.25</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Consent; Governmental Authorizations</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">58</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.26</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Healthcare Representations and Warranties</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>58</strike></font><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">59</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.27</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Security Interests</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">60</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.28</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">EEA Financial Institutions</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">60</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 3.29</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ERISA</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">60</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: middle; width: 70%;">&nbsp;</td>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE IV</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">CONDITIONS PRECEDENT</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: middle; width: 70%;">&nbsp;</td>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 4.1</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Conditions to Closing Date and Initial Revolving Loans</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">60</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 4.2</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Conditions to All Extensions of Credit</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">63</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: middle; width: 70%;">&nbsp;</td>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE V</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">AFFIRMATIVE COVENANTS</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: middle; width: 70%;">&nbsp;</td>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 5.1</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial Statements</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">64</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 5.2</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Certificates; Other Information</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>64</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">65</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 5.3</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Payment of Taxes and Other Obligations</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">65</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">66</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 5.4</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Conduct of Business and Maintenance of Existence</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">66</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 5.5</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Maintenance of Property; Insurance</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>66</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">67</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 5.6</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Books and Records</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">67</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 5.7</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Notices</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">67</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 5.8</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Environmental Laws</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">68</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 5.9</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial Covenants</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">68</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">69</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 5.10</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Additional Guarantors</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">69</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">70</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 5.11</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Compliance with Law</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">70</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 5.12</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Further Assurances</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">70</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 5.13</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Collateral Matters</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">71</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">Section 5.14</u></font></p>
</td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">Consolidated Cash
Balance</u></font></p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">72</u></font></p> </td>
</tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE VI</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">NEGATIVE COVENANTS</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 6.1</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Indebtedness</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>71</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">72</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 6.2</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Liens</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">72</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">73</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 6.3</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Nature of Business</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>72</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">73</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 6.4</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Consolidation, Merger, Sale or Purchase of Assets, etc.</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">73</p> </td> </tr> </table> <p style="margin: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-ii-</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 6.5</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Investments and Acquisitions</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>74</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">75</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 6.6</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Transactions with Affiliates</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">74</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">75</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 6.7</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Ownership of Subsidiaries; Restrictions</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">75</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 6.8</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Corporate Changes; Material Contracts</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">75</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 6.9</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Limitation on Restricted Actions</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>75</strike></font><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">76</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 6.10</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Restricted Payments</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">76</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 6.11</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Amendment of Subordinated Debt</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">76</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">77</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 6.12</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">No Further Negative Pledges</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>76</strike></font><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">77</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 6.13</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Restrictions Regarding PMG</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">77</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 6.14</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Use of Proceeds and Letters of Credit</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">77</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE VII</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">EVENTS OF DEFAULT</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 7.1</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Events of Default</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>77</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">78</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 7.2</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Acceleration; Remedies</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">80</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">81</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: middle; width: 70%;">&nbsp;</td>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE VIII</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">THE ADMINISTRATIVE AGENT</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: middle; width: 70%;">&nbsp;</td>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:0pt;">Section 8.1</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Appointment and Authority</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">80</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">81</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:0pt;">Section 8.2</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Nature of Duties</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">81</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:0pt;">Section 8.3</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exculpatory Provisions</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>81</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">82</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:0pt;">Section 8.4</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Reliance by Administrative Agent</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">82</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:0pt;">Section 8.5</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Notice of Default</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">82</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">83</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:0pt;">Section 8.6</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Non-Reliance on Administrative Agent and Other Lenders</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>82</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">83</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:0pt;">Section 8.7</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Indemnification</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">83</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:0pt;">Section 8.8</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Administrative Agent in Its Individual Capacity</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">83</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:0pt;">Section 8.9</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Successor Administrative Agent</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>83</strike></font><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">84</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:0pt;">Section 8.10</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Guaranty Matters</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">84</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">85</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:0pt;">Section 8.11</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Bank Products</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>84</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">85</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:0pt;">Section 8.12</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Withholding Tax</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">85</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE IX</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">MISCELLANEOUS</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.1</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Amendments and Waivers</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>85</strike></font><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">86</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.2</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Notices</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">87</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">88</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.3</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">No Waiver; Cumulative Remedies</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">89</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.4</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Survival of Representations and Warranties</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">89</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.5</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Payment of Expenses; Indemnity</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>89</strike></font><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">90</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.6</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Successors and Assigns; Participations</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">91</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.7</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Right of Setoff; Sharing of Payments</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>93</strike></font><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">94</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.8</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Table of Contents and Section Headings</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">94</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">95</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.9</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Counterparts; Integration; Effectiveness; Electronic Execution</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>94</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">95</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.10</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Severability</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">95</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">96</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.11</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Integration</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>95</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">96</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.12</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Governing Law</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">95</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">96</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.13</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Consent to Jurisdiction; Service of Process and Venue</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>95</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">96</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.14</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Confidentiality</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">96</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.15</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Acknowledgments</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">97</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.16</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Waivers of Jury Trial</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">97</p> </td> </tr> </table> <p style="margin: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-iii-</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.17</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Patriot Act Notice</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>97</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">98</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.18</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Resolution of Drafting Ambiguities</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">97</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">98</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.19</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Continuing Agreement</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>97</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">98</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.20</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Lender Consent</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">98</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.21</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Press Releases and Related Matters</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">98</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.22</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Appointment of Borrower</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>98</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">99</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.23</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Certain Waivers, Subordinations and Consents</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">98</font></strike><u style="border-bottom:#000000 thin double;"><font
style="color:#0000ff;">99</font></u></p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.24</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">No Advisory or Fiduciary Responsibility</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>99</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">100</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.25</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">[Reserved]</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">100</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.26</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Release of Liens and Guarantees</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">100</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.27</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Acknowledgement and Consent of Bail-In of EEA Financial Institutions</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">100</font></strike><u style="border-bottom:#000000 thin double;"><font style="color:#0000ff;">101</font></u></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.28</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Certain ERISA Matters</p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">101</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">Section 9.29</u></font></p>
</td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">Acknowledgement Regarding
Any Supported QFCs</u></font></p> </td>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">103</u></font></p> </td>
</tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: middle; width: 70%;">&nbsp;</td>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE X</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td colspan="3" style="vertical-align: middle; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">GUARANTY</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 15%;">&nbsp;</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 10.1</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Guaranty</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">102</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">103</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 10.2</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Bankruptcy</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>102</strike></font><u style="border-bottom:#000000 thin double;"><font style="color:#0000ff;">104</font></u></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 10.3</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Nature of Liability</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">103</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">104</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 10.4</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Independent Obligation</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>103</strike></font><u style="border-bottom:#000000 thin double;"><font style="color:#0000ff;">104</font></u></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 10.5</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Authorization</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>103</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">104</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 10.6</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Reliance</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>103</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">105</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 10.7</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Waiver</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">103</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">105</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 10.8</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Limitation on Enforcement</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>104</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">106</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 10.9</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Confirmation of Payment</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>104</strike></font><u style="border-bottom:#000000 thin double;"><font style="color:#0000ff;">106</font></u></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 10.10</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Agreements for Contribution</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><font style="color:#ff0000;"><strike>105</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">106</u></font></p>
</td> </tr>
<tr>
<td style="vertical-align: middle; width: 15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 10.11</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Keepwell</p> </td>
<td style="vertical-align: middle; width: 15%;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><strike><font style="color:#ff0000;">105</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">106</u></font></p>
</td> </tr> </table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u><b>Schedules</b></u></p> </td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Schedule 1.1(a)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Investments</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Schedule 1.1(b)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Liens</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Schedule 1.1(c)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Existing Letters of Credit</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Schedule 2.1(a)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Commitment Percentages</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Schedule 3.12</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Subsidiaries</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Schedule 3.18</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Labor Matters</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Schedule 3.21</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Insurance</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Schedule 5.12(e)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Post-Closing Deliveries</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Schedule 6.1(b)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Indebtedness</p> </td> </tr>
<tr>
<td style="vertical-align: bottom; width: 30%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:0pt;"><u><b>Exhibits</b></u></p> </td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;">&nbsp;</td>
<td style="vertical-align: bottom; width: 70%;">&nbsp;</td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit 1.1(a)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Account Designation Notice</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit 1.1(b)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Assignment and Assumption</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit 1.1(c)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Joinder Agreement</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit 1.1(d)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Notice of Borrowing</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit 1.1(e)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Notice of Conversion/Extension</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit 1.1(f)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Permitted Acquisition Certificate</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit 2.1(a)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Funding Indemnity Letter</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit 2.1(e)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Revolving Note</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit 2.16(f)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Forms of United States Tax Compliance Certificate</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit 4.1(a)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Lender Consent</p> </td> </tr> </table> <p style="margin: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-iv-</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width:99%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit 4.1(b)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Officer&#8217;s Certificate</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit 4.1(e)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Solvency Certificate</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit 4.1(n)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Financial Condition Certificate</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit 4.1(o)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Patriot Act Certificate</p> </td> </tr>
<tr>
<td style="vertical-align: middle; width: 30%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit 5.2(b)</p> </td>
<td style="vertical-align: middle; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Officer&#8217;s Compliance Certificate</p> </td> </tr> </table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-v-</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>THIS CREDIT AGREEMENT</b>, dated as of October 30, 2017, is by and among <b>MEDNAX, INC.</b>, a Florida corporation (the
&#8220;<u>Borrower</u>&#8221;), the Guarantors (as hereinafter defined), the Lenders (as hereinafter defined) and <b>JPMORGAN CHASE BANK, N.A.</b>, as administrative agent for the Lenders hereunder (in such capacity, the &#8220;<u>Administrative
Agent</u>&#8221;).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>ARTICLE I<br> <br> DEFINITIONS</b></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><u><b>Defined Terms</b></u>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">As used in this Agreement, terms defined in the preamble to this Agreement have the meanings therein indicated, and the following
terms have the following meanings:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Account Designation Notice</u>&#8221; shall mean the Account Designation Notice dated as of the Closing Date from the
Borrower to the Administrative Agent in substantially the form attached hereto as <u>Exhibit 1.1(a)</u>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Additional Credit Party</u>&#8221; shall mean each Person that becomes a Guarantor by execution of a Joinder Agreement in
accordance with Section 5.10.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Administrative Agent</u>&#8221; or &#8220;<u>Agent</u>&#8221; shall have the meaning set forth in the first paragraph of
this Agreement and shall include any successors in such capacity.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Administrative Questionnaire</u>&#8221; shall mean an Administrative Questionnaire in a form supplied by the Administrative
Agent.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Affiliate</u>&#8221; shall mean, with respect to a specified Person, another Person that directly, or indirectly through one
or more intermediaries, Controls or is Controlled by, or is under common Control with, the Person specified.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Agent Parties</u>&#8221; shall have the meaning set forth in Section 9.2(d)(ii).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Agreement</u>&#8221; or &#8220;<u>Credit Agreement</u>&#8221; shall mean this Agreement, as amended, modified, extended,
restated, replaced, or supplemented from time to time in accordance with its terms.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Alternate Base Rate</u>&#8221; shall mean, for any day, a rate per annum equal to the greatest of (a) the Prime Rate in
effect on such day, (b) the Federal Funds Effective Rate in effect on such day <u>plus</u> 1/2 of 1% and (c) the sum of (i) LIBOR (as determined pursuant to the definition of LIBOR), for an Interest Period of one (1) month commencing on such day
<u>plus</u> (ii) 1.00%, in each instance as of such date of determination. If for any reason the Administrative Agent shall have determined (which determination shall be conclusive in the absence of manifest error) that it is unable to ascertain the
Federal Funds Effective Rate, for any reason, including the inability or failure of the Administrative Agent to obtain sufficient quotations in accordance with the terms set forth in the definition of Federal Funds Effective Rate, the Alternate Base
Rate shall be determined without regard to clause (b) of the first sentence of this definition, as appropriate, until the circumstances giving rise to such inability no longer exist. Any change in the Alternate Base Rate due to a change in any of
the foregoing will become effective on the date of such change in the Federal Funds Rate, the Prime Rate or LIBOR for an Interest Period of one (1) month. Notwithstanding anything contained herein to the contrary, to the extent that the provisions
of Section 2.13 shall be in effect in determining LIBOR pursuant to clause (c) hereof, the Alternate Base Rate shall be the greater of (i) the Prime Rate in effect on such day and (ii) the Federal Funds Effective Rate in effect on such day
<u>plus</u> 1/2 of 1%. For the avoidance of doubt, if the Alternate Base Rate shall be less than zero, such rate shall be deemed to be zero for purposes of this Agreement.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Alternate Base Rate Loans</u>&#8221; shall mean Loans that bear interest at an interest rate based on the Alternate Base
Rate.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Amendment Lead Arranger</u>&#8221; shall have the meaning set forth in Amendment No. 1.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Amendment No. 1</u>&#8221; means Amendment No. 1 to this Agreement dated as of November 21, 2018.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Amendment No. 1 Effective Date</u>&#8221; means November 21, 2018.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Amendment No. 2</u>&#8221; means Amendment No. 2 to this Agreement dated as of March 28, 2019.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Amendment No. 2 Effective Date</u>&#8221; means March 28, 2019.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Amendment No. 2 Lead Arranger</u>&#8221; shall have the meaning set forth in Amendment No. 2.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><font
style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">&#8220;Amendment No. 3&#8221; means Amendment No. 3 to this Agreement dated as of March 25, 2020.</u></font></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><font
style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">&#8220;Amendment No. 3 Effective Date&#8221; means March 25, 2020.</u></font></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><font
style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">&#8220;Amendment No. 3 Lead Arranger&#8221; shall have the meaning set forth in Amendment No. 3.</u></font></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Anti-Corruption Laws</u>&#8221; means all laws, rules, and regulations of any jurisdiction applicable to the Borrower or its
Subsidiaries from time to time concerning or relating to bribery or corruption.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Applicable Margin</u>&#8221; shall mean, for any day, with respect to Revolving Loans and Unused Commitment Fees, the rate
per annum set forth below opposite the applicable level then in effect (based on the Consolidated Net Leverage Ratio), it being understood that the Applicable Margin for (a) Revolving Loans that are Alternate Base Rate Loans shall be the percentage
set forth under the column &#8220;Alternate Base Rate Margin,&#8221; (b) Revolving Loans that are LIBOR Rate Loans shall be the percentage set forth under the column &#8220;LIBOR Margin &amp; L/C Fee,&#8221; (c) the Letter of Credit Fee shall be the
percentage set forth under the column &#8220;LIBOR Margin &amp; L/C Fee,&#8221; and (d) the Unused Commitment Fee shall be the percentage set forth under the column &#8220;Unused Commitment Fee&#8221;:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
<tr>
<td colspan="5" style="vertical-align: top; border-width: thin; border-style: solid; border-color: rgb(0, 0, 0); width: 100%; padding: 0px; background-color: rgb(0, 0, 255);">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="color:#ffffff;">Applicable Margin</font></p> </td> </tr>
<tr>
<td style="vertical-align: middle; border-bottom: 1px solid rgb(0, 0, 0); width: 10.5%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level</p> </td>
<td style="vertical-align: middle; border-bottom: 1px solid rgb(0, 0, 0); width: 19.8%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Consolidated Net<br>
Leverage Ratio</p> </td>
<td style="vertical-align: middle; border-bottom: 1px solid rgb(0, 0, 0); width: 22.6%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">LIBOR Margin<br>
&amp; L/C Fee</p> </td>
<td style="vertical-align: middle; border-bottom: 1px solid rgb(0, 0, 0); width: 23.5%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Alternate Base
Rate<br> Margin</p> </td>
<td style="vertical-align: middle; border-bottom: 1px solid rgb(0, 0, 0); width: 23.5%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Unused<br> Commitment
Fee</p> </td> </tr>
<tr>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 10.5%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">I</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 19.8%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&gt; 3.50 to 1.0</p>
</td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 22.6%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">1.750%</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 23.5%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">0.750%</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 23.5%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">0.200%</p> </td> </tr>
<tr>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 10.5%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">II</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 19.8%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><u>&lt;</u> 3.50 to
1.0</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">and</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&gt; 2.75 to 1.0</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 22.6%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">1.500%</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 23.5%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">0.500%</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 23.5%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">0.200%</p> </td> </tr>
<tr>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 10.5%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">III</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 19.8%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><u>&lt;</u> 2.75 to
1.0</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">and</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&gt; 2.00 to 1.0</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 22.6%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">1.375%</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 23.5%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">0.375%</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 23.5%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">0.150%</p> </td> </tr>
<tr>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 10.5%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">IV</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 19.8%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><u>&lt;</u> 2.00 to
1.0</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">and</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&gt; 1.25 to 1.0</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 22.6%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">1.250%</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 23.5%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">0.250%</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 23.5%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">0.150%</p> </td> </tr>
<tr>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 10.5%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">V</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 19.8%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><u>&lt;</u> 1.25 to
1.0</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 22.6%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">1.125%</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 23.5%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">0.125%</p> </td>
<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 23.5%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">0.150%</p> </td> </tr>
</table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Applicable
Margin shall, in each case, be determined quarterly on the date five (5) Business Days after the date on which the Administrative Agent has received from the Borrower the quarterly financial information (in the case of the first three fiscal
quarters of the Borrower&#8217;s fiscal year), the annual financial information (in the case of the fourth fiscal quarter of the Borrower&#8217;s fiscal year) and the certifications required to be delivered to the Administrative Agent and the
Lenders in accordance with the provisions of Sections 5.1(a), 5.1(b) and 5.2(b) (each an &#8220;<u>Interest Determination Date</u>&#8221;). Such Applicable Margin shall be effective from such Interest Determination Date until the next such Interest
Determination Date. After the Closing Date, if the Credit Parties shall fail to provide the financial information or certifications in accordance with the provisions of Sections 5.1(a), 5.1(b) and 5.2(b), the Applicable Margin shall, on the date
five (5) Business Days after the date by which the Credit Parties</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">were
so required to provide such financial information or certifications to the Administrative Agent and the Lenders, be based on Level<b> </b>I<b> </b>until such time as such information or certifications or corrected information or corrected
certificates are provided, whereupon the Level shall be determined by the then current Consolidated Net Leverage Ratio. Notwithstanding the foregoing, the initial Applicable Margin shall be set at Level III until the financial information and
certificates required to be delivered pursuant to Section 5 for the period ending December 31, 2017 have been delivered to the Administrative Agent. In the event that any financial statement or certification delivered pursuant to Sections 5.1 or 5.2
is shown to be inaccurate (regardless of whether this Agreement or the Commitments are in effect when such inaccuracy is discovered), and such inaccuracy, if corrected, would have led to the application of a higher Applicable Margin for any period
(an &#8220;<u>Applicable Period</u>&#8221;) than the Applicable Margin applied for such Applicable Period, the Borrower shall promptly (a) deliver to the Administrative Agent a corrected compliance certificate for such Applicable Period, (b)
determine the Applicable Margin for such Applicable Period based upon the corrected compliance certificate, and (c) promptly pay to the Administrative Agent for the benefit of the Lenders the accrued additional interest and other fees owing as a
result of such increased Applicable Margin for such Applicable Period, which payment shall be promptly distributed by the Administrative Agent to the Lenders entitled thereto. It is acknowledged and agreed that nothing contained herein shall limit
the rights of the Administrative Agent and the Lenders under the Credit Documents, including their rights under Sections 2.8 and 7.1.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Approved Bank</u>&#8221; shall have the meaning set forth in the definition of &#8220;Cash Equivalents.&#8221;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Approved Fund</u>&#8221; shall mean any Fund that is Controlled or managed by (a) a Lender, (b) an Affiliate of a Lender or
(c) an entity or an Affiliate of an entity that Controls or manages a Lender.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Arrangers</u>&#8221; shall mean JPMCB, Wells Fargo Securities, LLC, Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated,
MUFG Bank, Ltd., SunTrust Robinson Humphrey, Inc., Mizuho Bank, Ltd. and Fifth Third Bank, the Amendment Lead Arranger<font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">, the Amendment No. 2 Lead Arranger</u></font> and the
Amendment No. <font style="color:#ff0000;"><strike>2</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">3</u></font> Lead Arranger.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Assignment and Assumption</u>&#8221; shall mean an assignment and assumption entered into by a Lender and an Eligible
Assignee (with the consent of any party whose consent is required by Section 9.6), and accepted by the Administrative Agent, in substantially the form of <u>Exhibit 1.1(b)</u> or any other form (including electronic records generated by the use of
an electronic platform) approved by the Administrative Agent.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Bail-In Action</u>&#8221; means the exercise of any Write-Down and Conversion Powers by the applicable EEA Resolution
Authority in respect of any liability of an EEA Financial Institution.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Bail-In Legislation</u>&#8221; means, with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU
of the European Parliament and of the Council of the European Union, the implementing law for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Bank Product</u>&#8221; shall mean any of the following products, services or facilities extended to any Credit Party or any
Subsidiary by any Bank Product Provider: (a) Cash Management Services; (b) products under any Hedging Agreement (other than obligations with respect to any such Credit Party&#8217;s Hedging Agreements that constitute Excluded Swap Obligations solely
with respect to such Credit Party); and (c) commercial credit card, purchase card and merchant card services. Any Bank Product established from and after the time that the Lenders have received written notice from the Borrower or the Administrative
Agent that an Event of Default exists, until such Event of Default has been waived in accordance with Section 9.1, shall not be included as &#8220;Credit Party Obligations&#8221; for purposes of a distribution under Section 2.11(b).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Bank Product Debt</u>&#8221; shall mean the Indebtedness and other obligations of any Credit Party or Subsidiary relating to
Bank Products.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Bank Product Provider</u>&#8221; shall mean any Person that provides Bank Products to a Credit Party or any Subsidiary to
the extent that (a) such Person is a Lender, an Affiliate of a Lender or any other Person that was a Lender (or an Affiliate of a Lender) at the time it entered into the Bank Product but has ceased to be a Lender (or whose Affiliate has ceased to be
a Lender) under the Credit Agreement or (b) such Person is a Lender or an Affiliate of a Lender on the Closing Date and the Bank Product was entered into on or prior to the Closing Date (even if such Person ceases to be a Lender or such
Person&#8217;s Affiliate ceased to be a Lender).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Bankruptcy Code</u>&#8221; shall mean the Bankruptcy Code in Title 11 of the United States Code, as amended, modified,
succeeded or replaced from time to time.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Bankruptcy Event</u>&#8221; shall mean any of the events described in Section 7.1(f).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Beneficial Ownership Certification</u>&#8221; means a certification regarding beneficial ownership or control as required by
the Beneficial Ownership Regulation.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Beneficial Ownership Regulation</u>&#8221; means 31 C.F.R. &#167; 1010.230.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Benefit Plan</u>&#8221; means any of (a) an &#8220;employee benefit plan&#8221; (as defined in ERISA) that is subject to
Title I of ERISA, (b) a &#8220;plan&#8221; as defined in Section 4975 of the Code or (c) any Person whose assets include (for purposes of ERISA Section 3(42) or otherwise for purposes of Title I of ERISA or Section 4975 of the Code) the assets of
any such &#8220;employee benefit plan&#8221; or &#8220;plan&#8221;.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">&#8220;BHC Act Affiliate&#8221; of a party shall mean an
&#8220;affiliate&#8217; (as such term is defined under, and interpreted in accordance with, 12 U.S.C. 1841(k)) of such party.</u></font></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Borrower</u>&#8221; shall have the meaning set forth in the first paragraph of this Agreement.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Borrowing Date</u>&#8221; shall mean, in respect of any Loan, the date such Loan is made.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Business</u>&#8221; shall have the meaning set forth in Section 3.10.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Business Day</u>&#8221; shall mean any day other than a Saturday, Sunday or other day on which commercial banks in New York,
New York are authorized or required by law to close; <u>provided</u>, <u>however</u>, that when used in connection with a rate determination, borrowing or payment in respect of a LIBOR Rate Loan, the term &#8220;Business Day&#8221; shall also
exclude any day on which banks in London, England are not open for dealings in Dollar deposits in the London interbank market.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Capital Lease</u>&#8221; shall mean any lease of property, real or personal, the obligations with respect to which are
required to be capitalized on a balance sheet of the lessee in accordance with GAAP; <u>provided</u> that for purposes of calculating Indebtedness hereunder, and notwithstanding Section 1.3 hereof, the term &#8220;<u>Capital Lease</u>&#8221; shall
not include any Capital Lease that was classified as an Operating Lease on the Closing Date or would have been classified as an Operating Lease had such agreement been in effect on the Closing Date prior to a relevant change in law or change in GAAP
(from GAAP as in effect on the Closing Date) which has the effect of re-classifying such agreement as a Capital Lease.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Capital Lease Obligations</u>&#8221; shall mean the capitalized lease obligations, determined in accordance with GAAP,
relating to a Capital Lease.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Cash Collateralize</u>&#8221; shall mean to pledge and deposit with or deliver to the Administrative Agent, for the benefit
of the Issuing Lenders (as applicable) and the Lenders, as collateral for LOC Obligations or obligations of Lenders to fund participations in respect thereof (as the context may require), cash or deposit account balances or, if the applicable
Issuing Lender benefiting from such collateral shall agree in its sole discretion, other credit support, in each case pursuant to documentation in form and substance reasonably satisfactory to (a) the Administrative Agent and (b) such Issuing
Lender. &#8220;Cash Collateral&#8221; shall have a meaning correlative to the foregoing and shall include the proceeds of such cash collateral and other credit support.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Cash Equivalents</u>&#8221; shall mean (a) securities issued or directly and fully guaranteed or insured by the United
States of America or any agency or instrumentality thereof (<u>provided</u> that the full faith and credit of the United States of America is pledged in support thereof) having maturities of not more than twelve months from the</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">date
of acquisition (&#8220;<u>Government Obligations</u>&#8221;), (b) Dollar denominated time deposits, certificates of deposit, eurodollar time deposits and eurodollar certificates of deposit of (i) any domestic commercial bank of recognized standing
having capital and surplus in excess of $500,000,000, (ii) any U.S. branch or agency of a non-U.S. commercial bank of internationally recognized standing, having capital and surplus in excess of $500,000,000 or (iii) any bank whose short-term
commercial paper rating is at least A-2 or the equivalent thereof from S&amp;P or at least P-2 or the equivalent thereof from Moody&#8217;s (any such bank being an &#8220;<u>Approved Bank</u>&#8221;), in each case with maturities of not more than
three hundred sixty-four (364) days from the date of acquisition, (c) commercial paper and variable or fixed rate notes issued by any Approved Bank (or by the parent company thereof) or any variable rate notes issued by, or guaranteed by any
domestic corporation rated A-2 (or the equivalent thereof) or better by S&amp;P or P-2 (or the equivalent thereof) or better by Moody&#8217;s and maturing within six months of the date of acquisition, (d) repurchase agreements with a term of not
more than thirty (30) days with a bank or trust company (including a Lender) or a recognized securities broker dealer having capital and surplus in excess of $500,000,000 for direct obligations issued by or fully guaranteed by the United States of
America, (e) obligations of any state of the United States or any political subdivision thereof for the payment of the principal and redemption price of and interest on which there shall have been irrevocably deposited Government Obligations
maturing as to principal and interest at times and in amounts sufficient to provide such payment, (f) money market accounts subject to Rule 2a-7 of the Investment Company Act of 1940 (&#8220;<u>Rule 2a-7</u>&#8221;) which consist primarily of cash
and cash equivalents set forth in clauses (a) through (e) above and of which 95% shall at all times be comprised of First Tier Securities (as defined in Rule 2a-7) and any remaining amount shall at all times be comprised of Second Tier Securities
(as defined in Rule 2a-7) and (g) shares of any so-called &#8220;money market fund&#8221;; <u>provided</u> that such fund is registered under the Investment Company Act of 1940, has net assets of at least $500,000,000 and has an investment portfolio
with an average maturity of three hundred sixty-five (365) days or less.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Cash Management Services</u>&#8221; shall mean any services provided from time to time to any Credit Party or Subsidiary in
connection with operating, collections, payroll, trust, or other depository or disbursement accounts, including automatic clearinghouse, controlled disbursement, depository, electronic funds transfer, information reporting, lockbox, stop payment,
overdraft and/or wire transfer services and all other treasury and cash management services.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Change in Law</u>&#8221; shall mean the occurrence, after the date of this Agreement, of any of the following: (a) the
adoption or taking effect of any law, rule, regulation or treaty, (b) any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof by any Governmental Authority or (c) the making
or issuance of any request, rule, guideline or directive (whether or not having the force of law) by any Governmental Authority; <u>provided</u>, that notwithstanding anything herein to the contrary, (i) the Dodd-Frank Wall Street Reform and
Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (ii) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee
on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a &#8220;Change in Law,&#8221; regardless of the date
enacted, adopted or issued.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Change of Control</u>&#8221; shall mean at any time,<b> </b>the occurrence of any of the following events:(a) any
&#8220;person&#8221; or &#8220;group&#8221; (as such terms are used in Section 13(d) and 14(d) of the Exchange Act), is or becomes the &#8220;beneficial owner&#8221; (as defined in Rules 13d-3 and 13d-5 under the Exchange Act, except that a person
shall be deemed to have &#8220;beneficial ownership&#8221; of all securities that such person has the right to acquire, whether such right is exercisable immediately or only after the passage of time), directly or indirectly, of<b> </b>thirty-five
percent (35%)<b> </b>or more of the then outstanding Voting Stock of the Borrower; (b) during any period of 12 consecutive months, a majority of the members of the board of directors or other equivalent governing body of the Borrower shall cease to
be composed of individuals (i) who were members of that board or equivalent governing body on the first day of such period, (ii) whose election or nomination to that board or equivalent governing body was approved by individuals referred to in
clause (i) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body or (iii) whose election or nomination to that board or other equivalent governing body was approved by
individuals referred to in clauses (i) and (ii) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body; or (c) any Person or two or more Persons acting in concert shall have
entered into a contract or arrangement that, upon consummation thereof, would result in the occurrence of an event that would violate either (a) or (b) above.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Closing Date</u>&#8221; shall mean October 30, 2017.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>CMS</u>&#8221; shall mean the Centers for Medicare and Medicaid Services.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Code</u>&#8221; shall mean the Internal Revenue Code of 1986, as amended from time to time.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Collateral</u>&#8221; shall mean, (a) 100% of the Equity Interests of each Guarantor, (b) Equity Interests in any Foreign
Subsidiary or FSHCO up to but not in excess of 65% of the voting Equity Interests and 100% of the non-voting Equity Interests of such Foreign Subsidiary or FSHCO, as applicable and (c) all tangible and intangible personal property of any Credit
Party (including but not limited to accounts receivable, inventory, equipment, general intangibles (including contract rights), deposit and securities accounts, investment property, intellectual property, intercompany notes, instruments, chattel
paper and documents, letter of credit rights, commercial tort claims and proceeds of the foregoing), other than Excluded Assets.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Collateral Agreement</u>&#8221; shall mean an agreement among each of the Credit Parties and the Administrative Agent,
whereby the perfected first-priority security interests required by the definition of &#8220;Collateral Event&#8221; are granted to the Administrative Agent on behalf of each of the Lenders and Bank Product Providers.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Collateral Event</u>&#8221; shall mean the date, if any, upon which each of the following events has occurred (it being
understood that the decision whether or not to cause any of the following events to occur shall be within the Borrower&#8217;s sole discretion, but that no &#8220;Collateral Event&#8221; shall have occurred until all of the following are completed
or the completion thereof is waived by the Administrative Agent):</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Administrative Agent shall have received from each Credit Party, a counterpart of the Collateral
Agreement duly executed and delivered on behalf of such Credit Party, which Collateral Agreement, when taken together with the other requirements of this definition of &#8220;Collateral Event&#8221; shall grant first priority security interests in
favor of the Administrative Agent in all of the Collateral;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Administrative Agent for the benefit of the Lenders and Bank Product Providers shall have
received all certificates (if any) representing the Equity Interests pledged as Collateral, together with stock powers or other instruments of transfer with respect thereto endorsed in blank;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all Indebtedness having, in the case of each instance of Indebtedness, an aggregate principal amount
in excess of $5,000,000 (other than to the extent that a pledge of such promissory note or instrument would violate applicable law) that is owing to any Credit Party and evidenced by a promissory note or an instrument and constitutes Collateral
shall have been pledged pursuant to the Collateral Agreement, and the Administrative Agent shall have received all such promissory notes or instruments, together with note powers or other instruments of transfer with respect thereto endorsed in
blank;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Administrative Agent shall have received from each Credit Party, a counterpart of the Global
Intercompany Note, duly executed and delivered on behalf of such Credit Party;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except as contemplated by any Security Document or otherwise agreed by the Administrative Agent, all
documents and instruments, including Uniform Commercial Code financing statements and filings with the United States Copyright Office and the United States Patent and Trademark Office, and all other actions required by law or reasonably requested by
the Administrative Agent to be filed, registered or recorded to create the Liens intended to be created by the Security Documents (in each case, including any supplements thereto) and perfect such Liens to the extent required by, and with the
priority required by, the Security Documents, shall have been filed, registered or recorded or delivered to the Administrative Agent for filing, registration or the recording concurrently with, or promptly following, the execution and delivery of
each such Security Document and at all times thereafter (it being understood and agreed that (A) control agreements shall not be required with respect to any deposit accounts, securities accounts or commodities accounts and (B) no perfection actions
shall be required with respect to (x) commercial tort claims not exceeding $5,000,000, (y) motor vehicles and other assets subject to certificates of title, and (z) letter of credit rights, except to the extent constituting a support obligation for
other Collateral as to which perfection is accomplished solely by the filing of a Uniform Commercial Code financing statement or equivalent);</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Administrative Agent shall have received insurance certificates from the Borrower&#8217;s
insurance broker or other evidence reasonably satisfactory to it that all insurance required to be maintained pursuant to this Credit Agreement is in full force and effect and such certificates shall comply with the requirements set forth in this
Credit Agreement;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(g) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Administrative Agent shall (i) have received (A) searches of Uniform Commercial Code filings in
the jurisdiction of incorporation or formation, as applicable, of each Credit Party and each jurisdiction where any Collateral is located or where a filing would need to be made in order to perfect the Administrative Agent&#8217;s security interest
in the Collateral, copies of the financing statements on file in such jurisdictions and evidence that no Liens exist other than Permitted Liens and (B) tax lien and judgment searches and (ii) evidence of the release of Liens that are not Permitted
Liens;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(h) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Administrative Agent shall have received, for the benefit of the Lenders and Bank Product
Providers, an opinion or opinions (including, if relevant, local counsel opinions) of counsel for the Credit Parties, dated as of the date of the Collateral Event, and addressed to the Administrative Agent and the Lenders, in customary form and
substance reasonably acceptable to the Administrative Agent (which shall include opinions regarding the validity and perfection of the Liens granted in connection with the Collateral Event).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Commitment</u>&#8221; shall mean the Revolving Commitments, the LOC Commitment and any Incremental Commitment, individually
or collectively, as appropriate.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Commitment Letter</u>&#8221; shall mean the commitment letter agreement dated as of October 23, 2017, among the Borrower,
JPMCB, Wells Fargo Bank, National Association, Bank of America, N.A., SunTrust Bank, Mizuho Bank Ltd., Fifth Third Bank and the Arrangers.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Commitment Percentage</u>&#8221; shall mean the Revolving Commitment Percentage and any such other &#8220;Commitment
Percentage&#8221; determined pursuant to Section 2.22(d).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Commitment Period</u>&#8221; shall mean (a) with respect to Revolving Loans the period from and including the Closing Date
to but excluding the Maturity Date and (b) with respect to Letters of Credit, the period from and including the Closing Date to but excluding the date that is thirty (30) days prior to the Maturity Date.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Committed Funded Exposure</u>&#8221; shall mean, as to any Lender at any time, the aggregate principal amount at such time
of its outstanding Loans, LOC Obligations and Participation Interests at such time.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Commonly Controlled Entity</u>&#8221; shall mean an entity, whether or not incorporated, which is under common control with
the Borrower within the meaning of Section 4001(b)(1) of ERISA or is part of a group which includes the Borrower and which is treated as a single employer under Section 414(b) or 414(c) of the Code or, solely for purposes of Section 412 of the Code
to the extent required by such Section, Section 414(m) or 414(o) of the Code.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Communications</u>&#8221; shall mean, collectively, any notice, demand, communication, information, document or other
material provided by or on behalf of the Borrower pursuant to any Credit Document or the transactions contemplated therein which is distributed to the Administrative Agent, any Lender or any Issuing Lender by means of electronic communications
pursuant to Section 9.2, including through the Platform.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Consolidated</u>&#8221; shall mean, when used with reference to financial statements or financial statement items of the
Borrower and its Subsidiaries or any other Person, such statements or items on a consolidated basis in accordance with the consolidation principles of GAAP.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Consolidated Assets</u>&#8221; shall mean, as of any date of determination, the Consolidated assets of the Credit Parties
and their Subsidiaries at such date, as determined in accordance with GAAP.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><u style="border-bottom:#000000 thin double;"><font style="color:#0000ff;">&#8220;Consolidated Cash Balance&#8221; shall mean, at any
time, (a) the aggregate amount of cash and Cash Equivalents, in each case, held or owned by (either directly or indirectly), credited to the account of or would otherwise be required to be reflected as an asset on the balance sheet of the Borrower
and its Subsidiaries (other than PMG) less (b) the sum of (i) any cash or Cash Equivalents to pay working interest obligations, suspense payments, severance payments, severance taxes, payroll, payroll taxes, other taxes, employee wage and benefit
payments, deferred health payments, independent contractor payments and trust and fiduciary obligations or other obligations of the Borrower or any Subsidiary to third parties, and for which the Borrower or such Subsidiary has issued checks or has
initiated wires or ACH transfers (or, in the Borrower&#8217;s discretion, will issue checks or initiate wires or ACH transfers within five (5) business days), (ii) other amounts for which the Borrower or such Subsidiary has issued checks or has
initiated wires or ACH transfers but have not yet been subtracted from the balance in the relevant account of the Borrower or such Subsidiary, (iii) any cash or Cash Equivalents of the Borrower or any Subsidiaries constituting purchase price
deposits held in escrow pursuant to a binding and enforceable purchase and sale agreement with a third party containing customary provisions regarding the payment and refunding of such deposits or subject to a Permitted Lien in favor of such a third
party related to such purchase and sale agreement or similar arrangement and (iv) any cash or Cash Equivalents of the Borrower or any Subsidiaries subject to a Permitted Lien pursuant to clauses (f) and (g) of the definition thereof.</font></u></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Consolidated EBITDA</u>&#8221; shall mean, as of any date of determination for the four consecutive fiscal quarter period
ending on such date, without duplication, (a) Consolidated Net Income for such period plus (b) the sum of the following to the extent deducted in calculating Consolidated Net Income for such period: (i) Consolidated Interest Expense for such period,
(ii) tax expense (including, without limitation, any federal, state, local and foreign income and similar taxes) of the Credit Parties and their Subsidiaries for such period, (iii) depreciation and amortization expense of the Credit Parties and
their Subsidiaries for such period, (iv) non-cash expenses of the Borrower and its Subsidiaries related to the equity compensation of any current or former employee or director of the Borrower or any Subsidiary or pursuant to any equity compensation
plan of the Borrower, (v) other non-cash charges (excluding reserves for future cash charges) of the Credit Parties and their Subsidiaries for such period, (vi) actual fees and expenses incurred in connection with the transactions relating to this
Agreement during the period ending on the 30th day following the Closing Date, the Amendment No. 1 Effective Date<u style="border-bottom:#000000 thin double;"><font style="color:#0000ff;">, the Amendment No. 2 Effective Date</font></u> or the
Amendment No. <strike><font style="color:#ff0000;">2</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">3</u></font> Effective Date, as applicable, (vii) costs and expenses for pending or threatened
non-ordinary course litigation or disputes incurred during such period, (viii) the amount of all extraordinary, unusual or non-recurring losses, expenses or charges incurred during such period, and (ix) any costs, fees, charges, accruals and
reserves incurred during such period in connection with any integration, transition, facilities openings, vacant facilities, consolidations, relocations, closing, acquisitions, Permitted JV Investments and Dispositions, business optimization and
entry into new markets, including technology, systems and infrastructure design, upgrade and implementation costs, consulting fees, restructuring costs, severance and curtailments or modifications to pension or postretirement employee benefit plans,
plus (c) the amount of net cost savings, operating expense reductions and synergies projected by the Borrower (for the Borrower and/or its Subsidiaries) in good faith to be realized as a result of any transaction, restructuring initiative, cost
savings initiative or operational change (which cost savings, operating expense reductions or synergies shall be calculated on a pro forma basis as though such cost savings, operating expense reductions or synergies had been realized on the first
day of such period), net of the amount of actual benefits realized during such period from such transaction, initiative or change; provided that (A) such cost savings, operating expense reductions or synergies are reasonably identifiable and
factually supportable and (B) such actions have been taken or are to be taken within 18 months of the consummation of such transaction or the date of commencement of such initiative or change, as applicable, minus (d) federal, state, local and
foreign income tax credits of the Borrower and its Subsidiaries for such period minus (e) all non-cash items increasing Consolidated Net Income for such period minus (f) non-cash charges previously added back to Consolidated Net Income in
determining Consolidated EBITDA to the extent such non-cash charges have become cash charges during such period; provided that the amounts included under clauses (b)(vii), (b)(viii), (b)(ix) and (c) above shall not exceed 20% of Consolidated EBITDA
(prior to giving effect to the such clauses).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><u style="border-bottom:#000000 thin double;"><font style="color:#0000ff;">Notwithstanding anything to the contrary contained herein,
Consolidated EBITDA for each of (a) the fiscal quarter ended June 30, 2020 and (b) the fiscal quarter ended September 30, 2020, shall be deemed to be $139,217,000.</font></u></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Consolidated Funded Debt</u>&#8221; shall mean, as of any date of determination, Funded Debt of the Credit Parties and their
Subsidiaries<b> </b>on a Consolidated basis.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Consolidated Interest Expense</u>&#8221; shall mean, as of any date of determination for the four consecutive fiscal quarter
period ending on such date, all interest expense (excluding amortization of debt discount and premium, but including the interest component under Capital Leases and synthetic leases, tax retention operating leases, off-balance sheet loans and
similar off-balance sheet financing products) for such period of the Credit Parties and their Subsidiaries<b> </b>on a Consolidated basis.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Consolidated Net Leverage Ratio</u>&#8221; shall mean, as of the date of the last day of any fiscal quarter of the Borrower,
for the Credit Parties and their Subsidiaries<b> </b>on a Consolidated basis, the ratio of (a)(i) Consolidated Funded Debt of the Credit Parties and their Subsidiaries<b> </b>on such date minus (ii) the aggregate amount of unrestricted cash and Cash
Equivalents of the Credit Parties and their Subsidiaries on a Consolidated basis in each case as of such date, to (b) Consolidated EBITDA.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Consolidated Net Income</u>&#8221; shall mean, as of any date of determination for the four consecutive fiscal quarter
period ending on such date, for the Credit Parties and their Subsidiaries on a Consolidated basis, the net income of the Credit Parties and their Subsidiaries (excluding extraordinary gains, including the write-up of assets, but including
extraordinary losses) for that period, <u>minus</u> the income of any Subsidiary of the Borrower (including income of a Subsidiary of such Subsidiary attributed thereto) to the extent the payment of such income in the form of a Restricted Payment or
repayment of Indebtedness to the Borrower or to another Subsidiary not so restricted is not permitted on account of any provision of any organization document, Contractual Obligation or law applicable to such Subsidiary. Consolidated Net Income
shall exclude any income or loss attributable to a Permitted JV (other than dividends or distributions received in cash or Cash Equivalents from such Permitted JV by a Credit Party or Subsidiary (other than another Permitted JV)) to the extent the
financial results of such Permitted JV are not Consolidated with the financial results of the Borrower and its Subsidiaries.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Consolidated Total Assets</u>&#8221; shall mean, as of any date of determination, Consolidated Assets as set forth in the
Consolidated balance sheet of the Credit Parties and their Subsidiaries most recently delivered pursuant to S<u>ection 5.1(a)</u> or <u>(b)</u>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Contractual Obligation</u>&#8221; shall mean, as to any Person, any obligations or liabilities of such Person arising under
any provision of any security issued by such Person or of any contract, agreement, instrument or undertaking to which such Person is a party or by which it or any of its property is bound.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Control</u>&#8221; shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the
management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise. &#8220;<u>Controlling</u>&#8221; and &#8220;<u>Controlled</u>&#8221; have meanings correlative thereto.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Copyright Licenses</u>&#8221; shall mean any agreement, whether written or oral, providing for the grant by or to a Person
of any right under any Copyright.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Copyrights</u>&#8221; shall mean all copyrights in all Works, all registrations and recordings thereof, and all applications
in connection therewith, including, without limitation, registrations, recordings and applications in the United States Copyright Office or in any similar office or agency of the United States, any state thereof or any other country or any political
subdivision thereof, or otherwise and all renewals thereof.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><u style="border-bottom:#000000 thin double;"><font style="color:#0000ff;">&#8220;Covered Entity&#8221; shall mean any of the
following: (i) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R.
&#167; 47.3(b); or (iii) a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b).</font></u></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Credit Documents</u>&#8221; shall mean this Agreement, Amendment No. 1, Amendment No. 2,
<font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">Amendment No. 3,</u></font> each of the Notes, any Joinder Agreement, the Letters of Credit, the LOC Documents and the Security Documents, if any, and all other agreements,
documents, certificates and instruments delivered to the Administrative Agent or any Lender by any Credit Party in connection therewith (other than any agreement, document, certificate or instrument related to a Bank Product).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Credit Party</u>&#8221; shall mean any of the Borrower or the Guarantors.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Credit Party Obligations</u>&#8221; shall mean, without duplication, (a) the Obligations and (b) for purposes of the
Guaranty, the sharing thereof and/or payments from proceeds thereof, all Bank Product Debt.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Debtor Relief Laws</u>&#8221; shall mean the Bankruptcy Code and all other liquidation, conservatorship, bankruptcy,
assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws of the United States or other applicable jurisdictions from time to time in effect.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Default</u>&#8221; shall mean any of the events specified in Section 7.1, whether or not any requirement for the giving of
notice or the lapse of time, or both, or any other condition, has been satisfied.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Default Rate</u>&#8221; shall mean (a) when used with respect to the Loans, an interest rate equal to (i) for Alternate Base
Rate Loans (A) the Alternate Base Rate <u>plus</u> (B) the Applicable Margin, if any, applicable to Alternate Base Rate Loans <u>plus</u> (C) 2% per annum and (ii) for LIBOR Rate Loans, (A) the LIBOR Rate <u>plus</u> (B) the Applicable Margin
applicable to LIBOR Rate Loans <u>plus</u> (C) 2% per annum, (b) when used with respect to Letter of Credit Fees, a rate equal to the Applicable Margin <u>plus</u> 2% per annum and (c) when used with respect to any other fee, overdue interest or any
other Obligations or amount due hereunder, an interest rate equal to (A) the Alternate Base Rate <u>plus</u> (B) the Applicable Margin, if any, applicable to Alternate Base Rate Loans <u>plus</u> (C) 2% per annum.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><font
style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">&#8220;Default Right&#8221; shall have the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as
applicable.</u></font></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Defaulting Lender</u>&#8221; shall mean, subject to Section 2.21(b) any Lender that, (a) has failed to (i) fund all or any
portion of its Revolving Loans, Incremental Loans, or participations in LOC Obligations required to be funded by it hereunder within two (2) Business Days of the date such Loans were required to be funded hereunder unless such Lender notifies the
Administrative Agent and the Borrower in writing that such failure is the result of such Lender&#8217;s determination that one or more conditions precedent to funding (each of which conditions precedent, together with any applicable default, shall
be specifically identified in such writing) has not been satisfied, or (ii) pay to the Administrative Agent, the Issuing Lenders or any other Lender any other amount required to be paid by it hereunder (including in respect of its participation in
Letters of Credit) within two (2) Business Days of the date when due, (b) has notified the Borrower, the Administrative Agent or any Issuing Lender in writing that it does not intend to comply with its funding obligations hereunder, or has made a
public statement to that effect (unless such writing or public statement relates to such Lender&#8217;s obligation to fund a Loan hereunder and states that such position is based on such Lender&#8217;s determination that a condition precedent to
funding (which condition precedent, together with any applicable default, shall be specifically identified in such writing or public statement) cannot be satisfied), (c) has failed, within three (3) Business Days after written request by the
Administrative Agent or the Borrower, to confirm in writing to the Administrative Agent and the Borrower that it will comply with its prospective funding obligations hereunder (provided that such Lender shall cease to be a Defaulting Lender pursuant
to this clause (c) upon receipt of such written confirmation by the Administrative Agent and the Borrower), or (d) has, or has a direct or indirect parent company that has, (i) become the subject of a proceeding under any Debtor Relief Law, (ii) had
appointed for it a receiver, custodian, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business or assets, including the Federal Deposit Insurance
Corporation or any other state or federal regulatory authority acting in such a capacity or (iii) become the subject of a Bail-In Action; <u>provided</u> that a Lender shall not be a Defaulting Lender solely by virtue of the ownership or acquisition
of any equity interest in that Lender or any direct or indirect parent company thereof by a Governmental Authority so long as such ownership interest does not result in or provide such Lender with immunity from the jurisdiction of courts within the
United States or from the enforcement of judgments or writs of attachment on its assets or permit such Lender (or such Governmental Authority) to reject, repudiate, disavow or disaffirm any contracts or agreements made with such Lender. Any
determination by the Administrative Agent that a Lender is a Defaulting Lender under clauses (a) through (d) above shall be conclusive and binding absent manifest error, and such Lender shall be deemed to be a Defaulting Lender (subject to Section
2.21(b)) upon delivery of written notice of such determination to the Borrower, each Issuing Lender and each Lender.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Disposition</u>&#8221; shall have the meaning set forth in Section 6.4(a).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Dividing Person</u>&#8221; has the meaning assigned to it in the definition of &#8220;Division&#8221;.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Division</u>&#8221; means the division of the assets, liabilities and/or obligations of a Person (the &#8220;Dividing
Person&#8221;) among two or more Persons (whether pursuant to a &#8220;plan of division&#8221; or similar arrangement), which may or may not include the Dividing Person and pursuant to which the Dividing Person may or may not survive.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Division Successor</u>&#8221; means any Person that, upon the consummation of a Division of a Dividing Person, holds all or
any portion of the assets, liabilities and/or obligations previously held by such Dividing Person immediately prior to the consummation of such Division. A Dividing Person which retains any of its assets, liabilities and/or obligations after a
Division shall be deemed a Division Successor upon the occurrence of such Division.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Dollars</u>&#8221; and &#8220;<u>$</u>&#8221; shall mean dollars in lawful currency of the United States of America.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Domestic Lending Office</u>&#8221; shall mean, initially, the office of each Lender designated as such Lender&#8217;s
Domestic Lending Office shown in such Lender&#8217;s Administrative Questionnaire; and thereafter, such other office of such Lender as such Lender may from time to time specify to the Administrative Agent and the Borrower as the office of such
Lender at which Alternate Base Rate Loans of such Lender are to be made.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Domestic Subsidiary</u>&#8221; shall mean any Subsidiary that is organized under the laws of the United States or any state
thereof or under the laws of the District of Columbia.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>EEA Financial Institution</u>&#8221; means (a) any institution established in any EEA Member Country which is subject to the
supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition, or (c) any institution established in an EEA Member Country which is a
subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>EEA Member Country</u>&#8221; means any of the member states of the European Union, Iceland, Liechtenstein, and Norway.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>EEA Resolution Authority</u>&#8221; means any public administrative authority or any Person entrusted with public
administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Eligible Assignee</u>&#8221; shall mean (a) a Lender, (b) an Affiliate of a Lender, (c) an Approved Fund and (d) any other
Person (other than a natural person) approved by (i) the Administrative Agent, (ii) in the case of any assignment of a Revolving Commitment, the Issuing Lenders and (iii) unless an Event of Default under <u>Section 7.1(a)</u> or <u>(f)</u> has
occurred and is continuing and so long as the Primary<b> </b>Syndication of the Loans has been completed as determined by JPMCB, the Borrower (each such approval not to be unreasonably withheld or delayed); <u>provided</u> that notwithstanding the
foregoing, &#8220;Eligible Assignee&#8221; shall not include (A) any Credit Party or any of the Credit Party&#8217;s Affiliates or Subsidiaries, (B) any Person holding Subordinated Debt of the Credit Parties or (C) any Defaulting Lender.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Environmental Laws</u>&#8221; shall mean any and all applicable foreign, federal, state, local or municipal laws, rules,
orders, regulations, statutes, ordinances, codes, decrees, requirements of any Governmental Authority or other Requirement of Law (including common law) regulating, relating to or imposing liability or standards of conduct concerning protection of
the environment, as now or may at any time be in effect during the term of this Agreement.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Equity Holder</u>&#8221; shall mean any Person that owns the Equity Interests in any Practice that is a party to any
Management Agreement.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Equity Interests</u>&#8221; shall mean (a) in the case of a corporation, capital stock, (b) in the case of an association or
business entity, any and all shares, interests, participations, rights or other equivalents (however designated) of capital stock, (c) in the case of a partnership, partnership interests (whether general, preferred or limited), (d) in the</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">case
of a limited liability company, membership interests and (e) any other interest or participation that confers or could confer on a Person the right to receive a share of the profits and losses of, or distributions of assets of, the issuing Person,
without limitation, options, warrants and any other &#8220;equity security&#8221; as defined in Rule 3a11-1 of the Exchange Act.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>ERISA</u>&#8221; shall mean the Employee Retirement Income Security Act of 1974, as amended from time to time.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>EU
Bail-in Legislation Schedule</u>&#8221; means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor Person), as in effect from time to time.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Eurodollar Reserve Percentage</u>&#8221; shall mean for any day, the percentage (expressed as a decimal and rounded upwards,
if necessary, to the next higher 1/100th of 1%) which is in effect for such day as prescribed by the Board of Governors of the Federal Reserve System (the &#8220;<u>Board</u>&#8221;) (or any successor) for determining the maximum reserve requirement
(including, without limitation, any basic, supplemental or emergency reserves) in respect of eurocurrency liabilities, as defined in Regulation D of the Board as in effect from time to time, or any similar category of liabilities for a member bank
of the Federal Reserve System in New York City.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Event of Default</u>&#8221; shall mean any of the events specified in Section 7.1; <u>provided</u>, <u>however</u>, that any
requirement for the giving of notice or the lapse of time, or both, or any other condition, has been satisfied.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Exchange Act</u>&#8221; shall mean the Securities Exchange Act of 1934, as amended.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Excluded Assets</u>&#8221; shall mean (i) any real property (including real property leasehold interests), (ii) any
governmental licenses or state or local franchises, charters or authorizations, to the extent a security interest in any such licenses, franchise, charter or authorization would be prohibited or restricted thereby (including any legally effective
prohibition or restriction), (iii) any assets the pledge of which, or the ownership of which by any Person other than a licensed physician, would be prohibited by applicable law, rule or regulation, (iv) margin stock, (v) any intent-to-use trademark
application prior to the filing of a &#8220;Statement of Use&#8221; or &#8220;Amendment to Allege Use&#8221; with respect thereto, (vi) any lease, license or other agreement or contract or any property subject to a purchase money security interest,
capital lease obligation or similar arrangement to the extent that a grant of a security interest therein would violate or invalidate such lease, license or agreement or contract or purchase money, capital lease or similar arrangement or create a
right of termination in favor of any other party thereto (other than the Borrower or any of its affiliates) after giving effect to the applicable anti-assignment provisions of the Uniform Commercial Code or other similar applicable law, other than
proceeds and receivables thereof, the assignment of which is expressly deemed effective under the Uniform Commercial Code or other similar applicable law notwithstanding such prohibition, (vii) Equity Interests in any Foreign Subsidiary or FSHCO
that would not qualify as &#8220;Collateral&#8221; under clause (b) of such definition and (viii) assets held by any Foreign Subsidiaries of the Borrower. The Collateral may also exclude those assets as to which the Administrative Agent and the
Borrower reasonably agree in writing that the cost of obtaining such a security interest or perfection thereof is excessive in relation to the benefit to the Lenders of the security to be afforded thereby.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Excluded Swap Obligation</u>&#8221; shall mean, with respect to any Guarantor, any obligation to pay or perform under any
agreement, contract, or transaction that constitutes a &#8220;swap&#8221; within the meaning of section 1a(47) of the Commodity Exchange Act (any such obligation, a &#8220;<u>Swap Obligation</u>&#8221;), if, and to the extent that, all or a portion
of the guarantee of such Guarantor pursuant to the Guarantee of, or the grant by such Guarantor of a security interest to secure, such Swap Obligation (or any guarantee pursuant to the Guarantee thereof) is or becomes illegal under the Commodity
Exchange Act or any rule, regulation, or order of the Commodity Futures Trading Commission (or the application or official interpretation of any thereof).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Excluded Taxes</u>&#8221; shall mean, with respect to the Administrative Agent, any Lender, any Issuing Lender or any other
recipient of any payment to be made by or on account of any obligation of the Borrower hereunder or under any other Credit Document, (a) taxes imposed on or measured by its net income (however denominated), and franchise taxes imposed on it (in lieu
of net income taxes), by any jurisdiction (or any political subdivision thereof) as a result of such recipient being organized under the laws of or having its principal office or, in the case of any Lender, an applicable lending office in the
jurisdiction imposing such Tax (or any political subdivision thereof) or as</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">a
result of any other present or former connection other than a connection resulting at least in part from this Agreement, any other Credit Document, or any actions related thereto, (b) any United States branch profits taxes, or any similar tax,
imposed by any jurisdiction described in (a), (c) any United States federal backup withholding tax imposed under Section 3406 of the Code, (d) in the case of a Foreign Lender (other than a Foreign Lender becoming a party hereto pursuant to the
Borrower&#8217;s request under Section 2.19), any United States federal withholding tax that is imposed on amounts payable to such Foreign Lender pursuant to a law in effect at the time such Foreign Lender becomes a party hereto (or designates a new
lending office), except to the extent that such Foreign Lender (or its assignor, if any) was entitled, immediately prior to the time of designation of a new lending office (or assignment), to receive additional amounts from the Borrower with respect
to such withholding tax pursuant to Section 2.16, (e) any withholding tax attributable to a Lender&#8217;s failure to comply with Section 2.16(e) or (f), and (f) any withholding tax to the extent imposed pursuant to FATCA.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Existing Credit Agreement</u>&#8221; means the Credit Agreement, dated as of October 29, 2014, as amended by Amendment No. 1
dated as of June 5, 2015 and as further amended or otherwise modified prior to the date hereof, among the Borrower, the guarantors party thereto, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Existing Lenders</u>&#8221; means the lenders party to the Existing Credit Agreement.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Existing Letter of Credit</u>&#8221; shall mean each of the letters of credit described by applicant, date of issuance,
letter of credit number, amount, beneficiary and the date of expiry on <u>Schedule 1.1(c)</u> hereto.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Extension of Credit</u>&#8221; shall mean, as to any Lender, the making of a Loan by such Lender, any conversion of a Loan
from one Type to another Type, any extension of any Loan or the issuance, extension or renewal of, or participation in, a Letter of Credit by such Lender.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Facility</u>&#8221; shall mean an Incremental Facility and/or the Revolving Facility, as appropriate.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>FATCA</u>&#8221; means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor
version that is substantively comparable and not materially more onerous to comply with or any agreements entered into pursuant to Section 1471(b)(1) of the Code) and any current or future regulations or official interpretations thereof.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Federal Funds Effective Rate</u>&#8221; means, for any day, the weighted average (rounded upwards, if necessary, to the next
1/100 of 1%) of the rates on overnight Federal funds transactions with members of the Federal Reserve System arranged by Federal funds brokers, as published on the next succeeding Business Day by the Federal Reserve Bank of New York, or, if such
rate is not so published for any day that is a Business Day, the average (rounded upwards, if necessary, to the next 1/100 of 1%) of the quotations for such day for such transactions received by the Administrative Agent from three Federal funds
brokers of nationally recognized standing selected by it; <u>provided</u>, that, if the Federal Funds Effective Rate shall be less than zero, such rate shall be deemed to be zero for purposes of this Agreement.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Fee Letters</u>&#8221; shall mean, collectively, (a) the fee letter agreement dated October 23, 2017, addressed to the
Borrower from JPMCB, as amended, modified, extended, restated, replaced, or supplemented from time to time and (b) any other fee letter entered into prior to the Closing Date with any Agent or Arranger relating to this Credit Agreement.</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Foreign
Lender</u>&#8221; shall mean any Lender that is not a &#8220;United States person&#8221; as defined in Section 7701(a)(30) of the Code.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Foreign Subsidiary</u>&#8221; shall mean any Subsidiary that is not a Domestic Subsidiary.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Fronting Exposure</u>&#8221; shall mean, at any time there is a Defaulting Lender, with respect to the Issuing Lenders, such
Defaulting Lender&#8217;s Commitment Percentage of the outstanding LOC Obligations with respect to Letters of Credit issued by the Issuing Lenders other than LOC Obligations as to which such Defaulting Lender&#8217;s participation obligation has
been reallocated to other Lenders or Cash Collateralized in accordance with the terms hereof.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>FSHCO</u>&#8221; shall mean any Domestic Subsidiary that owns no material assets other than the capital stock of one or more
Foreign Subsidiaries that are &#8220;controlled foreign corporations&#8221; within the meaning of Section 957 of the Code.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Fund</u>&#8221; shall mean any Person (other than a natural person) that is (or will be) engaged in making, purchasing,
holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Funded Debt</u>&#8221; shall mean, with respect to any Person, without duplication, all Indebtedness of such Person (other
than Indebtedness set forth in clauses (e) and (i) of such definition).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>GAAP</u>&#8221; shall mean generally accepted accounting principles in effect in the United States of America (or, in the
case of Foreign Subsidiaries with significant operations outside the United States of America, generally accepted accounting principles in effect from time to time in their respective jurisdictions of organization or formation) applied on a
consistent basis, <u>subject</u>, <u>however</u>, in the case of determination of compliance with the financial covenants set out in Section 5.9 to the provisions of Section 1.3.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Global Intercompany Note</u>&#8221; shall mean a promissory note, in form and substance satisfactory to the Administrative
Agent, evidencing all intercompany loans at any time owed by any Credit Party to the Borrower or any of its Subsidiaries, declaring such loans to be subordinate in all respects to the payment of the Obligations at any time owing to the Lenders.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Government Acts</u>&#8221; shall have the meaning set forth in Section 2.17(a).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Government Obligations</u>&#8221; shall have the meaning set forth in the definition of &#8220;Cash Equivalents.&#8221;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Government Reimbursement Program</u>&#8221; shall mean (to the extent that any Credit Party participates in one or more of
the following): (a) Medicare, the Federal Employees Health Benefit Program under 5 U.S.C. &#167;&#167; 8902 <i>et seq</i>., the TRICARE program established by the Department of Defense under 10 U.S.C. &#167;&#167; 1071 <i>et seq</i>. or the Civilian
Health and Medical Program of the Uniformed Services under 10 U.S.C. &#167;&#167; 1079 and 1086, (b) Medicaid or (c) any agent, administrator, intermediary or carrier for any of the foregoing.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Governmental Authority</u>&#8221; shall mean the government of the United States of America or any other nation, or of any
political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or
functions of or pertaining to government (including any supra-national bodies such as the European Union or the European Central Bank) and any group or body charged with setting financial accounting or regulatory capital rules or standards
(including, without limitation, the Financial Accounting Standards Board, the Bank for International Settlements or the Basel Committee on Banking Supervision or any successor or similar authority to any of the foregoing).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Guarantor</u>&#8221; shall mean the Domestic Subsidiaries of the Borrower as are, or may from time to time become parties to
this Agreement.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Guaranty</u>&#8221; shall mean the guaranty of the Guarantors set forth in <u>Article X</u>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Guaranty Obligations</u>&#8221; shall mean, with respect to any Person, without duplication, any obligations of such Person
(other than endorsements in the ordinary course of business of negotiable instruments for deposit or collection) guaranteeing or intended to guarantee any Indebtedness of any other Person in any manner, whether direct or indirect, and including,
without limitation, any obligation, whether or not contingent, (a) to purchase any such Indebtedness or any property constituting security therefor, (b) to advance or provide funds or other support for the payment or purchase of any such
Indebtedness or to maintain working capital, solvency or other balance sheet condition of such other Person</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">(including, without limitation, keep well agreements, maintenance agreements, comfort letters or similar agreements or arrangements)
for the benefit of any holder of Indebtedness of such other Person, (c) to lease or purchase property, securities or services primarily for the purpose of assuring the holder of such Indebtedness, or (d) to otherwise assure or hold harmless the
holder of such Indebtedness against loss in respect thereof. The amount of any Guaranty Obligation hereunder shall (subject to any limitations set forth therein) be deemed to be an amount equal to the outstanding principal amount (or maximum
principal amount, if larger) of the Indebtedness in respect of which such Guaranty Obligation is made.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Healthcare Laws</u>&#8221; shall mean, collectively, any and all federal, state or local laws, rules, regulations and to the
extent publicly available to providers, administrative manuals, orders, guidelines and requirements issued under or in connection with Medicare, Medicaid or any Government Reimbursement Program, or any law governing the licensure of or regulating
healthcare providers, professionals, facilities or payors or otherwise governing or regulating the provision of, or payment for, medical services, including, without limitation, the delivery of home healthcare services by the Credit Parties and any
other medical, nursing or other patient-related services now or hereafter provided by the Credit Parties. Healthcare Laws include, but are not limited to, HIPAA; 31 U.S.C. Section 3729, <i>et seq</i>.; 42 U.S.C. Section 1320a-7(b); and 42 U.S.C.
1395nn.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Hedging Agreements</u>&#8221; shall mean, with respect to any Person, any agreement entered into to protect such Person
against fluctuations in interest rates, or currency or raw materials values, including, without limitation, any interest rate swap, cap or collar agreement or similar arrangement between such Person and one or more counterparties, any foreign
currency exchange agreement, currency protection agreements, commodity purchase or option agreements or other interest or exchange rate hedging agreements.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>HIPAA</u>&#8221; shall mean the (a) Health Insurance Portability and Accountability Act of 1996; (b) the Health Information
Technology for Economic and Clinical Health Act (Title XIII of the American Recovery and Reinvestment Act of 2009); and (c) any state and local laws regulating the privacy and/or security of individually identifiable information, including state
laws providing for notification of breach of privacy or security of individually identifiable information, in each case with respect to the laws described in clauses (a), (b) and (c) of this definition, as the same may be amended, modified or
supplemented from time to time, any successor statutes thereto, any and all rules or regulations promulgated from time to time thereunder.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Holder Purchase Grant</u>&#8221; shall have the meaning set forth in Section 9.23(a).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Increased Revolver Commitment</u>&#8221; shall have the meaning set forth in Section 2.22(a).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Incremental Facility</u>&#8221; shall have the meaning set forth in Section 2.22(a).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Incremental Facility Commitment</u>&#8221; shall have the meaning set forth in Section 2.22(a).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Incremental Lender</u>&#8221; shall have the meaning set forth in Section 2.22(c).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Incremental Loans</u>&#8221; shall have the meaning set forth in Section 2.22(a).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Incremental Commitments</u>&#8221; shall have the meaning set forth in Section 2.22(a).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Indebtedness</u>&#8221; shall mean, with respect to any Person, without duplication, (a) all obligations of such Person for
borrowed money, (b) all obligations of such Person evidenced by bonds, debentures, notes or similar instruments, or upon which interest payments are customarily made, (c) all obligations of such Person under conditional sale or other title retention
agreements relating to property purchased by such Person (other than customary reservations or retentions of title under agreements with suppliers entered into in the ordinary course of business), (d) all obligations (including, without limitation,
earnout obligations) of such Person incurred, issued or assumed as the deferred purchase price of property or services purchased by such Person (other than trade debt incurred in the ordinary course of business and due within six months of the
incurrence thereof) which would appear as liabilities on a balance sheet of such Person, (e) all obligations of such Person under take-or-pay or similar arrangements or under commodities agreements, (f) all Indebtedness of others secured by (or for
which the holder of such Indebtedness has an existing right, contingent or</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">otherwise, to be secured by) any Lien on, or payable out of the proceeds of production from, property owned or acquired by such
Person, whether or not the obligations secured thereby have been assumed, (g) all Guaranty Obligations of such Person with respect to Indebtedness of another Person, (h) the principal portion of all Capital Lease Obligations <u>plus</u> any accrued
interest thereon, (i) the Swap Termination Value of all Hedging Agreements of such Person, (j) the maximum amount of all letters of credit issued or bankers&#8217; acceptances facilities created for the account of such Person and, without
duplication, all drafts drawn thereunder (to the extent unreimbursed), (k) all preferred Equity Interest issued by such Person and which by the terms thereof could be (at the request of the holders thereof or otherwise) subject to mandatory sinking
fund payments, redemption or other acceleration, (l) the principal balance outstanding under any synthetic lease, tax retention operating lease, off-balance sheet loan or similar off-balance sheet financing product <u>plus</u> any accrued interest
thereon and (m) all obligations of any partnership or unincorporated joint venture in which such Person is a general partner or a joint venturer to the extent such Indebtedness is recourse to such Person.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Indemnified Taxes</u>&#8221; shall mean all Taxes imposed on or with respect to any payment made by or on account of any
obligation of any Credit Party under any Credit Document, other than Excluded Taxes.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Indemnitee</u>&#8221; shall have the meaning set forth in Section 9.5(b).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Insolvency</u>&#8221; shall mean, with respect to any Multiemployer Plan, the condition that such Plan is insolvent within
the meaning of such term as used in Section 4245 of ERISA.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Intellectual Property</u>&#8221; shall mean, collectively, all Copyrights, Copyright Licenses, Patents, Patent Licenses,
Trademarks and Trademark Licenses of the Credit Parties and their Subsidiaries, all goodwill associated therewith and all rights to sue for infringement thereof.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Interest Coverage Ratio</u>&#8221; shall mean, as of the last day of any fiscal quarter of the Borrower, for the Credit
Parties and their Subsidiaries on a Consolidated basis, the ratio of (a) Consolidated EBITDA to (b) Consolidated Interest Expense paid or payable in cash during the four consecutive fiscal quarter period ending on such date.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Interest Determination Date</u>&#8221; shall have the meaning specified in the definition of &#8220;Applicable
Margin.&#8221;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Interest Payment Date</u>&#8221; shall mean (a) as to any Alternate Base Rate Loan, the last Business Day of each March,
June, September and December, (b) as to any LIBOR Rate Loan having an Interest Period of three months or less, the last day of such Interest Period, (c) as to any LIBOR Rate Loan having an Interest Period longer than three months, (i) each three (3)
month anniversary following the first day of such Interest Period and (ii) the last day of such Interest Period, (d) as to any Loan which is the subject of a mandatory prepayment required pursuant to Section 2.7(b), the date on which such mandatory
prepayment is due, and (e) as to any Loan then outstanding, on the Maturity Date; provided that the Amendment No. 2 Effective Date shall also constitute an Interest Payment Date with respect to Loans outstanding immediately prior to the Amendment
No. 2 Effective Date.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Interest Period</u>&#8221; shall mean, with respect to any LIBOR Rate Loan,</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;initially, the period commencing on the
Borrowing Date or conversion date, as the case may be, with respect to such LIBOR Rate Loan and ending one, two, three or six months thereafter, subject to availability to all applicable Lenders, as selected by the Borrower in the Notice of
Borrowing or Notice of Conversion given with respect thereto; and</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;thereafter, each period commencing on the
last day of the immediately preceding Interest Period applicable to such LIBOR Rate Loan and ending one, two, three or six months thereafter, subject to availability to all applicable Lenders, as selected by the Borrower by irrevocable notice to the
Administrative Agent not less than three (3) Business Days prior to the last day of the then current Interest Period with respect thereto; <u>provided</u> that the foregoing provisions are subject to the following:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:121.5pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if any Interest Period pertaining to a
LIBOR Rate Loan would otherwise end on a day that is not a Business Day, such Interest Period shall be extended to the next succeeding Business Day unless the result of such extension would be to carry such Interest Period into another calendar
month in which event such Interest Period shall end on the immediately preceding Business Day;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">16</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:121.5pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any Interest Period pertaining to a LIBOR
Rate Loan that begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of the relevant calendar
month;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:121.5pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if the Borrower shall fail to give
notice as provided above, the Borrower shall be deemed to have selected an Alternate Base Rate Loan to replace the affected LIBOR Rate Loan;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:121.5pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;no Interest Period in respect of any
Revolving Loans shall extend beyond the Maturity Date; and</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:121.5pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;no more than ten (10)<b> </b>LIBOR Rate
Loans may be in effect at any time. For purposes hereof, LIBOR Rate Loans with different Interest Periods shall be considered as separate LIBOR Rate Loans, even if they shall begin on the same date, although borrowings, extensions and conversions
may, in accordance with the provisions hereof, be combined at the end of existing Interest Periods to constitute a new LIBOR Rate Loan with a single Interest Period;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">provided
further, that the first Interest Period as of the Amendment No. 2 Effective Date shall be as set forth in Section 2.1 in Amendment No. 2.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Interpolated Rate</u>&#8221; means, at any time, for any Interest Period, the rate per annum (rounded to the same number of
decimal places as the LIBO Screen Rate) determined by the Administrative Agent (which determination shall be conclusive and binding absent manifest error) to be equal to the rate that results from interpolating on a linear basis between: (a) the
LIBO Screen Rate for the longest period for which the LIBO Screen Rate is available for Dollars) that is shorter than the Impacted Interest Period; and (b) the LIBO Screen Rate for the shortest period (for which that LIBO Screen Rate is available
for Dollars) that exceeds the Impacted Interest Period, in each case, at such time.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Investment</u>&#8221; shall mean (a) the acquisition (whether for cash, property, services, assumption of Indebtedness,
securities or otherwise) of shares of Equity Interest, other ownership interests or other securities of any Person or bonds, notes, debentures or all or substantially all of the assets of any Person (including pursuant to any merger with, or as a
Division Successor pursuant to the Division of, any Person that was not a wholly-owned Subsidiary prior to such merger or Division), (b) any deposit with, or advance, loan or other extension of credit to, any Person (other than deposits made in the
ordinary course of business) or (c) any other capital contribution to or investment in any Person, including, without limitation, any Guaranty Obligation (including any support for a letter of credit issued on behalf of such Person) incurred for the
benefit of such Person.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Issuing Lender</u>&#8221; shall mean, with respect to Letters of Credit, (a) each of JPMCB (including in its capacity as
issuing lender under any Existing Letter of Credit), Wells Fargo Bank, National Association (including in its capacity as issuing lender under any Existing Letter of Credit), Bank of America, N.A., MUFG Bank, Ltd., SunTrust Bank, Mizuho Bank, Ltd.,
Fifth Third Bank, BBVA Compass and PNC Bank, National Association together with any successor thereto and (b) each Successor Issuing Lender.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Issuing Lender Fees</u>&#8221; shall have the meaning set forth in Section 2.5(c).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Issuing Lender Sublimit</u>&#8221; shall mean, (a) with respect to each Issuing Lender as of the Amendment No. 2 Effective
Date, the LOC Committed Amount multiplied by 11.1111111%, as such amount may be modified pursuant to a Successor Issuing Lender Agreement and (b) with respect to any Successor Issuing Lender, such amount as specified in the applicable Successor
Issuing Lender Agreement.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Joinder Agreement</u>&#8221; shall mean a Joinder Agreement in substantially the form of <u>Exhibit 1.1(c)</u>, executed and
delivered by an Additional Credit Party in accordance with the provisions of Section 5.10.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">17</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Joint Commission</u>&#8221; shall mean<b> </b>the Joint Commission (formerly known as the Joint Commission on Accreditation
of Healthcare Organizations).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>JPMCB</u>&#8221; shall mean JPMorgan Chase Bank, N.A., together with its successors and/or assigns.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>JPMS</u>&#8221; shall mean J. P. Morgan Securities LLC, together with its successors and/or assigns.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Lender</u>&#8221; shall mean any of the several banks and other financial institutions as are, or may from time to time
become parties to this Agreement; <u>provided</u> that notwithstanding the foregoing, &#8220;Lender&#8221; shall not include any Credit Party or any of the Credit Party&#8217;s Affiliates or Subsidiaries.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Lender Consent</u>&#8221; shall mean any lender consent delivered by a Lender on the Closing Date in the form of <u>Exhibit
4.1(a)</u>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Letter of Credit</u>&#8221; shall mean (a) any letter of credit issued by any Issuing Lender pursuant to the terms hereof,
as such letter of credit may be amended, modified, restated, extended, renewed, increased, replaced or supplemented from time to time and (b) any Existing Letter of Credit, in each case as such letter of credit may be amended, modified, extended,
renewed or replaced from time to time.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Letter of Credit Facing Fee</u>&#8221; shall have the meaning set forth in Section 2.5(c).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Letter of Credit Fee</u>&#8221; shall have the meaning set forth in Section 2.5(b).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>LIBO Screen Rate</u>&#8221; shall have the meaning assigned to such term in the definition of LIBOR.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>LIBOR</u>&#8221; shall mean, for any LIBOR Rate Loan for any Interest Period therefor, the rate per annum (rounded upwards,
if necessary, to the nearest 1/100 of 1%) appearing on pages LIBOR01 or LIBOR02 of the Reuters screen (or any successor page) as the London interbank offered rate as administered by ICE Benchmark Association (or any other Person that takes over the
administration of such rate) for deposits in Dollars at approximately 11:00 a.m. (London time) two (2) Business Days prior to the first day of such Interest Period for a term comparable to such Interest Period; <u>provided</u> that if the rate per
annum appearing on pages LIBOR01 or LIBOR02 of the Reuters screen (or any successor page) shall be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement (such London interbank offered rate, the &#8220;<u>LIBO Screen
Rate</u>&#8221;). If for any reason such LIBO Screen Rate is not available at such time for such Interest Period (an &#8220;<u>Impacted Interest Period</u>&#8221;), then &#8220;LIBOR&#8221; for such Impacted Interest Period shall mean the
Interpolated Rate.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>LIBOR Lending Office</u>&#8221; shall mean, initially, the office(s) of each Lender designated as such Lender&#8217;s LIBOR
Lending Office in such Lender&#8217;s Administrative Questionnaire; and thereafter, such other office of such Lender as such Lender may from time to time specify to the Administrative Agent and the Borrower as the office of such Lender at which the
LIBOR Rate Loans of such Lender are to be made.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>LIBOR Rate</u>&#8221; shall mean, for any Interest Period, a rate per annum (rounded upwards, if necessary, to the next
higher 1/100th of 1%) determined by the Administrative Agent pursuant to the following formula:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">LIBOR Rate = &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
&nbsp; &nbsp; &nbsp; &nbsp;LIBOR&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp;</u></p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 108pt;">1.0 minus the Eurodollar Reserve Percentage</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>LIBOR Rate Loan</u>&#8221; shall mean Loans the rate of interest applicable to which is based on the LIBOR Rate.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>LIBOR Tranche</u>&#8221; shall mean the collective reference to LIBOR Rate Loans whose Interest Periods begin and end on the
same day.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">18</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Lien</u>&#8221; shall mean any mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien
(statutory or other), charge or other security interest or any preference, priority or other security agreement or preferential arrangement of any kind or nature whatsoever (including, without limitation, (a) any conditional sale or other title
retention agreement and any Capital Lease having substantially the same economic effect as any of the foregoing and (b) the filing of, or the agreement to give, any UCC financing statement).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>LLC</u>&#8221; means any Person that is a limited liability company under the laws of its jurisdiction of formation.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Loan</u>&#8221; or &#8220;<u>Loans</u>&#8221; shall mean a Revolving Loan and/or an Incremental Loan, as appropriate.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>LOC Commitment</u>&#8221; shall mean (a) with respect to each Issuing Lender&#8217;s commitment to issue Letters of Credit,
such Issuing Lender&#8217;s Issuing Lender Sublimit and (b) with respect to each Revolving Lender, the commitment of such Revolving Lender to purchase Participation Interests in the Letters of Credit up to such Revolving Lender&#8217;s Revolving
Commitment Percentage of the LOC Committed Amount.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>LOC Committed Amount</u>&#8221; shall have the meaning set forth in Section 2.3(a).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>LOC Documents</u>&#8221; shall mean, with respect to each Letter of Credit, such Letter of Credit, any amendments thereto,
any documents delivered in connection therewith, any application therefor, and any agreements, instruments, guarantees or other documents (whether general in application or applicable only to such Letter of Credit) governing or providing for (a) the
rights and obligations of the parties concerned or (b) any collateral for such obligations.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>LOC Obligations</u>&#8221; shall mean, at any time, the sum of (a) the maximum amount which is, or at any time thereafter
may become, available to be drawn under Letters of Credit then outstanding, assuming compliance with all requirements for drawings referred to in such Letters of Credit <u>plus</u> (b) the aggregate amount of all drawings under Letters of Credit
honored by the Issuing Lenders but not theretofore reimbursed. For purposes of computing the amount available to be drawn under any Letter of Credit, the amount of such Letter of Credit shall be determined in accordance with Section 1.6. For all
purposes of this Agreement, if on any date of determination a Letter of Credit has expired by its terms but any amount may still be drawn thereunder by reason of the operation of Rule 3.14 of the ISP, such Letter of Credit shall be deemed to be
&#8220;outstanding&#8221; in the amount so remaining available to be drawn.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Management Agreement</u>&#8221; shall mean each agreement pursuant to which a Manager agrees to provide certain
administrative services to a Practice.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Manager</u>&#8221; shall mean, with respect to any particular Management Agreement, the Borrower or its applicable
Subsidiary that is a party to such Management Agreement as the administrative manager of the relevant medical practice or practices.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Mandatory LOC Borrowing</u>&#8221; shall have the meaning set forth in Section 2.3(e).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Material Adverse Effect</u>&#8221; shall mean a material adverse effect on (a) the business, operations, property, assets or
financial condition of the Credit Parties and their Subsidiaries taken as a whole, (b) the ability of the Credit Parties and their Subsidiaries taken as a whole to perform their obligations, when such obligations are required to be performed, under
this Agreement, any of the Notes or any other Credit Document or (c) the validity or enforceability of this Agreement, any of the Notes, any Joinder Agreement, any of the Letters of Credit, the LOC Documents or the Security Documents (if any) or the
rights or remedies of the Administrative Agent or the Lenders hereunder or thereunder. The inclusion of any dollar amount threshold in any representation, warranty, covenant, notice provision, Default or Event of Default or any other provision of
this Agreement shall not be deemed to constitute a mutual agreement as to a standard that is determinative of whether a Material Adverse Effect exists or may exist.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Material Contract</u>&#8221; shall mean (a) any Management Agreement and any Restrictive Agreement and (b) any other
contract, agreement, permit or license, written or oral, of the Credit Parties or any of their Subsidiaries as to which the breach, nonperformance, cancellation or failure to renew by any party thereto, individually or in the aggregate, could
reasonably be expected to have a Material Adverse Effect.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">19</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Material Domestic Subsidiary</u>&#8221; shall mean any Domestic Subsidiary of the Borrower that, together with its
Subsidiaries, (a) generated more than 10% of the net revenues (whether denominated in the financial statements of the Credit Parties as net patient service revenues or similar nomenclature) of the Credit Parties on a Consolidated basis for the four
(4) fiscal quarter period most recently ended or (b) owns more than 10% of the Consolidated Assets as of the last day of the most recently ended fiscal quarter of the Borrower; <u>provided</u>, <u>however</u>, that if at any time there are Domestic
Subsidiaries which are not classified as &#8220;Material Domestic Subsidiaries&#8221; but which collectively (i) generated more than 20% of the net revenues (whether denominated in the financial statements of the Credit Parties as net patient
service revenues or similar nomenclature) of the Credit Parties on a Consolidated basis for the four (4) fiscal quarters most recently ended or (ii) own more than 20% of the Consolidated Assets as of the last day of the most recently ended fiscal
quarter of the Borrower, then the Borrower shall promptly, and in any event within thirty (30) days after the financial statements for such fiscal quarter become available, designate one or more of such Domestic Subsidiaries as Material Domestic
Subsidiaries and cause any such Domestic Subsidiaries to comply with the provisions of Section 5.10 such that, after such Domestic Subsidiaries become Guarantors hereunder, the Domestic Subsidiaries that are not Guarantors shall (iii) generate less
than 20% of the net revenues (whether denominated in the financial statements of the Credit Parties as net patient service revenues or similar nomenclature) of the Credit Parties and (iv) own less than 20% of the Consolidated Assets. For purposes of
determining whether or not any newly formed or acquired Subsidiary is a &#8220;Material Domestic Subsidiary,&#8221; the foregoing calculations shall be performed at the time of such acquisition or formation (including any asset contributions made to
such Subsidiary concurrently with such acquisition or formation) giving effect to such acquisition or formation (including any asset contributions made to such Subsidiary concurrently with such acquisition or formation) on a Pro Forma Basis as of
the last day of the most recently ended fiscal quarter of the Borrower. It is understood and agreed that in no event shall PMG be considered a Material Domestic Subsidiary.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Materials of Environmental Concern</u>&#8221; shall mean any gasoline or petroleum (including crude oil or any extraction
thereof) or petroleum products or any hazardous or toxic substances, materials or wastes, defined or regulated as such in or under any Environmental Law, including, without limitation, asbestos, perchlorate, polychlorinated biphenyls and
urea-formaldehyde insulation.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Maturity Date</u>&#8221; shall mean March 28, 2024; <u>provided</u>, <u>however</u>, if such date is not a Business Day, the
Maturity Date shall be the next preceding Business Day.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Medicaid</u>&#8221; means the medical assistance programs administered by state agencies and approved by CMS pursuant to the
terms of Title XIX of the Social Security Act, codified at 42 U.S.C. 1396 <i>et seq</i>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Medicare</u>&#8221; means the program of health benefits for the aged and disabled administered by CMS pursuant to the terms
of Title XVIII of the Social Security Act, codified at 42 U.S.C. 1395 <i>et seq</i>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Moody&#8217;s</u>&#8221; shall mean Moody&#8217;s Investors Service, Inc.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Multiemployer Plan</u>&#8221; shall mean a Plan that is a multiemployer plan as defined in Section 4001(a)(3) of ERISA.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Non-Consenting Lender</u>&#8221; shall mean any Lender (other than JPMCB) that does not approve any consent, waiver or
amendment that has been obtained as to one or more Lenders and that is not effective with respect to an affected Lender not approving such consent, waiver or amendment in accordance with the terms of Section 9.1.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Non-Defaulting Lender</u>&#8221; shall mean, at any time, each Lender that is not a Defaulting Lender at such time.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Note</u>&#8221; or &#8220;<u>Notes</u>&#8221; shall mean the Revolving Notes, collectively or individually, as
appropriate.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Notice of Borrowing</u>&#8221; shall mean a request for a Revolving Loan borrowing pursuant to Section 2.1(b)(i).. A Form of
Notice of Borrowing is attached as <u>Exhibit 1.1(d)</u>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">20</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Notice of Conversion/Extension</u>&#8221; shall mean the written notice of conversion of a LIBOR Rate Loan to an Alternate
Base Rate Loan or an Alternate Base Rate Loan to a LIBOR Rate Loan, or extension of a LIBOR Rate Loan, in each case substantially in the form of <u>Exhibit 1.1(e)</u>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Obligations</u>&#8221; shall mean, collectively, all of the obligations, Indebtedness and liabilities of the Credit Parties
to the Lenders (including the Issuing Lenders) and the Administrative Agent, whenever arising, under this Agreement, the Notes or any of the other Credit Documents, including principal, interest, fees, costs, charges, expenses, professional fees,
reimbursements, all sums chargeable to the Credit Parties or for which any Credit Party is liable as an indemnitor and whether or not evidenced by a note or other instrument and indemnification obligations and other amounts (including, but not
limited to, any interest accruing after the occurrence of a filing of a petition of bankruptcy under the Bankruptcy Code with respect to any Credit Party, regardless of whether such interest is an allowed claim under the Bankruptcy Code).
Obligations with respect to any Guarantor shall in no event include any Excluded Swap Obligations of such Guarantor.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Operating Lease</u>&#8221; shall mean, as to any Person as determined in accordance with GAAP, any lease of property
(whether real, personal or mixed) by such Person as lessee which is not a Capital Lease, or which is classified as an operating lease under the definition of &#8220;Capital Lease.&#8221;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Other Taxes</u>&#8221; shall mean all present or future stamp or documentary Taxes or any other excise or property Taxes,
charges or similar levies arising from any payment made hereunder or under any other Credit Document or from the execution, delivery or enforcement of, or otherwise with respect to, this Agreement or any other Credit Document.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Participant</u>&#8221; shall have the meaning assigned to such term in Section 9.6(d).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Participant Register</u>&#8221; shall have the meaning assigned to such term in Section 9.6(d).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Participation Interest</u>&#8221; shall mean a participation interest purchased by a Revolving Lender in LOC Obligations as
provided in Section 2.3(c).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Patent Licenses</u>&#8221; shall mean any agreement, whether written or oral, providing for the grant by or to a Person of
any right to manufacture, use or sell any invention covered by a Patent.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Patents</u>&#8221; shall mean (a) all letters patent of the United States or any other country, now existing or hereafter
arising, and all improvement patents, reissues, reexaminations, patents of additions, renewals and extensions thereof and (b) all applications for letters patent of the United States or any other country and all provisionals, divisions,
continuations and continuations-in-part and substitutes thereof.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Patriot Act</u>&#8221; shall mean Title III of The Uniting and Strengthening America by Providing Appropriate Tools Required
to Intercept and Obstruct Terrorism Act of 2001 (Title III of Pub. L. No. 107-56 (signed into law October 26, 2001)), as amended or modified from time to time.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>PBGC</u>&#8221; shall mean the Pension Benefit Guaranty Corporation established pursuant to Subtitle A of Title IV of
ERISA.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Permitted Acquisition</u>&#8221; shall mean an acquisition (other than a Division) or any series of related acquisitions by
a Credit Party of (a) all or substantially all of the assets or a majority of the outstanding Voting Stock or economic interests of a Person that is incorporated, formed or organized in the United States, (b) a Person that is incorporated, formed or
organized in the United States by a merger, amalgamation or consolidation or any other combination with such Person or (c) any division, line of business or other business unit of a Person that is incorporated, formed or organized in the United
States (such Person or such division, line of business or other business unit of such Person shall be referred to herein as the &#8220;<u>Target</u>&#8221;), in each case that is a type of business (or assets used in a type of business) permitted to
be engaged in by the Credit Parties and their Subsidiaries pursuant to Section 6.3, in each case so long as:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">21</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:85.5pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;no Default or Event of Default shall then
exist or would exist after giving effect thereto;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:85.5pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Credit Parties shall have furnished to
the Administrative Agent within fifteen (15) Business Days after the consummation of such acquisition (A) Consolidated pro forma financial statements of the Borrower (giving pro forma effect to all acquisitions made during the previous four fiscal
quarter period as if they had occurred on the first day of such period) as of the most recent date that financial statements have been furnished pursuant to Section 5.1(a) or (b) demonstrating that, after giving effect to the acquisition on a Pro
Forma Basis, the Credit Parties are in compliance with each of the financial covenants set forth in Section 5.9 <font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">(provided that for purposes of this clause (ii) the applicable
Consolidated Net Leverage Ratio shall be 4.50 to 1.00 for any fiscal quarter)</u></font> and (B) a certificate substantially in the form of <u>Exhibit 1.1(f)</u> executed by a Responsible Officer of the Borrower certifying that such Permitted
Acquisition complies with the requirements of this Agreement;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:85.5pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Target, if a Person, shall have
executed a Joinder Agreement to the extent required by the terms of Section 5.10 within the applicable time period specified in Section 5.10; and</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:85.5pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Target does not oppose such
acquisition (other than in the case of an acquisition pursuant to a Holder Purchase Grant).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Permitted Investments</u>&#8221; shall mean:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;cash and Cash Equivalents;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments existing as of the Closing Date
as set forth on <u>Schedule 1.1(a)</u>, and any renewals, refinancings or extensions thereof in a principal amount not in excess of that outstanding as of the date of such renewal, refinancing or extension;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;receivables owing to the Credit Parties or
any of their Subsidiaries or any receivables and advances to suppliers, in each case if created, acquired or made in the ordinary course of business and payable or dischargeable in accordance with customary trade terms;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments in and loans to any Credit
Party;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments in and loans to Subsidiaries of
Credit Parties (other than Credit Parties) and Permitted JV Investments in an aggregate amount not to exceed at any one time 15% of Consolidated total shareholders&#8217; equity as determined in accordance with GAAP and as set forth on the then most
recent Consolidated balance sheet of the Borrower<b> </b>and its Consolidated Subsidiaries furnished to the Administrative Agent pursuant to Section 5.1(for the avoidance of doubt, the calculation of the aggregate amount of all Permitted JV
Investments shall not include any accretion (or reduction) for equity in income (loss) in any Permitted JV to the extent the financial results of such Permitted JV are not Consolidated with the financial results of the Borrower and its Subsidiaries
except to the extent of dividends or distributions received in cash or Cash Equivalents from a Permitted JV by a Credit Party or Subsidiary (other than another Permitted JV));</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;loans and advances to employees;
<u>provided</u> that such loans and advances shall comply with all Requirements of Law (including Sarbanes-Oxley);</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments (including debt obligations)
received in connection with the bankruptcy or reorganization of suppliers and customers and in settlement of delinquent obligations of, and other disputes with, customers and suppliers arising in the ordinary course of business;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments, acquisitions or transactions
permitted under Section 6.4(a)(xiii) or Section 6.4(b) and Guaranty Obligations permitted under Section 6.1;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permitted Acquisitions;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">22</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hedging Agreements to the extent permitted
hereunder;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments by PMG in accordance with
applicable law and past practices; and</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments in PMG (in addition to
Investments in PMG outstanding on the Closing Date and set forth on Schedule 1.1(a)) in an aggregate principal amount outstanding at any time not to exceed the greater of (i) $500,000,000 and (ii) 10.0% of Consolidated Total Assets at such time;
and</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional loans, advances and/or Investments
of a nature not contemplated by the foregoing clauses hereof so long as after giving effect to each such additional loans, advances and/or Investments on a Pro Forma Basis the Consolidated Net Leverage Ratio of the Credit Parties would be in
compliance with Section 5.9(a) <font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">(provided that for purposes of this clause (m) the applicable Consolidated Net Leverage Ratio shall be 4.50 to 1.00 for any fiscal
quarter)</u></font>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Permitted JV</u>&#8221; shall mean a Person that is (a) not a wholly-owned Subsidiary of the Borrower and (b) a type of
business (or assets used in a type of business) permitted to be engaged in by the Credit Parties and their Subsidiaries pursuant to Section 6.3.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Permitted JV Investment</u>&#8221; shall mean an Investment after the Closing Date in a Permitted JV (other than an
Investment pursuant to clause (b) of the definition of Permitted Investment) so long as no Default or Event of Default shall then exist or would exist after giving effect thereto.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Permitted Liens</u>&#8221; shall mean:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens created by or otherwise existing under
or in connection with this Agreement or the other Credit Documents in favor of the Administrative Agent on behalf of the Lenders;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens in favor of a Bank Product Provider in
connection with a Bank Product; <u>provided</u> that such Liens shall secure the Credit Party Obligations on a ratable and pari passu basis;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens securing purchase money Indebtedness
and Capital Lease Obligations (and refinancings thereof) to the extent permitted under Section 6.1(c); <u>provided</u>, that (i) any such Lien attaches to such property concurrently with or within thirty (30) days after the acquisition thereof and
(ii) such Lien attaches solely to the property so acquired in such transaction;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens for taxes, assessments, charges or
other governmental levies not yet due or as to which the period of grace (not to exceed sixty (60) days), if any, related thereto has not expired or which are being contested in good faith by appropriate proceedings; <u>provided</u> that adequate
reserves with respect thereto are maintained on the books of any Credit Party or its Subsidiaries, as the case may be, in conformity with GAAP;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;statutory Liens such as carriers&#8217;,
warehousemen&#8217;s, mechanics&#8217;, materialmen&#8217;s, landlords&#8217;, repairmen&#8217;s or other like Liens arising in the ordinary course of business which are not overdue for a period of more than one hundred twenty (120) days or which
are being contested in good faith by appropriate proceedings;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pledges or deposits in connection with
workers&#8217; compensation, unemployment insurance and other social security legislation (other than any Lien imposed by ERISA) and deposits securing liability to insurance carriers under insurance or self-insurance arrangements in accordance with
historical practice and in the ordinary course of business;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;deposits to secure the performance of bids,
trade contracts (other than for borrowed money), leases, statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature incurred in the ordinary course of business;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">23</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;easements, rights of way, restrictions and
other similar encumbrances affecting real property which, in the aggregate, are not substantial in amount, and which do not in any case materially detract from the value of the property subject thereto or materially interfere with the ordinary
conduct of the business of the applicable Person;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens existing on the Closing Date and set
forth on <u>Schedule 1.1(b)</u>; <u>provided</u> that (i) no such Lien shall at any time be extended to cover property or assets other than the property or assets subject thereto on the Closing Date and subsequent improvements thereon, (ii) the
principal amount of the Indebtedness secured by such Lien shall not be extended, renewed, refunded or refinanced except as permitted by Section 6.1(b) and (iii) the direct or any contingent obligor with respect thereto is not changed;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any extension, renewal or replacement (or
successive extensions, renewals or replacements), in whole or in part, of any Lien referred to in this definition (other than Liens set forth on <u>Schedule 1.1(b)</u>); <u>provided</u> that such extension, renewal or replacement Lien shall be
limited to all or a part of the property which secured the Lien so extended, renewed or replaced (plus subsequent improvements on such property);</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens arising in the ordinary course of
business by virtue of any contractual, statutory or common law provision relating to (i) landlord&#8217;s Liens arising under leases of real property in the ordinary course of business and (ii) banker&#8217;s Liens, rights of set-off or similar
rights and remedies covering deposit or securities accounts (including funds or other assets credited thereto) or other funds maintained with a depository institution or securities intermediary;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any zoning, building or similar laws or
rights reserved to or vested in any Governmental Authority;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;restrictions on transfers of securities
imposed by applicable Securities Laws or laws governing the practice of medicine;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens arising out of judgments or awards not
resulting in an Event of Default; <u>provided</u> that the applicable Credit Party or Subsidiary shall in good faith be prosecuting an appeal or proceedings for review;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens on the property of a Person existing at
the time such Person becomes a Subsidiary of a Credit Party in a transaction permitted hereunder securing Indebtedness in an aggregate principal amount not to exceed the greater of (i) $85,000,000 and (ii) 2.0% of Consolidated Total Assets at such
time, for all such Persons; <u>provided</u>, <u>however</u>, that any such Lien may not extend to any other property of any Credit Party or any other Subsidiary that is not a Subsidiary of such Person; <u>provided</u>, <u>further</u>, that any such
Lien was not created in anticipation of or in connection with the transaction or series of transactions pursuant to which such Person became a Subsidiary of a Credit Party;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any interest or title of a lessor, licensor
or sublessor under any lease, license or sublease entered into by any Credit Party or any Subsidiary thereof in the ordinary course of its business and covering only the assets so leased, licensed or subleased;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;assignments of insurance or condemnation
proceeds provided to landlords (or their mortgagees) pursuant to the terms of any lease and Liens or rights reserved in any lease for rent or for compliance with the terms of such lease;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens arising under Restrictive
Agreements;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens to the extent arising out of judgments,
orders, attachments, decrees or awards not resulting in an Event of Default; and</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">24</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional Liens so long as the aggregate
principal amount of Indebtedness secured thereby at any time does not exceed the greater of (i) $170,000,000 and (ii) 3.5% of Consolidated Total Assets at such time.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Person</u>&#8221; shall mean any natural person, corporation, limited liability company, trust, joint venture, association,
company, partnership, Governmental Authority or other entity.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Plan</u>&#8221; shall mean, as of any date of determination, any employee benefit plan which is covered by Title IV of ERISA
and in respect of which any Credit Party or a Commonly Controlled Entity is (or, if such plan were terminated at such time, would under Section 4069 of ERISA be deemed to be) an &#8220;employer&#8221; as defined in Section 3(5) of ERISA.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Platform</u>&#8221; shall have the meaning set forth in Section 9.2(d)(i).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>PMG</u>&#8221; means PMG Indemnity Ltd., a corporation organized under the laws of Grand Cayman, British West Indies, and a
Subsidiary of the Borrower.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Practice</u>&#8221; shall mean that Person party to any Management Agreement that is not the Manager under such Management
Agreement and that engages in the practice of providing medical services or of owning the Equity Interests of other Persons engaged in the practice of medical services.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Primary Syndication</u>&#8221; shall mean any assignments by the Administrative Agent in order to effectuate the initial
post-closing syndication made on or prior to the earlier of (a) the date that is ninety (90) days after the Closing Date and (b) the completion of all assignments relating to the completion of a successful syndication.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Prime Rate</u>&#8221; means the rate of interest per annum publicly announced from time to time by JPMCB as its prime rate
in effect at its office located at 270 Park Avenue, New York, New York, or any successor office announced by JPMCB; each change in the Prime Rate shall be effective from and including the date such change is publicly announced as being
effective.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Private Payor</u>&#8221;<b> </b>means any insurance company, health maintenance organization, preferred provider
organization or similar entity that is obligated to make payments for goods or services provided to a patient, but shall not include a Government Reimbursement Program.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Private Payor Arrangement</u>&#8221;<b> </b>means a written agreement or arrangement with a Private Payor pursuant to which
the Private Payor pays all or a portion of the charges of any Credit Party for providing goods and services to a patient.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Pro Forma Basis</u>&#8221; shall mean, with respect to any transaction, that such transaction shall be deemed to have
occurred as of the first day of the four-quarter period ending as of the Borrower&#8217;s most recent fiscal quarter end preceding the date of such transaction.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Properties</u>&#8221; shall have the meaning set forth in Section 3.10(a).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>PTE</u>&#8221; means a prohibited transaction class exemption issued by the U.S. Department of Labor, as any such exemption
may be amended from time to time.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><u style="border-bottom:#000000 thin double;"><font style="color:#0000ff;">&#8220;QFC&#8221; shall have the meaning assigned to the
term &#8220;qualified financial contract&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. 5390(c)(8)(D).</font></u></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><u style="border-bottom:#000000 thin double;"><font style="color:#0000ff;">&#8220;QFC Credit Support&#8221; shall have the meaning
assigned to it in Section 9.29.</font></u></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Qualified ECP Guarantor</u>&#8221; means, in respect of any Swap Obligation, each Credit Party that has total assets
exceeding $10,000,000 at the time the relevant Guaranty or grant of the relevant security interest becomes or would become effective with respect to such Swap Obligation or such other person as constitutes an &#8220;eligible</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">25</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">contract participant&#8221; under the Commodity Exchange Act or any regulations promulgated thereunder and can cause another person to
qualify as an &#8220;eligible contract participant&#8221; at such time by entering into a keepwell under Section 1a(18)(A)(v)(II) of the Commodity Exchange Act.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Recipient</u>&#8221; shall mean (a) the Administrative Agent, (b) any Lender and (c) any Issuing Lender, as applicable.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Recovery Event</u>&#8221; shall mean the receipt by any Credit Party or its Subsidiaries of any cash insurance proceeds or
condemnation award payable by reason of theft, loss, physical destruction or damage, taking or similar event with respect to any of their respective property or assets.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Register</u>&#8221; shall have the meaning set forth in Section 9.6(c).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Reimbursement Obligation</u>&#8221; shall mean the obligation of the Borrower to reimburse the Issuing Lenders pursuant to
Section 2.3(d) for amounts drawn under Letters of Credit.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Related Parties</u>&#8221; shall mean, with respect to any Person, such Person&#8217;s Affiliates and the partners,
directors, officers, employees, agents, trustees and advisors of such Person and of such Person&#8217;s Affiliates.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Reorganization</u>&#8221; shall mean, with respect to any Multiemployer Plan, the condition that such Plan is in
reorganization within the meaning of such term as used in Section 4241 of ERISA.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Reportable Event</u>&#8221; shall mean any of the events set forth in Section 4043(c) of ERISA, other than those events as
to which the thirty-day notice period is waived under PBGC Reg. &#167;4043.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Required Facility Lenders</u>&#8221; shall mean, as of any date of determination, either (as the context may require) (a)
Revolving Lenders holding at least a majority of the outstanding Revolving Commitments and if the Revolving Commitments have been terminated, the outstanding Revolving Loans and Participation Interests, under the Revolving Facility, or (b)
Incremental Lenders holding at least a majority of the outstanding Loans and/or Commitments under an Incremental Facility; provided, however, that if any Lender shall be a Defaulting Lender at such time, then there shall be excluded from the
determination of Required Facility Lenders, Obligations (including Participation Interests) owing to such Defaulting Lender and such Defaulting Lender&#8217;s Commitments.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Required Lenders</u>&#8221; shall mean, as of any date of determination, Lenders holding at least a majority of (a) the
outstanding Commitments and Loans or (b) to the extent Commitments have been terminated, the outstanding Loans and Participation Interests; <u>provided</u>, <u>however</u>, that if any Lender shall be a Defaulting Lender at such time, then there
shall be excluded from the determination of Required Lenders, Obligations (including Participation Interests) owing to such Defaulting Lender and such Defaulting Lender&#8217;s Commitments.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Requirement of Law</u>&#8221; shall mean, as to any Person, (a) all international, foreign, Federal, state and local
statutes, treaties, rules, guidelines, regulations, ordinances, codes, executive orders, and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the
enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority (in each case whether or not having
the force of law) and (b) all Healthcare Laws; in each case applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Responsible Officer</u>&#8221; shall mean, for any Credit Party, any duly authorized officer or authorized signatory thereof
and as to whom the Administrative Agent has received an incumbency certificate that has not been terminated or revoked indicating such officer or authorized signatory is a duly authorized officer thereof.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Restricted Payment</u>&#8221; shall mean (a) any dividend or other distribution, direct or indirect, on account of any
shares (or equivalent) of any class of Equity Interest of any Credit Party or any of its Subsidiaries, now or hereafter outstanding, (b) any redemption, retirement, sinking fund or similar payment, purchase or other acquisition for value, direct or
indirect, of any shares (or equivalent) of any class of Equity Interest of any Credit Party or any of its</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">26</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Subsidiaries, now or hereafter outstanding, (c) any payment made to retire, or to obtain the surrender of, any outstanding warrants,
options or other rights to acquire shares of any class of Equity Interest of any Credit Party or any of its Subsidiaries, now or hereafter outstanding, (d) any payment with respect to any earnout obligation, (e) any payment or prepayment of
principal of, premium, if any, or interest on, redemption, purchase, retirement, defeasance, sinking fund or similar payment with respect to, any Subordinated Debt of any Credit Party or any of its Subsidiaries, (f) the payment by any Credit Party
or any of its Subsidiaries of any management, advisory or consulting fee to any Person (other than such fees incurred in the ordinary course of business) or (g) the payment of any extraordinary salary, bonus or other form of compensation for
services to any Person who is directly or indirectly a significant partner, shareholder, owner or executive officer of any such Person, to the extent such extraordinary salary, bonus or other form of compensation is not or would not be an expense
reflected on such Person&#8217;s financial statements in accordance with GAAP.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Restrictive Agreement</u>&#8221; shall have the meaning set forth in Section 9.23(a).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Revolving Commitment</u>&#8221; shall mean, with respect to each Revolving Lender, the commitment of such Revolving Lender
to make Revolving Loans in an aggregate principal amount at any time outstanding up to an amount equal to such Revolving Lender&#8217;s Revolving Commitment Percentage of the Revolving Committed Amount.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Revolving Commitment Percentage</u>&#8221; shall mean for each Revolving Lender, the percentage identified as its Revolving
Commitment Percentage on Schedule 2.1(a) or in the Assignment and Assumption pursuant to which such Revolving Lender became a Revolving Lender hereunder, as such percentage may be modified after the Amendment No. 2 Effective Date in accordance with
the provisions of this Credit Agreement.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Revolving Committed Amount</u>&#8221; shall have the meaning set forth in Section 2.1(a).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Revolving Facility</u>&#8221; shall have the meaning set forth in Section 2.1(a).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Revolving Lender</u>&#8221; shall mean, as of any date of determination, a Lender holding a Revolving Commitment, a
Revolving Loan or a Participation Interest on such date.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Revolving Loans</u>&#8221; shall have the meaning set forth in Section 2.1(a).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Revolving Note</u>&#8221; or &#8220;<u>Revolving Notes</u>&#8221; shall mean the promissory notes of the Borrower provided
pursuant to Section 2.1(e) in favor of any of the Revolving Lenders evidencing the Revolving Loan provided by any such Revolving Lender pursuant to Section 2.1(a), individually or collectively, as appropriate, as such promissory notes may be
amended, modified, extended, restated, replaced, or supplemented from time to time.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>S&amp;P</u>&#8221; shall mean Standard &amp; Poor&#8217;s Ratings Services, a division of The McGraw Hill Companies,
Inc.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Sale and Leaseback Transaction</u>&#8221; shall mean any arrangement pursuant to which any Credit Party or Subsidiary,
directly or indirectly, becomes liable as lessee, guarantor or other surety with respect to any lease, whether an Operating Lease or a Capital Lease, of any property or assets (a) which a Credit Party or Subsidiary has sold or transferred (or is to
sell or transfer) to a Person which is not a Credit Party or Subsidiary or (b) which such Credit Party or Subsidiary intends to use for substantially the same purpose as any other property or assets which have been sold or transferred (or is to be
sold or transferred) by a Credit Party or Subsidiary to another Person which is not a Credit Party or Subsidiary in connection with such lease.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Sanctioned Country</u>&#8221; means, at any time, a country, region or territory which is itself the subject or target of
any Sanctions (at the time of this Agreement, Cuba, Iran, North Korea, Sudan, Syria and Crimea).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Sanctioned Person</u>&#8221; means, at any time, (a) any Person listed in any Sanctions-related list of designated Persons
maintained by the Office of Foreign Assets Control of the U.S. Department of the Treasury, the U.S. Department of State, or by the United Nations Security Council, the European Union or any EU member state, (b) any Person operating, organized or
resident in a Sanctioned Country or (c) any Person owned or controlled by any such Person or Persons.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">27</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Sanctions</u>&#8221; means economic or financial sanctions or trade embargoes imposed, administered or enforced from time to
time by (a) the U.S. government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, (b) the government of Canada or (c) the United Nations Security Council,
the European Union or Her Majesty&#8217;s Treasury of the United Kingdom</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Sarbanes-Oxley</u>&#8221; shall mean the Sarbanes-Oxley Act of 2002.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>SEC</u>&#8221; shall mean the Securities and Exchange Commission or any successor Governmental Authority.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Securities Act</u>&#8221; shall mean the Securities Act of 1933, together with any amendment thereto or replacement thereof
and any rules or regulations promulgated thereunder.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Securities Laws</u>&#8221; shall mean the Securities Act, the Exchange Act, Sarbanes-Oxley and the applicable accounting and
auditing principles, rules, standards and practices promulgated, approved or incorporated by the SEC or the Public Company Accounting Oversight Board, as each of the foregoing may be amended and in effect on any applicable date hereunder.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Security Documents</u>&#8221; shall mean the Collateral Agreement and each of the security agreements, pledge agreements and
other instruments and documents executed and delivered pursuant to the occurrence of the Collateral Event or pursuant to Section 5.13.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Single Employer Plan</u>&#8221; shall mean any Plan that is not a Multiemployer Plan.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Subordinated Debt</u>&#8221; shall mean any Indebtedness incurred by any Credit Party which by its terms is specifically
subordinated in right of payment to the prior payment of the Credit Party Obligations and contains subordination and other terms acceptable to the Administrative Agent.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Subsidiary</u>&#8221; shall mean, as to any Person, a corporation, partnership, limited liability company or other entity of
which shares of stock or other ownership interests having ordinary voting power (other than stock or such other ownership interests having such power only by reason of the happening of a contingency) to elect a majority of the board of directors or
other managers of such corporation, limited liability company, partnership or other entity are at the time owned, or the management of which is otherwise controlled, directly or indirectly through one or more intermediaries, or both, by such Person;
<u>provided</u>, that notwithstanding the foregoing, each Practice and each of its Subsidiaries shall constitute a Subsidiary of the Borrower for the purposes of the Credit Documents. Unless otherwise qualified, all references to a
&#8220;Subsidiary&#8221; or to &#8220;Subsidiaries&#8221; in this Agreement shall refer to a Subsidiary or Subsidiaries of the Borrower.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Successor Issuing Lender</u>&#8221; shall have the meaning set forth in Section 2.3(f).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Successor Issuing Lender Agreement</u>&#8221; shall have the meaning set forth in Section 2.3(f).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><font
style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">&#8220;Supported QFC&#8221; shall have the meaning assigned to it in Section 9.29.</u></font></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Swap Termination Value</u>&#8221; shall mean, in respect of any one or more Hedging Agreements, after taking into account
the effect of any legally enforceable netting agreement relating to such Hedging Agreements, (a) for any date on or after the date such Hedging Agreements have been closed out and termination value(s) determined in accordance therewith, such
termination value(s), and (b) for any date prior to the date referenced in clause (a), the amount(s) determined as the mark-to-market value(s) for such Hedging Agreements, as determined based upon one or more mid-market or other readily available
quotations provided by any recognized dealer in such Hedging Agreements (which may include a Lender or any Affiliate of a Lender).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Target</u>&#8221; shall have the meaning set forth in the definition of &#8220;Permitted Acquisition.&#8221;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">28</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Taxes</u>&#8221; shall mean all present or future taxes, levies, imposts, duties, deductions, withholdings, assessments,
fees and other like charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Trademark License</u>&#8221; shall mean any agreement, whether written or oral, providing for the grant by or to a Person of
any right to use any Trademark.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Trademarks</u>&#8221; shall mean (a) all trademarks, trade names, corporate names, company names, business names, fictitious
business names, service marks, elements of package or trade dress of goods or services, logos and other source or business identifiers, together with the goodwill associated therewith, all registrations and recordings thereof, and all applications
in connection therewith, whether in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof and (b) all renewals thereof.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Transactions</u>&#8221; shall mean the closing of this Agreement and the other Credit Documents and the other transactions
contemplated hereby to occur in connection with such closing (including, without limitation, the initial borrowings under the Credit Documents and the payment of fees and expenses in connection with all of the foregoing).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Transfer Effective Date</u>&#8221; shall have the meaning set forth in each Assignment and Assumption.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Type</u>&#8221; shall mean, as to any Loan, its nature as an Alternate Base Rate Loan or LIBOR Rate Loan, as the case may
be.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>UCC</u>&#8221; shall mean the Uniform Commercial Code from time to time in effect in any applicable jurisdiction.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>United States</u>&#8221; shall mean the United States of America and the states, territories and possessions thereof,
including, without limitation, Puerto Rico.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Unused Commitment Fee</u>&#8221; shall have the meaning set forth in Section 2.5(a).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>U.S. Lender</u>&#8221; shall mean any Lender that is a &#8220;United States person&#8221; as defined in Section 7701(a)(30)
of the Code.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">&#8220;U.S. Special Resolution Regime&#8221; shall have the
meaning provided in Section 9.29.</u></font></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Voting Stock</u>&#8221; shall mean, with respect to any Person, Equity Interest issued by such Person the holders of which
are ordinarily, in the absence of contingencies, entitled to vote for the election of directors (or persons performing similar functions) of such Person, even though the right so to vote may be or have been suspended by the happening of such a
contingency.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Works</u>&#8221; shall mean all works which are subject to copyright protection pursuant to Title 17 of the United States
Code.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Write-Down and Conversion Powers</u>&#8221; means, with respect to any EEA Resolution Authority, the write-down and
conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Other Definitional Provisions</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The definitions of terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context may
require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without
limitation.&#8221; The word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall.&#8221; Unless the</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">29</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">context requires otherwise (a) any definition of or reference to any agreement, instrument or other document herein shall be construed
as referring to such agreement, instrument or other document as from time to time amended, restated, supplemented, amended and restated or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth
herein), (b) any reference herein to any Person shall be construed to include such Person&#8217;s successors and assigns, (c) the words &#8220;herein,&#8221; &#8220;hereof&#8221; and &#8220;hereunder,&#8221; and words of similar import, shall be
construed to refer to this Agreement in its entirety and not to any particular provision hereof of this Agreement, (d) all references herein to Articles, Sections, Exhibits and Schedules shall be construed to refer to Articles and Sections of, and
Exhibits and Schedules to, this Agreement, (e) any reference to any law or regulation herein shall, unless otherwise specified, refer to such law or regulation as amended, modified or supplemented from time to time, (f) the words &#8220;asset&#8221;
and &#8220;property&#8221; shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and contract rights and (g) all terms defined in this
Agreement shall have the defined meanings when used in any other Credit Document or any certificate or other document made or delivered pursuant hereto. The phrase, &#8220;to the actual knowledge,&#8221; &#8220;to the best knowledge,&#8221;
&#8220;to the knowledge&#8221; or similar uses of &#8220;knowledge&#8221; of a Responsible Officer of the Borrower or other specified Credit Party with respect to any statement made herein means that no information that would give such Responsible
Officer current actual knowledge of the inaccuracy of such statement has come to the attention of such Responsible Officer, nor, except as otherwise expressly indicated, that such Responsible Officer has undertaken any independent investigation to
determine the accuracy of such statement other than due inquiry of other executive employees of such Credit Party who have management responsibilities with respect to the subject matter of such statement in the ordinary course of such employees'
duties.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Accounting Terms</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Unless
otherwise specified herein, all accounting terms used herein shall be interpreted, all accounting determinations hereunder shall be made, and all financial statements required to be delivered hereunder shall be prepared in accordance with GAAP
applied on a basis consistent with the most recent audited Consolidated financial statements of the Borrower<b> </b>delivered to the Lenders. If at any time any change in GAAP would affect the computation of any financial ratio or requirement set
forth in any Credit Document, and either the Borrower or the Required Lenders shall so request, the Administrative Agent, the Lenders and the Borrower shall negotiate in good faith to amend such ratio or requirement to preserve the original intent
thereof in light of such change in GAAP (subject to the approval of the Required Lenders); provided, that, until so amended, (a) such ratio or requirement shall continue to be computed in accordance with GAAP prior to such change therein and (b) the
Borrower shall provide to the Administrative Agent and the Lenders financial statements and other documents required under this Agreement or as reasonably requested hereunder setting forth a reconciliation between calculations of such ratio or
requirement made before and after giving effect to such change in GAAP.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Borrower shall deliver to the Administrative Agent and each Lender at the same time as the delivery of any annual or quarterly
financial statements given in accordance with the provisions of Section 5.1, (a) a description in reasonable detail of any material change in the application of accounting principles employed in the preparation of such financial statements from
those applied in the most recently preceding quarterly or annual financial statements as to which no objection shall have been made in accordance with the provisions above and (b) a reasonable estimate of the effect on the financial statements on
account of such changes in application.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Time References</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Unless
otherwise specified, all references herein to times of day shall be references to Eastern time (daylight or standard, as applicable).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Execution of Documents</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Unless otherwise specified, all Credit Documents and all other certificates executed in connection therewith must be signed by a
Responsible Officer.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">30</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Letter of Credit Amounts</u></b>. Unless otherwise specified herein, the amount of a
Letter of Credit at any time shall be deemed to be the stated amount of such Letter of Credit in effect at such time; provided, however, that with respect to any Letter of Credit that, by its terms or the terms of any LOC Document related thereto,
provides for one or more automatic increases in the stated amount thereof, the amount of such Letter of Credit shall be deemed to be the maximum stated amount of such Letter of Credit after giving effect to all such increases, whether or not such
maximum stated amount is in effect at such time.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 1.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>LIBOR Notification</u></b>. The interest rate on LIBOR Rate Loans is determined by
reference to the LIBOR Rate, which is derived from the London interbank offered rate. The London interbank offered rate is intended to represent the rate at which contributing banks may obtain short-term borrowings from each other in the London
interbank market. In July 2017, the U.K. Financial Conduct Authority announced that, after the end of 2021, it would no longer persuade or compel contributing banks to make rate submissions to the ICE Benchmark Administration (together with any
successor to the ICE Benchmark Administrator, the &#8220;IBA&#8221;) for purposes of the IBA setting the London interbank offered rate. As a result, it is possible that commencing in 2022, the London interbank offered rate may no longer be available
or may no longer be deemed an appropriate reference rate upon which to determine the interest rate on LIBOR Rate Loans. In light of this eventuality, public and private sector industry initiatives are currently underway to identify new or
alternative reference rates to be used in place of the London interbank offered rate. In the event that the London interbank offered rate is no longer available or in certain other circumstances as set forth in Section 2.13(b) of this Agreement,
such Section 2.13(b) provides a mechanism for determining an alternative rate of interest. The Administrative Agent will notify the Borrower, pursuant to Section 2.13, in advance of any change to the reference rate upon which the interest rate on
LIBOR Loans is based. However, the Administrative Agent does not warrant or accept any responsibility for, and shall not have any liability with respect to, the administration, submission or any other matter related to the London interbank offered
rate or other rates in the definition of &#8220;LIBOR Rate&#8221; or with respect to any alternative or successor rate thereto, or replacement rate thereof, including without limitation, whether the composition or characteristics of any such
alternative, successor or replacement reference rate, as it may or may not be adjusted pursuant to Section 2.13(b), will be similar to, or produce the same value or economic equivalence of, the LIBOR Rate or have the same volume or liquidity as did
the London interbank offered rate prior to its discontinuance or unavailability.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>ARTICLE II<br> <br> THE LOANS; AMOUNT AND TERMS</b></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Revolving Loans</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Revolving Commitment</u>. During the Commitment Period, subject to the terms and conditions
hereof, each Revolving Lender severally, but not jointly, shall make revolving credit loans in Dollars (&#8220;<u>Revolving Loans</u>&#8221;) to the Borrower from time to time in an aggregate principal amount not at any time exceeding the total of
Revolving Commitments of all the Lenders, which amount on the Amendment No. 2 Effective Date shall equal <b>ONE BILLION TWO HUNDRED MILLION DOLLARS ($1,200,000,000) </b>(as increased from time to time as provided in Section 2.22 and as such
aggregate maximum amount may be reduced from time to time as provided in Section 2.6, the &#8220;<u>Revolving Committed Amount</u>&#8221;) for the purposes hereinafter set forth (the &#8220;<u>Revolving Facility</u>&#8221;);<u> </u><u>provided</u>,
<u>however</u><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">, that from the Amendment No. 3 Effective Date through September 30, 2021, the aggregate amount of undrawn Revolving Commitments shall be at least $300,000,000
at all times; provided, further</u></font>, that (i) with regard to each Revolving Lender individually, the sum of such Revolving Lender&#8217;s Revolving Commitment Percentage of the aggregate principal amount of outstanding Revolving Loans
<u>plus</u> such Revolving Lender&#8217;s Revolving Commitment Percentage of the outstanding principal amount of the LOC Obligations shall not exceed such Revolving Lender&#8217;s Revolving Commitment and (ii) with regard to the Revolving Lenders
collectively, the sum of the aggregate principal amount of outstanding Revolving Loans <u>plus</u> the aggregate principal amount of outstanding LOC Obligations shall not exceed the Revolving Committed Amount then in effect. Revolving Loans may
consist of Alternate Base Rate Loans or LIBOR Rate Loans, or a combination thereof, as the Borrower may request, and may be repaid and reborrowed in accordance with the provisions hereof; <u>provided</u>, <u>however</u>, the Revolving Loans made on
the Closing Date or any of the three (3) Business Days following the Closing Date, may only consist of Alternate Base Rate Loans unless the Borrower delivers a funding indemnity letter, substantially in the form of <u>Exhibit 2.1(a)</u>, reasonably
acceptable to the Administrative Agent on or before the Closing Date, in which case LIBOR Rate Loans are available to the Borrower. LIBOR Rate Loans shall be made by each Revolving Lender at its LIBOR Lending Office and Alternate Base Rate Loans at
its Domestic Lending Office.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">31</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Revolving Loan Borrowings</u>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 50.4pt;">(i)&nbsp; &nbsp; &nbsp;<u>Notice of Borrowing</u>. The Borrower shall request a Revolving Loan
borrowing by delivering a written Notice of Borrowing (or telephone notice promptly confirmed in writing by delivery of a written Notice of Borrowing, which delivery may be by fax) to the Administrative Agent not later than 2:00 p.m. on the Business
Day of the requested borrowing in the case of Alternate Base Rate Loans, and on the third Business Day prior to the date of the requested borrowing in the case of LIBOR Rate Loans. Each such Notice of Borrowing shall be irrevocable and shall specify
(A) that a Revolving Loan is requested, (B) the date of the requested borrowing (which shall be a Business Day), (C) the aggregate principal amount to be borrowed and (D) whether the borrowing shall be comprised of Alternate Base Rate Loans, LIBOR
Rate Loans or a combination thereof, and if LIBOR Rate Loans are requested, the Interest Period(s) therefor. If the Borrower shall fail to specify in any such Notice of Borrowing (1) an applicable Interest Period in the case of a LIBOR Rate Loan,
then such notice shall be deemed to be a request for an Interest Period of one month, or (2) the Type of Revolving Loan requested, then such notice shall be deemed to be a request for an Alternate Base Rate Loan hereunder. The Administrative Agent
shall give notice to each Revolving Lender promptly upon receipt of each Notice of Borrowing, the contents thereof and each such Revolving Lender&#8217;s share thereof.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 50.4pt;">(ii)&nbsp; &nbsp; &nbsp;<u>Minimum Amounts</u>. Each Revolving Loan that is made as an Alternate
Base Rate Loan shall be in a minimum aggregate amount of $1,000,000 and in integral multiples of $500,000 in excess thereof (or the remaining amount of the Revolving Committed Amount, if less). Each Revolving Loan that is made as a LIBOR Rate Loan
shall be in a minimum aggregate amount of $1,000,000 and in integral multiples of $500,000 in excess thereof (or the remaining amount of the Revolving Committed Amount, if less).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 50.4pt;">(iii)&nbsp; &nbsp; &nbsp;<u>Advances</u>. Each Revolving Lender will make its Revolving Commitment
Percentage of each Revolving Loan borrowing available to the Administrative Agent for the account of the Borrower at the office of the Administrative Agent specified in Section 9.2, or at such other office as the Administrative Agent may designate
in writing, by 1:00 P.M. (or in the case of a borrowing of Alternative Base Rate Loans by 3:00 P.M.) on the date specified in the applicable Notice of Borrowing, in Dollars and in funds immediately available to the Administrative Agent. Such
borrowing will then be made available to the Borrower by the Administrative Agent by crediting the account of the Borrower on the books of such office (or such other account that the Borrower may designate in writing to the Administrative Agent)
with the aggregate of the amounts made available to the Administrative Agent by the Revolving Lenders and in like funds as received by the Administrative Agent.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Repayment</u>. Subject to the terms of this Agreement, Revolving Loans may be borrowed, repaid and
reborrowed during the Commitment Period. The principal amount of all Revolving Loans shall be due and payable in full on the Maturity Date, unless accelerated sooner pursuant to Section 7.2. The Borrower shall have the right to repay Revolving Loans
in whole or in part from time to time in accordance with Section 2.7.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Interest</u>. Subject to the provisions of Section 2.8, Revolving Loans shall bear interest as
follows:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Alternate Base Rate Loans</u>. During
such periods as any Revolving Loans shall be composed of Alternate Base Rate Loans, each such Alternate Base Rate Loan shall bear interest at a per annum rate equal to the sum of the Alternate Base Rate <u>plus</u> the Applicable Margin; and</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>LIBOR Rate Loans</u>. During such
periods as Revolving Loans shall be composed of LIBOR Rate Loans, each such LIBOR Rate Loan shall bear interest at a per annum rate equal to the sum of the LIBOR Rate <u>plus</u> the Applicable Margin.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Interest on
Revolving Loans shall be payable in arrears on each Interest Payment Date.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">32</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Revolving Notes; Covenant to Pay</u>. The Borrower&#8217;s obligation to pay each Revolving Lender
shall be evidenced by this Agreement and, upon such Revolving Lender&#8217;s request, by a duly executed promissory note of the Borrower to such Revolving Lender in substantially the form of <u>Exhibit 2.1(e)</u>. The Borrower covenants and agrees
to pay the Revolving Loans in accordance with the terms of this Agreement.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Reserved]</b><b>.</b></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Letter of Credit Subfacility</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Issuance</u>. Subject to the terms and conditions hereof and of the LOC Documents, if any, and any
other terms and conditions which the Issuing Lenders may reasonably require, during the Commitment Period each Issuing Lender shall issue, and the Revolving Lenders shall participate in, Letters of Credit for the account of the Borrower from time to
time upon request in a form acceptable to the applicable Issuing Lender; <u>provided</u>, <u>however</u>, that (i) the aggregate principal amount of LOC Obligations shall not at any time exceed <b>THIRTY-SEVEN MILLION, FIVE HUNDRED THOUSAND DOLLARS
($37,500,000)</b> (the &#8220;<u>LOC Committed Amount</u>&#8221;), (ii) the sum of the aggregate principal amount of outstanding Revolving Loans <u>plus</u> the aggregate principal amount of outstanding LOC Obligations shall not at any time exceed
the Revolving Committed Amount then in effect, (iii) no Issuing Lender will be required to issue Letters of Credit in an aggregate amount in excess of such Issuing Lender&#8217;s Issuing Lender Sublimit, (iv) all Letters of Credit shall be
denominated in Dollars and (v) Letters of Credit shall be issued for any lawful corporate purposes and may be issued as standby letters of credit, including in connection with workers&#8217; compensation and other insurance programs and commercial
letters of credit. Except as otherwise expressly agreed upon by all the Revolving Lenders, no Letter of Credit shall have an original expiry date more than twelve (12) months from the date of issuance; <u>provided</u>, <u>however</u>, so long as no
Default or Event of Default has occurred and is continuing and subject to the other terms and conditions to the issuance of Letters of Credit hereunder, the expiry dates of Letters of Credit may be extended annually or periodically from time to time
on the request of the Borrower or by operation of the terms of the applicable Letter of Credit to a date not more than twelve (12) months from the date of extension; <u>provided</u>, <u>further</u>, that no Letter of Credit, as originally issued or
as extended, shall have an expiry date extending beyond the date that is thirty (30) days prior to the Maturity Date. Each Letter of Credit shall comply with the related LOC Documents. The issuance and expiry date of each Letter of Credit shall be a
Business Day. Each Letter of Credit issued hereunder shall be in a minimum original face amount of $100,000 or such lesser amount as approved by the applicable Issuing Lender. The Borrower&#8217;s Reimbursement Obligations in respect of each
Existing Letter of Credit, and each Revolving Lender&#8217;s participation obligations in connection therewith, shall be governed by the terms of this Credit Agreement. The Existing Letters of Credit shall, as of the Closing Date, be deemed to have
been issued as Letters of Credit hereunder and subject to and governed by the terms of this Agreement.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice and Reports</u>. The request for the issuance of a Letter of Credit shall be submitted to
the applicable Issuing Lender at least five (5) Business Days prior to the requested date of issuance. The applicable Issuing Lender will promptly upon request provide to the Administrative Agent for dissemination to the Revolving Lenders a detailed
report specifying the Letters of Credit which are then issued by such Issuing Lender and outstanding and any activity with respect thereto which may have occurred since the date of any prior report, and including therein, among other things, the
account party, the beneficiary, the face amount, expiry date as well as any payments or expirations which may have occurred. Each Issuing Lender will further provide to the Administrative Agent promptly upon request copies of the Letters of Credit.
Each Issuing Lender will provide to the Administrative Agent promptly upon request a summary report of the nature and extent of LOC Obligations then outstanding.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Participations</u>. Each Revolving Lender, (i) on the Closing Date with respect to each Existing
Letter of Credit and (ii) upon issuance of a Letter of Credit, shall be deemed to have purchased without recourse a risk participation from the applicable Issuing Lender in such Letter of Credit and the obligations arising thereunder, in each case
in an amount equal to its Revolving Commitment Percentage of the obligations under such Letter of Credit and shall absolutely, unconditionally and irrevocably assume, as primary obligor and not as surety, and be obligated to pay to the applicable
Issuing Lender therefor and discharge when due, its Revolving Commitment Percentage of the obligations arising under such Letter of Credit; <u>provided</u> that any Person that becomes a Revolving Lender after the Closing Date shall be deemed to
have purchased a Participation Interest in all outstanding Letters of Credit on the date it becomes a Lender hereunder and any Letter of Credit issued on or after such date, in each case in accordance with the foregoing terms. Without limiting the
scope and nature of each Revolving Lender&#8217;s participation in any Letter of Credit, to the extent that the applicable Issuing Lender has not been reimbursed as required hereunder or under any LOC Document, each such Revolving Lender shall pay
to such Issuing Lender its</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">33</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Revolving Commitment Percentage of such unreimbursed drawing in same day funds pursuant to and in accordance with the provisions of
subsection (d) hereof. The obligation of each Revolving Lender to so reimburse the Issuing Lenders shall be absolute and unconditional and shall not be affected by the occurrence of a Default, an Event of Default or any other occurrence or event.
Any such reimbursement shall not relieve or otherwise impair the obligation of the Borrower to reimburse the Issuing Lenders under any Letter of Credit, together with interest as hereinafter provided.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reimbursement</u>. In the event of any drawing under any Letter of Credit, the applicable Issuing
Lender will promptly notify the Borrower and the Administrative Agent. The Borrower shall reimburse the applicable Issuing Lender on the day of drawing under any Letter of Credit if notified prior to 3:00 P.M. on a Business Day or, if after 3:00
P.M., on the following Business Day (either with the proceeds of a Revolving Loan obtained hereunder or otherwise) in same day funds as provided herein or in the LOC Documents. If the Borrower shall fail to reimburse the Issuing Lenders as provided
herein, the unreimbursed amount of such drawing shall bear interest at a per annum rate equal to the Default Rate. Unless the Borrower shall immediately notify the applicable Issuing Lender and the Administrative Agent of its intent to otherwise
reimburse such Issuing Lender, the Borrower shall be deemed to have requested a Mandatory LOC Borrowing (as defined in Section 2.3(e)) in the amount of the drawing as provided in subsection (e) hereof, the proceeds of which will be used to satisfy
the Reimbursement Obligations. The Borrower&#8217;s Reimbursement Obligations hereunder shall be absolute and unconditional under all circumstances irrespective of any rights of set-off, counterclaim or defense to payment the Borrower may claim or
have against the Issuing Lenders, the Administrative Agent, the Lenders, the beneficiary of the Letter of Credit drawn upon or any other Person, including, without limitation, any defense based on any failure of the Borrower to receive consideration
or the legality, validity, regularity or unenforceability of the Letter of Credit. Each Issuing Lender will promptly notify the other Revolving Lenders of the amount of any unreimbursed drawing and each Revolving Lender shall promptly pay to the
Administrative Agent for the account of such Issuing Lender, in Dollars and in immediately available funds, the amount of such Revolving Lender&#8217;s Revolving Commitment Percentage of such unreimbursed drawing. Such payment shall be made on the
Business Day such notice is received by such Revolving Lender from the applicable Issuing Lender if such notice is received at or before 2:00 P.M., otherwise such payment shall be made at or before noon on the Business Day next succeeding the
Business Day such notice is received. If such Revolving Lender does not pay such amount to the applicable Issuing Lender in full upon such request, such Revolving Lender shall, on demand, pay to the Administrative Agent for the account of such
Issuing Lender interest on the unpaid amount during the period from the date of such drawing until such Revolving Lender pays such amount to such Issuing Lender in full at a rate per annum equal to, if paid within two (2) Business Days of the date
of drawing, the Federal Funds Effective Rate and thereafter at a rate equal to the Alternate Base Rate. Each Revolving Lender&#8217;s obligation to make such payment to the Issuing Lenders, and the right of the Issuing Lenders to receive the same,
shall be absolute and unconditional, shall not be affected by any circumstance whatsoever and without regard to the termination of this Agreement or the Commitments hereunder, the existence of a Default or Event of Default or the acceleration of the
Obligations hereunder and shall be made without any offset, abatement, withholding or reduction whatsoever.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Repayment with Revolving Loans</u>. On any day on which the Borrower shall have requested, or been
deemed to have requested, a Revolving Loan to reimburse a drawing under a Letter of Credit, the Administrative Agent shall give notice to the Revolving Lenders that a Revolving Loan has been requested or deemed requested in connection with a drawing
under a Letter of Credit, in which case a Revolving Loan borrowing comprised entirely of Alternate Base Rate Loans (each such borrowing, a &#8220;<u>Mandatory LOC Borrowing</u>&#8221;) shall be made (without giving effect to any termination of the
Commitments pursuant to Section 7.2) pro rata based on each Revolving Lender&#8217;s respective Revolving Commitment Percentage (determined before giving effect to any termination of the Commitments pursuant to Section 7.2) and the proceeds thereof
shall be paid directly to the applicable Issuing Lender for application to the respective LOC Obligations. Each Revolving Lender hereby irrevocably agrees to make such Revolving Loans on the day such notice is received by the Revolving Lenders from
the Administrative Agent if such notice is received at or before 2:00 P.M., otherwise such payment shall be made at or before noon on the Business Day next succeeding the day such notice is received, in each case <u>notwithstanding</u> (i) the
amount of Mandatory LOC Borrowing may not comply with the minimum amount for borrowings of Revolving Loans otherwise required hereunder, (ii) whether any conditions specified in Section 4.2 are then satisfied, (iii) whether a Default or an Event of
Default then exists, (iv) failure for any such request or deemed request for Revolving Loan to be made by the time otherwise required in Section 2.1(b), (v) the date of such Mandatory LOC Borrowing, or (vi) any reduction in the Revolving Committed
Amount after any such Letter of Credit may have</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">34</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">been
drawn upon. In the event that any Mandatory LOC Borrowing cannot for any reason be made on the date otherwise required above (including, without limitation, as a result of the occurrence of a Bankruptcy Event), then each such Revolving Lender hereby
agrees that it shall forthwith fund its Participation Interests in the outstanding LOC Obligations on the Business Day such notice to fund is received by such Revolving Lender from the Administrative Agent if such notice is received at or before
2:00 P.M., otherwise such payment shall be made at or before 12:00 Noon on the Business Day next succeeding the Business Day such notice is received; <u>provided</u>, <u>further</u>, that in the event any Revolving Lender shall fail to fund its
Participation Interest as required herein, then the amount of such Revolving Lender&#8217;s unfunded Participation Interest therein shall automatically bear interest payable by such Revolving Lender to the Administrative Agent for the account of the
Issuing Lenders upon demand, at the rate equal to, if paid within two (2) Business Days of such date, the Federal Funds Effective Rate, and thereafter at a rate equal to the Alternate Base Rate.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Modification, Extension</u>. The issuance of any supplement, modification, amendment, renewal, or
extension to any Letter of Credit shall, for purposes hereof, be treated in all respects the same as the issuance of a new Letter of Credit hereunder.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>ISP98 and UCP</u>. Unless otherwise expressly agreed by the applicable Issuing Lender and the
Borrower, when a Letter of Credit is issued, (i) the rules of the &#8220;International Standby Practices 1998,&#8221; published by the Institute of International Banking Law &amp; Practice (or such later version thereof as may be in effect at the
time of issuance) shall apply to each standby Letter of Credit, and (ii) the rules of The Uniform Customs and Practice for Documentary Credits, as most recently published by the International Chamber of Commerce at the time of issuance, shall apply
to each commercial Letter of Credit.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Conflict with LOC Documents</u>. In the event of any conflict between this Agreement and any LOC
Document (including any letter of credit application and any LOC Documents relating to the Existing Letters of Credit), this Agreement shall control.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Designation of Subsidiaries as Account Parties</u>. Notwithstanding anything to the contrary set
forth in this Agreement, including, without limitation, Section 2.3(a), a Letter of Credit issued hereunder may contain a statement to the effect that such Letter of Credit is issued for the account of a Subsidiary of the Borrower; <u>provided</u>
that, notwithstanding such statement, the Borrower shall be the actual account party for all purposes of this Agreement for such Letter of Credit and such statement shall not affect the Borrower&#8217;s Reimbursement Obligations hereunder with
respect to such Letter of Credit.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Cash Collateral</u>. At any point in time in which there is a Defaulting Lender, the Issuing
Lenders may require the Borrower to Cash Collateralize the LOC Obligations pursuant to Section 2.20.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Resignation of Issuing Lender</u>. An Issuing Lender may resign by giving 30 days&#8217; prior
written notice to each of the Administrative Agent, the Borrower and the Revolving Lenders in the event that such Person and its Affiliates no longer hold any Revolving Commitments; provided that no such resignation shall be effective if there shall
not be one or more other Issuing Lender (or Revolving Lenders willing to become an Issuing Lender) (each, a &#8220;<u>Successor Issuing Lender</u>&#8221;) at such time that will provide a LOC Commitment (or in the case of existing Issuing Lenders,
that will increase its LOC Commitment) in an amount not less than such resigning Issuing Lender&#8217;s Issuing Lender Sublimit. Notwithstanding the foregoing, no such resignation shall be effective if it results (after giving effect to the proviso
of the immediately preceding sentence) in a decrease in the LOC Committed Amount then in effect. The acceptance of any appointment as an Issuing Lender hereunder by a Successor Issuing Lender shall be evidenced by an agreement entered into by such
resigning Issuing Lender and Successor Issuing Lender, in a form satisfactory to the Borrower and the Administrative Agent (each, a &#8220;<u>Successor Issuing Lender Agreement</u>&#8221;). Upon the acceptance of any appointment as an Issuing Lender
hereunder and the effectiveness of the applicable Successor Issuing Lender Agreement, (i) such Successor Issuing Lender shall succeed to and become vested with all of the rights, powers, privileges and duties of the resigning Issuing Lender in in
its capacity as a resigning Issuing Lender, (ii) such resigning Issuing Lender shall be discharged from all of its respective duties and obligations hereunder or under the other Credit Documents, and (iii) the Successor Issuing Lender shall issue
letters of credit in substitution for the Letters of Credit, if any, outstanding at the time of such succession or make other arrangements satisfactory to the resigning Issuing Lender and the Borrower to effectively assume the obligations of such
resigning Issuing Lender with respect to such Letters of Credit. Such resignation shall not affect the validity or effectiveness of any Letter of Credit issued prior to such resignation by the resigning Issuing Lender. At the time such resignation
of an Issuing Lender shall become effective, the Borrower shall pay all accrued and unpaid Letter of Credit Facing Fees to such resigning Issuing Lender.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">35</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Reserved]</b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Fees</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Unused Commitment Fee</u>. Subject to Section 2.21, in consideration of the Revolving Commitments,
the Borrower agrees to pay to the Administrative Agent, for the ratable benefit of the Revolving Lenders, a commitment fee (the &#8220;<u>Unused Commitment Fee</u>&#8221;) at an annual rate equal to the Applicable Margin multiplied by the average
daily unused amount of the Revolving Committed Amount. For purposes of computation of the Unused Commitment Fee, LOC Obligations shall be considered usage of the Revolving Committed Amount. The Unused Commitment Fee shall be calculated by the
Administrative Agent and shall be payable by the Borrower quarterly in arrears on the last Business Day of each calendar quarter or, in the case of Revolving Commitments in effect immediately prior to the Amendment No. 2 Effective Date, on the
Amendment No. 2 Effective Date with respect to the portion of the calendar quarter ended immediately prior to such Amendment No. 2 Effective Date.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Letter of Credit Fees</u>. Subject to Section 2.21, in consideration of the LOC Commitments, the
Borrower agrees to pay to the Administrative Agent, for the ratable benefit of the Revolving Lenders, a fee (the &#8220;<u>Letter of Credit Fee</u>&#8221;) equal to the Applicable Margin for Revolving Loans that are LIBOR Rate Loans per annum on the
average daily maximum amount available to be drawn under each Letter of Credit from the date of issuance to the date of expiration. The Letter of Credit Fee shall be calculated by the Administrative Agent and shall be payable by the Borrower
quarterly in arrears on the last Business Day of each calendar quarter.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Issuing Lender Fees</u>. In addition to the Letter of Credit Fees payable pursuant to subsection
(b) hereof, the Borrower shall pay to each Issuing Lender for its own account without sharing by the other Lenders the reasonable and customary charges from time to time of such Issuing Lender with respect to the amendment, transfer, administration,
cancellation and conversion of, and drawings under, the Letters of Credit issued by such Issuing Lender (collectively, the &#8220;<u>Issuing Lender Fees</u>&#8221;). Each Issuing Lender may charge, and retain for its own account without sharing by
the other Lenders, an additional facing fee (the &#8220;<u>Letter of Credit Facing Fee</u>&#8221;) of 0.125% per annum on the average daily maximum amount available to be drawn under each such Letter of Credit issued by it. The Issuing Lender Fees
and the Letter of Credit Facing Fee shall be calculated by the Administrative Agent and shall be payable by the Borrower quarterly in arrears on the last Business Day of each calendar quarter.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Administrative Fee</u>. The Borrower agrees to pay to the Administrative Agent the annual
administrative fee as described in its Fee Letter.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Revolving Commitment Reductions</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Voluntary Reductions</u>. The Borrower shall have the right to terminate or permanently reduce the
unused portion of the Revolving Committed Amount at any time or from time to time subject to Section 2.15 but otherwise without premium or penalty upon not less than five (5) Business Days&#8217; prior written notice to the Administrative Agent
(which shall notify the Lenders thereof as soon as practicable) of each such termination or reduction, which notice shall specify the effective date thereof and the amount of any such reduction which shall be in a minimum amount of $1,000,000 or a
whole multiple of $500,000 in excess thereof and shall be irrevocable and effective upon receipt by the Administrative Agent; <u>provided</u> that no such reduction or termination shall be permitted if after giving effect thereto, and to any
prepayments of the Revolving Loans made on the effective date thereof, the sum of the aggregate principal amount of outstanding Revolving Loans <u>plus</u> the aggregate principal amount of outstanding LOC Obligations would exceed the Revolving
Committed Amount then in effect; <u>provided</u>, further that such notice may be conditioned upon the effectiveness of other credit facilities or the consummation of a transaction, the proceeds of which shall be used to repay the Obligations in
connection with any such termination, in which case such notice may be revoked by the Borrower (by notice to the Administrative Agent on or prior to the specified effective date) if such condition or conditions are not satisfied.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">36</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>LOC Committed Amount</u>. If the Revolving Committed Amount is reduced below the then current LOC
Committed Amount, the LOC Committed Amount shall automatically be reduced by an amount such that the LOC Committed Amount equals the Revolving Committed Amount.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Maturity Date</u>. The Revolving Commitments and the LOC Commitment shall automatically terminate
on the Maturity Date.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Repayments</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Optional Repayments</u>. The Borrower shall have the right to repay<b> </b>Loans in whole or in
part from time to time; <u>provided</u>, <u>however</u>, that each partial repayment of (i) Alternate Base Rate Loans shall be in a minimum principal amount of $1,000,000 and integral multiples of $500,000 in excess thereof (or the remaining
outstanding principal amount), (ii) LIBOR Rate Loans shall be in a minimum principal amount of $1,000,000 and integral multiples of $500,000 in excess thereof (or the remaining outstanding principal amount). The Borrower shall give three (3)
Business Days&#8217; irrevocable notice of repayment in the case of LIBOR Rate Loans and same-day irrevocable notice on any Business Day in the case of Alternate Base Rate Loans, to the Administrative Agent (which shall notify the applicable Lenders
thereof as soon as practicable); provided, that such notice may be conditioned upon the effectiveness of other credit facilities or the consummation of a transaction, the proceeds of which shall be used to repay the Loans in full or in part, in
which case such notice may be revoked by the Borrower (by notice to the Administrative Agent on or prior to the specified effective date) if such condition or conditions are not satisfied. Within the foregoing parameters, repayments under this
Section shall be applied first to Alternate Base Rate Loans and then to LIBOR Rate Loans in direct order of Interest Period maturities. All repayments under this Section shall be subject to Section 2.15, but otherwise without premium or penalty.
Interest on the principal amount repaid shall be payable on the next occurring Interest Payment Date that would have occurred had such loan not been repaid or, at the request of the Administrative Agent, interest on the principal amount repaid shall
be payable on any date that a repayment is made hereunder through the date of repayment.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Mandatory Repayments</u>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 50.4pt;">(i)&nbsp; &nbsp; &nbsp;<u>Revolving Committed Amount</u>. If at any time after the Closing Date, the
sum of the aggregate principal amount of outstanding Revolving Loans <u>plus</u> the aggregate principal amount of outstanding LOC Obligations shall exceed the Revolving Committed Amount, the Borrower shall immediately repay the Revolving Loans or
(after all Revolving Loans have been repaid) Cash Collateralize the LOC Obligations in an amount sufficient to eliminate such excess (such repayment to be applied as set forth in clause (ii) below) and on terms and conditions reasonably satisfactory
to the Administrative Agent.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 50.4pt;">(ii)&nbsp; &nbsp; &nbsp;<u>Application of Mandatory Repayments</u>. All amounts required to be paid
pursuant to this Section shall be applied (1) <i>first</i> to the outstanding Revolving Loans and (2) <i>second</i> to Cash Collateralize the LOC Obligations.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Within the
parameters of the applications set forth above, repayments shall be applied first to Alternate Base Rate Loans and then to LIBOR Rate Loans in direct order of Interest Period maturities. All repayments under this Section shall be subject to Section
2.15 and be accompanied by interest on the principal amount repaid through the date of repayment, but otherwise without premium or penalty.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Bank Products Unaffected</u>. Any repayment made pursuant to this Section shall not affect the
Borrower&#8217;s obligation to continue to make payments under any Bank Product, which shall remain in full force and effect notwithstanding such repayment, subject to the terms of such Bank Product.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Default Rate and Payment Dates</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If all or a portion of the principal amount of any Loan which is a LIBOR Rate Loan shall not be paid
when due or continued as a LIBOR Rate Loan in accordance with the provisions of Section 2.9 (whether at the stated maturity, by acceleration or otherwise), such overdue principal amount of such Loan shall be converted to an Alternate Base Rate Loan
at the end of the Interest Period applicable thereto.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">37</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the occurrence, and during the continuance, of any Event of Default hereunder, the principal of
and, to the extent permitted by law, interest on the Loans and any other amounts owing hereunder or under the other Credit Documents shall bear interest, payable on demand, at a per annum rate which is equal to the Default Rate.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest on each Loan shall be payable in arrears on each Interest Payment Date; <u>provided</u> that
interest accruing pursuant to paragraph (b) of this Section shall be payable from time to time on demand.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 2.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Conversion Options</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Borrower may elect from time to time to convert Alternate Base Rate Loans to LIBOR Rate Loans or
to continue LIBOR Rate Loans, by delivering a Notice of Conversion/Extension to the Administrative Agent at least three (3) Business Days prior to the proposed date of conversion or continuation. In addition, the Borrower may elect from time to time
to convert all or any portion of a LIBOR Rate Loan to an Alternate Base Rate Loan by giving the Administrative Agent irrevocable written notice thereof by 11:00 A.M. one (1) Business Day prior to the proposed date of conversion. If the date upon
which an Alternate Base Rate Loan is to be converted to a LIBOR Rate Loan is not a Business Day, then such conversion shall be made on the next succeeding Business Day and during the period from such last day of an Interest Period to such succeeding
Business Day such Loan shall bear interest as if it were an Alternate Base Rate Loan. LIBOR Rate Loans may only be converted to Alternate Base Rate Loans on the last day of the applicable Interest Period. If the date upon which a LIBOR Rate Loan is
to be converted to an Alternate Base Rate Loan is not a Business Day, then such conversion shall be made on the next succeeding Business Day and during the period from such last day of an Interest Period to such succeeding Business Day such Loan
shall bear interest as if it were an Alternate Base Rate Loan. All or any part of outstanding Alternate Base Rate Loans may be converted as provided herein; <u>provided</u> that (i) no Loan may be converted into a LIBOR Rate Loan when any Default or
Event of Default has occurred and is continuing and (ii) partial conversions shall be in an aggregate principal amount of $1,000,000 or a whole multiple of $1,000,000 in excess thereof. All or any part of outstanding LIBOR Rate Loans may be
converted as provided herein; <u>provided</u> that partial conversions shall be in an aggregate principal amount of $1,000,000 or a whole multiple of $1,000,000 in excess thereof.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any LIBOR Rate Loans may be continued as such upon the expiration of an Interest Period with respect
thereto by compliance by the Borrower with the notice provisions contained in Section 2.9(a); <u>provided</u>, that no LIBOR Rate Loan may be continued as such when any Default or Event of Default has occurred and is continuing, in which case such
Loan shall be automatically converted to an Alternate Base Rate Loan at the end of the applicable Interest Period with respect thereto. If the Borrower shall fail to give timely notice of an election to continue a LIBOR Rate Loan, or the
continuation of LIBOR Rate Loans is not permitted hereunder, such LIBOR Rate Loans shall be automatically converted to Alternate Base Rate Loans at the end of the applicable Interest Period with respect thereto.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
2.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Computation of Interest and Fees; Usury</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest payable hereunder with respect to any Alternate Base Rate Loan based on the Prime Rate shall
be calculated on the basis of a year of three hundred sixty-five (365) days (or three hundred sixty-six (366) days, as applicable) for the actual days elapsed. All other fees, interest and all other amounts payable hereunder shall be calculated on
the basis of a three hundred sixty (360) day year for the actual days elapsed. The Administrative Agent shall as soon as practicable notify the Borrower and the Lenders of each determination of a LIBOR Rate on the Business Day of the determination
thereof. Any change in the interest rate on a Loan resulting from a change in the Alternate Base Rate shall become effective as of the opening of business on the day on which such change in the Alternate Base Rate shall become effective. The
Administrative Agent shall as soon as practicable notify the Borrower and the Lenders of the effective date and the amount of each such change.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each determination of an interest rate by the Administrative Agent pursuant to any provision of this
Agreement shall be conclusive and binding on the Borrower and the Lenders in the absence of manifest error. The Administrative Agent shall, at the request of the Borrower, deliver to the Borrower a statement showing the computations used by the
Administrative Agent in determining any interest rate.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">38</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is the intent of the Lenders and the Credit Parties to conform to and contract in strict
compliance with applicable usury law from time to time in effect. All agreements between the Lenders and the Credit Parties are hereby limited by the provisions of this subsection which shall override and control all such agreements, whether now
existing or hereafter arising and whether written or oral. In no way, nor in any event or contingency (including, but not limited to, prepayment or acceleration of the maturity of any Obligation), shall the interest taken, reserved, contracted for,
charged, or received under this Agreement, under the Notes or otherwise, exceed the maximum nonusurious amount permissible under applicable law. If, from any possible construction of any of the Credit Documents or any other document, interest would
otherwise be payable in excess of the maximum nonusurious amount, any such construction shall be subject to the provisions of this paragraph and such interest shall be automatically reduced to the maximum nonusurious amount permitted under
applicable law, without the necessity of execution of any amendment or new document. If any Lender shall ever receive anything of value which is characterized as interest on the Loans under applicable law and which would, apart from this provision,
be in excess of the maximum nonusurious amount, an amount equal to the amount which would have been excessive interest shall, without penalty, be applied to the reduction of the principal amount owing on the Loans and not to the payment of interest,
or refunded to the Borrower or the other payor thereof if and to the extent such amount which would have been excessive exceeds such unpaid principal amount of the Loans. The right to demand payment of the Loans or any other Indebtedness evidenced
by any of the Credit Documents does not include the right to receive any interest which has not otherwise accrued on the date of such demand, and the Lenders do not intend to charge or receive any unearned interest in the event of such demand. All
interest paid or agreed to be paid to the Lenders with respect to the Loans shall, to the extent permitted by applicable law, be amortized, prorated, allocated, and spread throughout the full stated term (including any renewal or extension) of the
Loans so that the amount of interest on account of such Indebtedness does not exceed the maximum nonusurious amount permitted by applicable law.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
2.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Pro Rata Treatment and Payments</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Allocation of Payments Prior to Exercise of Remedies</u>. Each borrowing of Revolving Loans and
any reduction of the Revolving Commitments shall be made pro rata according to the respective Revolving Commitment Percentages of the Revolving Lenders. Unless otherwise required by the terms of this Agreement, each payment under this Agreement or
any Note shall be applied, <u>first</u>, to any fees then due and owing by the Borrower pursuant to Section 2.5, <u>second</u>, to interest then due and owing hereunder and under the Notes of the Borrower and, <u>third</u>, to principal then due and
owing hereunder and under the Notes of the Borrower. Each payment on account of any fees pursuant to Section 2.5 shall be made pro rata in accordance with the respective amounts due and owing (except as to the Letter of Credit Facing Fees and the
Issuing Lender Fees). Each payment or prepayment by the Borrower on account of principal of and interest on the Revolving Loans shall be applied to such Loans, as applicable, on a pro rata basis. Each mandatory prepayment on account of principal of
the Loans as required by Section 2.7(b)(i) shall be applied in accordance with Section 2.7(b)(ii). All payments (including prepayments) to be made by the Borrower on account of principal, interest and fees shall be made without defense, set-off or
counterclaim (except as provided in Section 2.16(b)) and shall be made to the Administrative Agent for the account of the Lenders at the Administrative Agent&#8217;s office specified in Section 9.2 in Dollars and in immediately available funds not
later than 1:00 P.M. on the date when due. The Administrative Agent shall distribute such payments to the Lenders entitled thereto promptly upon receipt in like funds as received. If any payment hereunder (other than payments on the LIBOR Rate
Loans) becomes due and payable on a day other than a Business Day, such payment shall be extended to the next succeeding Business Day, and, with respect to payments of principal, interest thereon shall be payable at the then applicable rate during
such extension. If any payment on a LIBOR Rate Loan becomes due and payable on a day other than a Business Day, such payment date shall be extended to the next succeeding Business Day unless the result of such extension would be to extend such
payment into another calendar month, in which event such payment shall be made on the immediately preceding Business Day.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Allocation of Payments After Exercise of Remedies</u>. Notwithstanding any other provisions of
this Agreement to the contrary, after the exercise of remedies (other than the invocation of default interest pursuant to Section 2.8) by the Administrative Agent or the Lenders pursuant to Section 7.2 (or after the Commitments shall automatically
terminate and the Loans (with accrued interest thereon) and all other amounts under the Credit Documents (including, without limitation, the maximum amount of all contingent liabilities under Letters of Credit) shall automatically become due and
payable in accordance with the terms of such Section), all amounts collected or received by the Administrative Agent or any Lender on account of the Credit Party Obligations or any other amounts outstanding under any of the Credit Documents shall be
paid over or delivered as follows (irrespective of whether the following costs, expenses, fees, interest, premiums, scheduled periodic payments or Credit Party Obligations are allowed, permitted or recognized as a claim in any proceeding resulting
from the occurrence of a Bankruptcy Event):</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">39</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">FIRST, to the payment of all reasonable out-of-pocket costs and expenses
(including, without limitation, reasonable attorneys&#8217; fees) of the Administrative Agent in connection with enforcing the rights of the Lenders under the Credit Documents;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">SECOND, to the payment of any fees owed to the Administrative Agent and the
Issuing Lenders;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">THIRD, to the payment of all reasonable out-of-pocket costs and expenses
(including, without limitation, reasonable and documented attorneys&#8217; fees) of each of the Lenders in connection with enforcing its rights under the Credit Documents or otherwise with respect to the Credit Party Obligations owing to such Lender
to the extent due and payable by any Credit Party pursuant to Section 9.5;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">FOURTH, to the payment of all of the Credit Party Obligations consisting of
accrued fees and interest, and including, with respect to any Bank Product, any fees, premiums and scheduled periodic payments due under such Bank Product (other than payments on account of principal) and any interest accrued thereon;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">FIFTH, to the payment of the outstanding principal amount of the Credit Party
Obligations and the payment or Cash Collateralization of the outstanding LOC Obligations, and including with respect to any Bank Product, any breakage, termination or other payments due under such Bank Product;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">SIXTH, to all other Credit Party Obligations and other obligations which shall
have become due and payable under the Credit Documents or otherwise and not repaid pursuant to clauses &#8220;FIRST&#8221; through &#8220;FIFTH&#8221; above; and</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">SEVENTH, to the payment of the surplus, if any, to whoever may be lawfully
entitled to receive such surplus.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">In carrying out the foregoing, (a) amounts received shall be applied in the numerical order provided until exhausted prior to
application to the next succeeding category; (b) each of the Lenders and any Bank Product Provider shall receive an amount equal to its pro rata share (based on the proportion that the then outstanding Loans and LOC Obligations held by such Lender
or the outstanding obligations payable to such Bank Product Provider bears to the aggregate then outstanding Loans and LOC Obligations and obligations payable under all Bank Products) of amounts available to be applied pursuant to clauses
&#8220;THIRD,&#8221; &#8220;FOURTH,&#8221; &#8220;FIFTH&#8221; and &#8220;SIXTH&#8221; above; and (c) to the extent that any amounts available for distribution pursuant to clause &#8220;FIFTH&#8221; above are attributable to the issued but undrawn
amount of outstanding Letters of Credit, such amounts shall be held by the Administrative Agent in a Cash Collateral account and applied (i) first, to reimburse the applicable Issuing Lenders from time to time for any drawings under such Letters of
Credit and (ii) then, following the expiration of all Letters of Credit, to all other obligations of the types described in clauses &#8220;FIFTH&#8221; and &#8220;SIXTH&#8221; above in the manner provided in this Section. Notwithstanding the
foregoing terms of this Section, (x) only payments under the Guaranty (as opposed to ordinary course principal, interest and fee payments hereunder) shall be applied to obligations under any Bank Product and (y) Excluded Swap Obligations with
respect to any Guarantor shall not be paid with amounts received from such Guarantor or its assets, but appropriate adjustments shall be made with respect to payments from other Credit Parties to preserve the allocation to Credit Party Obligations
otherwise set forth above in this Section.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 2.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Receipt of Funds by the Administrative Agent</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Funding by Lenders; Presumption by Administrative Agent</u>. Unless the Administrative Agent shall
have received written notice from a Lender prior to the proposed time of any Extension of Credit that such Lender will not make available to the Administrative Agent such Lender&#8217;s share of such Extension of Credit, the Administrative Agent may
assume that such Lender has made such share available on such date in accordance with this Agreement and may, in reliance upon such assumption, make available to the Borrower a corresponding</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">40</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">amount. In such event, if a Lender has not in fact made its share of the applicable Extension of Credit available to the
Administrative Agent, then the applicable Lender and the Borrower severally agree to pay to the Administrative Agent forthwith on demand such corresponding amount with interest thereon, for each day from and including the date such amount is made
available to the Borrower to but excluding the date of payment to the Administrative Agent, at (i) in the case of a payment to be made by such Lender, the greater of the Federal Funds Effective Rate and a rate determined by the Administrative Agent
in accordance with banking industry rules on interbank compensation and (ii) in the case of a payment to be made by the Borrower, the interest rate applicable to Alternate Base Rate Loans. If the Borrower and such Lender shall pay such interest to
the Administrative Agent for the same or an overlapping period, the Administrative Agent shall promptly remit to the Borrower the amount of such interest paid by the Borrower for such period. If such Lender pays its share of the applicable Extension
of Credit to the Administrative Agent, then the amount so paid shall constitute such Lender&#8217;s Loan included in such Extension of Credit. Any payment by the Borrower shall be without prejudice to any claim the Borrower may have against a Lender
that shall have failed to make such payment to the Administrative Agent.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Payments by Borrower; Presumptions by Administrative Agent</u>. Unless the Administrative Agent
shall have received notice from the Borrower prior to the date on which any payment is due to the Administrative Agent for the account of the Lenders or the Issuing Lenders hereunder that the Borrower will not make such payment, the Administrative
Agent may assume that the Borrower has made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Lenders or the Issuing Lenders, as the case may be, the amount due. In such event, if the
Borrower has not in fact made such payment, then each of the Lenders or the Issuing Lenders, as the case may be, severally agrees to repay to the Administrative Agent forthwith on demand the amount so distributed to such Lender or such Issuing
Lender, with interest thereon, for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Administrative Agent, at the greater of the Federal Funds Effective Rate and a rate determined by
the Administrative Agent in accordance with banking industry rules on interbank compensation.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">A notice of the Administrative Agent to any Lender or the Borrower with respect to any amount owing under subsections (a) and (b) of
this Section shall be conclusive, absent manifest error.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Failure to Satisfy Conditions Precedent</u>. If any Lender makes available to the Administrative
Agent funds for any Loan to be made by such Lender as provided in the foregoing provisions of this <u>Article II</u>, and such funds are not made available to the Borrower by the Administrative Agent because the conditions to the applicable
Extension of Credit set forth in <u>Article IV</u> are not satisfied or waived in accordance with the terms thereof, the Administrative Agent shall return such funds (in like funds as received from such Lender) to such Lender, without interest.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Obligations of Lenders Several</u>. The obligations of the Lenders hereunder to make Revolving
Loans, to fund participations in Letters of Credit and to make payments pursuant to Section 9.5(c) are several and not joint. The failure of any Lender to make any Loan, to fund any such participation or to make any such payment under Section 9.5(c)
on any date required hereunder shall not relieve any other Lender of its corresponding obligation to do so on such date, and no Lender shall be responsible for the failure of any other Lender to so make its Loan, to purchase its participation or to
make its payment under Section 9.5(c).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Funding Source</u>. Nothing herein shall be deemed to obligate any Lender to obtain the funds for
any Loan in any particular place or manner or to constitute a representation by any Lender that it has obtained or will obtain the funds for any Loan in any particular place or manner.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
2.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Alternate Rate of Interest</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If prior to the commencement of any Interest Period for a LIBOR Rate Loan:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Administrative Agent determines (which
determination shall be conclusive absent manifest error) that adequate and reasonable means do not exist for ascertaining the LIBOR Rate (including, without limitation, because the LIBO Screen Rate is not available or published on a current basis),
for Dollars and such Interest Period; or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">41</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Administrative Agent is advised by the
Required Lenders that the LIBOR Rate for such Interest Period will not adequately and fairly reflect the cost to such Lenders (or Lender) of making or maintaining their Loans (or its Loan) included in such borrowing for such Interest Period;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">then the Administrative Agent
shall give notice thereof to the Borrower and the Lenders by telephone or telecopy, confirmed in writing, as promptly as practicable thereafter, and until the Administrative Agent notifies the Borrower and the Lenders that the circumstances giving
rise to such notice no longer exist, any Notice of Conversion/Extension submitted by Borrower during such period that requests the conversion of any Revolving Loan to, or continuation of any Revolving Loan as, a LIBOR Rate Loan, shall be
ineffective.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If at any time the Administrative Agent determines (which determination shall be conclusive absent
manifest error) that (i) the circumstances set forth in clause (a)(i) have arisen and such circumstances are unlikely to be temporary or (ii) the circumstances set forth in clause (a)(i) have not arisen but the supervisor for the administrator of
the LIBO Screen Rate or a Governmental Authority having jurisdiction over the Administrative Agent has made a public statement identifying a specific date after which the LIBO Screen Rate shall no longer be used for determining interest rates for
loans, then the Administrative Agent and the Borrower shall endeavor to establish an alternate rate of interest to the LIBOR Rate that gives due consideration to the then prevailing market convention for determining a rate of interest for syndicated
loans in the United States at such time, and shall enter into an amendment to this Agreement to reflect such alternate rate of interest and such other related changes to this Agreement as may be applicable. Notwithstanding anything to the contrary
in Section 9.1, such amendment shall become effective without any further action or consent of any other party to this Agreement so long as the Administrative Agent shall not have received, within ten (10) Business Days of the date notice of such
alternate rate of interest is provided to the Lenders, a written notice from the Required Lenders stating that such Required Lenders object to such amendment. Until an alternate rate of interest shall be determined in accordance with this clause (b)
(but, in the case of the circumstances described in clause (ii) of the first sentence of this Section 2.13(b), only to the extent the LIBO Screen Rate for such Interest Period is not available or published at such time on a current basis), any
Notice of Borrowing or Notice of Conversion/Extension submitted by Borrower during such period that requests a Loan as, or the conversion of any Loans to, or continuation of any Loans as, a LIBOR Rate Loan shall be ineffective; <u>provided</u> that,
if such alternate rate of interest shall be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
2.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Yield Protection</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Increased Costs Generally</u>. If any Change in Law shall:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;impose, modify or deem applicable any
reserve, special deposit, compulsory loan, insurance charge or similar requirement against assets of, deposits with or for the account of, or credit extended or participated in by, any Lender (except any reserve requirement reflected in the LIBOR
Rate) or any Issuing Lender;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subject any Recipient to any Taxes (other
than Indemnified Taxes and Excluded Taxes) on or with respect to its loans, letters of credit, commitments, or other obligations, or its deposits, reserves, other liabilities or capital actually attributable thereto; or</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;impose on any Lender or any Issuing
Lender or the London interbank market any other condition, cost or expense affecting this Agreement or LIBOR Rate Loans made by such Lender or any Letter of Credit or participation therein;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">and the result of any of the
foregoing shall be to increase the cost to such Lender or such other Recipient of making, converting to, continuing or maintaining any LIBOR Rate Loan or of maintaining its obligation to make any such Loan, or to increase the cost to such Lender,
such Issuing Lender or such other Recipient of participating in, issuing or maintaining any Letter of Credit (or of maintaining its obligation to participate in or to issue any Letter of Credit), or to reduce the amount of any sum received or
receivable by such Lender, such Issuing Lender or other Recipient hereunder (whether of principal, interest or any other amount) then, upon request of such Lender, such Issuing Lender or other Recipient, the Borrower will pay to such Lender, such
Issuing Lender or other Recipient, as the case may be, such additional amount or amounts as will compensate such Lender, such Issuing Lender or other Recipient, as the case may be, for such additional costs incurred or reduction suffered. The
agreements in this Section shall survive termination of this Agreement and payment of the Credit Party Obligations.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">42</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Capital Requirements</u>. If any Lender or any Issuing Lender determines that any Change in Law
affecting such Lender or such Issuing Lender or any lending office of such Lender or such Lender&#8217;s or such Issuing Lender&#8217;s holding company, if any, regarding capital or liquidity requirements has or would have the effect of reducing the
rate of return on such Lender&#8217;s or such Issuing Lender&#8217;s capital or on the capital of such Lender&#8217;s or such Issuing Lender&#8217;s holding company, if any, as a consequence of this Agreement, the Commitments of such Lender or the
Loans made by, or participations in Letters of Credit held by, such Lender, or the Letters of Credit issued by the such Issuing Lender, to a level below that which such Lender or such Issuing Lender or such Lender&#8217;s or such Issuing
Lender&#8217;s holding company could have achieved but for such Change in Law (taking into consideration such Lender&#8217;s or such Issuing Lender&#8217;s policies and the policies of such Lender&#8217;s or such Issuing Lender&#8217;s holding
company with respect to capital adequacy and liquidity), then from time to time the Borrower will pay to such Lender or such Issuing Lender, as the case may be, such additional amount or amounts as will compensate such Lender or such Issuing Lender
or such Lender&#8217;s or such Issuing Lender&#8217;s holding company for any such reduction suffered.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certificates for Reimbursement</u>. Subject to Section 2.14(d) below, each Lender and each Issuing
Lender shall promptly notify the Borrower and the Administrative Agent of any event of which it has knowledge, occurring after the date hereof, which will entitle such Lender or such Issuing Lender, as the case may be, to compensation pursuant to
this Section. Any Lender or any Issuing Lender claiming compensation under this Section shall furnish to the Borrower and the Administrative Agent a certificate of such Lender or such Issuing Lender, as the case may be, setting forth the amount or
amounts necessary to compensate such Lender or such Issuing Lender or its holding company, as the case may be, as specified in paragraph (a) or (b) of this Section, which shall be conclusive absent manifest error. The Borrower shall pay such Lender
or such Issuing Lender, as the case may be, the amount shown as due on any such certificate within ten (10) days after receipt thereof.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Delay in Requests</u>. Failure or delay on the part of any Lender or any Issuing Lender to demand
compensation pursuant to this Section shall not constitute a waiver of such Lender&#8217;s or such Issuing Lender&#8217;s right to demand such compensation, <u>provided</u> that the Borrower shall not be required to compensate a Lender or an Issuing
Lender pursuant to this Section for any increased costs incurred or reductions suffered more than 180 days prior to the date such Lender or such Issuing Lender, as the case may be, notifies the Borrower in writing of the Change in Law giving rise to
such increased costs or reductions, and of such Lender&#8217;s or such Issuing Lender&#8217;s intention to claim compensation therefore (except that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the
180-day period referred to above shall be extended to include the period of retroactive effect thereof).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other provision of this Section 2.14, no Lender or Issuing Lender shall demand
compensation for any increased costs under this Section 2.14 if it shall not be the general policy or practice of such Lender or such Issuing Lender to demand such compensation in similar circumstances and unless such demand is generally consistent
with such Lender&#8217;s or such Issuing Lender&#8217;s, as applicable, treatment of comparable borrowers of such Lender or Issuing Lender in the United States with respect to similarly affected commitments or loans</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
2.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnity</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Credit Parties hereby agree to indemnify each Lender and to hold such Lender harmless from any actual funding loss or expense
which such Lender may sustain or incur as a consequence of (a) the failure by the Borrower to pay the principal amount of or interest on any Loan by such Lender in accordance with the terms hereof, (b) the failure by the Borrower to accept a
borrowing after the Borrower has given a notice in accordance with the terms hereof, (c) default by the Borrower in making any prepayment after the Borrower has given a notice in accordance with the terms hereof, (d) any assignment of a LIBOR Rate
Loan on a day other than the last day of the interest Period therefore as a result of a request by the Borrower pursuant to Section 2.19 and/or (e) the making by the Borrower of a prepayment of a LIBOR Rate Loan, or the conversion thereof, on a day
which is not the last day of the Interest Period with respect thereto, in each case including, but not limited to, any such loss or expense arising from interest or fees payable by such Lender to lenders of funds obtained by it in order to maintain
its</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">43</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">LIBOR
Rate Loans hereunder. A certificate setting forth in reasonable detail as to any additional amounts payable pursuant to this Section submitted by any Lender, through the Administrative Agent, to the Borrower (which certificate must be delivered to
the Administrative Agent within thirty (30) days following such default, prepayment, conversion or assignment) shall be conclusive in the absence of manifest error. The agreements in this Section shall survive termination of this Agreement and
payment of the Credit Party Obligations.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 2.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Taxes</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Payments Free of Taxes</u>. Except as otherwise required by Requirements of Law, any and all
payments by or on account of any obligation of any Credit Party hereunder or under any other Credit Document shall be made free and clear of and without reduction or withholding for any Taxes, <u>provided</u> that if any applicable withholding agent
shall be required by applicable law to deduct any Taxes from such payments, then (i) if such Taxes are Indemnified Taxes (including any Other Taxes), the sum payable shall be increased as necessary so that after making all required deductions
(including deductions applicable to additional sums payable under this Section) the applicable Lender (or, in the case of payments made to the Administrative Agent for its own account, the Administrative Agent), receives an amount equal to the sum
it would have received had no such deductions been made, (ii) the applicable withholding agent shall make such deductions and (iii) the applicable withholding agent shall timely pay the full amount deducted to the relevant Governmental Authority in
accordance with Requirements of Law.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Payment of Other Taxes by the Borrower</u>. Without limiting the provisions of paragraph (a)
above, the Borrower shall timely pay any Other Taxes to the relevant Governmental Authority in accordance with Requirements of Law.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification by the Borrower</u>. The Borrower shall indemnify the Administrative Agent and
each Lender, within ten (10) days after demand therefor, for the full amount of any Indemnified Taxes or Other Taxes (including Indemnified Taxes or Other Taxes imposed or asserted on or attributable to amounts payable under this Section) paid by
the Administrative Agent or such Lender, as the case may be, and any penalties, interest and reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes or Other Taxes were correctly or legally imposed or
asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability (setting forth in reasonable detail the basis for such demand) delivered to the Borrower by a Lender (with a copy to the Administrative
Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Evidence of Payments</u>. As soon as practicable after any payment of any Taxes by the Borrower to
a Governmental Authority, the Borrower shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other
evidence of such payment reasonably satisfactory to the Administrative Agent.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Status of Lenders</u>. Each Lender that is entitled to an exemption from or reduction of any
applicable withholding Tax with respect to payments hereunder or under any other Credit Document shall deliver to the Borrower (with a copy to the Administrative Agent), at the time or times prescribed by Requirements of Law or reasonably requested
by the Borrower or the Administrative Agent, such properly completed and executed documentation prescribed by Requirements of Law as will permit such payments to be made without withholding or at a reduced rate of withholding. Each such Lender
shall, whenever a lapse in time or change in circumstances renders any such documentation (including any specific documentation required below in Section 2.16(f)) obsolete, expired or inaccurate in any respect, deliver promptly to the Borrower and
the Administrative Agent updated or other appropriate documentation (including any new documentation reasonably requested by the Borrower or the Administrative Agent) or promptly notify the Borrower and the Administrative Agent in writing of its
legal ineligibility to do so. In addition, any Lender, if requested by the Borrower or the Administrative Agent, shall deliver such other documentation prescribed by Requirements of Law or reasonably requested by the Borrower or the Administrative
Agent as will enable the Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without limiting the generality of the foregoing,</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">44</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each U.S. Lender shall deliver to the
Borrower and the Administrative Agent on or prior to the date on which such U.S. Lender becomes a Lender under this Agreement (and from time to time thereafter upon the request of the Borrower or the Administrative Agent) two duly completed
originals of Internal Revenue Service Form W-9 certifying that such U.S. Lender is exempt from United States federal backup withholding.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Foreign Lender shall deliver to the
Borrower and the Administrative Agent on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the request of the Borrower or the Administrative Agent), whichever of the
following is applicable:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;two duly completed originals of Internal
Revenue Service Form W-8BEN or W-8BEN-E (or any successor forms) claiming eligibility for benefits of an income tax treaty to which the United States of America is a party,</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;two duly completed originals of Internal
Revenue Service Form W-8ECI (or any successor forms),</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in the case of a Foreign Lender claiming
the benefits of the exemption for portfolio interest under section 881(c) of the Code, (i) a certificate to the effect that such Foreign Lender is not (A) a &#8220;bank&#8221; within the meaning of section 881(c)(3)(A) of the Code, (B) a &#8220;10
percent shareholder&#8221; of the Borrower within the meaning of section 881(c)(3)(B) of the Code, or (C) a &#8220;controlled foreign corporation&#8221; described in section 881(c)(3)(C) of the Code and that no payments in connection with any Credit
Document are effectively connected with such Lender&#8217;s conduct of a United States trade or business (a &#8220;United States Tax Compliance Certificate&#8221;) and (ii) two duly completed originals of Internal Revenue Service Form W-8BEN or
W-8BEN-E (or any successor forms),</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(D)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to the extent a Foreign Lender is not the
beneficial owner of a Loan (for example, where the Foreign Lender is a partnership or a participating Lender), two duly completed originals of Internal Revenue Service Form W-8IMY (or any successor forms) of the Foreign Lender, accompanied by a Form
W-8ECI, W-8BEN or W-8BEN-E, United States Tax Compliance Certificate, Form W-9, Form W-8IMY or any other required information (or any successor forms) from each beneficial owner that would be required under this Section 2.16(f) if such beneficial
owner were a Lender, as applicable (provided that if the Foreign Lender is a partnership (and not a participating Lender) and one or more direct or indirect partners are claiming the portfolio interest exemption, the United States Tax Compliance
Certificate may be provided by such Foreign Lender on behalf of such direct or indirect partner(s)), or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(E)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any other form prescribed by Requirements
of Law as a basis for claiming exemption from or a reduction in United States federal withholding Tax duly completed together with such supplementary documentation as may be prescribed by Requirements of Law to permit the Borrower or Administrative
Agent to determine the withholding or deduction required to be made.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If a payment made to a Lender under any
Credit Document would be subject to United States federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Sections 1471(b) or 1472(b) of the
Code, as applicable), such Lender shall deliver to the Borrower and the Administrative Agent at the time or times prescribed by Requirements of Law and at such time or times reasonably requested by the Borrower or the Administrative Agent such
documentation prescribed by Requirements of Law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Administrative Agent as may be necessary for the Borrower
and the Administrative Agent to comply with their FATCA obligations, to determine whether such Lender has or has not complied with such Lender&#8217;s FATCA obligations and to determine the amount, if any, to deduct and withhold from such payment;
<u>provided</u>, <u>however</u>, that the Borrower shall have no obligation to request any documentation or take any other action to decrease any withholding obligation under FATCA.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">45</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other provision of
Section 2.16(e) or this Section 2.16(f), a Lender shall not be required to deliver any documentation that such Lender is not legally eligible to deliver. Each Lender hereby authorizes the Administrative Agent to deliver to the Credit Parties and to
any successor Administrative Agent any documentation provided by such Lender pursuant to these Sections 2.16(e) and (f).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Treatment of Certain Refunds</u>. If the Administrative Agent or a Lender determines, in its sole
discretion, that it has received a refund of any Indemnified Taxes or Other Taxes as to which it has been indemnified by any Credit Party or with respect to which any Credit Party has paid additional amounts pursuant to this Section, it shall pay to
such Credit Party an amount equal to such refund (but only to the extent of indemnity payments made, or additional amounts paid, by such Credit Party under this Section 2.16 with respect to the Indemnified Taxes or Other Taxes giving rise to such
refund), net of all out-of-pocket expenses (including any Taxes) of the Administrative Agent or such Lender, as the case may be, and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund),
<u>provided</u> that such Credit Party, upon the request of the Administrative Agent or such Lender shall repay the amount paid over to such Credit Party (plus any penalties, interest or other charges imposed by the relevant Governmental Authority)
to the Administrative Agent or such Lender in the event the Administrative Agent or such Lender is required to repay such refund to such Governmental Authority. This paragraph shall not be construed to require the Administrative Agent or any Lender
to make available its tax returns (or any other information relating to its Taxes that it deems confidential) to the Borrower or any other Person.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the avoidance of doubt, the term &#8220;Lender&#8221; shall, for purposes of this Section 2.16,
include any Issuing Lender.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 2.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification; Nature of Issuing Lenders&#8217; Duties</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to its other obligations under Section 2.3, the Credit Parties hereby agree to protect,
indemnify, pay and save each Issuing Lender and each Lender harmless from and against any and all claims, demands, liabilities, damages, losses, costs, charges and expenses (including reasonable and documented attorneys&#8217; fees) that such
Issuing Lender or such Lender may incur or be subject to as a consequence, direct or indirect, of (i) the issuance of any Letter of Credit or (ii) the failure of any Issuing Lender to honor a drawing under any Letter of Credit as a result of any act
or omission, whether rightful or wrongful, of any present or future de jure or de facto government or Governmental Authority (all such acts or omissions, herein called &#8220;<u>Government Acts</u>&#8221;).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As among the Credit Parties, each Issuing Lender and each Lender, the Credit Parties shall assume all
risks of the acts, omissions or misuse of any Letter of Credit by the beneficiary thereof. In the absence of their gross negligence or willful misconduct, neither any Issuing Lender nor any Lender shall be responsible: (i) for the form, validity,
sufficiency, accuracy, genuineness or legal effect of any document submitted by any party in connection with the application for and issuance of any Letter of Credit, even if it should in fact prove to be in any or all respects invalid,
insufficient, inaccurate, fraudulent or forged; (ii) for the validity or sufficiency of any instrument transferring or assigning or purporting to transfer or assign any Letter of Credit or the rights or benefits thereunder or proceeds thereof, in
whole or in part, that may prove to be invalid or ineffective for any reason; (iii) for failure of the beneficiary of a Letter of Credit to comply fully with conditions required in order to draw upon a Letter of Credit; (iv) for errors, omissions,
interruptions or delays in transmission or delivery of any messages, by mail, cable, telegraph, telex or otherwise, whether or not they be in cipher; (v) for errors in interpretation of technical terms; (vi) for any loss or delay in the transmission
or otherwise of any document required in order to make a drawing under a Letter of Credit or of the proceeds thereof; and (vii) for any consequences arising from causes beyond the control of any Issuing Lender or any Lender, including, without
limitation, any Government Acts. None of the above shall affect, impair, or prevent the vesting of the Issuing Lenders&#8217; rights or powers hereunder.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In furtherance and extension and not in limitation of the specific provisions hereinabove set forth,
any action taken or omitted by any Issuing Lender or any Lender, under or in connection with any Letter of Credit or the related certificates, if taken or omitted in the absence of gross negligence or willful misconduct, shall not put</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">46</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">such
Issuing Lender or such Lender under any resulting liability to the Credit Parties. It is the intention of the parties that this Agreement shall be construed and applied to protect and indemnify each Issuing Lender and each Lender against any and all
risks involved in the issuance of the Letters of Credit, all of which risks are hereby assumed by the Credit Parties, including, without limitation, any and all risks of the acts or omissions, whether rightful or wrongful, of any Government
Authority. The Issuing Lenders and the Lenders shall not, in any way, be liable for any failure by the Issuing Lenders or anyone else to pay any drawing under any Letter of Credit as a result of any Government Acts or any other cause beyond the
control of the Issuing Lenders and the Lenders.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing in this Section is intended to limit the Reimbursement Obligation of the Borrower contained
in Section 2.3(d) hereof. The obligations of the Credit Parties under this Section shall survive the termination of this Agreement. No act or omissions of any current or prior beneficiary of a Letter of Credit shall in any way affect or impair the
rights of the Issuing Lenders and the Lenders to enforce any right, power or benefit under this Agreement.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary contained in this Section, the Credit Parties shall have no
obligation to indemnify any Issuing Lender or any Lender in respect of any liability incurred by such Issuing Lender or such Lender arising out of the gross negligence or willful misconduct of the Issuing Lenders (including action not taken by such
Issuing Lender or such Lender), as determined by a court of competent jurisdiction or pursuant to arbitration.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 2.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Illegality</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Notwithstanding any other provision of this Credit Agreement, if any Change in Law shall make it unlawful for such Lender or its
LIBOR Lending Office to make or maintain LIBOR Rate Loans as contemplated by this Credit Agreement or to obtain in the interbank eurodollar market through its LIBOR Lending Office the funds with which to make such Loans, (a) such Lender shall
promptly notify the Administrative Agent and the Borrower thereof, (b) the commitment of such Lender hereunder to make LIBOR Rate Loans or continue LIBOR Rate Loans as such shall forthwith be suspended until the Administrative Agent shall give
notice that the condition or situation which gave rise to the suspension shall no longer exist, and (c) such Lender&#8217;s Loans then outstanding as LIBOR Rate Loans, if any, shall be converted on the last day of the Interest Period for such Loans
or within such earlier period as required by law as Alternate Base Rate Loans. The Borrower hereby agrees to promptly pay any Lender, upon its demand, any additional amounts necessary to compensate such Lender for actual and direct costs (but not
including anticipated profits) reasonably incurred by such Lender in making any repayment in accordance with this Section including, but not limited to, any interest or fees payable by such Lender to lenders of funds obtained by it in order to make
or maintain its LIBOR Rate Loans hereunder. A certificate (which certificate shall include a description of the basis for the computation) as to any additional amounts payable pursuant to this Section submitted by such Lender, through the
Administrative Agent, to the Borrower shall be conclusive in the absence of manifest error. Each Lender agrees to use reasonable efforts (including reasonable efforts to change its LIBOR Lending Office) to avoid or to minimize any amounts which may
otherwise be payable pursuant to this Section; <u>provided</u>, <u>however</u>, that such efforts shall not cause the imposition on such Lender of any additional costs or legal or regulatory burdens deemed by such Lender in its sole discretion to be
material.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 2.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Replacement of Lenders</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Designation of a Different Lending Office</u>. If any Lender requests compensation under Section
2.14, or requires the Borrower to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 2.16 or 2.18, then such Lender shall use reasonable efforts to designate a different lending
office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or affiliates, if, in the reasonable judgment of such Lender, such designation or assignment (i) would eliminate
or reduce amounts payable pursuant to Section 2.14, Section 2.16 or Section 2.18, as the case may be, in the future and (ii) would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender.
The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">47</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Replacement of Lenders</u>. (i) If any Lender requests compensation under Section 2.14 or if the
Borrower is required to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 2.16 or Section 2.18 and, in each case, such Lender has declined or is unable to designate a different
lending office in accordance with Section 2.19(a) or (ii) if any Lender is a Defaulting Lender or a Non-Consenting Lender, then the Borrower may, at its sole expense and effort, upon notice to such Lender and the Administrative Agent, require such
Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, Section 9.6), all of its interests, rights (other than its existing rights to payments pursuant to Section
2.14, Section 2.16 or Section 2.18) and obligations under this Agreement and the related Credit Documents to an Eligible Assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment),
<u>provided</u> that:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Borrower shall have paid to the
Administrative Agent the assignment fee specified in Section 9.6;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such Lender shall have received payment
of an amount equal to the outstanding principal of its Loans and participations in Letters of Credit, accrued interest thereon, accrued fees and all other amounts payable to it hereunder and under the other Credit Documents (including any amounts
under Section 2.15) from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Borrower (in the case of all other amounts);</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in the case of any such assignment
resulting from a claim for compensation under Section 2.14 or payments required to be made pursuant to Section 2.16 or Section 2.18, such assignment will result in a reduction in such compensation or payments thereafter;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(D)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such assignment does not conflict with
Requirements of Law; and</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(E)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in the case of any assignment resulting
from a Lender becoming a Non-Consenting Lender, the applicable assignee shall have consented to the applicable amendment, waiver or consent.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">A Lender
shall not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower to require such assignment and delegation cease to apply.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
2.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Cash Collateral</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Cash Collateral</u>. At any time that there shall exist a Defaulting Lender, within one (1)
Business Day following the written request of the Administrative Agent, the Issuing Lenders (with a copy to the Administrative Agent), the Borrower shall Cash Collateralize all Fronting Exposure of the Issuing Lenders with respect to such Defaulting
Lender (determined after giving effect to Section 2.21(a)(iv) and Section 2.21(b) and any Cash Collateral provided by the Defaulting Lender).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Grant of Security Interest</u>. The Borrower, and to the extent provided by any Defaulting Lender,
such Defaulting Lender, hereby grants to the Administrative Agent, for the benefit of the Administrative Agent, the Issuing Lenders and the Lenders, and agrees to maintain, a first priority security interest in all such Cash Collateral as security
for the Defaulting Lenders&#8217; obligations to which such Cash Collateral may be applied pursuant to clause (c) below. If at any time the Administrative Agent or any Issuing Lender determines that Cash Collateral is subject to any right or claim
of any Person other than the Administrative Agent as herein provided, or that the total amount of such Cash Collateral is less than the applicable Fronting Exposure, the Borrower will, promptly upon demand by the Administrative Agent or such Issuing
Lender, pay or provide to the Administrative Agent additional Cash Collateral in an amount sufficient to eliminate such deficiency (after giving effect to any Cash Collateral provided by the Defaulting Lender).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Application</u>. Notwithstanding anything to the contrary contained in this Agreement, Cash
Collateral provided under any of this Section or Section 2.21 in respect of Letters of Credit, shall be held and applied to the satisfaction of the specific LOC Obligations, obligations to fund participations therein (including, as to Cash
Collateral provided by a Defaulting Lender, any interest accrued on such obligation) and other obligations for which the Cash Collateral was so provided, prior to any other application of such property as may be provided for herein.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">48</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination of Requirement</u>. Cash Collateral (or the appropriate portion thereof) provided to
reduce Fronting Exposure or other obligations shall no longer be required to be held as Cash Collateral pursuant to this Section 2.20 and shall promptly be released to the Person providing such Cash Collateral following (i) the elimination of the
applicable Fronting Exposure or other obligations giving rise thereto (including by the termination of Defaulting Lender status of the applicable Lender), or (ii) the determination by the Administrative Agent or any Issuing Lender that there exists
excess Cash Collateral; <u>provided</u> that, subject to Section 2.21, the Person providing Cash Collateral and the applicable Issuing Lenders may agree that Cash Collateral shall be held to support future anticipated Fronting Exposure or other
obligations.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 2.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Defaulting Lenders</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Defaulting Lender Adjustments</u>. Notwithstanding anything to the contrary contained in this
Agreement, if any Lender becomes a Defaulting Lender, then, until such time as such Lender is no longer a Defaulting Lender, to the extent permitted by applicable law:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Waivers and Amendments</u>. Such
Defaulting Lender&#8217;s right to approve or disapprove any amendment, waiver or consent with respect to this Agreement shall be restricted as set forth in the definition of Required Lenders and Section 9.1.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Defaulting Lender Waterfall</u>. Any
payment of principal, interest, fees or other amounts received by the Administrative Agent for the account of such Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to Article VII or otherwise) or received by the
Administrative Agent from a Defaulting Lender pursuant to Section 9.7 shall be applied at such time or times as may be determined by the Administrative Agent as follows: <i>first</i>, to the payment of any amounts owing by such Defaulting Lender to
the Administrative Agent hereunder; <i>second</i>, to the payment on a pro rata basis of any amounts owing by such Defaulting Lender to the Issuing Lenders hereunder; <i>third</i>, to Cash Collateralize the Issuing Lenders&#8217; Fronting Exposure
in accordance with Section 2.20; <i>fourth</i>, as the Borrower may request (so long as no Default or Event of Default exists), to the funding of any Loan in respect of which such Defaulting Lender has failed to fund its portion thereof as required
by this Agreement, as determined by the Administrative Agent; <i>fifth</i>, if so determined by the Administrative Agent and the Borrower, to be held in a non-interest bearing deposit account and released pro rata in order to (x) satisfy such
Defaulting Lender&#8217;s potential future funding obligations with respect to Loans under this Agreement and (y) Cash Collateralize the Issuing Lenders&#8217; future Fronting Exposure with respect to such Defaulting Lender with respect to future
Letters of Credit issued under this Agreement in accordance with Section 2.20; <i>sixth</i>, to the payment of any amounts owing to the Lenders, the Issuing Lenders as a result of any judgment of a court of competent jurisdiction obtained by any
Lender or by any Issuing Lender against such Defaulting Lender as a result of such Defaulting Lender&#8217;s breach of its obligations under this Agreement; <i>seventh</i>, so long as no Default or Event of Default exists, to the payment of any
amounts owing to the Borrower as a result of any judgment of a court of competent jurisdiction obtained by the Borrower against such Defaulting Lender as a result of such Defaulting Lender&#8217;s breach of its obligations under this Agreement; and
<i>eighth</i>, to such Defaulting Lender or as otherwise directed by a court of competent jurisdiction; <u>provided</u> that if (A) such payment is a payment of the principal amount of any Loans or LOC Obligations in respect of which such Defaulting
Lender has not fully funded its appropriate share and (B) such Loans were made or the related Letters of Credit were issued at a time when the conditions set forth in Section 4.2 were satisfied or waived, such payment shall be applied solely to pay
the Loans of, and LOC Obligations owed to, all Non-Defaulting Lenders on a pro rata basis prior to being applied to the payment of any Loans of, or LOC Obligations owed to, such Defaulting Lender until such time as all Loans and funded and unfunded
participations in LOC Obligations are held by the Lenders pro rata in accordance with the Commitments under the applicable facility without giving effect to Section 2.21(a) (iv). Any payments, prepayments or other amounts paid or payable to a
Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender or to post Cash Collateral pursuant to this Section 2.21(a)(ii) shall be deemed paid to and redirected by such Defaulting Lender, and each Lender irrevocably
consents hereto.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">49</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Fees</u>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Unused Commitment Fees</u>. No
Defaulting Lender shall be entitled to receive any Unused Commitment Fee for any period during which that Lender is a Defaulting Lender (and the Borrower shall not be required to pay any such fee that otherwise would have been required to have been
paid to that Defaulting Lender).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Letter of Credit Fees</u>. Each
Defaulting Lender shall be entitled to receive Letter of Credit Fees for any period during which that Lender is a Defaulting Lender only to the extent allocable to its Revolving Commitment Percentage of the stated amount of Letters of Credit for
which it has provided Cash Collateral pursuant Section 2.20.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reallocation of Fees</u>. With respect
to any Letter of Credit Fee not required to be paid to any Defaulting Lender pursuant to clause (B) above, the Borrower shall (x) pay to each Non-Defaulting Lender that portion of any such fee otherwise payable to such Defaulting Lender with respect
to such Defaulting Lender&#8217;s participation in LOC Obligations that has been reallocated to such Non-Defaulting Lender pursuant to clause (iv) below, (y) pay to each Issuing Lender, the amount of any such fee otherwise payable to such Defaulting
Lender to the extent allocable to such Issuing Lender&#8217; Fronting Exposure to such Defaulting Lender, and (z) not be required to pay the remaining amount of any such fee.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reallocation of Participations to
Reduce Fronting Exposure</u>. All or any part of such Defaulting Lender&#8217;s participation in LOC Obligations shall be reallocated among the Non-Defaulting Lenders in accordance with their respective Revolving Commitment Percentage (calculated
without regard to such Defaulting Lender&#8217;s Revolving Commitment) but only to the extent that (x) the conditions set forth in Section 4.2 are satisfied at the time of such reallocation (and, unless the Borrower shall have otherwise notified the
Administrative Agent at such time, the Borrower shall be deemed to have represented and warranted that such conditions are satisfied at such time) and (y) such reallocation does not cause the aggregate Committed Funded Exposure of any Non-Defaulting
Lender to exceed such Non-Defaulting Lender&#8217;s Revolving Commitment. Subject to Section 9.27, no reallocation hereunder shall constitute a waiver or release of any claim of any party hereunder against a Defaulting Lender arising from that
Lender having become a Defaulting Lender, including any claim of a Non-Defaulting Lender as a result of such Non-Defaulting Lender&#8217;s increased exposure following such reallocation.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Cash Collateral</u>. If the reallocation
described in clause (iv) above cannot, or can only partially, be effected, the Borrower shall, without prejudice to any right or remedy available to it hereunder or under law, Cash Collateralize the Issuing Lenders&#8217; Fronting Exposure in
accordance with the procedures set forth in Section 2.20.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Defaulting Lender Cure</u>. If the Borrower, the Administrative Agent and the Issuing Lenders
agree in writing that a Lender is no longer a Defaulting Lender, the Administrative Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set forth therein (which may
include arrangements with respect to any Cash Collateral), that Lender will, to the extent applicable, purchase at par that portion of outstanding Loans of the other Lenders or take such other actions as the Administrative Agent may determine to be
necessary to cause the Loans and funded and unfunded participations in Letters of Credit to be held on a pro rata basis by the Lenders in accordance with their Revolving Commitment Percentages (without giving effect to Section 2.21(a)(iv)),
whereupon such Lender will cease to be a Defaulting Lender; <u>provided</u> that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrower while that Lender was a Defaulting Lender; and
<u>provided</u>, further, that except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising from that
Lender&#8217;s having been a Defaulting Lender.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>New Letters of Credit</u>. So long as any Lender is a Defaulting Lender, no Issuing Lender shall
be required to issue, extend, renew or increase any Letter of Credit unless it is reasonably satisfied that it will have no Fronting Exposure after giving effect thereto.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">50</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 2.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Incremental Facilities</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms and conditions set forth herein and so long as no Default or Event of Default
has occurred and is continuing, the Borrower shall have the right, at any time and from time to time prior to the Maturity Date, to incur additional Indebtedness under this Credit Agreement in the form of (i) one or more increases to the Revolving
Committed Amount (each an &#8220;<u>Increased Revolver Commitment</u>&#8221;) which shall constitute one and the same Facility as the existing Revolving Commitments or (ii) one or more commitments (each, an &#8220;<u>Incremental Facility
Commitment</u>&#8221;, and together with the Increased Revolver Commitments, the &#8220;<u>Incremental Commitments</u>&#8221;) for term loan facilities which shall constitute a new Facility as provided in 2.22(d) below (an &#8220;<u>Incremental
Facility,</u>&#8221; and the loans thereunder, &#8220;<u>Incremental Loans</u>&#8221;), up to a maximum<u> </u>aggregate amount of Incremental Commitments not to exceed $400,000,000; <u>provided</u> that, if the Collateral Event has occurred, the
aggregate amount of all Incremental Commitments shall not exceed at the time any such Incremental Commitments are entered into the greater of (x) $400,000,000 and (y) an amount such that, on a Pro Forma Basis after giving effect to such Incremental
Commitments (and assuming such Incremental Commitments are fully drawn and/or funded, as applicable, and applied for the purpose intended) the Consolidated Net Leverage Ratio does not exceed 3.00 to
<font style="color:#ff0000;"><strike>1.00.</strike></font><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">1.00; provided, further, that no Incremental Commitments shall be permitted from the Amendment No. 3 Effective Date
through September 30, 2021.</u></font></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following terms and conditions shall apply to each Increased Revolver Commitment: (i) Obligations
thereunder shall constitute Credit Party Obligations and will be guaranteed (and secured, to the extent applicable) with the other Credit Party Obligations on a pari passu basis and will not be guaranteed by any obligor or secured by any assets that
do not guarantee or secure, respectively, the Credit Party Obligations, (ii) each Increased Revolver Commitment shall have the same terms (including interest rate and maturity date but other than with respect to any upfront fees) as the existing
Revolving Commitments, (iii) each Increased Revolver Commitment shall be entitled to the same voting rights as the existing Revolving Commitments, voting as one class, and shall be entitled to receive a pro rata share of proceeds of prepayments on
the same basis as the existing Revolving Loans and shall be considered an increase to the existing Revolving Commitments, (iv) each Increased Revolver Commitment shall be obtained from existing Lenders or from other banks, financial institutions or
Funds, in each case in accordance with the terms set forth below, (v) the proceeds of all Loans thereunder will be used for the purposes set forth in Section 3.11, (vi) the Borrower shall execute a Note in favor of any new Lender or any existing
Lender requesting a Note whose Revolving Commitment is increased, (vii) on the effective date of each such increase, the conditions to Extensions of Credit in Section 4.2 shall have been satisfied, (viii) each such Increased Revolver Commitment
shall be in a minimum amount of $5,000,000 (and $1,000,000 increments in excess thereof), and (ix) the Administrative Agent shall have received from the Borrower (A) resolutions, legal opinions and other corporate authority documents reasonably
requested by the Administrative Agent, substantially the same in form and substance as those delivered on the Closing Date pursuant to Section 4.1 and (B) updated financial projections and an officer&#8217;s certificate, in each case in form and
substance reasonably satisfactory to the Administrative Agent, demonstrating that, after giving effect to such Increased Revolver Commitment and any borrowings thereunder and the application thereof on a Pro Forma Basis, the Credit Parties will be
in compliance with the financial covenants set forth in Section 5.9 (<font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">provided that for purposes of this clause (b) the applicable Consolidated Net Leverage Ratio shall be
4.50 to 1.00 for any fiscal quarter</u></font> and, if the Collateral Event has occurred, the condition in the proviso set forth in Section 2.22(a)) and no Default or Event of Default shall exist. Any new banks, financial institutions and Funds that
become Revolving Lenders that were not previously Lenders hereunder shall enter into such joinder agreements to give effect thereto as the Administrative Agent may reasonably request. In connection with the closing of any Increased Revolver
Commitment, the outstanding Revolving Loans and Participation Interests shall be reallocated by causing such fundings and repayments (which shall not be subject to any processing and/or recordation fees) among the Revolving Lenders (with the
Borrower responsible for any costs arising under Section 2.15 resulting from such reallocation and repayments) of Revolving Loans as necessary such that, after giving effect to such Increased Revolver Commitments, each Revolving Lender will hold
Revolving Loans and Participation Interests based on its Revolving Commitment Percentage (after giving effect to such Increased Revolver Commitments).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following terms and conditions shall apply to each Incremental Facility: (i) Obligations
thereunder shall constitute Credit Party Obligations and will be guaranteed (and secured, to the extent applicable) with the other Credit Party Obligations on a pari passu basis and will not be guaranteed by any obligor or secured by any assets that
do not guarantee or secure, respectively, the Credit Party Obligations, (ii) each Incremental Facility</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">51</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">shall
otherwise have terms (including pricing terms) to be agreed by the Borrower and the Lenders providing the Incremental Commitments (the &#8220;<u>Incremental Lenders</u>&#8221;) subject to the following parameters: (A) no Incremental Facility shall
mature prior to the Maturity Date applicable to the Revolving Loans, (B) mandatory prepayments customary for a term loan (which for the avoidance of doubt may include prepayments with the proceeds of non-ordinary course asset sales and &#8220;excess
cash flow&#8221; (to be defined in a manner satisfactory to the Borrower and the Administrative Agent)) may be included on then-market terms, and (C) all terms of any Incremental Facility not set forth herein, shall be reasonably satisfactory to the
Administrative Agent, (iii) each Incremental Facility shall constitute a separate Facility hereunder, and shall be incorporated into the Credit Documents such that the Incremental Lenders have similar rights and privileges to the Lenders, (iv) each
Incremental Facility shall be obtained from existing Lenders or from other banks, financial institutions or Funds, in each case in accordance with the terms set forth below; provided that any Lender or any Incremental Lender offered or approached to
provide all or a portion of any Incremental Facility Commitment may elect or decline, in its sole discretion, to provide such Incremental Facility Commitment, (v) the proceeds of each Incremental Facility will be used for the purposes set forth in
Section 3.11, (vi) the Borrower shall execute a Note in favor of any Incremental Lender requesting a Note representing its Loans under the Incremental Facility, (vii) on the date of incurrence of the Incremental Loans, the conditions to Extensions
of Credit in Section 4.2 shall have been satisfied, (viii) each such commitment for an Incremental Facility shall be in a minimum amount of $5,000,000 (and $1,000,000 increments in excess thereof), and (ix) the Administrative Agent shall have
received from the Borrower (A) resolutions, legal opinions and other corporate authority documents reasonably requested by the Administrative Agent, substantially the same in form and substance as those delivered on the Closing Date pursuant to
Section 4.1 and (B) updated financial projections and an officer&#8217;s certificate, in each case in form and substance reasonably satisfactory to the Administrative Agent, demonstrating that, after giving effect to the borrowing of such
Incremental Loans and the application thereof on a Pro Forma Basis, the Credit Parties will be in compliance with the financial covenants set forth in Section 5.9 (<u style="border-bottom:#000000 thin double;"><font style="color:#0000ff;">provided
that for purposes of this clause (c) the applicable Consolidated Net Leverage Ratio shall be 4.50 to 1.00 for any fiscal quarter</font></u> and, if the Collateral Event has occurred, the condition in the proviso set forth in Section 2.22(a)) and no
Default or Event of Default shall exist. All Incremental Lenders shall enter into such joinder agreements to give effect thereto as the Administrative Agent may reasonably request.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary in Section 9.1 or elsewhere in this Credit Agreement, the
Administrative Agent is authorized to enter into, on behalf of the Lenders, any amendment to this Credit Agreement or any other Credit Document as may be necessary solely to incorporate the terms of each Increased Revolver Commitment or Incremental
Facility therein. For the avoidance of doubt, such amendments may provide for, among other things, the incorporation of such Incremental Facility into the definitions of &#8220;Required Lenders&#8221;, &#8220;Required Facility Lenders&#8221;,
&#8220;Commitment Percentage&#8221;, and similar terms and sections of this Credit Agreement on a similar basis to each other existing Facility, and may provide for sharing of payments and inclusion in the waterfall, and the inclusion of customary
provisions for a term loan throughout the Credit Documents.\</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon executing the joinder documentation requested by the Administrative Agent, each bank, financial
institution or other entity committing to be a new Revolving Lender or Incremental Lender shall become a Lender for all purposes and to the same extent as if originally a party hereto and shall be bound by and entitled to the benefits of this
Agreement and the other Credit Documents, and shall benefit equally and ratably from the Guarantees and security interests (if applicable) created by the Security Documents, if any; provided that any Lender offered or approached to provide all or a
portion of any Increased Revolver Commitment may elect or decline, in its sole discretion, to provide such Increased Revolver Commitments.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>ARTICLE III<br> <br>
REPRESENTATIONS AND WARRANTIES</b></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">To induce the Lenders to enter into this Agreement and to make Loans and to issue, extend, renew or participate in Letters of Credit,
in each case as herein provided for, the Credit Parties hereby represent and warrant to the Administrative Agent and to each Lender that:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">52</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Financial Condition</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The audited Consolidated financial statements of the<b> </b>Borrower and its Consolidated
Subsidiaries for the fiscal years ended December 31, 2014, 2015 and 2016 set forth in the Borrower&#8217;s annual report on Form 10-K for the fiscal year ended December 31, 2016 and (ii) the unaudited Consolidated financial statements of the
Borrower and its Consolidated Subsidiaries for the year-to-date period ended on June 30, 2017 set forth in the Borrower&#8217;s quarterly report on Form 10-Q for the period ended June 30, 2017:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;were prepared in accordance with GAAP
consistently applied throughout the periods covered thereby, except as otherwise expressly noted therein;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;fairly present in all material respects
the financial condition of the Borrower and its Consolidated Subsidiaries as of the dates thereof (subject, in the case of the unaudited financial statements, to normal year-end adjustments) and results of operations for the period covered thereby;
and</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reflect in accordance with GAAP all
material Indebtedness and other liabilities, direct or contingent, of the Borrower and its Consolidated Subsidiaries, as applicable, as of the date thereof, including liabilities for taxes, material commitments and contingent obligations.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The five-year projections of the Borrower and its Consolidated Subsidiaries delivered to the Lenders
on or prior to the Closing Date have been prepared in good faith based upon reasonable assumptions.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Material Adverse Effect</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Since
December 31, 2016 (and, in addition, after delivery of annual audited financial statements in accordance with Section 5.1(a), from the date of the most recently delivered annual audited financial statements), there has been no development or event
which has had or could reasonably be expected to have a Material Adverse Effect.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Corporate Existence; Compliance with Law</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Each of the
Credit Parties (a) is duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation, organization or formation, (b) except as could not reasonably be expected, individually or in the aggregate, to have
a Material Adverse Effect, has the requisite power and authority and the legal right to own and operate all its property, to lease the property it operates as lessee and to conduct the business in which it is currently engaged and has taken all
actions necessary to maintain all rights, privileges, licenses and franchises necessary or required in the normal conduct of its business, (c) is duly qualified to conduct business and in good standing under the laws of each other jurisdiction where
its ownership, lease or operation of property or the conduct of its business requires such qualification except to the extent that the failure to so qualify or be in good standing in any such other jurisdiction could not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect and (d) is in compliance with all Requirements of Law, organizational documents, government permits and government licenses except to the extent such non-compliance could not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. No Credit Party has any oral or written operating agreement (or other similar document) which regulates the affairs of such Credit Party, the conduct of its
business, establishes duties and/or governs the relations among any member, manager and such Credit Party, other than such documents as have been previously delivered to the Administrative Agent.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Corporate Power; Authorization; Enforceable Obligations</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Each of the Credit Parties has full power and authority and the legal right to make, deliver and perform the Credit Documents to which
it is party and has taken all necessary limited liability company, partnership or corporate action to authorize the execution, delivery and performance by it of the Credit Documents to which it is party. Each Credit Document to which it is a party
has been duly executed and delivered on behalf of each Credit Party. Each Credit Document to which it is a party constitutes a legal, valid and binding obligation of each Credit Party,</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">53</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">enforceable against such Credit Party in accordance with its terms, except as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or other laws affecting the enforcement of creditors&#8217; rights generally and by general equitable principles (whether enforcement is sought by proceedings in equity or at law).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Legal Bar; No Default</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The execution, delivery and performance by each Credit Party of the Credit Documents to which such Credit Party is a party, the
borrowings thereunder and the use of the proceeds of the Loans (a) will not violate in any material respect any Requirement of Law (except those as to which waivers or consents have been obtained), (b) will not conflict with, result in a breach of
or constitute a default under (i) the articles of incorporation, bylaws, articles of organization, operating agreement or other organization documents of the Credit Parties or (ii) any Material Contract to which such Person is a party or by which
any of its properties may be bound or any material approval or material consent from any Governmental Authority relating to such Person (except those as to which waivers or consents have been obtained) which conflict, breach or default in any such
case in this clause (ii) could reasonably be expected to have a Material Adverse Effect, and (c) will not result in, or require, the creation or imposition of any Lien on any Credit Party&#8217;s properties or revenues pursuant to any Requirement of
Law, the articles of incorporation, bylaws, articles of organization, operating agreement or other organization documents of such Credit Party or Contractual Obligation other than the Liens arising under or contemplated in connection with the Credit
Documents or Permitted Liens. No Credit Party is in default under or with respect to any of its Material Contracts in any material respect. No Default or Event of Default has occurred and is continuing.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Material Litigation</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">No litigation, investigation, claim, criminal prosecution, civil investigative demand, imposition of criminal or civil fines and
penalties, or any other proceeding of or before any arbitrator or Governmental Authority is pending or, to the actual knowledge of the Responsible Officers of the Borrower, threatened (in writing) by or against any Credit Party or any of its
Subsidiaries or against any of its or their respective properties or revenues (a) with respect to the Credit Documents or any Extension of Credit or any of the transactions contemplated hereby, or (b) which, individually or in the aggregate, could
reasonably be expected to have a Material Adverse Effect. No permanent injunction, temporary restraining order or similar decree has been issued against any Credit Party or any of its Subsidiaries which, individually or in the aggregate, could
reasonably be expected to have a Material Adverse Effect.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Investment Company Act; etc.</u></b></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">No Credit
Party is an &#8220;investment company,&#8221; or a company &#8220;controlled&#8221; by an &#8220;investment company,&#8221; within the meaning of the Investment Company Act of 1940, as amended. No Credit Party is subject to regulation under the
Federal Power Act, the Interstate Commerce Act, the Public Utility Holding Company Act of 2005 or any federal or state statute or regulation limiting its ability to incur the Credit Party Obligations.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Margin Regulations</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">No part of the proceeds of any Extension of Credit hereunder will be used directly or indirectly for any purpose that violates, or
that would require any Lender to make any filings in accordance with, the provisions of Regulation T, U or X of the Board of Governors of the Federal Reserve System as now and from time to time hereafter in effect. The Credit Parties and their
Subsidiaries (a) are not engaged, principally or as one of their important activities, in the business of extending credit for the purpose of &#8220;purchasing&#8221; or &#8220;carrying&#8221; &#8220;margin stock&#8221; within the respective
meanings of each of such terms under Regulation U and (b) taken as a group do not own &#8220;margin stock&#8221; except as identified in the financial statements referred to in Section 3.1 or delivered pursuant to Section 5.1 and the aggregate value
of all &#8220;margin stock&#8221; owned by the Credit Parties and their Subsidiaries taken as a group does not exceed 25% of the value of their assets.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">54</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>ERISA</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Except as
could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt;">(a)&nbsp; &nbsp; &nbsp;Neither a Reportable Event nor an &#8220;accumulated funding deficiency&#8221;
(within the meaning of Section 412 of the Code or Section 302 of ERISA) has occurred during the five-year period prior to the date on which this representation is made or deemed made with respect to any Plan, and each Plan has complied in all
material respects with the applicable provisions of ERISA and the Code.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt;">(b)&nbsp; &nbsp; &nbsp;No termination of a Single Employer Plan has occurred resulting in any
liability that has remained underfunded, and no Lien in favor of the PBGC or a Plan has arisen, during such five-year period.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt;">(c)&nbsp; &nbsp; &nbsp;The present value of all accrued benefits under each Single Employer Plan
(based on those assumptions used to fund such Plans) did not, as of the last annual valuation date prior to the date on which this representation is made or deemed made, exceed the value of the assets of such Plan allocable to such accrued
benefits.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt;">(d)&nbsp; &nbsp; &nbsp;Neither any Credit Party nor any Commonly Controlled Entity is currently
subject to any liability for a complete or partial withdrawal from a Multiemployer Plan.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Environmental Matters</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Except as
could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt;">(a)&nbsp; &nbsp; &nbsp;To the actual knowledge of the Responsible Officers of the Borrower, the
facilities and properties owned, leased or operated by the Credit Parties or any of their Subsidiaries (the &#8220;<u>Properties</u>&#8221;) do not contain any Materials of Environmental Concern in amounts or concentrations which (i) constitute a
violation of, or (ii) could give rise to liability on behalf of any Credit Party under, any Environmental Law.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt;">(b)&nbsp; &nbsp; &nbsp;To the actual knowledge of the Responsible Officers of the Borrower, the
Properties and all operations of the Credit Parties and/or their Subsidiaries at the Properties are in compliance, and have in the last five years been in compliance, with all applicable Environmental Laws, and there is no contamination at, under or
about the Properties or violation of any Environmental Law with respect to the Properties or the business operated by the Credit Parties or any of their Subsidiaries (the &#8220;Business&#8221;).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt;">(c)&nbsp; &nbsp; &nbsp;Neither the Credit Parties nor their Subsidiaries have received any written or
actual notice of violation, alleged violation, non-compliance, liability or potential liability on behalf of any Credit Party with respect to environmental matters or Environmental Laws regarding any of the Properties or the Business, nor do the
Responsible Officers of the Borrower have actual knowledge or reason to believe that any such notice will be received or is being threatened.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt;">(d)&nbsp; &nbsp; &nbsp;To the actual knowledge of the Responsible Officers of the Borrower, Materials
of Environmental Concern have not been transported or disposed of from the Properties in violation of, or in a manner or to a location that could give rise to liability on behalf of any Credit Party under any Environmental Law, and no Materials of
Environmental Concern have been generated, treated, stored or disposed of at, on or under any of the Properties in violation of, or in a manner that could give rise to liability on behalf of any Credit Party under, any applicable Environmental
Law.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt;">(e)&nbsp; &nbsp; &nbsp;No judicial proceeding or governmental or administrative action is pending or,
to the actual knowledge of the Responsible Officers of the Borrower, threatened, under any Environmental Law to which any Credit Party or any Subsidiary is or will be named as a party with respect to the Properties or the Business, nor are there any
consent decrees or other decrees, consent orders, administrative orders or other orders, or other administrative or judicial requirements outstanding under any Environmental Law with respect to the Properties or the Business.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">55</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt;">(f)&nbsp; &nbsp; &nbsp;To the actual knowledge of the Responsible Officers of the Borrower, there has
been no release or threat of release of Materials of Environmental Concern at or from the Properties, or arising from or related to the operations of any Credit Party or any Subsidiary in connection with the Properties or otherwise in connection
with the Business, in violation of or in amounts or in a manner that could give rise to liability on behalf of any Credit Party under Environmental Laws.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Notwithstanding anything set
forth in this Section 3.10, the term &#8220;Properties&#8221; shall not include any hospital or other medical facility at which a Credit Party or its Subsidiaries provides services unless such facility is owned or leased by a Credit Party or its
Subsidiaries.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Use of Proceeds</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The proceeds
of the Extensions of Credit shall be used by the Borrower solely (a) to refinance the Existing Credit Agreement, (b) to pay any costs, fees and expenses associated with this Agreement on the Closing Date and (c) for working capital and other general
corporate purposes of the Credit Parties and their Subsidiaries (including, without limitation, Permitted Acquisitions and Restricted Payments).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
3.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsidiaries; Joint Ventures; Partnerships</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Set forth on <u>Schedule 3.12</u> is (a) the exact legal name of each Credit Party, the state of incorporation or organization, the
chief executive office, the principal place of business, the jurisdictions in which the Credit Parties are qualified to do business, the federal tax identification number and organization identification number of each of the Credit Parties as of the
Closing Date (and for the four (4) months prior to the Closing Date) and (b) a complete and accurate list of all Subsidiaries, joint ventures and partnerships of the Credit Parties as of the Closing Date and as of the last date such Schedule was
required to be updated in accordance with Section 5.2. Information on the attached Schedule includes the following: (a) the percentage of outstanding shares of each class of Equity Interest owned by the Credit Parties and their Subsidiaries and (b)
the name and address of each Equity Holder that owns, directly or indirectly, Equity Interests in any Subsidiary of the Borrower. The outstanding Equity Interest and other equity interests of all such Subsidiaries is validly issued, fully paid and
non-assessable and is owned free and clear of all Liens.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Ownership</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Except as
could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt;">(a)&nbsp; &nbsp; &nbsp;Each of the Credit Parties and its Subsidiaries is the owner of, and has good
and marketable title to or a valid leasehold interest in, all of its respective assets, which, together with assets leased or licensed by the Credit Parties and their Subsidiaries, represents all assets in the aggregate material to the conduct of
the business of the Credit Parties and their Subsidiaries, and (after giving effect to the Transactions) none of such assets is subject to any Lien other than Permitted Liens.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 36pt;">(b)&nbsp; &nbsp; &nbsp;Each Credit Party and its Subsidiaries enjoys peaceful and undisturbed
possession under all of its leases and all such leases are valid and subsisting and in full force and effect.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Taxes</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Each of the
Credit Parties and its Subsidiaries has filed, or caused to be filed, all income Tax returns and all other material Tax returns (federal, state, local and foreign) required to be filed and paid (a) all amounts of taxes shown thereon to be due
(including interest and penalties) and (b) all other material Taxes, fees, assessments and other governmental charges (including mortgage recording Taxes, documentary stamp Taxes and intangibles Taxes) owing by it, except for such Taxes (i) that are
not yet delinquent or (ii) that are being contested in good faith and by</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">56</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">proper proceedings, and against which adequate reserves are being maintained in accordance with GAAP. Except as could not reasonably
be expected, individually or in the aggregate, to have a Material Adverse Effect, none of the Credit Parties or their Subsidiaries is aware as of the Closing Date of any proposed Tax assessments against it or any of its Subsidiaries.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
3.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Solvency</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">After giving effect to the Transactions, (a) the Credit Parties taken as a whole are solvent and are able to pay their debts and other
liabilities, contingent obligations and other commitments as they mature in the normal course of business, and (b) the fair saleable value of the Credit Parties&#8217; assets taken as a whole, measured on a going concern basis, exceeds all probable
liabilities, including those to be incurred pursuant to this Agreement. After giving effect to the Transactions, none of the Credit Parties (i) has unreasonably small capital in relation to the business in which it is or proposes to be engaged or
(ii) has incurred, or believes that it will incur debts beyond its ability to pay such debts as they become due. In executing the Credit Documents and consummating the Transactions, none of the Credit Parties intends to hinder, delay or defraud
either present or future creditors or other Persons to which one or more of the Credit Parties is or will become indebted.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Burdensome Restrictions</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">None of the
Credit Parties or their Subsidiaries is a party to any agreement or instrument or subject to any other obligation or any charter or corporate restriction or any provision of any applicable law, rule or regulation which, individually or in the
aggregate, could reasonably be expected to have a Material Adverse Effect.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Brokers&#8217; Fees</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">None of the
Credit Parties or their Subsidiaries has any obligation to any Person in respect of any finder&#8217;s, broker&#8217;s, investment banking or other similar fee in connection with any of the transactions contemplated under the Credit Documents other
than the closing and other fees payable pursuant to this Agreement and as set forth in the Fee Letters.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Labor Matters</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Except as
could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, there are no collective bargaining agreements or Multiemployer Plans covering the employees of the Credit Parties or any of their Subsidiaries as
of the Closing Date, other than as set forth in <u>Schedule 3.18</u> hereto, and none of the Credit Parties or their Subsidiaries (a) has suffered any strikes, walkouts, work stoppages or other material labor difficulty within the last five years,
other than as set forth in <u>Schedule 3.18</u> hereto, or (b) has knowledge of any potential or pending strike, walkout or work stoppage. Other than as set forth on <u>Schedule 3.18</u>, no unfair labor practice complaint is pending against any
Credit Party or any of its Subsidiaries that could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect, there are no strikes, walkouts, work stoppages or other material labor difficulty pending or threatened against any Credit Party.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
3.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Accuracy and Completeness of Information</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">All written factual information (other than (i) any projections, (ii) other forward-looking information and (iii) information of a
general economic or industry nature) concerning any Credit Party and its Subsidiaries and the transactions contemplated by the Credit Documents heretofore, contemporaneously or hereafter furnished by or on behalf of any Credit Party or any of its
Subsidiaries to the Administrative Agent, the Arrangers or any Lender for purposes of or in connection with this Agreement or any other Credit Document, or any transaction contemplated hereby or thereby, when taken as a whole, is or, in the case of
such information furnished after the date hereof, will be, true and accurate in all material respects and not incomplete by omitting to state any material fact necessary to make such information in light of the circumstances in which such
information is provided not materially misleading, in each case, after giving effect to all supplements and updates thereto from time to time prior to the date this representation is made; <u>provided</u>, that with respect to projected financial
information, the Credit Parties</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">57</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">represent only that such information was prepared in good faith on assumptions believed to be reasonable at the time made and are not
to be viewed as facts and are subject to significant uncertainties and contingencies many of which are beyond your control, that no assurance can be given that any projections will be realized and actual results may vary materially from the
projected financial information.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Material Contracts</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Each
Material Contract is, and after giving effect to the Transactions will be, in full force and effect in accordance with the terms thereof.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
3.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Insurance</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The insurance coverage of the Credit Parties and their Subsidiaries is outlined as to carrier, policy number, expiration date, type
and amount on <u>Schedule 3.21</u> as of the Closing Date and as of the last date such Schedule was required to be updated in accordance with Section 5.2 and such insurance coverage complies with the requirements set forth in Section 5.5(b).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
3.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Intellectual Property Matters</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Except as could not reasonably be expected to have a Material Adverse Effect, the Credit Parties and their Subsidiaries own, or
possess the right to use, all of the Intellectual Property, trade names, franchises, licenses and other intellectual property rights (collectively, &#8220;<u>IP Rights</u>&#8221;) that are reasonably necessary for the operation of their respective
businesses as now conducted by them in all material respects, without infringement of the rights of any other Person. To the actual knowledge of the Responsible Officers of the Borrower, no slogan or other advertising device, product, process,
method, substance, part or other material now employed, or now contemplated to be employed, by any Credit Party or any Subsidiary infringes in any material respect upon any rights held by any other Person. No event has occurred which permits, or
after the notice or lapse of time or both would permit, the revocation or termination of any such license, franchise or other right or which affects the rights of any of the Credit Parties or any of their Subsidiaries thereunder which, individually
or in the aggregate, could reasonably be expected to have a Material Adverse Effect. No claim or litigation regarding any of the foregoing is pending or, to the best knowledge of each Credit Party, threatened (in writing), which, individually or in
the aggregate, could reasonably be expected to have a Material Adverse Effect. No representation is made in this Section 3.22 regarding &#8220;shrink wrap&#8221; or &#8220;off the shelf&#8221; software, or software embedded in commercially available
electronic hardware.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Classification of Senior Indebtedness</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Credit
Party Obligations constitute &#8220;Senior Indebtedness,&#8221; &#8220;Designated Senior Indebtedness&#8221; or any similar designation under and as defined in any agreement governing any Subordinated Debt and the subordination provisions set forth
in each such agreement are legally valid and enforceable against the parties thereto.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Anti-Corruption Laws and Sanctions</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Borrower
has implemented and maintains in effect policies and procedures designed to ensure compliance by the Borrower, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions, and
the Borrower, its Subsidiaries and their respective officers and employees and to the knowledge of the Borrower its directors and agents, are in compliance with Anti-Corruption Laws and applicable Sanctions in all material respects and are not
knowingly engaged in any activity that would reasonably be expected to result in the Borrower being designated as a Sanctioned Person. None of (a) the Borrower, any Subsidiary or any of their respective directors, officers or employees, or (b) to
the knowledge of the Borrower any agent of the Borrower or any Subsidiary that will act in any capacity in connection with or benefit from the credit facility established hereby, is a Sanctioned Person. <sup
style="vertical-align:top;line-height:120%;font-size:pt"> </sup>No Loan or Letter of Credit, use of proceeds or other transaction contemplated by the Credit Agreement will violate Anti-Corruption Laws or applicable Sanctions.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">58</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Consent; Governmental Authorizations</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">No approval,
consent or authorization of, filing with, notice to or other act by or in respect of, any Governmental Authority or any other Person (including any Equity Holder) is required in connection with acceptance of Extensions of Credit by the Borrower or
the making of the Guaranty hereunder or with the execution, delivery or performance of any Credit Document by the Credit Parties (other than those which have been obtained) or with the validity or enforceability of any Credit Document against the
Credit Parties.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Healthcare Representations and Warranties</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reports; Audits</u>. Except for matters that could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect: (i) as applicable, the Credit Parties have timely filed or caused to be timely filed, all cost reports and other reports of every kind whatsoever required by law or by written contracts or
otherwise to have been filed or made with respect to such Credit Party&#8217;s business and operations; (ii) there are no claims, actions or appeals pending (and each Credit Party has not filed any claims or reports which should result in any such
claims, actions or appeals) before any commission, board or agency, including, without limitation, any intermediary or carrier, the Provider Reimbursement Review Board or the Administrator of CMS, with respect to cost reports or claims filed by any
Credit Party under any Government Reimbursement Program, or any disallowance by any commission, board or agency in connection with any audit of such cost reports or claims; and (iii) no validation review or program integrity review related to any
Credit Party, or the consummation of the transactions contemplated in the Credit Documents, have been conducted by any commission, board or agency in connection with any Government Reimbursement Program, and to the actual knowledge of the
Responsible Officers of the Borrower, no such reviews are scheduled, pending or threatened against or affecting any Credit Party, any Credit Party&#8217;s employees or agents, or the consummation of the transactions contemplated hereby.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance With Health Care Laws</u>. Each Credit Party is in compliance with all applicable
Healthcare Laws except where the failure to comply, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect. To the extent applicable to each Credit Party, each Credit Party has maintained in all material
respects all records required to be maintained by the Joint Commission, Government Reimbursement Programs, and the Healthcare Laws, and, to the actual knowledge of the Responsible Officers of the Borrower, there are no presently existing
circumstances which could reasonably be expected to constitute or result in a violation of any Healthcare Law, in each case that could, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. To the actual
knowledge of the Responsible Officers of the Borrower, no Credit Party is currently subject to any federal, state, local governmental or private payor civil or criminal inspections, investigations, inquiries or audits involving and/or related to its
activities or compliance with Healthcare Laws, except for audits and inspections that could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Except as could not reasonably be expected to have a
Material Adverse Effect, no Credit Party: (i) has had a civil monetary penalty assessed against it pursuant to 42 U.S.C. &#167;1320a-7a; (ii) has been excluded from participation in a Federal Health Care Program (as that term is defined in 42 U.S.C.
&#167;1320a-7b); (iii) has been convicted (as that term is defined in 42 C.F.R. &#167;1001.2) of any of those offenses described in 42 U.S.C. &#167;1320a-7b or 18 U.S.C. &#167;&#167;669, 1035, 1347, 1518; or (iv) to the actual knowledge of the
Responsible Officers of the Borrower, is involved or named in a U.S. Attorney complaint made or any other action taken pursuant to the False Claims Act under 31 U.S.C. &#167;&#167;3729-3731 or qui tam action brought pursuant to 31 U.S.C. &#167;3729
<i>et seq</i>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Licenses, Permits, and Certifications</u>. Each Credit Party has, and to the actual knowledge of
one or more Responsible Officers of the Borrower, each Equity Holder has, such permits, licenses, franchises, certificates and other approvals or authorizations of Governmental Authorities as are necessary under applicable law or regulations to own
its properties and to conduct its business and to submit claims for and receive reimbursement under all applicable Government Reimbursement Programs and Private Payor Arrangements (including without limitation such permits as are required under
Healthcare Laws and under such HMO or similar licensure laws and such insurance laws and regulations, as are applicable thereto) other than such failures as could not reasonably be expected to have a Material Adverse Effect. Each Credit Party has,
and to the actual knowledge of one or more Responsible Officers of the Borrower, each Equity Holder has, all Medicare, Medicaid and related agency supplier billing number(s) and related documentation necessary for it to receive reimbursement claims
under all applicable Government Reimbursement Programs for any medical services or supplies furnished by any Credit Party in any jurisdiction where any Credit Party conducts business other than such failures as could not reasonably be expected
to</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">59</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">have
a Material Adverse Effect. No Credit Party (and, to the actual knowledge of one or more Responsible Officer of the Borrower, no Equity Holder) is currently subject to, suspension, revocation, renewal or denial of any applicable certification,
provider or supplier billing number(s), or any participation agreement(s) under any applicable Government Reimbursement Program which could reasonably be expected to cause a Material Adverse Effect. There currently exist no restrictions,
deficiencies, required plans of corrective action or other such remedial measures with respect to any certifications, accreditations or licensures (whether under any Government Reimbursement Program, or Healthcare Law) other than restrictions,
deficiencies, required plans of corrective action or other remedial measures that could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Participation Agreements</u>. To the actual knowledge of the Responsible Officers of the Borrower,
there is no threatened termination of any participation agreements under any Private Payor Arrangements to which any Credit Party is a party and which termination would reasonably be expected to have a Material Adverse Effect.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>HIPAA Compliance</u>. To the actual knowledge of the Responsible Officers of the Borrower, no
Credit Party is the subject of any civil or criminal penalty, process, claim, action or proceeding, or any administrative or other regulatory review, survey, process or proceeding alleging a violation of HIPAA that could, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Equity Holder Compliance</u>. Other than where failure to do so could not reasonably be expected
to have a Material Adverse Effect, to the actual knowledge of one or more Responsible Officers of the Borrower, each Equity Holder is duly licensed (where license is required) by each state or state agency or commission, or any other Governmental
Authority having jurisdiction over the provision of such services by such Person in the locations in which the Equity Holder and the applicable Subsidiaries conduct business, required to enable such Person to provide the professional services
provided by such Person and otherwise as is necessary to enable the Equity Holder and each such applicable Subsidiary to operate as currently operated and as presently contemplated to be operated. To the actual knowledge of the Borrower&#8217;s
Responsible Officers, all such required licenses are in full force and effect on the date hereof and have not been revoked or suspended or otherwise limited in any material respect.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">60</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.27</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Security Interests</u>. At any time following the Collateral Event, the Security
Documents are effective to create in favor of the Administrative Agent, for the ratable benefit of the Lenders and the Bank Product Providers, legal, valid and enforceable first priority Liens (subject to Permitted Liens) on, and security interests
in, the Collateral and, when (a) each (i) financing statement on form UCC-1 made pursuant to the Security Documents is filed in the appropriate office as required by the Uniform Commercial Code, (ii) Security Documents (or short form security
agreement with respect to intellectual property) are filed with the United States Patent and Trademark Office and the United States Copyright Office, as applicable, and (iii) all other appropriate filings or recordings are made in the appropriate
offices as may be required under applicable law, and in each case, all filing and recording fees have been paid, and (b) upon the taking of possession, control or other action by the Administrative Agent of such Collateral with respect to which a
security interest may be perfected only by possession, control or other action, such security interests will constitute fully perfected Liens on, and security interests in, all right, title and interest of the Credit Parties in such Collateral, in
each case subject to no Liens other than Permitted Liens.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.28</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>EEA Financial Institutions</u><b> </b>No Credit Party is an EEA Financial
Institution.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 3.29</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>ERISA</u> The Borrower represents and warrants as of the Closing Date that the
Borrower is not and will not be using &#8220;plan assets&#8221; (within the meaning of 29 CFR &#167; 2510.3-101, as modified by Section 3(42) of ERISA) of one or more Benefit Plans in connection with the Loans, the Letters of Credit or the
Commitments.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>ARTICLE
IV<br> <br> CONDITIONS PRECEDENT</b></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Conditions to Closing Date and Initial Revolving Loans</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">This
Agreement shall become effective upon, and the obligation of each Lender to make the initial Extensions of Credit on the Closing Date is subject to, the satisfaction, or waiver by the Administrative Agent, of the following conditions precedent:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Execution of Credit Agreement; Credit
Documents and Lender Consents</u>. The Administrative Agent shall have received (i) counterparts of this Agreement, executed by a duly authorized officer of each party hereto, (ii) counterparts of any other Credit Document, executed by the duly
authorized officers of the parties thereto and (iii) executed consents, in substantially the form of Exhibit 4.1(a), from each Lender authorizing the Administrative Agent to enter this Credit Agreement on their behalf.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Authority Documents</u>. The
Administrative Agent shall have received the following:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Articles of Incorporation/Charter Documents.
Original certified articles of incorporation or other charter documents, as applicable, of each Credit Party certified (A) by an officer of such Credit Party (pursuant to an officer&#8217;s certificate in substantially the form of Exhibit 4.1(b)
attached hereto) as of the Closing Date to be true and correct and in force and effect as of such date, and (B) with respect to the articles of incorporation of the Borrower, to be true and complete as of a recent date by the appropriate
Governmental Authority of the State of Florida.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Resolutions. Copies of resolutions of the
board of directors or comparable managing body of each Credit Party approving and adopting the Credit Documents, the transactions contemplated therein and authorizing execution and delivery thereof, certified by an officer of such Credit Party
(pursuant to an officer&#8217;s certificate in substantially the form of Exhibit 4.1(b) attached hereto) as of the Closing Date to be true and correct and in force and effect as of such date.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bylaws/Operating Agreement. A copy of the
bylaws or comparable operating agreement of each Credit Party certified by an officer of such Credit Party (pursuant to an officer&#8217;s certificate in substantially the form of Exhibit 4.1(b) attached hereto) as of the Closing Date to be true and
correct and in force and effect as of such date.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">61</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Good Standing. Copies of certificates of
good standing, existence or its equivalent with respect to each Credit Party certified as of a recent date by the appropriate Governmental Authorities of the state of incorporation or organization and each other state in which the failure to so
qualify and be in good standing could reasonably be expected to have a Material Adverse Effect; provided that any certificate of good standing set forth on Schedule 5.12(e) may instead be provided within the time period set forth in Schedule
5.12(e).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incumbency. An incumbency certificate of each
Credit Party certified by an officer (pursuant to an officer&#8217;s certificate in substantially the form of Exhibit 4.1(b) attached hereto) to be true and correct as of the Closing Date.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Florida Stamp Tax. To the extent reasonably
requested by the Administrative Agent, and in such case reasonably satisfactory to the Administrative Agent, either (i) such affidavits relative to the execution and delivery of any Credit Document as required to support the determination that no
Florida documentary stamp taxes are required to be paid ,or (ii) evidence of payment by the Borrower of any Florida documentary stamp taxes applicable to the execution and delivery of the Credit Documents.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Legal Opinion of Counsel</u>. The
Administrative Agent shall have received an opinion or opinions (including, if requested by the Administrative Agent, local counsel opinions) of counsel for the Credit Parties, dated the Closing Date and addressed to the Administrative Agent and the
Lenders, in form and substance acceptable to the Administrative Agent (which shall include, without limitation, opinions with respect to the due organization and valid existence of each Credit Party and opinions as to the non-contravention of the
Credit Parties&#8217; organizational documents and Material Contracts); provided that the opinion of counsel set forth on Schedule 5.12(e) may instead be provided within the time period set forth in Schedule 5.12(e).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Liability, Casualty, Property and Business
Interruption Insurance</u>. The Administrative Agent shall have received copies of insurance policies or certificates and endorsements of insurance evidencing general liability, casualty, property and business interruption insurance. The
Administrative Agent shall be named as additional insured on behalf of the Lenders with respect to any such insurance providing general liability coverage, and the Credit Parties will use their commercially reasonable efforts to have each provider
of any such insurance agree, by endorsement upon the policy or policies issued by it or by independent instruments to be furnished to the Administrative Agent, that it will give the Administrative Agent thirty (30) days&#8217; (or ten (10) days in
the case of nonpayment) prior written notice before any such policy or policies shall be materially altered or cancelled.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Solvency Certificate</u>. The
Administrative Agent shall have received an officer&#8217;s certificate prepared by the chief financial officer of the Borrower as to the financial condition, solvency and related matters of the Credit Parties and their Subsidiaries, after giving
effect to the Transactions and the initial borrowings under the Credit Documents, in substantially the form of Exhibit 4.1(e) hereto.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Account Designation Notice</u>. The
Administrative Agent shall have received the executed Account Designation Notice in the form of Exhibit 1.1(a) hereto.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice of Borrowing</u>. The
Administrative Agent shall have received a Notice of Borrowing with respect to the Loans to be made on the Closing Date.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Consents</u>. The Administrative Agent
shall have received evidence that any applicable boards of directors, governmental, shareholder and material third party consents and approvals necessary in connection with the Transactions have been obtained and all applicable waiting periods have
expired without any action being taken by any authority that could restrain, prevent or impose any material adverse conditions on such transactions or that could seek or threaten any of the foregoing.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">62</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Laws</u>. The Transactions
contemplated hereby shall be in compliance in all material respects with all applicable laws and regulations (including all applicable securities and banking laws, rules and regulations).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Bankruptcy</u>. There shall be no
bankruptcy or insolvency proceedings pending with respect to any Credit Party or any Subsidiary thereof.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Existing Indebtedness of the Credit
Parties</u>. All of the existing Indebtedness for borrowed money of the Credit Parties and their Subsidiaries (other than Indebtedness permitted to exist pursuant to Section 6.1) shall be repaid in full and all security interests related thereto
(other than Permitted Liens) shall be terminated on or prior to the Closing Date.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Financial Statements</u>. The
Administrative Agent and the Lenders shall have received copies of the financial statements referred to in Section 3.1, each in form and substance satisfactory to each of them.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Material Adverse Change</u>. Since
December 31, 2016 there shall have been no material adverse change in the business, properties, prospects, operations or condition (financial or otherwise) of the Credit Parties or any of their respective Subsidiaries.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Financial Condition Certificate</u>. The
Administrative Agent shall have received a certificate or certificates executed by a Responsible Officer of the Borrower as of the Closing Date, substantially in the form of Exhibit 4.1(n) stating that (i) to the actual knowledge of the Responsible
Officers of the Borrower, there does not exist any pending or ongoing, action, suit, investigation, litigation or proceeding in any court or before any other Governmental Authority (A) affecting this Agreement or the other Credit Documents, that has
not been settled, dismissed, vacated, discharged or terminated prior to the Closing Date or (B) that purports to affect any Credit Party or any of its Subsidiaries, or any transaction contemplated by the Credit Documents, which action, suit,
investigation, litigation or proceeding could reasonably be expected to have a Material Adverse Effect, that has not been settled, dismissed, vacated, discharged or terminated prior to the Closing Date, (ii) immediately after giving effect to this
Agreement, the other Credit Documents, and all the Transactions contemplated to occur on such date, (A) no Default or Event of Default exists, (B) all representations and warranties contained herein and in the other Credit Documents (1) with respect
to representations and warranties that contain a materiality qualification, are true and correct and (2) with respect to representations and warranties that do not contain a materiality qualification, are true and correct in all material respects
and (C) the Credit Parties are in pro forma compliance with each of the initial financial covenants set forth in Section 5.9 (as evidenced through detailed calculations of such financial covenants on a schedule to such certificate) as of the last
day of the quarter ending at least twenty (20) days preceding the Closing Date and (iii) each of the other conditions precedent in Section 4.1 have been satisfied, except to the extent the satisfaction of any such condition is subject to the
reasonable judgment of the Administrative Agent or any Lender.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Patriot Act Certificate</u>. At least
three (3) Business Days prior to the Closing Date, to the extent requested by the Administrative Agent at least ten (10) Business Days prior to the Closing Date, the Administrative Agent shall have received a certificate satisfactory thereto,
substantially in the form of Exhibit 4.1(o), for benefit of itself and the Lenders, provided by the Borrower that sets forth information required by the Patriot Act including, without limitation, the identity of the Credit Parties, the name and
address of the Credit Parties and other information that will allow the Administrative Agent or any Lender, as applicable, to identify the Credit Parties in accordance with the Patriot Act.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Fees and Expenses</u>. The Administrative
Agent and the Lenders shall have received all fees and expenses, if any, owing pursuant to any Fee Letter, the Commitment Letter and Section 2.5.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">63</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Additional Matters</u>. All other
documents and legal matters in connection with the transactions contemplated by this Agreement shall be reasonably satisfactory in form and substance to the Administrative Agent and its counsel.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Without
limiting the generality of the provisions of Section 8.4, for purposes of determining compliance with the conditions specified in this Section 4.1, each Lender that has signed this Agreement or a Lender Consent shall be deemed to have consented to,
approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless the Administrative Agent shall have received notice from such Lender
prior to the proposed Closing Date specifying its objection thereto.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Conditions to All Extensions of Credit</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The
obligation of each Lender to make any Extension of Credit hereunder is subject to the satisfaction of the following conditions precedent on the date of making such Extension of Credit:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Representations and Warranties</u>. The
representations and warranties made by the Credit Parties herein and which are contained in any certificate furnished at any time under or in connection herewith shall (i) with respect to representations and warranties that contain a materiality
qualification, be true and correct and (ii) with respect to representations and warranties that do not contain a materiality qualification, be true and correct in all material respects, in each case on and as of the date of such Extension of Credit
as if made on and as of such date except for any representation or warranty made as of an earlier date, which representation and warranty shall remain true and correct (subject to the applicable materiality threshold in the preceding clauses (i) or
(ii)) as of such earlier date.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Default or Event of Default</u>. No
Default or Event of Default shall have occurred and be continuing on such date or after giving effect to the Extension of Credit to be made on such date unless such Default or Event of Default shall have been waived in accordance with this
Agreement.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Commitments</u>.
Immediately after giving effect to the making of any such Extension of Credit (and the application of the proceeds thereof), (i) the sum of the aggregate principal amount of outstanding Revolving Loans plus the aggregate principal amount of
outstanding LOC Obligations shall not exceed the Revolving Committed Amount then in effect, and (ii) the aggregate principal amount of the outstanding LOC Obligations shall not exceed the LOC Committed Amount.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Additional Conditions to Revolving
Loans</u>. If a Revolving Loan is requested, all conditions set forth in Section 2.1 shall have been satisfied.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Incremental Commitment</u>. If an
Incremental Commitment is requested, all conditions set forth in Section 2.22 shall have been satisfied.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Additional Conditions to Letters of
Credit</u>. If the issuance of a Letter of Credit is requested, (i) all conditions set forth in Section 2.3 shall have been satisfied and (ii) there shall exist no Lender that is a Defaulting Lender unless the Issuing Lenders have entered into
reasonably satisfactory arrangements with the Borrower or such Defaulting Lender to eliminate the Issuing Lenders&#8217; risk with respect to such Defaulting Lender&#8217;s LOC Obligations.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Each request
for an Extension of Credit and each acceptance by the Borrower of any such Extension of Credit shall be deemed to constitute representations and warranties by the Credit Parties as of the date of such Extension of Credit that the conditions set
forth above in paragraphs (a) through (f), as applicable, have been satisfied.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">64</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>ARTICLE V<br>
<br> AFFIRMATIVE COVENANTS</b></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Each of the Credit Parties hereby covenants and agrees that on the Closing Date, and thereafter (a) for so long as this Agreement is
in effect, (b) until the Commitments have terminated, and (c) until no Note remains outstanding and unpaid and the Credit Party Obligations and all other amounts owing to the Administrative Agent or any Lender hereunder are paid in full, such Credit
Party shall, and shall cause each of their Subsidiaries, to:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Financial Statements</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Furnish to
the Administrative Agent for prompt further distribution to each Lender:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Annual Financial Statements</u>. As soon
as available and in any event no later than the fifth Business Day following the earlier of (i) to the extent applicable, the date the Borrower is required by the SEC to file its Form 10-K for each fiscal year of the Borrower and (ii) ninety (90)
days after the end of each fiscal year of the Borrower, a copy of the Consolidated<b> </b>balance sheet of the Borrower and its Consolidated Subsidiaries as at the end of such fiscal year and the related Consolidated statements of income and
retained earnings and of cash flows of the Borrower and its Consolidated Subsidiaries for such year, which shall be audited by an independent registered certified public accounting firm of nationally recognized standing reasonably acceptable to the
Administrative Agent, setting forth in each case in comparative form the figures for the previous year, reported on without a &#8220;going concern&#8221; or like qualification or exception, or qualification indicating that the scope of the audit was
inadequate to permit such independent certified public accountants to certify such financial statements without such qualification;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Quarterly Financial Statements</u>. As
soon as available and in any event no later than the fifth Business Day following the earlier of (i) to the extent applicable, the date the Borrower is required by the SEC to file its Form 10-Q for any fiscal quarter of the Borrower and (ii)
forty-five (45) days after the end of each of the first three fiscal quarters of the Borrower, a copy of the Consolidated balance sheet of the Borrower and its Consolidated Subsidiaries as at the end of such period and related Consolidated
statements of income and retained earnings and of cash flows for the Borrower and its Consolidated Subsidiaries for such quarterly period and for the portion of the fiscal year ending with such period, in each case setting forth in comparative form
Consolidated figures for the corresponding period or periods of the preceding fiscal year (subject to normal recurring year-end audit adjustments); and</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Annual Operating Budget and Cash Flow</u>.
As soon as available, but in any event within forty-five (45) days after the end of each fiscal year (including the fiscal year ending December 31, 2017), a copy of the detailed annual operating budget or plan including cash flow projections of the
Borrower and its Consolidated Subsidiaries for the next four fiscal quarter period prepared on a quarterly basis, in form and detail reasonably acceptable to the Administrative Agent and the Lenders, together with a summary of the material
assumptions made in the preparation of such annual budget or plan;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">all such historical financial statements to be complete and correct in all material respects (subject, in the case of interim statements, to normal
recurring year-end audit adjustments) and to be prepared in reasonable detail and, in the case of the annual and quarterly financial statements provided in accordance with subsections (a) and (b) above, in accordance with GAAP applied consistently
throughout the periods reflected therein (except as required by a change in GAAP as set forth therein) and further accompanied by a description of, and an estimation of the effect on the financial statements on account of, a change, if any, in the
application of accounting principles as provided in Section 1.3. The financial statements provided in accordance with subsection (c) above shall have been prepared in good faith based upon reasonable assumptions.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Notwithstanding the foregoing, financial statements and reports required to be delivered pursuant to the foregoing provisions of this
Section may be delivered electronically (including via a link to the SEC&#8217;s EDGAR system) and if so, shall be deemed to have been delivered on the date on which the Administrative Agent receives such reports from the Borrower through electronic
mail.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">65</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certificates; Other Information</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Furnish to
the Administrative Agent for prompt further distribution to each Lender:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Accountants&#8217; Certificate</u>.
Concurrently with the delivery of the financial statements referred to in Section 5.1(a) above, a certificate of the independent certified public accountants reporting on such financial statements stating that in making the examination necessary
therefor no knowledge was obtained of any Default or Event of Default, except as specified in such certificate.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Officer&#8217;s Certificate</u>.
Concurrently with the delivery of the financial statements referred to in Sections 5.1(a) and 5.1(b) above, a certificate of a Responsible Officer substantially in the form of Exhibit 5.2(b) stating that (i) such financial statements present fairly
in all material respects the consolidated financial position of the Borrower and its Consolidated Subsidiaries for the periods indicated in conformity with GAAP applied on a consistent basis, (ii) each of the Credit Parties during such period
observed or performed in all material respects all of its covenants and other agreements, and satisfied every condition, contained in this Agreement to be observed, performed or satisfied by it, and (iii) such Responsible Officer has obtained no
knowledge of any Default or Event of Default except as specified in such certificate and such certificate shall include the calculations in reasonable detail required to indicate (A) compliance with Section 5.9 as of the last day of such period, (B)
that each Investment made during the most recently completed fiscal quarter pursuant to clause (e) of the definition of Permitted Investment, together with each other then-existing Investment pursuant to clause (e) of the definition of Permitted
Investment, did not, when such Investment was made, exceed 15% of Consolidated total shareholders&#8217; equity as determined in accordance with GAAP and as set forth on the then most recent Consolidated balance sheet of the Borrower and its
Consolidated Subsidiaries furnished to the Administrative Agent pursuant to Section 5.1 above and (C) the amount of all Restricted Payments paid and all Investments (including Permitted Acquisitions) that were made during such period.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Updated Schedules</u>. Concurrently with
or prior to the delivery of the financial statements referred to in Sections 5.1(a) and 5.1(b) above, (i) an updated copy of Schedule 3.12 if the Credit Parties or any of their Subsidiaries has formed or acquired a new Subsidiary since the Closing
Date or since such Schedule was last updated, as applicable and (ii) an updated copy of Schedule 3.21 if the Credit Parties or any of their Subsidiaries has materially altered or acquired any insurance policies since the Closing Date or since
Schedule 3.21 was last updated.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reports; SEC Filings; Regulatory Reports;
Press Releases; Etc</u>. Promptly upon their becoming available, (i) copies of all reports (other than those provided pursuant to Section 5.1 and those which are of a promotional nature) and other financial information which the Borrower sends to
its shareholders, (ii) copies of all reports and all registration statements and prospectuses (other than those on or pursuant to Form S-8 or any successor form), if any, which any Credit Party may make to, or file with, the SEC (or any successor or
analogous Governmental Authority) that are not available on the SEC&#8217;s EDGAR system (or any successor system) and (iii) all press releases and other statements made available by any of the Credit Parties to the public concerning material
developments in the business of any of the Credit Parties.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Reserved]</u>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Management Letters; Etc</u>. Promptly upon
receipt thereof, a copy or summary of any other report, or &#8220;management letter&#8221; or similar report submitted by independent accountants to any Credit Party or any of their Subsidiaries in connection with any annual, interim or special
audit of the books of such Person.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Debt Securities Information</u>. Promptly
after the furnishing thereof, copies of any statement or report furnished to any holder of debt securities of any Credit Party or any Subsidiary thereof pursuant to the terms of any indenture, loan or credit or similar agreement and not otherwise
required to be furnished to the Lenders pursuant to Section 5.1 or any other clause of this Section 5.2.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">66</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>General Information</u>. Except as may be
prohibited by a Requirement of Law, promptly, such additional financial and other information as the Administrative Agent, on behalf of any Lender, may from time to time reasonably request.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Payment of Taxes and Other Obligations</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Pay, discharge or otherwise satisfy at or before maturity or before they become delinquent, as the case may be, subject, where
applicable, to specified grace periods, (a) all of its material Taxes (Federal, state, local and any other Taxes) and (b) all of its other material obligations and liabilities of whatever nature in accordance with industry practice and (c) any
additional material costs that are imposed as a result of any failure to so pay, discharge or otherwise satisfy such Taxes, obligations and liabilities, except when the amount or validity of any such Taxes, obligations and liabilities is currently
being contested in good faith by appropriate proceedings and reserves, if applicable, in conformity with GAAP with respect thereto have been provided on the books of the Credit Parties.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Conduct of Business and Maintenance of Existence</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as expressly permitted under Section 6.3, continue to engage in business of the same general
type as now conducted by it on the Closing Date.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as permitted by Section 6.4, preserve, renew and keep in full force and effect its corporate
or other formative existence and good standing, take all reasonable action to maintain all rights, privileges and franchises necessary or desirable in the normal conduct of its business and to maintain its goodwill and comply with all Contractual
Obligations and Requirements of Law, except to the extent where the failure to comply, individually or in the aggregate, has not had and could not reasonably be expected to have a Material Adverse Effect.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as could not reasonably be expected, individually or in the aggregate, to have a Material
Adverse Effect, (i) obtain and maintain all certificates of need, provider numbers, permits and other licenses required to operate such Person&#8217;s business and its business locations under applicable law and maintain such Person&#8217;s
qualification for participation in, and payment under all applicable Government Reimbursement Programs and (ii) properly file all cost reports required under any applicable Government Reimbursement Program.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Provide goods or services to its customers in compliance with ethical standards, laws, rules and
regulations applicable to it or any facility or location it operates; (ii) assure that each of its employees and each employee of such facility or location has all required licenses, credentials, approvals and other certifications to perform his or
her duties and services for such location; and (iii) maintain all permits and other licenses required to operate its facilities and locations and conduct its business under applicable law; except to the extent, with respect to each of clauses (i),
(ii), and (iii) above, where the failure to comply, individually or in the aggregate, has not had and could not reasonably be expected to have a Material Adverse Effect.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Implement and maintain policies that are in material compliance with HIPAA and (ii) undertake to
be in compliance with each of the HIPAA provisions applicable to such Credit Party that relate to or regulate billing practices, procedures and codes, standard transactions, and privacy and security of protected health information except to the
extent any failure could not reasonably be expected to have a Material Adverse Effect.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Maintenance of Property; Insurance</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Keep all material property useful and necessary in its business in good working order and condition
(ordinary wear and tear and obsolescence excepted).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maintain with financially sound and reputable insurance companies liability, casualty, property and
business interruption insurance in at least such amounts and against at least such risks as are usually insured against in the same general areas by companies engaged in the same or a similar size and type of business; and furnish to the
Administrative Agent, upon the request of the Administrative Agent, full information as to the insurance carried. The Administrative Agent shall be named as additional insured, as its interest may appear, with respect to any such general liability
insurance, and use commercially reasonable efforts to cause each provider of</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">67</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">any
such insurance to agree, on a blanket basis or by endorsement upon the policy or policies issued by it or by independent instruments to be furnished to the Administrative Agent, that it will give the Administrative Agent thirty (30) days prior
written notice before any such policy or policies shall be materially altered or canceled, and such policies shall provide that no act or default of the Credit Parties or any of their Subsidiaries or any other Person shall affect the rights of the
Administrative Agent or the Lenders under such policy or policies; <u>provided</u>, <u>however</u>, that the Credit Parties may effect workers&#8217; compensation insurance or similar coverage with respect to operations in any particular state or
other jurisdiction through an insurance fund operated by such state or jurisdiction or by meeting the self-insurance requirements of such state or jurisdiction.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as could not reasonably be expected, individually or in the aggregate, to have a Material
Adverse Effect, preserve or renew all of its Intellectual Property.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Books and Records</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Keep proper
books, records and accounts in which full, true and correct entries in conformity in all material respects with GAAP and all Requirements of Law shall be made of all dealings and transactions in relation to its businesses and activities.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Give notice in writing to the Administrative Agent (which shall promptly transmit such notice to each Lender) of:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;promptly, but in any event within two (2)
Business Days after any Credit Party knows thereof, the occurrence of any Default or Event of Default;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;promptly, any default or event of default
under any Contractual Obligation of any Credit Party or any of its Subsidiaries which, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect or involve a monetary claim in excess of $10,000,000;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;promptly, any litigation, or any
investigation or proceeding known or threatened in writing to any Credit Party (i) affecting any Credit Party or any of its Subsidiaries which, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect or
involve a monetary claim in excess of $50,000,000 or involving injunctions or requesting injunctive relief by or against any Credit Party or any Subsidiary of any Credit Party, (ii) affecting or with respect to this Agreement, any other Credit
Document or any security interest created thereunder, (iii) involving an environmental claim or potential liability under Environmental Laws which could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, or
(iv) by any Governmental Authority relating to any Credit Party or any Subsidiary thereof and alleging fraud, deception or willful misconduct by such Person which could reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of any labor controversy that has resulted
in, or threatens to result in, a strike or other work action against any Credit Party which could, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of any attachment, judgment, lien, levy or
order exceeding $22,500,000 that could reasonably be expected to be assessed against or which has been threatened in writing against any Credit Party other than Permitted Liens;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as soon as possible and in any event within
thirty (30) days after any Credit Party knows or has reason to know thereof: (i) the occurrence or expected occurrence of any Reportable Event with respect to any Plan, a failure to make any required contribution to a Plan, the creation of any Lien
in favor of the PBGC (other than a Permitted Lien) or a Plan or any withdrawal from, or the termination, Reorganization or Insolvency of, any Multiemployer Plan or (ii) the institution of proceedings or the taking of any other action by the PBGC
with respect to the withdrawal from, or the terminating, Reorganization or Insolvency of, any Multiemployer Plan;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">68</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;promptly, any notice of any violation
received by any Credit Party from any Governmental Authority including, without limitation, any notice of violation of Environmental Laws which could reasonably be expected to cause a Material Adverse Effect;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as soon as possible and in any event within
two (2) Business Days following the occurrence of any of the following events: (i) any notice is received, through letter or otherwise, of a potential investigation relating to any Credit Party&#8217;s submission of claims to Government
Reimbursement Programs; (ii) the voluntary disclosure by any Credit Party to the Office of the Inspector General of the United States Department of Health and Human Services, a Medicare fiscal intermediary or any state&#8217;s Medicaid program of a
potential overpayment matter involving the submission of claims to such payor other than refund payments made in the ordinary course of business and which are immaterial in amount or (iii) any notice is received from a Governmental Authority
initiating any action that could result in the loss or cancellation of any license, permit, authorization or other right related to any Healthcare Law;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any notice is received from any Governmental
Authority of the imposition of any forfeiture or the designation of a hearing that could result in the expiration, termination, revocation, impairment or suspension of any license, permit, authorization or other right related to any Healthcare Law
which could reasonably be expected to cause a Material Adverse Effect; and</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;promptly, any other development or event
which could reasonably be expected to have a Material Adverse Effect.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Each notice pursuant to this Section shall be accompanied by a statement of a Responsible Officer setting forth details of the occurrence referred to
therein and stating what action the Credit Parties propose to take with respect thereto. In the case of any notice of a Default or Event of Default, the Borrower shall specify that such notice is a Default or Event of Default notice on the face
thereof.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Environmental Laws</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as could not reasonably be expected, either individually or in the aggregate, to have a
Material Adverse Effect, comply with, all applicable Environmental Laws and obtain and comply with and maintain, any and all licenses, approvals, notifications, registrations or permits required by applicable Environmental Laws;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as could not reasonably be expected, either individually or in the aggregate, to have a
Material Adverse Effect, conduct and complete all investigations, studies, sampling and testing, and all remedial, removal and other actions required under Environmental Laws and promptly comply with all lawful orders and directives of all
Governmental Authorities regarding Environmental Laws except to the extent that the same are being contested in good faith by appropriate proceedings; and</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Defend, indemnify and hold harmless the Administrative Agent and the Lenders, and their respective
employees, agents, officers and directors and affiliates, from and against any and all claims, demands, penalties, fines, liabilities, settlements, damages, costs and expenses of whatever kind or nature, known or unknown, contingent or otherwise,
arising out of, or in any way relating to the violation of, noncompliance with or liability under, any Environmental Law applicable to the operations of the Credit Parties or any of their Subsidiaries or the Properties, or any orders, requirements
or demands of Governmental Authorities related thereto, including, without limitation, reasonable attorney&#8217;s and consultant&#8217;s fees, investigation and laboratory fees, response costs, court costs and litigation expenses, except to the
extent that any of the foregoing arise out of the gross negligence or willful misconduct of the party seeking indemnification therefor. The agreements in this paragraph shall survive repayment of the Credit Party Obligations and all other amounts
payable hereunder and termination of the Commitments and the Credit Documents.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">69</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Financial Covenants</u></b>. Comply with the following financial covenants:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Consolidated Net Leverage Ratio</u>. The
Consolidated Net Leverage Ratio, calculated as of the last day of each fiscal quarter (beginning with the fiscal quarter ending December 31, 2017) or as of any other date on a Pro Forma Basis,
<font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">(i) for (A) the fiscal quarter ended June 30, 2020 and (B) the fiscal quarter ended September 30, 2020, shall be less than or equal to 5.00 to 1.00, (ii) for the fiscal
quarter ended December 31, 2020, shall be less than or equal to 4.75 to 1.00 and (iii) for any other fiscal quarter,</u></font> shall be less than or equal to 4.50 to 1.00.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Interest Coverage Ratio</u>. The Interest
Coverage Ratio, calculated as of the last day of each fiscal quarter (beginning with the fiscal quarter ending December 31, 2017) or as of any other date on a Pro Forma Basis, shall be greater than or equal to 3.00 to 1.00.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Notwithstanding the above, the parties hereto acknowledge and agree that, for purposes of all calculations made in determining
compliance for any applicable period with the financial covenants set forth in this Section, (i) after consummation of any Permitted Acquisition, (A) income statement items and other balance sheet items (whether positive or negative) attributable to
the Target acquired in such transaction shall be included in such calculations to the extent relating to such applicable period as if such Permitted Acquisition had been consummated as of the first day of such applicable period (including by adding
any reasonable cost saving synergies associated with such Permitted Acquisition in a manner reasonably satisfactory to the Required Lenders), subject to reasonable adjustments mutually acceptable to the Borrower and the Required Lenders and (B)
Indebtedness of a Target which is retired in connection with a Permitted Acquisition shall be excluded from such calculations and deemed to have been retired as of the first day of such applicable period and (ii) after any Disposition permitted by
Section 6.4(a)(viii), (A) income statement items, cash flow statement items and balance sheet items (whether positive or negative) attributable to the property or assets disposed of shall be excluded from such calculations to the extent relating to
such applicable period as if such Disposition had been consummated as of the first day of such applicable period, subject to adjustments mutually acceptable to the Borrower and the Required Lenders and (B) Indebtedness that is repaid with the
proceeds of such Disposition shall be excluded from such calculations and deemed to have been repaid as of the first day of such applicable period.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">For purposes
of this Section 5.9, cost saving synergies and adjustments to income statement items, cash flow statement items and balance sheet items reflected in financial statements provided by the Credit Parties pursuant to this Credit Agreement shall be
deemed accepted by the Required Lenders, unless the Required Lenders object to such items in writing within thirty (30) days of the submission of such financial statements; <u>provided</u>, that to the extent the Credit Parties revise any financial
statements as a result of such objection by the Required Lenders, such financial statements shall be deemed delivered as of the date originally submitted for all purposes of this Credit Agreement (other than the thirty (30) day period set forth in
this paragraph, which shall begin to run with respect to such revised financial statements when such revisions are submitted).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Notwithstanding the foregoing, with respect to any Target acquired pursuant to a Permitted Acquisition, beginning with the third full
fiscal quarter end to occur after such Permitted Acquisition, income statement items and other balance sheet items (whether positive or negative) attributable to such Target and included in the calculations required by this Section 5.9 shall not
exceed the actual results generated by such Target (except to the extent that income statement items and other balance sheet items that vary from actual items are approved (such approval not to be unreasonably withheld, delayed or conditioned) in
writing by the Required Lenders) for the period beginning with the first day of the first full fiscal quarter that the Target&#8217;s results are included in the Borrower&#8217;s consolidated financial statements and ending as of the applicable date
of calculation, annualized for the full period applicable to such calculation.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Additional Guarantors</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Credit Parties will cause each of their Material Domestic Subsidiaries (and any other Domestic
Subsidiary that is required to become a Guarantor pursuant to the definition of Material Domestic Subsidiary), whether newly formed, after acquired or otherwise existing (including upon the formation of any Material Domestic Subsidiary that is a
Division Successor) to promptly (and in any event within 45 days after (as applicable) (i) such Material Domestic Subsidiary is formed or acquired or (ii) financial statements are delivered</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">70</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">pursuant to Section 5.1 which demonstrate that a Domestic Subsidiary has become a Material Domestic Subsidiary (or, in the case of (i)
or (ii), such longer period of time as agreed to by the Administrative Agent in its reasonable discretion)) become a Guarantor hereunder by way of execution of a Joinder Agreement.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Credit Parties will cause each of their Domestic Subsidiaries (including upon the formation of
any Domestic Subsidiary that is a Division Successor) (other than PMG), to the extent not already a Guarantor hereunder as of the end of any fiscal year (beginning with the fiscal year ending December 31, 2018), to become a Guarantor hereunder by
way of execution of a Joinder Agreement within ninety (90) days after the end of such fiscal year (or such longer period of time as agreed to by the Administrative Agent in its reasonable discretion); <u>provided</u>, <u>however</u>, that no
Domestic Subsidiary shall be required to become a Guarantor pursuant to this Section 5.10(b) if such Domestic Subsidiary (i) would be required to obtain a third-party consent in connection with the execution and delivery of a Joinder Agreement, (ii)
the execution and delivery of a Joinder Agreement would be prohibited by a provision of such Domestic Subsidiary&#8217;s articles of incorporation, bylaws, operating agreement or other comparable charter documents or (iii) is a shell company with
nominal assets and no or nominal business operations as of the end of such fiscal year.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the foregoing Sections 5.10(a) and (b), the Credit Parties shall deliver to the
Administrative Agent, with respect to each new Guarantor to the extent applicable, substantially the same documentation required pursuant to Sections 4.1(b) &#8211; (d) and such other documents or agreements as the Administrative Agent may
reasonably request.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Law</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Comply with
all Requirements of Law, the articles of incorporation, bylaws, articles of organization, operating agreement or other organization documents, and orders (including Environmental Laws), and all applicable restrictions imposed by all Governmental
Authorities applicable to it except (a) to the extent such Requirement of Law, articles of incorporation, bylaws, articles of organization, operating agreement or other organization documents, order or restriction is being contested in good faith by
appropriate proceedings diligently conducted or (b) to the extent noncompliance with any such Requirements of Law, articles of incorporation, bylaws, articles of organization, operating agreement or other organization documents, order or restriction
could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. The Borrower will maintain in effect and enforce policies and procedures designed to ensure compliance by the Borrower, its Subsidiaries and their
respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Further Assurances</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Public/Private Designation</u>. The Credit Parties will cooperate with the Administrative Agent in
connection with the publication of certain materials and/or information provided by or on behalf of the Credit Parties to the Administrative Agent and Lenders (collectively, &#8220;<u>Information Materials</u>&#8221;) and will designate Information
Materials (i) that are either available to the public or not material with respect to the Credit Parties and their<b> </b>Subsidiaries or any of their respective securities for purposes of United States federal and state securities laws, as
&#8220;<u>Public Information</u>&#8221; and (ii) that are not Public Information as &#8220;<u>Private Information</u>,&#8221; which Private Information the Administrative Agent and Lenders shall keep confidential, including from any securities
trading, brokerage or securities analyst operations through appropriate &#8220;Chinese Wall&#8221; methods.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Additional Information</u>. The Credit Parties shall provide such information regarding the
operations, business affairs and financial condition of the Credit Parties and their Subsidiaries as the Administrative Agent or any Lender may reasonably request.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Visits and Inspections</u>. Each of the Credit Parties shall permit representatives and
independent contractors of the Administrative Agent and each Lender up to two times (in the aggregate for the Administrative Agent and all Lenders) during any twelve month period to visit and inspect any of its properties, to examine its corporate,
financial and operating records, and make copies thereof or abstracts therefrom, and to discuss its affairs, finances and accounts with its directors, officers, and independent public accountants, all at the expense of the Borrower and at such
reasonable times during normal business hours, upon reasonable advance notice to the</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">71</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Borrower; <u>provided</u>, <u>however</u>, that when an Event of Default under Section 7.1(a) or (f) exists, the Administrative Agent
or any Lender (or any of their respective representatives or independent contractors) may do any of the foregoing at the expense of the Borrower at any time during normal business hours and without advance notice and without limit to the number of
visits.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Material Contracts</u>. Upon the occurrence and during the continuance of a Default or an Event of
Default, upon the request of the Administrative Agent, the Credit Parties shall provide a list of all Material Contracts, together with a copy of any Material Contract requested by the Administrative Agent (subject to any confidentiality
restrictions therein).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Post Closing Deliveries</u>. Notwithstanding any provision herein or in any other Credit Document
to the contrary, to the extent not actually delivered on or prior to the Closing Date, the Borrower shall, and shall cause each Credit Party, to take the actions set forth on <u>Schedule 5.12(e)</u> within the period set forth on <u>Schedule
5.12(e)</u>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Collateral Matters</u></b>. At all times following the occurrence of the Collateral
Event:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Execute any and all further documents, financing statements, agreements and instruments, and take all
such further customary actions (including the filing and recording of financing statements, fixture filings and other documents and recordings of Liens in stock registries), that may be required under any applicable law, or that the Administrative
Agent may reasonably request, to cause the requirements of the occurrence of the Collateral Event to remain satisfied.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any additional Guarantor or Foreign Subsidiary or FSHCO is formed or acquired (including any
Guarantor that is a Division Successor) after such Collateral Event, or if any additional Equity Interests of any Guarantor or Foreign Subsidiary or FSHCO are issued after such Collateral Event, (i) notify the Administrative Agent thereof, and (ii)
within 30 Business Days after such date or such longer period as the Administrative Agent shall agree, (A) pledge all outstanding Equity Interests of such new Guarantor issued after such Collateral Event, pledge Equity Interests in such new Foreign
Subsidiary or FSHCO issued after such Collateral Event up to an amount thereof that would qualify as &#8220;Collateral&#8221;, pledge all new Equity Interests of the Guarantor issued after such Collateral Event, pledge Equity Interests of the
Foreign Subsidiary or FSHCO issued after such Collateral Event up to an amount thereof that, together with other Equity Interests in such Foreign Subsidiary or FSHCO that have previously been pledged, would qualify as &#8220;Collateral&#8221;, in
each case to the Administrative Agent under the Collateral Agreement, except to the extent such Equity Interests constitute Excluded Assets, and (B) deliver to the Administrative Agent for the benefit of the Lenders and the Bank Product Providers
all certificates or other instruments (if any) representing such Equity Interests, together with stock powers or other instruments of transfer with respect thereto endorsed in blank.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any additional Guarantor or Foreign Subsidiary or FSHCO is formed or acquired (including any
Guarantor that is a Division Successor) after the Collateral Event, deliver to the Administrative Agent within 30 Business Days after such date or such longer period as the Administrative Agent shall agree, (i) a supplement to the Collateral
Agreement, in the form specified therein, duly executed and delivered on behalf of such Credit Party and (ii) supplements to the other Security Documents, if applicable, to cause the requirements of the occurrence of the Collateral Event to become
satisfied with respect to such new Credit Party.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furnish to the Administrative Agent prompt written notice (and in any event within 30 days) of any
change in (i) any Credit Party&#8217;s corporate or organizational name, (ii) any Credit Party&#8217;s organizational form or jurisdiction of organization , (iii) the location of any Credit Party&#8217;s chief executive office or (iv) any Credit
Party&#8217;s organizational identification number.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><u style="border-bottom:#000000 thin double;"><font style="color:#0000ff;"><b>Section 5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated
Cash Balance</b>. From the Amendment No. 3 Effective Date through June 30, 2021, comply with the following covenant:</font></u></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">72</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><font
style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">If, as of the final Business Day of each weekly period starting from the first complete calendar week after the Amendment No. 3 Effective Date (for the avoidance of doubt, with the
first such final Business Day being April 3, 2020), (A) Loans are outstanding and (B) the Consolidated Cash Balance exceeds $300,000,000 as of the end of such applicable Business Day, then the Borrower shall, within two (2) Business Days thereafter,
prepay the Loans in an aggregate principal amount equal to such excess.</u></font></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>ARTICLE VI<br> <br> NEGATIVE COVENANTS</b></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Each of the
Credit Parties hereby covenants and agrees that on the Closing Date, and thereafter (a) for so long as this Agreement is in effect, (b) until the Commitments have terminated, (c) until no Note remains outstanding and unpaid and the Credit Party
Obligations and all other amounts owing to the Administrative Agent or any Lender hereunder are paid in full, that:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Indebtedness</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">No Credit
Party will, nor will it permit any Subsidiary to, contract, create, incur, assume or permit to exist any Indebtedness, except:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness arising or existing under this
Agreement and the other Credit Documents;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness of the Credit Parties and their
Subsidiaries existing as of the Closing Date as referred to in the financial statements referenced in Section 3.1 (and set out more specifically in Schedule 6.1(b) hereto) and any renewals, refinancings or extensions thereof in a principal amount
not in excess of that outstanding as of the date of such renewal, refinancing or extension;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness of the Credit Parties and their
Subsidiaries incurred after the Closing Date consisting of Capital Leases or Indebtedness incurred to provide all or a portion of the purchase price or cost of construction of an asset; <u>provided</u> that (i) such Indebtedness when incurred shall
not exceed the purchase price or cost of construction of such asset; (ii) no such Indebtedness shall be renewed, refinanced or extended for a principal amount in excess of the principal balance outstanding thereon at the time of such renewal,
refinancing or extension; and (iii) the total amount of all such Indebtedness at any time outstanding shall not exceed the greater of $125,000,000 and 2.5% of Consolidated Total Assets at such time;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unsecured intercompany Indebtedness among the
Credit Parties or Subsidiaries of the Credit Parties that become Credit Parties within the time required by Section 5.10;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness and obligations owing under
Hedging Agreements entered into in order to manage existing or anticipated interest rate, exchange rate or commodity price risks and not for speculative purposes;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Guaranty Obligations in respect of
Indebtedness of a Credit Party to the extent such Indebtedness is permitted to exist or be incurred pursuant to this Section;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;earnout obligations incurred, issued or
assumed by any Credit Party as the deferred purchase price of property or services purchased by such Credit Party which appear as liabilities on a balance sheet of such Credit Party;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other unsecured Indebtedness of Credit
Parties; provided, that (i) the Credit Parties have delivered a certificate (including reasonably detailed supporting calculations related to the matters set forth in such certificate) of a Responsible Officer to the Administrative Agent to the
effect that, after giving effect to such Indebtedness on a Pro Forma Basis, no Default or Event of Default exists and the Credit Parties are in compliance with each of the financial covenants set forth in Section
<strike><font style="color:#ff0000;">5.9,</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">5.9 (provided that for purposes of this clause (h) the applicable Consolidated Net Leverage Ratio shall be 4.50 to
1.00 for any fiscal quarter),</u></font> (ii) the representations and warranties, affirmative covenants, negative covenants, financial</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">73</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 0pt;">covenants, defaults and events of default in the definitive documentation for such Indebtedness are no
more restrictive than the terms and conditions set forth in the Credit Documents and (iii) the terms of any such Indebtedness shall not restrict payments by the Credit Parties of the Credit Party Obligations in any way; and</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness of a Permitted JV to the extent
the financial results of such Permitted JV are not Consolidated with the financial results of the Borrower and its Subsidiaries.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Liens</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Credit Parties will not, nor will they permit any Subsidiary (other than a Subsidiary that is a Permitted JV) to, contract,
create, incur, assume or permit to exist any Lien with respect to any of their respective property or assets of any kind (whether real or personal, tangible or intangible), whether now owned or hereafter acquired, except for Permitted Liens.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Nature of Business</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Engage in any material line of business substantially different from those lines of business conducted by the Borrower and its
Subsidiaries as of the Closing Date or any business substantially related or incidental thereto, except as approved by the Required Lenders (such approval not to be unreasonably withheld, conditioned or delayed).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Consolidation, Merger, Sale or Purchase of Assets, etc</u></b><b>.</b></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Credit Parties will not, nor will they permit any Subsidiary to,</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dissolve, liquidate or wind up its affairs,
or sell, transfer, lease, consummate a Division as the Dividing Person or otherwise dispose of its property or assets (each a &#8220;<u>Disposition</u>&#8221;) or agree to do so at a future time, except the following, without duplication, shall be
expressly permitted:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: 36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) the sale, transfer, lease or other disposition of inventory and
materials in the ordinary course of business and (B) the conversion of cash into Cash Equivalents and Cash Equivalents into cash;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: 36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the sale, transfer or other disposition of property or assets to an
unrelated party not in the ordinary course of business where and to the extent that they are the result of a Recovery Event;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: 36pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the sale, lease, transfer or other disposition of (A) machinery,
parts and equipment no longer used or useful in the conduct of the business of the Credit Parties or any of their Subsidiaries and (B) obsolete or worn out property, whether now owned or hereafter acquired, in the ordinary course of business;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: 36pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the sale, lease or transfer of property or assets from one Credit
Party to another Credit Party or dissolution of any Credit Party to the extent any and all assets are distributed to another Credit Party;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: 36pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the termination of any Hedging Agreement;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: 36pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dispositions of equipment or real property to the extent that (A)
such property is exchanged for credit against the purchase price of similar replacement property within twelve (12) months of such Disposition or (B) the proceeds of such Disposition are reasonably promptly applied to the purchase price of such
replacement property within 12 months of such Disposition;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">74</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: 36pt;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the licensing of Intellectual Property in the ordinary course of
business consistent with past practice;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: 36pt;">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dispositions by the Borrower or any Subsidiary; provided that at
any time after the Collateral Event, (i) with respect to asset sales for more than $300,000,000 per disposition or series of related dispositions, at least 75% of the consideration for any such asset sale shall consist of cash or cash equivalents
(provided that for purposes of the 75% cash consideration requirement (x) the amount of any Indebtedness or other liabilities of the Borrower or any Subsidiary (as shown on such person&#8217;s most recent balance sheet or in the notes thereto) that
are assumed by the transferee of any such assets, (y) the amount of any trade-in value applied to the purchase price of any replacement assets acquired in connection with such asset sale, and (z) any securities received by the Borrower or such
Subsidiary from such transferee that are converted by the Borrower or such Subsidiary into cash or cash equivalents (to the extent of the cash or cash equivalents received) within 270 days following the closing of the applicable asset sale, shall
each be deemed to be cash or cash equivalents) and (ii) immediately prior to the consummation of such asset sale, no Event of Default shall have occurred and be continuing and no Event of Default shall result therefrom;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: 36pt;">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the sale, lease or transfer of property or assets as part of a Sale
and Leaseback Transaction;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: 36pt;">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the merger of a Credit Party or a Subsidiary thereof with another
Credit Party or a Subsidiary thereof to the extent permitted by Section 6.4(b)(ii) below;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: 36pt;">(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dispositions of Equity Interests in Permitted JVs pursuant to the
terms of the joint venture or equivalent agreements governing such Permitted JVs so long as such joint venture or equivalent agreements are not solely between Persons that are Credit Parties, Subsidiaries or Affiliates of Credit Parties;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: 36pt;">(xii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;terminations of leases by a Credit Party or a Subsidiary in the
ordinary course of business that do not interfere in any material respect with the business of the Credit Parties or their Subsidiaries;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: 36pt;">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any Subsidiary that is an LLC may consummate a Division as the
Dividing Person if, immediately upon the consummation of the Division, the assets of the applicable Dividing Person are held by one or more Subsidiaries at such time, or, with respect to assets not so held by one or more Subsidiaries, such Division,
in the aggregate, would otherwise result in a Disposition permitted by Section 6.4(a)(viii) or (x) above; and</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 72pt; text-align: left; text-indent: 36pt;">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any sale, transfer, assignment, disposition, abandonment or lapse
of Intellectual Property that is no longer commercially practicable, usable or desirable in the conduct of business, in the ordinary course of business;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;"><u>provided</u> that (A) after giving effect to any Disposition pursuant to clauses (viii) and
(xi) above, the Credit Parties shall be in compliance on a Pro Forma Basis with the financial covenants set forth in Section 5.9 hereof <font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">(provided that for purposes of this
Section 6.4(a) the applicable Consolidated Net Leverage Ratio shall be 4.50 to 1.00 for any fiscal quarter),</u></font> recalculated for the most recently ended month for which information is available, and (B) with respect to clauses (v), (vi),
(viii) and (xi) above, no Default or Event of Default shall exist or shall result therefrom; or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) purchase, lease or otherwise acquire (in
a single transaction or a series of related transactions) the property or assets of any Person, other than (A) Permitted Investments and (B) except as otherwise limited or prohibited herein, purchases or other acquisitions of inventory, materials,
property and equipment in the ordinary course of business, or (ii) consummate any transaction of merger, Division as the Dividing Person or consolidation, except for (A) Investments or acquisitions (including pursuant to a</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">75</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 0pt;">Division) permitted pursuant to Section 6.5 so long as the Credit Party subject to such merger,
Division or consolidation is the surviving entity, (B) (y) the merger or consolidation of a Subsidiary that is not a Credit Party with and into a Credit Party; <u>provided</u> that such Credit Party will be the surviving entity and (z) the merger or
consolidation of a Credit Party with and into another Credit Party; <u>provided</u> that if the Borrower is a party thereto, the Borrower will be the surviving corporation, (C) the merger or consolidation of a Subsidiary that is not a Credit Party
with and into another Subsidiary that is not a Credit Party and (D) any Credit Party or any Subsidiary may consummate a Division as the Dividing Person if, immediately upon the consummation of the Division, (x) the assets of the applicable Dividing
Person are held by a Credit Party or one or more Subsidiaries at such time or, (y) with respect to assets not held by a Credit Party or one or more Subsidiaries, such Division, in the aggregate, would otherwise be permitted by this Section 6.4
(without reliance on this subclause (D)) and/or Section 6.5.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Investments and Acquisitions</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Credit
Parties will not, nor will they permit any Subsidiary (other than a Subsidiary that is a Permitted JV) to, make any Investment or contract to make any Investment except for Permitted Investments.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Transactions with Affiliates</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Other than execution, consummation and performance of each Management Agreement and Restrictive Agreement, the Credit Parties will
not, nor will they permit any Subsidiary to, enter into any transaction or series of transactions, whether or not in the ordinary course of business, with any officer, director, shareholder or Affiliate (other than a Subsidiary) other than on terms
and conditions substantially as favorable as would be obtainable in a comparable arm&#8217;s-length transaction with a Person other than an officer, director, shareholder or Affiliate, it being understood that payments of insurance premiums by any
Credit Party to PMG shall not violate this Section 6.6. Notwithstanding the foregoing, this Section 6.6 shall not apply to (a) any transaction that involves an amount less than or equal to the greater of (i) $120,000 or (ii) the amount set forth in
Item 404(a) of Regulation S-K of the SEC as in effect from time to time; provided, that such amount shall not exceed $250,000, (b) any transaction pertaining to director or executive officer compensation, benefits and perquisites that are approved
in accordance with the charter of the Compensation Committee of the Borrower&#8217;s Board of Directors or by the Borrower&#8217;s Board of Directors and (c) any transaction between a Credit Party or a Subsidiary thereof and another Credit Party or
a Subsidiary thereof.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 6.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Ownership of Subsidiaries; Restrictions</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Credit
Parties will not sell, transfer, pledge or otherwise dispose of any Equity Interest or other equity interests in any of their Subsidiaries, nor will they permit any of their Subsidiaries to issue, sell, transfer, pledge or otherwise dispose of any
of their Equity Interest or other equity interests, except in a transaction permitted by Section 6.4 or pursuant to the exercise of rights under a Restrictive Agreement.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
6.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Corporate Changes; Material Contracts</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">No Credit Party will, nor will it permit any of its Subsidiaries to, (a) change its fiscal year, (b) amend, modify or change its
articles of incorporation, certificate of designation (or corporate charter or other similar organizational document) operating agreement or bylaws (or other similar document) in any respect materially adverse to the interests of the Lenders without
the prior written consent of the Required Lenders; <u>provided</u> that no Credit Party shall (i) except as permitted under Section 6.4, alter its legal existence or, in one transaction or a series of transactions, merge into or consolidate with any
other entity or consummate a Division as the Dividing Person, (ii) sell all or substantially all of its assets, (iii) change its state of incorporation or organization or (iv) change its registered legal name, without providing thirty (30) days
prior written notice to the Administrative Agent, (c) have any oral operating agreement (or other similar agreement) or enter into a written operating agreement which regulates the affairs of such Credit Party, the conduct of its business,
establishes duties, and/or governs the relations among any members, managers and such Credit Party in either case that is materially adverse to the interests of the Lenders, it being further agreed that if any such oral or written agreement is
entered into, the Borrower shall provide a materially complete description of such oral agreement or a copy of such written agreement to the Administrative Agent within five (5) Business Days thereafter, (d) amend, modify, cancel or terminate or
refuse to renew or extend</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">76</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">or
permit the amendment, modification, cancellation or termination of any of its Material Contracts to the extent such amendment, modification, cancellation or termination could reasonably be expected to have a Material Adverse Effect, (e) have more
than one state of incorporation, organization or formation or (f) change its accounting method (except in accordance with GAAP or as required by a change in Tax law) in any manner adverse to the interests of the Lenders without the prior written
consent of the Required Lenders.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 6.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitation on Restricted Actions</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Credit
Parties will not, nor will they permit any Subsidiary (other than a Subsidiary that is a Permitted JV) to, directly or indirectly, create or otherwise cause or suffer to exist or become effective any encumbrance or restriction on the ability of any
such Person to (a) pay dividends or make any other distributions to any Credit Party on its Equity Interest or with respect to any other interest or participation in, or measured by, its profits, (b) pay any Indebtedness or other obligation owed to
any Credit Party, (c) make loans or advances to any Credit Party, (d) sell, lease or transfer any of its properties or assets to any Credit Party, or (e) act as a Guarantor pursuant to the Credit Documents or any renewals, refinancings, exchanges,
refundings or extension thereof or amend or otherwise modify the Credit Documents, except (in respect of any of the matters referred to in clauses (a)-(d) above) for such encumbrances or restrictions existing under or by reason of (i) this Agreement
and the other Credit Documents, (ii) applicable law, (iii) any document or instrument governing Indebtedness incurred pursuant to Section 6.1(c); <u>provided</u> that any such restriction contained therein relates only to the asset or assets
constructed or acquired in connection therewith, (iv) any Permitted Lien or any document or instrument governing any Permitted Lien; <u>provided</u> that any such restriction contained therein relates only to the asset or assets subject to such
Permitted Lien, (v) customary provisions in leases restricting the assignment thereof, or (vi) any Management Agreement.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 6.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Restricted Payments</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Credit
Parties will not, nor will they permit any Subsidiary to, directly or indirectly, declare, order, make or set apart any sum for or pay any Restricted Payment, except:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to make dividends payable solely in the same
class of Equity Interest of such Person;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to make Restricted Payments to any Credit
Party;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to purchase, redeem or otherwise acquire
Equity Interests issued by it with the proceeds received from the substantially concurrent issue of new shares of its common stock or other common Equity Interests;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;so long as after giving effect to such
payments the Credit Parties shall be in compliance with each of the financial covenants set forth in Section 5.9 hereof <font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">(provided that for purposes of this clause (d) the
applicable Consolidated Net Leverage Ratio shall be 4.50 to 1.00 for any fiscal quarter)</u></font>, to make regularly scheduled payments of (i) interest to the holders of Subordinated Debt and (ii) principal to the holders of Subordinated Debt
incurred in connection with any Permitted Acquisition, in each case in accordance with the terms thereof;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any payment with respect to any earnout
obligation incurred as the deferred purchase price of property or services purchased by such Person;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to make other Restricted Payments in an
aggregate amount not to exceed the greater of (x) $100,000,000 in any fiscal year and (y) an unlimited amount so long as, with respect to clause (y) after giving effect to each such Restricted Payment on a Pro Forma Basis (i) no Default or Event of
Default shall then exist or would result therefrom and (ii) the Consolidated Net Leverage Ratio of the Credit Parties would be in compliance with Section 5.9(a)<font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;"> (provided
that for purposes of this clause (f) the applicable Consolidated Net Leverage Ratio shall be 4.50 to 1.00 for any fiscal quarter);</u></font></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">77</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any redemption, retirement, sinking fund or
similar payment, purchase or other acquisition for value, direct or indirect, of any shares (or equivalent) of any class of Equity Interest of any Permitted JV, now or hereafter outstanding; and</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any payment made to retire, or to obtain the
surrender of, any outstanding warrants, options or other rights to acquire shares of any class of Equity Interest of any Permitted JV, now or hereafter
outstanding<strike><font style="color:#ff0000;">.</font></strike><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">;</u></font></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">provided, that the Credit Parties will not, nor will they permit any
Subsidiary to, directly or indirectly, declare, order, make or set apart any sum for or pay any Restricted Payment from the Amendment No. 3 Effective Date through December 31, 2020, except (i) Restricted Payments permitted pursuant to clause (b)
above and (ii) Restricted Payments consisting of the withholding of Equity Interests to satisfy Tax liabilities upon the vesting of awards issued under the Borrower&#8217;s 2008 Amended and Restated Incentive Compensation Plan subject to the
limitations set forth in clause (f) above.</u></font></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 6.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment of Subordinated Debt</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Credit
Parties will not, nor will they permit any Subsidiary (other than Indebtedness incurred pursuant to Section 6.1(i) by a Subsidiary that is a Permitted JV) to, without the prior written consent of the Required Lenders, amend, modify, waive or extend
or permit the amendment, modification, waiver or extension of any term of any document governing or relating to any Subordinated Debt in a manner that is materially adverse to the interests of the Lenders.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
6.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Further Negative Pledges</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Credit Parties will not, nor will they permit any Subsidiary (other than a Subsidiary that is a Permitted JV) to, enter into,
assume or become subject to any agreement prohibiting or otherwise restricting the creation or assumption of any Lien upon any of their properties or assets, whether now owned or hereafter acquired, or requiring the grant of any security for such
obligation if security is given for some other obligation, except (a) pursuant to this Agreement and the other Credit Documents, (b) pursuant to any document or instrument governing Indebtedness incurred pursuant to Section 6.1(c); <u>provided</u>
that any such restriction contained therein relates only to the asset or assets constructed or acquired in connection therewith, (c) pursuant to any document or instrument governing Indebtedness incurred pursuant to Sections 6.1(f) or 6.1(h), (d) in
connection with any Permitted Lien or any document or instrument governing any Permitted Lien; <u>provided</u> that any such restriction contained therein relates only to the asset or assets subject to such Permitted Lien, (e) customary provisions
in leases restricting the assignment thereof and (f) pursuant to any Management Agreement to the extent that any such Management Agreement is subject to the provisions of Section 9.23.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
6.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Restrictions Regarding PMG</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a) The Borrower will not, at any time, own less than 100% of the Equity Interests of PMG and (b) PMG shall not engage in any
business, or have any operations or liabilities, other than providing insurance services in the nature of a &#8220;captive&#8221; insurance company.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
6.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use of Proceeds and Letters of Credit</b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Borrower will not request any Loans or Letter of Credit, and the Borrower shall not use, and
shall procure that its Subsidiaries and its or their respective directors, officers, employees and agents shall not use, the proceeds of any Loans or Letter of Credit (A) in furtherance of an offer, payment, promise to pay, or authorization of the
payment or giving of money, or anything else of value, to any Person in violation of any Anti-Corruption Laws, (B) for the purpose of funding, financing or facilitating any activities, business or transaction of or with any Sanctioned Person, or in
any Sanctioned Country, or (C) in any manner that would result in the violation of any Sanctions applicable to any party hereto.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">78</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>ARTICLE
VII</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>EVENTS OF
DEFAULT</b></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Events of Default</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">An Event of
Default shall exist upon the occurrence of any of the following specified events (each an &#8220;<u>Event of Default</u>&#8221;):</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Payment</u>. (i) The Borrower shall fail
to pay any principal on any Loan or Note when due (whether at maturity, by reason of acceleration or otherwise) in accordance with the terms hereof or thereof; (ii) the Borrower shall fail to reimburse the Issuing Lenders for any LOC Obligations
when due (whether at maturity, by reason of acceleration or otherwise) in accordance with the terms hereof; (iii) the Borrower shall fail to pay any interest on any Loan or any fee or other amount payable hereunder when due (whether at maturity, by
reason of acceleration or otherwise) in accordance with the terms hereof and such failure shall continue unremedied for three (3) Business Days; or (iv) or any Guarantor shall fail to pay on the Guaranty in respect of any of the foregoing or in
respect of any other Guaranty Obligations hereunder (after giving effect to the grace period in clause (iii)); or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Misrepresentation</u>. Any representation
or warranty made or deemed made herein or in any of the other Credit Documents or which is contained in any certificate, document or financial or other statement furnished at any time under or in connection with this Agreement shall (i) with respect
to representations and warranties that contain a materiality qualification, prove to have been incorrect, false or misleading and (ii) with respect to representations and warranties that do not contain a materiality qualification, prove to have been
incorrect, false or misleading in any material respect, in each case on or as of the date made or deemed made; or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Covenant Default</u>. (i) Any Credit Party
shall fail to perform, comply with or observe any term, covenant or agreement applicable to it contained in Sections 5.1 (financial statements), 5.2(a) (accountants&#8217; certificate), 5.2(b) (officer&#8217;s certificate), 5.7(a) (notices), 5.9
(financial covenants), or <u>Article VI</u> hereof; (ii) any Credit Party shall fail to comply with Section 5.5(b) (insurance) and, with respect to this clause (ii) only, such breach or failure to comply is not cured within thirty (30) days after
its occurrence or (iii) any Credit Party shall fail to comply with any other covenant contained in this Agreement or the other Credit Documents or any other agreement, document or instrument among any Credit Party, the Administrative Agent and the
Lenders or executed by any Credit Party in favor of the Administrative Agent or the Lenders (other than as described in Sections 7.1(a), 7.1(c)(i) or 7.1(c)(ii) above) and, with respect to this clause (iii) only, such breach or failure to comply is
not cured within the earlier of (A) thirty (30) days after the Borrower became aware of its occurrence or (B) forty-five (45) days after its occurrence; or</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Material Indebtedness Cross-Default</u>.
(i) Any Credit Party or any of its Subsidiaries shall default in any payment of principal of or interest on any Indebtedness (other than the Loans, Reimbursement Obligations, the Guaranty and any other amounts payable under the Credit Documents) in
a principal amount outstanding of at least $60,000,000 for the Credit Parties and any of their Subsidiaries in the aggregate beyond any applicable grace period, if any, provided in the instrument or agreement under which such Indebtedness was
created; or (ii) any Credit Party or any of its Subsidiaries shall default in the observance or performance of any other agreement or condition relating to any Indebtedness (other than the Loans, Reimbursement Obligations, the Guaranty and any other
amounts payable under the Credit Documents) in a principal amount outstanding of at least $60,000,000 in the aggregate for the Credit Parties and their Subsidiaries or contained in any instrument or agreement evidencing, securing or relating
thereto, or any other event shall occur or condition exist, the effect of which default or other event or condition is to cause, or to permit the holder or holders of such Indebtedness or beneficiary or beneficiaries of such Indebtedness (or a
trustee or agent on behalf of such holder or holders or beneficiary or beneficiaries) to cause, with the giving of notice if required, all of such Indebtedness to become immediately due and payable prior to its stated maturity or to be repurchased,
prepaid, deferred or redeemed (automatically or otherwise); or (iii) there occurs under any Hedging Agreement that is a Bank Product an Early Termination Date (as defined in such Hedging Agreement) resulting from (A) any event</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">79</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: left; text-indent: 0pt;">of default under such Hedging Agreement as to which the Borrower or any Subsidiary is the Defaulting
Party (as defined in such Hedging Agreement) or (B) any Termination Event (as defined in such Hedging Agreement) under such Hedging Agreement as to which the Borrower or any Subsidiary is an Affected Party (as defined in such Hedging Agreement) and,
in either event, the Swap Termination Value owed by such Person as a result thereof is greater than $7,500,000; or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Other Cross-Defaults</u>. To the extent
any such default could reasonably be expected to have a Material Adverse Effect, the Credit Parties or any of their Subsidiaries shall default in (i) the payment when due under any Material Contract or (ii) the performance or observance, of any
obligation or condition of any Material Contract and, in the case of this clause (ii) only, such failure to perform or observe such other obligation or condition continues unremedied for a period of thirty (30) days after notice of the occurrence of
such default (or such longer grace or cure period as provided in the Material Contract) unless, but only as long as, the existence of any such default is being contested by the Credit Parties in good faith by appropriate proceedings and adequate
reserves in respect thereof have been established on the books of the Credit Parties to the extent required by GAAP; or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Bankruptcy Default</u>. (i) A Credit Party
or any of its Subsidiaries shall commence any case, proceeding or other action (A) under any existing or future law of any jurisdiction, domestic or foreign, relating to bankruptcy, insolvency, reorganization or relief of debtors, seeking to have an
order for relief entered with respect to it, or seeking to adjudicate it a bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, winding-up, liquidation, dissolution, composition or other relief with respect to it or its debts,
or (B) seeking appointment of a receiver, trustee, custodian, conservator or other similar official for it or for all or any substantial part of its assets, or a Credit Party or any of its Subsidiaries shall make a general assignment for the benefit
of its creditors; or (ii) there shall be commenced against a Credit Party or any of its Subsidiaries any case, proceeding or other action of a nature referred to in clause (i) above which (A) results in the entry of an order for relief or any such
adjudication or appointment or (B) remains undismissed, undischarged or unbonded for a period of sixty (60) days; or (iii) there shall be commenced against a Credit Party or any of its Subsidiaries any case, proceeding or other action seeking
issuance of a warrant of attachment, execution, distraint or similar process against all or any substantial part of their assets which results in the entry of an order for any such relief which shall not have been vacated, discharged, or stayed or
bonded pending appeal within sixty (60) days from the entry thereof; or (iv) a Credit Party or any of its Subsidiaries shall take any action in furtherance of, or indicating its consent to, approval of, or acquiescence in, any of the acts set forth
in clause (i), (ii), or (iii) above; or (v) a Credit Party or any of its Subsidiaries shall generally not, or shall be unable to, or shall admit in writing their inability to, pay its debts as they become due; or</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Judgment Default</u>. One or more
judgments or decrees shall be entered against a Credit Party or any of its Subsidiaries involving in the aggregate a liability (to the extent not covered by insurance) of $75,000,000 or more and all such judgments or decrees shall not have been paid
and satisfied, vacated, discharged, stayed or bonded pending appeal within twenty (20) Business Days from the entry thereof or any injunction, temporary restraining order or similar decree shall be issued against a Credit Party or any of its
Subsidiaries that, individually or in the aggregate, could result in a Material Adverse Effect; or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>ERISA Default</u>. The occurrence of any
of the following: (i) Any Person shall engage in any &#8220;prohibited transaction&#8221; (as defined in Section 406 of ERISA or Section 4975 of the Code) involving any Plan, (ii) any &#8220;accumulated funding deficiency&#8221; (as defined in
Section 302 of ERISA), whether or not waived, shall exist with respect to any Plan or any Lien in favor of the PBGC or a Plan (other than a Permitted Lien) shall arise on the assets of the Credit Parties or any Commonly Controlled Entity, (iii) a
Reportable Event shall occur with respect to, or proceedings shall commence to have a trustee appointed, or a trustee shall be appointed, to administer or to terminate, any Single Employer Plan, which Reportable Event or commencement of proceedings
or appointment of a trustee is, in the reasonable opinion of the Required Lenders, likely to result in the termination of such Plan for purposes of Title IV of ERISA, (iv) any Single Employer Plan shall terminate for purposes of Title IV of ERISA,
(v) a Credit Party, any of its Subsidiaries or any Commonly Controlled Entity shall, or in the reasonable opinion of the Required Lenders is likely to, incur any liability in connection with a withdrawal from, or the Insolvency or Reorganization of,
any Multiemployer Plan or (vi) any other similar event or condition shall occur or exist with respect to a Plan, which in any of the foregoing cases in clauses (i) through (vi), results in a liability to any Credit Party in excess of $30,000,000;
or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">80</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Change of Control</u>. There shall occur a
Change of Control; or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Invalidity of Guaranty</u>. At any time
after the execution and delivery thereof, the Guaranty, for any reason other than the satisfaction in full of all Credit Party Obligations, shall cease to be in full force and effect (other than in accordance with its terms) or shall be declared to
be null and void, or any Credit Party shall contest the validity, enforceability, perfection or priority of the Guaranty, any Credit Document, or any Lien granted thereunder in writing or deny in writing that it has any further liability, including
with respect to future advances by the Lenders, under any Credit Document to which it is a party; or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Invalidity of Credit Documents</u>. Any
Credit Document shall fail to be in full force and effect or to give the Administrative Agent and/or the Lenders the security interests, liens, rights, powers, priority and privileges purported to be created thereby (except as such documents may be
terminated or no longer in force and effect in accordance with the terms thereof, other than those indemnities and provisions which by their terms shall survive); or</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<u>Licenses/Permits/Certifications/Qualifications</u>. (i) A state or federal regulatory agency or other Governmental Authority shall have revoked, cancelled, failed to renew or adversely modified any license, permit, certificate, authorization or
Government Reimbursement Program qualification pertaining to the business of any Credit Party, regardless of whether such license, permit, certificate, authorization or qualification was held by or originally issued for the benefit of such Credit
Party, a tenant or any other Person except where such revocation could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect or (ii) any of the Credit Parties or their Subsidiaries or their officers,
employees or agents engage in activities which are prohibited by any of the federal Medicare and Medicaid Anti-Kickback States, 42 U.S.C. &#167;&#167;1320a-7b, the Ethics In Patient Referrals Act (the &#8220;Stark Law&#8221;), 42 U.S.C.
&#167;&#167;1395nn, as amended, the regulations promulgated thereunder, or related state or local statutes or regulations or which are prohibited by rules of professional conduct, except where failure to do so could not reasonably be expected,
individually or in the aggregate, to have a Material Adverse Effect; or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Subordinated Debt</u>. The subordination
provisions contained in any Subordinated Debt shall cease to be in full force and effect or shall cease to give the Lenders the rights, powers and privileges purported to be created thereby; or</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Classification as Senior Debt</u>. The
Credit Party Obligations shall cease to be classified as &#8220;Senior Indebtedness,&#8221; &#8220;Designated Senior Indebtedness&#8221; or any similar designation under any Subordinated Debt instrument; or</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Liens</u>. At any time following the
Collateral Event, (i) any Lien on any material portion of the Collateral granted in connection therewith or required to be granted pursuant to Section 5.13 to the Administrative Agent ceases to be a valid and perfected Lien (or the priority of such
Lien ceases to be in full force and effect), except to the extent that any such loss of validity, perfection or priority results from the failure of the Agent to maintain possession of Collateral requiring perfection through control or to file or
record any document, or (ii) any material provision of any Security Document ceases to be in full force and effect or any Credit Party denies in writing the enforceability thereof.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Once a
Default occurs under the Credit Documents, then such Default will continue to exist until it either is cured (to the extent specifically permitted) in accordance with the Credit Documents or is otherwise expressly waived by Administrative Agent
(with the approval of requisite Lenders (in their sole and absolute discretion) as determined in accordance with Section 9.1); and once an Event of Default occurs under the Credit Documents, then such Event of Default will continue to exist until it
is cured to the satisfaction of, or expressly waived by, Administrative Agent with the approval of the requisite Lenders, as required hereunder (in their sole and absolute discretion) in Section 9.1.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">81</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Acceleration; Remedies</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Upon the
occurrence and during the continuance of an Event of Default, then, and in any such event, (a) if such event is a Bankruptcy Event, automatically the Commitments shall immediately terminate and the Loans (with accrued interest thereon), and all
other amounts under the Credit Documents (including, without limitation, the maximum amount of all contingent liabilities under Letters of Credit) shall immediately become due and payable, and (b) if such event is any other Event of Default, any or
all of the following actions may be taken: (i) with the written consent of the Required Lenders, the Administrative Agent may, or upon the written request of the Required Lenders, the Administrative Agent shall, declare the Commitments to be
terminated forthwith, whereupon the Commitments shall immediately terminate; (ii) the Administrative Agent may, or upon the written request of the Required Lenders, the Administrative Agent shall, declare the Loans (with accrued interest thereon)
and all other amounts owing under this Agreement and the Notes to be due and payable forthwith and direct the Borrower to pay to the Administrative Agent Cash Collateral as security for the LOC Obligations for subsequent drawings under then
outstanding Letters of Credit an amount equal to the maximum amount of which may be drawn under Letters of Credit then outstanding, whereupon the same shall immediately become due and payable; and/or (iii) with the written consent of the Required
Lenders, the Administrative Agent may, or upon the written request of the Required Lenders, the Administrative Agent shall, exercise such other rights and remedies as provided under the Credit Documents and under applicable law.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>ARTICLE VIII<br> <br>
THE ADMINISTRATIVE AGENT</b></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Appointment and Authority</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Each of the
Lenders and each of the Issuing Lenders hereby irrevocably appoints JPMCB to act on its behalf as the Administrative Agent hereunder and under the other Credit Documents and authorizes the Administrative Agent to take such actions on its behalf and
to exercise such powers as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto. The provisions of this Article are solely for the benefit of the
Administrative Agent, the Lenders and the Issuing Lenders, and neither the Borrower nor any other Credit Party shall have rights as a third party beneficiary of any of such provisions. It is understood and agreed that the use of the term
&#8220;agent&#8221; herein or in any other Credit Documents (or any other similar term) with reference to the Administrative Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of
any applicable law. Instead such term is used as a matter of market custom, and is intended to create or reflect only an administrative relationship between contracting parties.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Nature of Duties</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Anything herein to the contrary notwithstanding, none of the bookrunners, arrangers, syndication agent or other agents listed on the
cover page hereof shall have any powers, duties or responsibilities under this Agreement or any of the other Credit Documents, except in its capacity, as applicable, as the Administrative Agent, a Lender or an Issuing Lender hereunder. Without
limiting the foregoing, none of the Lenders or other Persons so identified shall have or be deemed to have any fiduciary relationship with any Lender. Each Lender acknowledges that it has not relied, and will not rely, on any of the Lenders or other
Persons so identified in deciding to enter into this Agreement or in taking or not taking action hereunder.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Credit
Document by or through any one or more sub-agents appointed by the Administrative Agent. The Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Related
Parties. The exculpatory provisions of this Article shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such sub-agent, and shall apply to their respective activities in connection with the syndication of
the credit facilities provided for herein as well as activities as Administrative Agent. The Administrative Agent shall not be responsible for the negligence or misconduct of any subagents except to the extent that a court of competent jurisdiction
determines in a final and nonappealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such sub-agents.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">82</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exculpatory Provisions</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The
Administrative Agent shall not have any duties or obligations except those expressly set forth herein and in the other Credit Documents, and its obligations hereunder shall be administrative in nature. Without limiting the generality of the
foregoing, the Administrative Agent:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall not be subject to any fiduciary or
other implied duties, regardless of whether a Default has occurred and is continuing;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall not have any duty to take any
discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Credit Documents that the Administrative Agent is required to exercise as directed in writing by the
Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in the other Credit Documents), provided that the Administrative Agent shall not be required to take any action that, in its opinion or
the opinion of its counsel, may expose the Administrative Agent to liability or that is contrary to any Credit Document or applicable law, including for the avoidance of doubt any action that may be in violation of the automatic stay under any
Debtor Relief Law or that may effect a forfeiture, modification or termination of property of a Defaulting Lender in violation of any Debtor Relief Law; and</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall not, except as expressly set forth
herein and in the other Credit Documents, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to any Credit Party or any of its Affiliates that is communicated to or obtained by the Person serving
as the Administrative Agent or any of its Affiliates in any capacity.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Administrative Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the
Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith shall be necessary, under the circumstances as provided in Sections 9.1 and 7.2) or (ii) in the
absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment. The Administrative Agent shall be deemed not to have knowledge of any Default unless and until notice
describing such Default is given to the Administrative Agent in writing by the Borrower, a Lender or an Issuing Lender.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or
representation made in or in connection with this Agreement or any other Credit Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance
or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Credit Document
or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in <u>Article IV</u> or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reliance by Administrative Agent</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Administrative Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request,
certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise
authenticated by the proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon. In
determining compliance with any condition hereunder to the making of a Loan, or the issuance, extension, renewal or increase of a Letter of Credit, that by its terms must be fulfilled to the satisfaction of a Lender or an Issuing Lender, the
Administrative Agent may presume that such condition is satisfactory to such Lender or such Issuing Lender unless the Administrative Agent shall have received notice to the</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">83</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">contrary from such Lender or such Issuing Lender prior to the making of such Loan or the issuance of such Letter of Credit. The
Administrative Agent may consult with legal counsel (who may be counsel for the Borrower), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any
such counsel, accountants or experts.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 8.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice of Default</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The
Administrative Agent shall not be deemed to have knowledge or notice of the occurrence of any Default or Event of Default hereunder unless the Administrative Agent has received written notice from a Lender or the Borrower referring to this
Agreement, describing such Default or Event of Default and stating that such notice is a &#8220;notice of default.&#8221; In the event that the Administrative Agent receives such a notice, the Administrative Agent shall give prompt notice thereof to
the Lenders. The Administrative Agent shall take such action with respect to such Default or Event of Default as shall be reasonably directed by the Required Lenders; <u>provided</u>, <u>however</u>, that unless and until the Administrative Agent
shall have received such directions, the Administrative Agent may (but shall not be obligated to) take such action, or refrain from taking such action, with respect to such Default or Event of Default as it shall deem advisable in the best interests
of the Lenders except to the extent that this Agreement expressly requires that such action be taken, or not taken, only with the consent or upon the authorization of the Required Lenders, or all of the Lenders, as the case may be.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
8.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Reliance on Administrative Agent and Other Lenders</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Each Lender and each Issuing Lender expressly acknowledges that neither the Administrative Agent nor any of its officers, directors,
employees, agents, attorneys-in-fact or affiliates has made any representation or warranty to it and that no act by the Administrative Agent hereinafter taken, including any review of the affairs of any Credit Party, shall be deemed to constitute
any representation or warranty by the Administrative Agent to any Lender. Each Lender and each Issuing Lender acknowledges that it has, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related
Parties and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender and each Issuing Lender also acknowledges that it will, independently and without
reliance upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action
under or based upon this Agreement, any other Credit Document or any related agreement or any document furnished hereunder or thereunder.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
8.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Lenders agree to indemnify the Administrative Agent, the Issuing Lenders and their Affiliates and their respective officers,
directors, agents and employees (to the extent not reimbursed by the Credit Parties and without limiting the obligation of the Credit Parties to do so), ratably according to their respective Commitment Percentages in effect on the date on which
indemnification is sought under this Section, from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind whatsoever which may at any time (including,
without limitation, at any time following the payment of the Credit Party Obligations) be imposed on, incurred by or asserted against any such indemnitee in any way relating to or arising out of any Credit Document or any documents contemplated by
or referred to herein or therein or the transactions contemplated hereby or thereby or any action taken or omitted by any such indemnitee under or in connection with any of the foregoing; <u>provided</u>, <u>however</u>, that no Lender shall be
liable for the payment of any portion of such liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements to the extent resulting from such indemnitee&#8217;s gross negligence or willful
misconduct, as determined by a court of competent jurisdiction. The agreements in this Section shall survive the termination of this Agreement and payment of the Notes, any Reimbursement Obligation and all other amounts payable hereunder.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
8.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Administrative Agent in Its Individual Capacity</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Person serving as the Administrative Agent hereunder shall have the same rights and powers in its capacity as a Lender as any
other Lender and may exercise the same as though it were not the Administrative Agent and the term &#8220;Lender&#8221; or &#8220;Lenders&#8221; shall, unless otherwise expressly indicated or unless the context otherwise</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">84</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">requires, include the Person serving as the Administrative Agent hereunder in its individual capacity. Such Person and its Affiliates
may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with the Credit Parties or any Subsidiary or other Affiliate thereof as if
such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 8.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Successor Administrative Agent</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Administrative Agent may at any time give notice of its resignation to the Lenders, the Issuing
Lenders and the Borrower. Upon receipt of any such notice of resignation, the Required Lenders shall have the right to appoint a successor, which shall be a bank with an office in the United States (other than a Defaulting Lender), or an Affiliate
of any such bank with an office in the United States, and which appointment shall, provided no Event of Default exists under Section 7.1(a) or (f), be subject to the Borrower&#8217;s approval, which approval shall not be unreasonably withheld or
delayed. If no such successor shall have been so appointed by the Required Lenders, and shall have accepted such appointment, within thirty (30) days after the retiring Administrative Agent gives notice of its resignation (or such earlier day as
shall be agreed by the Borrower and the Required Lenders) (the &#8220;<u>Resignation Effective Date</u>&#8221;), then the retiring Administrative Agent may (but shall not be obligated to), on behalf of the Lenders and the Issuing Lenders, appoint a
successor Administrative Agent meeting the qualifications set forth above, which appointment shall, provided no Event of Default exists under Section 7.1(a) or (f), be subject to the Borrower&#8217;s approval, which approval shall not be
unreasonably withheld or delayed. Whether or not a successor has been appointed, such resignation shall nonetheless become effective in accordance with such notice on the Resignation Effective Date.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Person serving as Administrative Agent is a Defaulting Lender pursuant to clause (d) of the
definition thereof, the Required Lenders may, to the extent permitted by applicable law, by notice in writing to the Borrower and such Person, remove such Person as Administrative Agent and appoint a successor, which appointment shall, provided no
Event of Default exists under Section 7.1(a) or (f), be subject to the Borrower&#8217;s approval, which approval shall not be unreasonably withheld or delayed. If no such successor shall have been so appointed by the Required Lenders and shall have
accepted such appointment within 30 days (or such earlier day as shall be agreed by the Borrower and the Required Lenders) (the &#8220;<u>Removal Effective Date</u>&#8221;), then such removal shall nonetheless become effective in accordance with
such notice on the Removal Effective Date.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With effect from the Resignation Effective Date or the Removal Effective Date (as applicable) (i) the
retiring or removed Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Credit Documents (except that in the case of any Collateral held by the Administrative Agent on behalf of the Lenders or the
Issuing Lenders under any of the Credit Documents, the retiring Administrative Agent shall continue to hold such Collateral until such time as a successor Administrative Agent is appointed) and (ii) all payments, communications and determinations
provided to be made by, to or through the Administrative Agent shall instead be made by or to each Lender and each Issuing Lender directly, until such time, if any, as the Required Lenders appoint a successor Administrative Agent as provided for
above. Upon the acceptance of a successor&#8217;s appointment as Administrative Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring or removed Administrative Agent,
and the retiring or removed Administrative Agent shall be discharged from all of its duties and obligations hereunder or under the other Credit Documents (if not already discharged therefrom as provided above in this paragraph). The fees payable by
the Borrower to a successor Administrative Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Borrower and such successor. After the retiring Administrative Agent&#8217;s resignation or removal hereunder
and under the other Credit Documents, the provisions of this Article and Section 9.5 shall continue in effect for the benefit of such retiring or removed Administrative Agent, its sub-agents and their respective Related Parties in respect of any
actions taken or omitted to be taken by any of them while the retiring Administrative Agent was acting as Administrative Agent.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any resignation by JPMCB, as Administrative Agent pursuant to this Section shall also constitute its
resignation as an Issuing Lender. Upon the acceptance of a successor&#8217;s appointment as Administrative Agent hereunder, (i) such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of JPMCB in its
capacity as a retiring Issuing Lender, (ii) such retiring Issuing Lender shall be discharged from all of their respective duties and obligations hereunder or under the other Credit Documents, and (iii) the successor</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">85</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Issuing Lender shall issue letters of credit in substitution for the Letters of Credit, if any, outstanding at the time of such
succession or make other arrangements satisfactory to the retiring Issuing Lender to effectively assume the obligations of such retiring Issuing Lender with respect to such Letters of Credit. Such resignation shall not affect the validity or
effectiveness of any Letter of Credit issued prior to such resignation by JPMCB as Administrative Agent.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 8.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Guaranty Matters</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Lenders and each Bank Product Provider irrevocably authorize and direct the Administrative Agent
to release any Guarantor from its obligations under the applicable Guaranty if such Person ceases to be a Guarantor as a result of a transaction permitted hereunder.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with a termination or release pursuant to this Section, the Administrative Agent shall
promptly execute and deliver to the applicable Credit Party, at the Borrower&#8217;s expense, all documents that the applicable Credit Party shall reasonably request to evidence such termination or release. Upon request by the Administrative Agent
at any time, the Required Lenders will confirm in writing the Administrative Agent&#8217;s authority to release any Guarantor from its obligations under the Guaranty pursuant to this Section.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
8.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Bank Products</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Except as otherwise provided herein, no Bank Product Provider that obtains the benefits of Sections 2.8 and 7.2 or any Guaranty by
virtue of the provisions hereof or of any Guaranty shall have any right to notice of any action or to consent to, direct or object to any action hereunder or under any other Credit Document other than in its capacity as a Lender and, in such case,
only to the extent expressly provided in the Credit Documents. The Administrative Agent shall not be required to verify the payment of, or that other satisfactory arrangements have been made with respect to, Credit Party Obligations arising under
Bank Products unless the Administrative Agent has received written notice of such Credit Party Obligations, together with such supporting documentation as the Administrative Agent may request, from the applicable Bank Product Provider.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
8.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Withholding Tax</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">To the extent required by any Requirements of Law (as determined in good faith by the Administrative Agent), the Administrative Agent
may withhold from any payment to any Lender under any Credit Document an amount equivalent to any applicable withholding Tax. Without limiting or expanding the provisions of Section 2.16, each Lender shall indemnify and hold harmless the
Administrative Agent against, and shall make payable in respect thereof within 10 days after demand therefor, any and all Taxes and any and all related losses, claims, liabilities and expenses (including fees, charges and disbursements of any
counsel for the Administrative Agent) incurred by or asserted against the Administrative Agent by the IRS or any other Governmental Authority<b> </b>as a result of the failure of the Administrative Agent to properly withhold Tax from amounts paid to
or for the account of such Lender for any reason (including because the appropriate form was not delivered or not properly executed, or because such Lender failed to notify the Administrative Agent of a change in circumstance that rendered the
exemption from, or reduction of withholding Tax ineffective). A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error. Each Lender hereby authorizes
the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender under this Agreement or any other Credit Document against any amount due the Administrative Agent under this Section 8.12. The agreements in this
Section 8.12 shall survive the resignation and/or replacement of the Administrative Agent, any assignment of rights by, or the replacement of, a Lender, the termination of the Commitments and the repayment, satisfaction or discharge of all other
Obligations. For the avoidance of doubt, the term &#8220;Lender&#8221; shall, for purposes of this Section 8.12, include any Issuing Lender.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">86</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>ARTICLE IX<br>
<br> MISCELLANEOUS</b></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendments and Waivers</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to Section 2.13(b), Section 2.22(d) and Section 9.1(b) below, neither this Agreement nor any
of the other Credit Documents, nor any terms hereof or thereof may be amended, modified, extended, restated, replaced, or supplemented (by amendment, waiver, consent or otherwise) except in accordance with the provisions of this Section. The
Required Lenders may or, with the written consent of the Required Lenders, the Administrative Agent may, from time to time, (a) enter into with the Borrower written amendments, supplements or modifications hereto and to the other Credit Documents
for the purpose of adding any provisions to this Agreement or the other Credit Documents or changing in any manner the rights of the Lenders or of the Borrower hereunder or thereunder or (b) waive or consent to the departure from, on such terms and
conditions as the Required Lenders may specify in such instrument, any of the requirements of this Agreement or the other Credit Documents or any Default or Event of Default and its consequences; <u>provided</u>, <u>however</u>, that no such
amendment, supplement, modification, release, waiver or consent shall:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reduce the amount or extend the scheduled
date of maturity of any Loan or Note or any installment thereon, or reduce the amount or stated rate of any interest or fee payable hereunder (except in connection with a waiver of interest at the increased post-default rate set forth in Section 2.8
which shall be determined by a vote of the Required Lenders) or extend the scheduled date of any payment thereof or increase the amount or extend the expiration date of any Lender&#8217;s Commitment, in each case without the written consent of each
Lender directly affected thereby; or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;amend, modify or waive any provision of
this Section or reduce the percentage specified in the definition of Required Lenders or Required Facility Lenders, without the written consent of all the Lenders; or</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;release the Borrower or all or
substantially all of the Guarantors from obligations under the Guaranty, without the written consent of all of the Lenders and Bank Product Providers; or</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subordinate the Loans to any other
Indebtedness without the written consent of all of the Lenders; or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;permit a Letter of Credit to have an
original expiry date more than twelve (12) months from the date of issuance without the consent of each of the Revolving Lenders; <u>provided</u>, that the expiry date of any Letter of Credit may be extended in accordance with the terms of Section
2.3(a); or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;permit the Borrower to assign or transfer
any of its rights or obligations under this Agreement or other Credit Documents without the written consent of all of the Lenders; or</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;amend, modify or waive any provision of
the Credit Documents requiring consent, approval or request of the Required Lenders or Required Facility Lenders or all Lenders without the written consent of the Required Lenders or Required Facility Lenders or all the Lenders as appropriate;
or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;amend, modify or waive the order in
which Credit Party Obligations are paid or in a manner that would alter the pro rata sharing of payments by and among the Lenders in Section 2.11(b) or 9.7(b) without the written consent of each Lender and each Bank Product Provider directly
affected thereby; or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;amend, modify or waive any provision of
<u>Article VIII</u> without the written consent of the then Administrative Agent; or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">87</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;amend or modify the definition of Credit
Party Obligations to delete or exclude any obligation or liability described therein without the written consent of each Lender and each Bank Product Provider directly affected thereby; or</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;amend the definitions of &#8220;Hedging
Agreement,&#8221; &#8220;Bank Product,&#8221; or &#8220;Bank Product Provider&#8221; without the consent of any Bank Product Provider<b> </b>that would be adversely affected thereby; or</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(xii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;at any time following the Collateral
Event, release all or substantially all of the Collateral without the written consent of each Lender; or</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;allow the Credit Parties to Dispose of
all or substantially all of their assets, without the written consent of all of the Lenders and Bank Product Providers.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><u>provided</u>, <u>further</u>, that no amendment, waiver or consent affecting the rights or duties of the Administrative Agent or
any Issuing Lender under any Credit Document shall in any event be effective, unless in writing and signed by the Administrative Agent and such Issuing Lender, in addition to the Lenders required hereinabove to take such action.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Notwithstanding the foregoing, any amendment that would require the approval of the Required Lenders as set forth above but only
affects the Revolving Lenders (including, for the avoidance of doubt, paragraphs (a) through (d) and (f) of Section 4.2, insofar as they apply to the borrowing of Revolving Loans) or the Incremental Lenders of any series shall instead require the
approval of the applicable Required Facility Lenders (in addition to any other approvals that would otherwise be required).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Any such waiver, any such amendment, supplement or modification and any such release shall apply equally to each of the Lenders and
shall be binding upon the Borrower, the other Credit Parties, the Lenders, the Administrative Agent and all future holders of the Notes. In the case of any waiver, the Borrower, the other Credit Parties, the Lenders and the Administrative Agent
shall be restored to their former position and rights hereunder and under the outstanding Loans and Notes and other Credit Documents, and any Default or Event of Default waived shall be deemed to be cured and not continuing; but no such waiver shall
extend to any subsequent or other Default or Event of Default, or impair any right consequent thereon.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Notwithstanding any of the foregoing to the contrary, the consent of the Borrower and the other Credit Parties shall not be required
for any amendment, modification or waiver of the provisions of <u>Article VIII</u> (other than the provisions of Section 8.9).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Notwithstanding any of the foregoing to the contrary, the Credit Parties and the Administrative Agent, without the consent of any
Lender, may enter into any amendment, modification or waiver of any Credit Document, or enter into any new agreement or instrument, to correct any obvious error or omission of a technical nature, in each case that is immaterial (as determined by the
Administrative Agent), in any provision of any Credit Document, if the same is not objected to in writing by the Required Lenders within five (5) Business Days following receipt of notice thereof.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Notwithstanding (x) the fact that the consent of all the Lenders or of each Lender directly affected thereby is required in certain
circumstances as set forth above or (y) anything to the contrary contained in this Agreement, (a) each Lender is entitled to vote as such Lender sees fit on any bankruptcy reorganization plan that affects the Loans, and each Lender acknowledges that
the provisions of Section 1126(c) of the Bankruptcy Code supersedes the unanimous consent provisions set forth herein, (b) the Required Lenders may consent to allow a Credit Party to use cash collateral in the context of a bankruptcy or insolvency
proceeding and (c) no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder, except (i) that the Commitment of such Lender may not be increased or extended without the consent of such Lender and
(ii) to the extent such amendment, waiver or consent impacts such Defaulting Lender more than the other Lenders.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">88</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">For
the avoidance of doubt and notwithstanding any provision to the contrary contained in this Section 9.1, this Agreement may be amended (or amended and restated) with the written consent of the Credit Parties and the Administrative Agent in accordance
with Section 2.22.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Administrative Agent and the Borrower acting together identify any ambiguity, omission,
mistake, typographical error or other defect in any provision of this Agreement or any other Credit Document, then the Administrative Agent and the Borrower shall be permitted to amend, modify or supplement such provision to cure such ambiguity,
omission, mistake, typographical error or other defect, and such amendment shall become effective without any further action or consent of any other party to this Agreement.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices Generally</u>. Except in the case of notices and other communications expressly permitted
to be given by telephone (and except as provided in paragraph (b) below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered
mail or sent by telecopier as follows:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If to the Borrower or any other Credit
Party:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:left;">1301 Concord Terrace<br> Sunrise, Florida 33323<br>
Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer and General Counsel<br> Telephone:&nbsp; &nbsp;(954) 384-0175<br> Fax:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; &nbsp; &nbsp;(954) 384-7657</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If to the Administrative Agent:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:left;">JPMorgan Chase Bank, N.A., as Administrative Agent<br> 10 South Dearborn, Level 2</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:left;">Chicago, Illinois 60603-2300</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:left;">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jonathan Dowdy<br> Telephone:&nbsp; &nbsp;(312)
732-1891<br> Fax:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (888) 292-9533<br> Email:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; jpm.agency.servicing.1@jpmchase.com</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:left;"><br> with a copy to:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:left;">Cahill Gordon &amp; Reindel LLP</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:left;">80 Pine Street</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:left;">New York, New York 10005</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:left;">Attention: &nbsp;&nbsp; &nbsp;Jennifer B. Ezring</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:left;">Telephone:&nbsp;&nbsp; &nbsp;(212) 701-3822</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:left;">Fax:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (212) 378-2415</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:left;">Email:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; jezring@cahill.com</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if to a Lender, to it at its address (or
telecopier number) set forth in its Administrative Questionnaire.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Notices sent by hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when
received; notices sent by telecopier shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, shall be deemed to have been given at the opening of business on the next business day for
the recipient). Notices delivered through electronic communications to the extent provided in paragraph (b) below, shall be effective as provided in said paragraph (b).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">89</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Electronic Communications</u>. Notices and other communications to the Lenders and the Issuing
Lenders hereunder may be delivered or furnished by electronic communication (including e-mail and Internet or intranet websites) pursuant to procedures approved by the Administrative Agent, <u>provided</u> that the foregoing shall not apply to
notices to any Lender or any Issuing Lender pursuant to <u>Article II</u> if such Lender or such Issuing Lender, as applicable, has notified the Administrative Agent that it is incapable of receiving notices under such Article by electronic
communication. The Administrative Agent or the Borrower may, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it, <u>provided</u> that approval of
such procedures may be limited to particular notices or communications.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Unless the Administrative Agent otherwise prescribes, (i) notices and other communications sent to an e-mail address shall be deemed
received upon the sender&#8217;s receipt of an acknowledgement from the intended recipient (such as by the &#8220;return receipt requested&#8221; function, as available, return e-mail or other written acknowledgement), <u>provided</u> that if such
notice or other communication is not sent during the normal business hours of the recipient, such notice or communication shall be deemed to have been sent at the opening of business on the next business day for the recipient, and (ii) notices or
communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient at its e-mail address as described in the foregoing clause (i) of notification that such notice or communication is
available and identifying the website address therefor.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Change of Address, Etc</u>. Any party hereto may change its address or telecopier number for
notices and other communications hereunder by notice to the other parties hereto.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Platform</u>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Credit Party agrees that the
Administrative Agent may make the Communications available to the Lenders by posting the Communications on Intralinks or a substantially similar electronic transmission system (the &#8220;<u>Platform</u>&#8221;).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Platform is provided &#8220;as is&#8221;
and &#8220;as available.&#8221; The Agent Parties (as defined below) do not warrant the adequacy of the Platform and expressly disclaim liability for errors or omissions in the Communications effected thereby. No warranty of any kind, express,
implied or statutory, including, without limitation, any warranty of merchantability, fitness for a particular purpose, non-infringement of third-party rights or freedom from viruses or other code defects, is made by any Agent Party in connection
with the Communications or the Platform. In no event shall the Administrative Agent or any of its affiliates or any of their respective officers, directors, employees, agents, advisors or representatives (collectively, &#8220;<u>Agent
Parties</u>&#8221;) have any liability to the Credit Parties, any Lender or any other Person or entity for damages of any kind, including, without limitation, direct or indirect, special, incidental or consequential damages, losses or expenses
(whether in tort, contract or otherwise) arising out of any Credit Party&#8217;s or the Administrative Agent&#8217;s transmission of Communications through the Platform, unless determined by a court of competent jurisdiction by final and
nonappealable judgment to have resulted from the gross negligence, bad faith or willful misconduct of an Agent Party or from any material breach by an Agent Party of the obligations owing by it to the Credit Parties under this Agreement or the other
Credit Documents.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Waiver; Cumulative Remedies</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">No failure
to exercise and no delay in exercising, on the part of the Administrative Agent or any Lender, any right, remedy, power or privilege hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or
privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights, remedies, powers and privileges herein provided are cumulative and not exclusive of any rights, remedies,
powers and privileges provided by law.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Survival of Representations and Warranties</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">All
representations and warranties made hereunder and in any document, certificate or statement delivered pursuant hereto or in connection herewith shall survive the execution and delivery of this Agreement and the Notes and the making of the Loans;
<u>provided</u> that all such representations and warranties shall terminate on the date upon which the Commitments have been terminated and all amounts owing hereunder and under any Notes have been paid in full.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">90</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Payment of Expenses; Indemnity</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Costs and Expenses</u>. The Credit Parties shall pay (i) all reasonable and documented
out-of-pocket expenses incurred by the Administrative Agent and the Arrangers (including the reasonable and documented fees, charges and disbursements of one external counsel for the Administrative Agent and the Arrangers, taken as a whole, and one
external local counsel for the Administrative Agent and the Arrangers, taken as a whole, in each jurisdiction if required), in connection with the syndication of the credit facilities provided for herein, the preparation, negotiation, execution,
delivery and administration of this Agreement and the other Credit Documents or any amendments, modifications or waivers of the provisions hereof or thereof (whether or not the transactions contemplated hereby or thereby shall be consummated), (ii)
all reasonable and documented out-of-pocket expenses incurred by any Issuing Lender in connection with the issuance, amendment, renewal or extension of any Letter of Credit or any demand for payment thereunder and (iii) all reasonable and documented
out-of-pocket fees and expenses incurred by the Administrative Agent, any Lender, any Issuing Lender (including the reasonable and documented fees, charges and disbursements of one external counsel for the Administrative Agent, the Lenders and the
Issuing Lenders, taken as a whole, and one external local counsel for the Administrative Agent, the Lenders and the Issuing Lenders, taken as a whole (and to the extent any such person determines, after consultation with legal counsel, that an
actual or potential conflict may require use of separate counsel by such person, separate legal counsel (including separate local counsel) for such person)) in connection with the enforcement or protection of its rights (A) in connection with this
Agreement and the other Credit Documents, including its rights under this Section, or (B) in connection with the Loans made or Letters of Credit issued hereunder, including all such out-of-pocket expenses incurred during any workout, restructuring
or negotiations in respect of such Loans or Letters of Credit.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification by the Credit Parties</u>. The Credit Parties shall indemnify the Administrative
Agent (and any sub-agent thereof), each Lender, each Issuing Lender, and each Related Party of any of the foregoing Persons (each such Person being called an &#8220;<u>Indemnitee</u>&#8221;) against, and hold each Indemnitee harmless from, any and
all losses, claims, penalties, damages, liabilities and related expenses (including the reasonable and documented fees, charges and disbursements of one external counsel for the Indemnitees, taken as a whole, and one external local counsel for the
Indemnitees, taken as a whole, in each applicable jurisdiction if required (and to the extent an Indemnitee determines, after consultation with legal counsel, that an actual or potential conflict may require use of separate counsel by such
Indemnitee, separate legal counsel (including separate local counsel) for such Indemnitee)), incurred by any Indemnitee or asserted against any Indemnitee by any third party or by the Borrower or any other Credit Party arising out of, in connection
with, or as a result of (i) the execution or delivery of this Agreement, any other Credit Document or any agreement or instrument contemplated hereby or thereby, the performance by the parties hereto of their respective obligations hereunder or
thereunder or the consummation of the transactions contemplated hereby or thereby, (ii) any Loan or Letter of Credit or the use or proposed use of the proceeds therefrom (including any refusal by any Issuing Lender to honor a demand for payment
under a Letter of Credit if the documents presented in connection with such demand do not strictly comply with the terms of such Letter of Credit), (iii) any actual or alleged presence or release of Materials of Environmental Concern on or from any
property owned or operated by any Credit Party or any of its Subsidiaries, or any liability under Environmental Law related in any way to any Credit Party or any of its Subsidiaries, or (iv) any actual or prospective claim, litigation, investigation
or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory, whether brought by a third party or by the Borrower or any other Credit Party, and regardless of whether any Indemnitee is a party thereto,
<u>provided</u> that such indemnity shall not, as to any Indemnitee, be available to the extent that such losses, claims, damages, liabilities or related expenses (A) are determined by a court of competent jurisdiction by final and nonappealable
judgment to have resulted from the bad faith, gross negligence or willful misconduct of such Indemnitee, (B) result from a claim brought by the Borrower or any other Credit Party against such Indemnitee for material breach of such Indemnitee&#8217;s
obligations hereunder or under any other Credit Document, if the Borrower or such Credit Party has obtained a final non-appealable judgment in its favor on such claim as determined by a court of competent jurisdiction, (C) arise from disputes
arising solely among Indemnitees that do not involve any act or omission by any Credit Party or their respective Affiliates and are unrelated to any dispute involving the Administrative Agent in its capacity as such, or any claim by, the
Administrative Agent, any Lender or any Issuing Lender against any Credit Party or its Affiliates, or (D) are payable as a result of a settlement agreement related to the foregoing effected without the written consent of the Borrower (which consent
shall not to</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">91</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">be
unreasonably withheld or delayed); provided that (i) such consent shall be deemed given in the event that the Borrower has not objected thereto in writing within 15 days after receiving written notice thereof, (ii) such consent shall not be required
if any Credit Party has defaulted under its indemnification obligations (including obligations to indemnify the Indemnitees for legal fees and expenses related to such matter as requested by an Indemnitee from time to time) and (iii) no such consent
shall be required if there is a final judgment against an Indemnitee in any proceeding; <u>provided</u>, further however, that such Indemnitee shall promptly refund any amount to the extent that there is a final, non-appealable judicial
determination that such Indemnitee was not entitled to indemnification or contribution rights with respect to such payment pursuant to the express terms of this Section 9.5(b). This Section 9.5(b) shall not apply with respect to Taxes other than any
Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reimbursement by Lenders</u>. To the extent that the Credit Parties for any reason fail to
indefeasibly pay any amount required under paragraph (a) or (b) of this Section to be paid by it to the Administrative Agent (or any sub-agent thereof), any Issuing Lender or any Related Party of any of the foregoing, each Lender severally agrees to
pay to the Administrative Agent (or any such sub-agent), such Issuing Lender or such Related Party, as the case may be, such Lender&#8217;s Commitment Percentage (determined as of the time that the applicable unreimbursed expense or indemnity
payment is sought) of such unpaid amount, <u>provided</u> that the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent (or any such
sub-agent), any Issuing Lender in its capacity as such, or against any Related Party of any of the foregoing acting for the Administrative Agent (or any such sub-agent) or any Issuing Lender in connection with such capacity.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Waiver of Consequential Damages, Etc</u>. To the fullest extent permitted by applicable law, none
of the parties hereto or any Indemnitee shall assert, and each of them hereby waives, any claim against any other Person, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages)
arising out of, in connection with, or as a result of, this Agreement, any other Credit Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Loan or Letter of Credit or the use of the
proceeds thereof; <u>provided</u>, that such waiver shall not apply to any parties or any Indemnitee&#8217;s right to indemnification hereunder for losses, claims, penalties, damages, liabilities and related expenses incurred by any party or
Indemnitee as a result of a claim by any third party. No Indemnitee referred to in paragraph (b) above shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through
telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Credit Documents or the transactions contemplated hereby or thereby other than for direct or actual damages resulting from the
bad faith, gross negligence or willful misconduct of such Indemnitee as determined by a final and nonappealable judgment of a court of competent jurisdiction.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Payments</u>. All amounts due under this Section shall be payable promptly/not later than five (5)
Business Days after written demand therefor.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Survival</u>. The agreements contained in this Section shall survive the resignation of the
Administrative Agent and the replacement of any Issuing Lender, the replacement of any Lender, the termination of the Commitments and the repayment, satisfaction or discharge of the Credit Party Obligations.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
9.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns; Participations</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns Generally</u>. The provisions of this Agreement shall be binding upon and
inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby, except that neither the Borrower nor any other Credit Party may assign or otherwise transfer any of its rights or obligations hereunder without
the prior written consent of the Administrative Agent and each Lender and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except (i) to an assignee in accordance with the provisions of paragraph (b) of this
Section, (ii) by way of participation in accordance with the provisions of paragraph (d) of this Section or (iii) by way of pledge or assignment of a security interest subject to the restrictions of paragraph (f) of this Section (and any other
attempted assignment or transfer by any party hereto shall be null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns
permitted hereby, Participants to the extent provided in paragraph (d) of this Section and, to the extent expressly contemplated hereby, the Related Parties of each of the Administrative Agent and the Lenders) any legal or equitable right, remedy or
claim under or by reason of this Agreement.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">92</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Assignments by Lenders</u>. Any Lender may at any time assign to one or more Eligible Assignees
all or a portion of its rights and obligations under this Agreement (including all or a portion of its Commitment and the Loans at the time owing to it); <u>provided</u> that any such assignment shall be subject to the following conditions:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Minimum Amounts</u>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in the case of an assignment of the
entire remaining amount of the assigning Lender&#8217;s Commitment and the Loans at the time owing to it or in the case of an assignment to a Lender, an Affiliate of a Lender or an Approved Fund, no minimum amount need be assigned; and</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in any case not described in paragraph
(b)(i)(A) of this Section, the aggregate amount of the Commitment (which for this purpose includes Loans outstanding thereunder) or, if the applicable Commitment is not then in effect, the principal outstanding balance of the Loans of the assigning
Lender subject to each such assignment (determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or, if &#8220;Trade Date&#8221; is specified in the Assignment and Assumption,
as of the Trade Date) shall not be less than $5,000,000 (<u>provided</u>, <u>however</u>, that simultaneous assignments shall be aggregated in respect of a Lender and its Approved Funds), unless each of the Administrative Agent and, so long as no
Event of Default has occurred and is continuing, the Borrower otherwise consents (each such consent not to be unreasonably withheld or delayed).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Proportionate Amounts</u>. Each partial
assignment shall be made as an assignment of a proportionate part of all the assigning Lender&#8217;s rights and obligations under this Agreement with respect to the Loan or the Commitment assigned, except that this clause (ii) shall not prohibit
any Lender from assigning all or a portion of its rights and obligations among separate Facilities on a non-pro rata basis.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Required Consents</u>. No consent
shall be required for any assignment except to the extent required by paragraph (b)(i)(B) of this Section and, in addition:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the consent of the Borrower (such consent not
to be unreasonably withheld or delayed) shall be required unless (x) an Event of Default under Section 7.1(a) or (f) has occurred and is continuing at the time of such assignment or (y) such assignment is to a Lender, an Affiliate of a Lender or an
Approved Fund; provided that the Borrower will be deemed to have consented to any assignment to which it has not objected within ten (10) Business Days after receipt of a request for consent to such assignment;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the consent of the Administrative Agent (such
consent not to be unreasonably withheld or delayed) shall be required for assignments in respect of a Revolving Commitment if such assignment is to a Person that is not a Lender with a Commitment, an Affiliate of such Lender or an Approved Fund with
respect to such Lender; and</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the consent of the Issuing Lenders (such
consent not to be unreasonably withheld or delayed) shall be required for assignments in respect of a Revolving Commitment.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Assignment and Assumption</u>. The
parties to each assignment shall execute and deliver to the Administrative Agent an Assignment and Assumption, together with a processing and recordation fee of $3,500; <u>provided</u> that only one (1) such fee shall be payable in respect of
simultaneous assignments by a Lender and its Approved Funds), and the assignee, if it is not a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire; <u>provided,</u> <u>further,</u> that in the case of any assignment
resulting from a Lender becoming a Non-Consenting Lender, if such Non-Consenting Lender is being replaced pursuant to Section 2.19(b), such Non-Consenting Lender shall not be required to execute such Assignment and Assumption in order for such
assignment to be effective.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">93</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Assignment to Certain Persons</u>. No
such assignment shall be made to any Person that is not an Eligible Assignee.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;Certain Additional Payments</u>. In
connection with any assignment of rights and obligations of any Defaulting Lender hereunder, no such assignment shall be effective unless and until, in addition to the other conditions thereto set forth herein, the parties to the assignment shall
make such additional payments to the Administrative Agent in an aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright payment, purchases by the assignee of participations or subparticipations, or other
compensating actions, including funding, with the consent of the Borrower and the Administrative Agent, the applicable pro rata share of Loans previously requested but not funded by the Defaulting Lender, to each of which the applicable assignee and
assignor hereby irrevocably consent), to (A) pay and satisfy in full all payment liabilities then owed by such Defaulting Lender to the Administrative Agent or any Lender hereunder (and interest accrued thereon), and (B) acquire (and fund as
appropriate) its full pro rata share of all Loans and participations in Letters of Credit in accordance with its Revolving Commitment Percentage in the case of Revolving Lenders or its applicable Commitment Percentage in the case of Incremental
Lenders. Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Lender hereunder shall become effective under applicable Law without compliance with the provisions of this paragraph, then the
assignee of such interest shall be deemed to be a Defaulting Lender for all purposes of this Agreement until such compliance occurs.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Subject to
acceptance and recording thereof by the Administrative Agent pursuant to paragraph (c) of this Section, from and after the effective date specified in each Assignment and Assumption, the assignee thereunder shall be a party to this Agreement and, to
the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and
Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender&#8217;s rights and obligations under this Agreement, such Lender shall cease to be a party
hereto) but shall continue to be entitled to the benefits of Sections 2.14 and 9.5<i> </i>with respect to facts and circumstances occurring prior to the effective date of such assignment. Any assignment or transfer by a Lender of rights or
obligations under this Agreement that does not comply with this paragraph shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with paragraph (d) of this
Section.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Register</u>. The Administrative Agent, acting solely for this purpose as a non-fiduciary agent of
the Borrower, shall maintain at one of its offices in Charlotte, North Carolina a copy of each Assignment and Assumption delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and
principal amounts (and related interest amounts) of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the &#8220;<u>Register</u>&#8221;). The entries in the Register shall be conclusive absent manifest error, and the
Borrower, the Administrative Agent and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary. The
Register shall be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Participations</u>. Any Lender may at any time, without the consent of, or notice to, the Borrower
or the Administrative Agent, sell participations to any Person (other than a natural person or any Credit Party or any Credit Party&#8217;s Affiliates or Subsidiaries) (each, a &#8220;<u>Participant</u>&#8221;) in all or a portion of such
Lender&#8217;s rights and/or obligations under this Agreement (including all or a portion of its Commitment and/or the Loans owing to it); <u>provided</u> that (i) such Lender&#8217;s obligations under this Agreement shall remain unchanged, (ii)
such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the Borrower, the Administrative Agent, the Issuing Lenders and the other Lenders shall continue to deal solely and directly
with such Lender in connection with such Lender&#8217;s rights and obligations under this Agreement. For the avoidance of doubt, each Lender shall be responsible for the indemnity under Section 9.5(c)<b> </b>with respect to any payments made by such
Lender to its Participant(s).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">94</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Any
agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this
Agreement; <u>provided</u> that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, modification or waiver that affects such Participant. Subject to paragraph (e) of
this Section, the Borrower agrees that each Participant shall be entitled to the benefits of Sections 2.14 and 2.16 (subject to the requirements and limitations of such Sections and Section 2.19, and it being understood that the documentation
required under Section 2.16(e) and (f) shall be delivered solely to the participating Lender) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to paragraph (b) of this Section. To the extent permitted by
law, each Participant also shall be entitled to the benefits of Section 9.7<i> </i>as though it were a Lender, provided such Participant agrees to be subject to Section 2.11<i> </i>as though it were a Lender.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Each Lender
that sells a participation shall, acting solely for this purpose as an agent of the Borrower, maintain a register on which it enters the name and address of each Participant and the principal amounts (and related interest amounts) of each
Participant&#8217;s interest in the Loans or other obligations under the Credit Documents (the &#8220;<u>Participant Register</u>&#8221;); <u>provided</u> that no Lender shall have any obligation to disclose all or any portion of the Participant
Register to any Person (including the identity of any Participant or any information relating to a Participant's interest in any commitments, loans, letters of credit or its other obligations under any Credit Document) except to the extent that such
disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be
conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitations upon Participant Rights</u>. A Participant shall not be entitled to receive any
greater payment under Sections 2.14 and 2.16 than the applicable Lender would have been entitled to receive with respect to the participation sold to such Participant, unless the sale of the participation to such Participant is made with the
Borrower&#8217;s prior written consent (not to be unreasonably withheld or delayed).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Pledges</u>. Any Lender may at any time pledge or assign a security interest in all or any
portion of its rights under this Agreement to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; <u>provided</u> that no such pledge or assignment shall release such Lender from any
of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Right of Setoff; Sharing of Payments</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If an Event of Default shall have occurred and be continuing, each Lender, each Issuing Lender and
each of their respective Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by applicable law, to set off and apply any and all deposits (general or special, time or demand, provisional or final, in
whatever currency) at any time held and other obligations (in whatever currency) at any time owing by such Lender, such Issuing Lender or any such Affiliate to or for the credit or the account of the Borrower or any other Credit Party against any
and all of the obligations of the Borrower or such Credit Party now or hereafter existing under this Agreement or any other Credit Document to such Lender or such Issuing Lender, irrespective of whether or not such Lender or such Issuing Lender
shall have made any demand under this Agreement or any other Credit Document and although such obligations of the Borrower or such Credit Party may be contingent or unmatured or are owed to a branch, office or affiliate of such Lender or such
Issuing Lender different from the branch, office or Affiliate holding such deposit or obligated on such indebtedness; <u>provided</u> that in the event that any Defaulting Lender shall exercise any such right of setoff, (i) all amounts so set off
shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions of Section 2.21 and, pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held in
trust for the benefit of the Administrative Agent, the Issuing Lenders and the other Lenders, and (ii) the Defaulting Lender shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Credit Party Obligations
owing to such Defaulting Lender as to which it exercised such right of setoff. The rights of each Lender, each Issuing Lender and their respective Affiliates under this Section are in addition to other rights and remedies (including other rights of
setoff) that such Lender, such Issuing Lender or their respective Affiliates may have. Each Lender and each Issuing Lender agrees to notify the Borrower and the Administrative Agent promptly after any such setoff and application, <u>provided</u>
that the failure to give such notice shall not affect the validity of such setoff and application.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">95</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any Lender shall, by exercising any right of setoff or counterclaim or otherwise, obtain payment
in respect of any principal of or interest on any of its Loans or other obligations hereunder resulting in such Lender&#8217;s receiving payment of a proportion of the aggregate amount of its Loans and accrued interest thereon or other such
obligations greater than its <u>pro</u> <u>rata</u> share thereof as provided herein, then the Lender receiving such greater proportion shall (i) notify the Administrative Agent of such fact, and (ii) purchase (for cash at face value) participations
in the Loans and such other obligations of the other Lenders, or make such other adjustments as shall be equitable, so that the benefit of all such payments shall be shared by the Lenders ratably in accordance with the aggregate amount of principal
of and accrued interest on their respective Loans and other amounts owing them, <u>provided</u> that:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if any such participations are purchased
and all or any portion of the payment giving rise thereto is recovered, such participations shall be rescinded and the purchase price restored to the extent of such recovery, without interest; and</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:76.5pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the provisions of this paragraph shall
not be construed to apply to (x) any payment made by the Borrower pursuant to and in accordance with the express terms of this Agreement (including the application of funds arising from the existence of a Defaulting Lender), (y) any payment obtained
by a Lender as consideration for the assignment of or sale of a participation in any of its Loans or participations in Letters of Credit to any assignee or participant, other than to any Credit Party or any Subsidiary thereof (as to which the
provisions of this paragraph shall apply) or (z) any amounts received by any Issuing Lender to secure the obligations of a Defaulting Lender to fund risk participations hereunder.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Credit Party consents to the foregoing and agrees, to the extent it may effectively do so under
applicable law, that any Lender acquiring a participation pursuant to the foregoing arrangements may exercise against each Credit Party rights of setoff and counterclaim with respect to such participation as fully as if such Lender were a direct
creditor of each Credit Party in the amount of such participation.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Table of Contents and Section Headings</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The table
of contents and the Section and subsection headings herein are intended for convenience only and shall be ignored in construing this Agreement.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
9.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Counterparts; Integration; Effectiveness; Electronic Execution</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Counterparts; Integration; Effectiveness</u>. This Agreement may be executed in counterparts (and
by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Agreement and the other Credit Documents, and any separate letter
agreements with respect to fees payable to the Administrative Agent, the Issuing Lenders or any Arranger constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and
understandings, oral or written, relating to the subject matter hereof. Except as provided in Section 4.1, this Agreement shall become effective when it shall have been executed by the Administrative Agent and when the Administrative Agent shall
have received counterparts hereof that, when taken together, bear the signatures of each of the other parties hereto. Delivery of an executed signature page (counterpart or otherwise) of this Agreement or any Credit Document, or any certificates
executed in connection herewith or therewith by telecopy or email shall be effective as if delivered manually.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Electronic Execution of Assignments</u>. The words &#8220;execution,&#8221; &#8220;signed,&#8221;
&#8220;signature,&#8221; and words of like import in any Assignment and Assumption shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or
enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National
Commerce</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">96</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Act,
the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act; <u>provided</u> that nothing herein shall require the Administrative Agent to accept electronic signatures in
any form or format without its prior written consent.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Any
provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any
such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
9.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Integration</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">This Agreement and the other Credit Documents represent the agreement of the Borrower, the other Credit Parties, the Administrative
Agent and the Lenders with respect to the subject matter hereof, and there are no promises, undertakings, representations or warranties by the Administrative Agent, the Borrower, the other Credit Parties, or any Lender relative to the subject matter
hereof not expressly set forth or referred to herein or therein.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">This
Agreement shall be governed by, and construed in accordance with, the law of the State of New York without regard to its conflicts of law principals that would cause the law of another jurisdiction to apply (other than Sections 5-1401 and 5-1402 of
The New York General Obligations Law).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Consent to Jurisdiction; Service of Process and Venue</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Consent to Jurisdiction</u>. The Borrower and each other Credit Party irrevocably and
unconditionally submits, for itself and its property, to the nonexclusive jurisdiction of the Supreme Court of New York County, New York, the United States District Court for the Southern District of New York, and any appellate court from any
thereof, in any action or proceeding arising out of or relating to this Agreement or any other Credit Document, or for recognition or enforcement of any judgment, and each of the parties hereto irrevocably and unconditionally agrees that all claims
in respect of any such action or proceeding may be heard and determined in such New York<b> </b>sitting State court or, to the fullest extent permitted by applicable law, in such Federal court. Each of the parties hereto agrees that a final judgment
in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement or in any other Credit Document shall affect any right that the
Administrative Agent, any Lender or any Issuing Lender may otherwise have to bring any action or proceeding relating to this Agreement or any other Credit Document against the Borrower or any other Credit Party or its properties in the courts of any
jurisdiction.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Service of Process</u>. Each party hereto irrevocably consents to service of process in the manner
provided for notices in Section 9.2. Nothing in this Agreement will affect the right of any party hereto to serve process in any other manner permitted by applicable law.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Venue</u>. The Borrower and each other Credit Party irrevocably and unconditionally waives, to the
fullest extent permitted by applicable law, any objection that it may now or hereafter have to the laying of venue of any action or proceeding arising out of or relating to this Agreement or any other Credit Document in any court referred to in
paragraph (a) of this Section. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
9.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Confidentiality</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Each of the Administrative Agent, the Arrangers, the Lenders and the Issuing Lenders agree to maintain the confidentiality of the
Information (as defined below), except that Information may be disclosed (a) to its Affiliates and to its and its Affiliates&#8217; respective partners, directors, officers, employees, agents, advisors and other</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">97</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">representatives (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of
such Information and instructed to keep such Information confidential), (b) to the extent requested by any regulatory authority purporting to have jurisdiction over it (including any self-regulatory authority, such as the National Association of
Insurance Commissioners), (c) to the extent required by applicable laws or regulations or by any subpoena or similar legal process, (d) to any other party hereto, (e) in connection with the exercise of any remedies hereunder, under any other Credit
Document or Bank Product or any action or proceeding relating to this Agreement, any other Credit Document or Bank Product or the enforcement of rights hereunder or thereunder, (f) subject to an agreement containing provisions substantially the same
as those of this Section, to any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under this Agreement, (g) to (i) any actual or prospective counterparty (or its advisors) to any swap
or derivative transaction relating to the Borrower and its obligations, (ii) an investor or prospective investor in securities issued by an Approved Fund that also agrees that Information shall be kept confidential and used solely for the purpose of
evaluating an investment in such securities issued by the Approved Fund, (iii) a trustee, collateral manager, servicer, backup servicer, noteholder or secured party in connection with the administration, servicing and reporting on the assets serving
as collateral for securities issued by an Approved Fund, or (iv) a nationally recognized rating agency that requires access to information regarding the Credit Parties, the Loans and Credit Documents in connection with ratings issued in respect of
securities issued by an Approved Fund (in each case, it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such information and instructed to keep such information confidential), (h) with
the consent of the Borrower or (i) to the extent such Information (x) becomes publicly available other than as a result of a breach of this Section or (y) becomes available to the Administrative Agent, any Lender, any Issuing Lender or any of their
respective Affiliates on a nonconfidential basis from a source other than the Borrower.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">For purposes of this Section, &#8220;<u>Information</u>&#8221; means all information received from any Credit Party or any of its
Subsidiaries relating to any Credit Party or any of its Subsidiaries or any of their respective businesses, other than any such information that is available to the Administrative Agent, any Lender or any Issuing Lender on a nonconfidential basis
prior to disclosure by any Credit Party or any of its Subsidiaries; <u>provided</u> that, in the case of information received from any Credit Party or any of its Subsidiaries after the date hereof, such information is clearly identified at the time
of delivery as confidential. Any Person required to maintain the confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to
maintain the confidentiality of such Information as such Person would accord to its own confidential information. Each Lender acknowledges that federal law prohibits the purchase or sale of any of the Borrower&#8217;s securities while in possession
of material non-public information. Each of the Administrative Agent and the Lenders acknowledges that (a) the Information may include material non-public information concerning the Credit Parties and their Subsidiaries, as the case may be, (b) it
has developed compliance procedures regarding the use of material non-public information and (c) it will handle such material non-public information in accordance with applicable law, including federal and state securities laws and regulations.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
9.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Acknowledgments</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Borrower and the other Credit Parties each hereby acknowledges that:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it has been advised by counsel in the
negotiation, execution and delivery of each Credit Document;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;neither the Administrative Agent nor any
Lender has any fiduciary relationship with or duty to the Borrower or any other Credit Party arising out of or in connection with this Agreement and the relationship between the Administrative Agent and the Lenders, on one hand, and the Borrower and
the other Credit Parties, on the other hand, in connection herewith is solely that of creditor and debtor; and</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;no joint venture exists among the Lenders and
the Administrative Agent or among the Borrower, the Administrative Agent or the other Credit Parties and the Lenders.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">98</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Waivers of Jury Trial</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">EACH PARTY
HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER CREDIT DOCUMENT OR
THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH
OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER CREDIT DOCUMENTS BY, AMONG OTHER THINGS,
THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Patriot Act Notice</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Each Lender
and the Administrative Agent (for itself and not on behalf of any other party) hereby notifies the Borrower that, pursuant to the requirements of the Patriot Act, it is required to obtain, verify and record information that identifies the Borrower
and the other Credit Parties, which information includes the name and address of the Borrower and the other Credit Parties and other information that will allow such Lender or the Administrative Agent, as applicable, to identify the Borrower and the
other Credit Parties in accordance with the Patriot Act.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Resolution of Drafting Ambiguities</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Each Credit
Party acknowledges and agrees that it was represented by counsel in connection with the execution and delivery of this Agreement and the other Credit Documents to which it is a party, that it and its counsel reviewed and participated in the
preparation and negotiation hereof and thereof and that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be employed in the interpretation hereof or thereof.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
9.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Continuing Agreement</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">This Credit Agreement shall be a continuing agreement and shall remain in full force and effect until all Credit Party Obligations
(other than those obligations that expressly survive the termination of this Credit Agreement) have been paid in full and all Commitments and Letters of Credit have been terminated, after which this Credit Agreement automatically shall terminate.
Upon termination, the Credit Parties shall have no further obligations (other than those obligations that expressly survive the termination of this Credit Agreement) under the Credit Documents; <u>provided</u> that should any payment, in whole or in
part, of the Credit Party Obligations be rescinded or otherwise required to be restored or returned by the Administrative Agent or any Lender, whether as a result of any proceedings in bankruptcy or reorganization or otherwise, then the Credit
Documents shall automatically be reinstated and all Liens, if any, under the LOC Documents of the Administrative Agent shall reattach to the collateral and all amounts required to be restored or returned and all costs and expenses incurred by the
Administrative Agent or any Lender in connection therewith shall be deemed included as part of the Credit Party Obligations.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
9.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Lender Consent</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Each Person signing a Lender Consent (a) approves the Credit Agreement, (b) authorizes and appoints the Administrative Agent as its
agent in accordance with the terms of <u>Article VIII</u>, (c) authorizes the Administrative Agent to execute and deliver this Agreement on its behalf, (d) is a Lender hereunder and therefore shall have all the rights and obligations of a Lender
under this Agreement as if such Person had directly executed and delivered a signature page to this Agreement and (e) has consented to, approved or accepted or is satisfied with, each document or other matter required under Section 4.1 to be
consented to or approved by or be acceptable or satisfactory to a Lender.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">99</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Press Releases and Related Matters</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Credit
Parties and their Affiliates agree that they will not in the future issue any press releases or other public disclosure using the name of Administrative Agent or any Lender or their respective Affiliates or referring to this Agreement or any of the
Credit Documents without the prior written consent of such Person, unless (and only to the extent that) a Credit Party or such Affiliate is required to do so under law and then, in any event, the Credit Parties or such Affiliate will to the extent
practicable consult with such Person before issuing such press release or other public disclosure, provided, that no consultation shall be required in connection with disclosures in a periodic or other report filed with or furnished to the SEC. The
Credit Parties consent to the publication by Administrative Agent or any Lender of customary advertising material relating to the transactions contemplated by this Agreement and the Credit Documents using the name, product photographs, logo or
trademark of the Credit Parties.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Appointment of Borrower</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Each of the
Guarantors hereby appoints the Borrower to act as its agent for all purposes under this Agreement and agrees that (a) the Borrower may execute such documents on behalf of such Guarantor as the Borrower deems appropriate in its sole discretion and
each Guarantor shall be obligated by all of the terms of any such document executed on its behalf, (b) any notice or communication delivered by the Administrative Agent or the Lender to the Borrower shall be deemed delivered to each Guarantor and
(c) the Administrative Agent or the Lenders may accept, and be permitted to rely on, any document, instrument or agreement executed by the Borrower on behalf of each Guarantor.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
9.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Waivers, Subordinations and Consents</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the Credit Parties acknowledges and agrees that certain Credit Parties and their Equity
Holders are, or in the future may be or become, subject to the terms of one or more Contractual Obligations with the Borrower or another Credit Party (including those arising under the terms of Management Agreements) (i) which conflict with the
terms of the Credit Documents to which such Credit Parties are a party, the execution and delivery thereof by such Credit Parties, or the performance by such Credit Parties of the terms thereof, including undertakings not to incur debt, not to
pledge assets to third parties, not to pay dividends and not to enter into material agreements without obtaining certain consents (collectively, the &#8220;<u>Credit Party Intercompany Restrictions</u>&#8221;), (ii) pursuant to which such Credit
Parties grant to the Borrower or such other Credit Party a Lien on various assets of such Credit Parties (collectively, the &#8220;<u>Borrower Pledges</u>&#8221;), (iii) pursuant to which Equity Holders grant to the Borrower or such other Credit
Party the right, upon the occurrence of certain circumstances, to acquire Equity Interests in such Credit Parties from the applicable Equity Holders (collectively, the &#8220;<u>Holder Purchase Grants</u>&#8221;), (iv) pursuant to which Equity
Holders are restricted from transferring their Equity Interests in a Practice (the &#8220;<u>Equity Holder Transfer Restrictions</u>&#8221;), and/or (v) pursuant to which Equity Holders grant to the Borrower or such other Credit Party a Lien on the
Equity Interests in the applicable Credit Parties owned by such Equity Holders (collectively, the &#8220;<u>Holder Lien Grants</u>&#8221;) (each agreement, including each Management Agreement, containing any such restriction being referred to herein
as a &#8220;<u>Restrictive Agreement</u>&#8221;).</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the Credit Parties hereby absolutely and irrevocably waives the Credit Party Intercompany
Restrictions and the Equity Holder Transfer Restrictions insofar as any of such Credit Party Intercompany Restrictions or Equity Holder Transfer Restrictions conflict with or would otherwise prohibit or impair the due, punctual and full performance
and observance of any term, covenant or condition now or hereafter contained in any Credit Document.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Borrower and each other Credit Party party to any such Restrictive Agreement hereby agree that,
except as expressly permitted hereunder or under the terms of any other Credit Document, no Credit Party shall exercise its rights under any of the Holder Purchase Grants.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;So long as no Default or Event of Default has occurred and is continuing:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">100</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any Credit Party may at its expense
exercise rights under Borrower Pledges and Holder Lien Grants as it may determine to be reasonably necessary in the ordinary course of business (including the taking of possession of and selling or otherwise disposing of property subject to Borrower
Pledges and Holder Lien Grants and retaining the proceeds thereof, in each case to the extent permitted by applicable law) to recover amounts owed or otherwise remedy defaults in payment or performance obligations arising under Management
Agreements; <u>provided</u>, that the Borrower shall set forth in the next officer&#8217;s certificate delivered to the Administrative Agent pursuant to Section 5.2(b) for the period during which such rights are exercised a reasonably detailed
description of the circumstances giving rise to such exercise and the remedies exercised; and</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Borrower may at its expense exercise
Holder Purchase Grants to the extent that such exercise would otherwise be permitted hereunder as a Permitted Investment.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Advisory or Fiduciary Responsibility</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">In
connection with all aspects of each Transaction, each of the Credit Parties acknowledges and agrees, and acknowledges its Affiliates&#8217; understanding, that: (a) the credit facility provided for hereunder and any related arranging or other
services in connection therewith (including in connection with any amendment, waiver or other modification hereof or of any other Credit Document) are an arm&#8217;s-length commercial transaction between the Credit Parties and their Affiliates, on
the one hand, and the Administrative Agent, the Arrangers and the Lenders, on the other hand, and the Credit Parties are capable of evaluating and understanding and understand and accept the terms, risks and conditions of the Transactions and by the
other Credit Documents (including any amendment, waiver or other modification hereof or thereof); (b) in connection with the process leading to such transaction, each of the Administrative Agent, each Arranger and each Lender is and has been acting
solely as a principal and is not the financial advisor, agent or fiduciary, for any Credit Party or any of their Affiliates, stockholders, creditors or employees or any other Person; (c) neither the Administrative Agent nor any Arranger nor any
Lender has assumed or will assume an advisory, agency or fiduciary responsibility in favor of any Credit Party with respect to any of the Transactions or the process leading thereto, including with respect to any amendment, waiver or other
modification hereof or of any other Credit Document (irrespective of whether the Administrative Agent, any Arranger or any Lender has advised or is currently advising any Credit Party or any of its Affiliates on other matters) and neither the
Administrative Agent, nor any Arranger nor any Lender has any obligation to any Credit Party or any of their Affiliates with respect to the Transactions except those obligations expressly set forth herein and in the other Credit Documents; (d) the
Administrative Agent, the Arrangers, the Lenders and their respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Credit Parties and their Affiliates, and neither the Administrative
Agent, nor any Arranger nor any Lender has any obligation to disclose any of such interests by virtue of any advisory, agency or fiduciary relationship; and (e) the Administrative Agent, the Arrangers and the Lenders have not provided and will not
provide any legal, accounting, regulatory or tax advice with respect to any of the Transactions (including any amendment, waiver or other modification hereof or of any other Credit Document) and the Credit Parties have consulted their own legal,
accounting, regulatory and tax advisors to the extent it has deemed appropriate. Each of the Credit Parties hereby waives and releases, to the fullest extent permitted by law, any claims that it may have against the Administrative Agent, the
Arrangers, the Lenders and their respective Affiliates with respect to any breach or alleged breach of agency or fiduciary duty.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
9.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Reserved]</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Release of Liens and Guarantees</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The
Administrative Agent shall (and each Lender hereby irrevocably authorizes the Administrative Agent to):</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;release any Lien granted to the Administrative Agent under any Credit Document on any asset of any
Credit Party (i) upon payment in full of the Credit Party Obligations and the cancellation of all Commitments hereunder, (ii) that is sold, transferred, encumbered or otherwise disposed of or to be sold, transferred, encumbered or otherwise disposed
of as part of, or in connection with, any sale, transfer or disposition permitted under the Credit Documents to a Person that is not (and is not required to become) a Credit Party, (iii) that does not constitute (or ceases to constitute) Collateral,
(iv) if such Credit Party has guaranteed the Obligations, upon the release of such Credit Party&#8217;s guaranty in accordance with the terms of the Credit Documents, (v) that constitutes Excluded Assets, or (vi) to the extent such release is
approved, authorized or ratified in writing by the Required Lenders in accordance with <u>Section 9.1</u>;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">101</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;automatically release any Person that has guaranteed the Obligations from its guaranty if such Person
ceases to be a Domestic Subsidiary as a result of a transaction or series of transactions that is permitted under the Credit Documents; and</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subordinate any Lien granted to the Administrative Agent (or any sub-agent or collateral agent) under
any Credit Document to any Lien that is permitted by clauses (c), (i) or (o) of the definition of Permitted Liens, or otherwise having priority by operation of law.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The
Administrative Agent will, and each Lender hereby authorizes the Administrative Agent to, at the expense of the Borrower, execute and deliver to the relevant Credit Party such documents and/or instruments as such Credit Party may reasonably request
to evidence or effectuate the release of any Lien or guarantee or the subordination of any Lien contemplated by this <u>Section 9.26</u>; <u>provided</u>, that the Administrative Agent shall have received a certificate of a Responsible Officer of
the Borrower containing certifications regarding compliance with the provisions of the Credit Documents permitting the action giving rise to such action. Upon the request of the Administrative Agent, the Required Lenders will confirm in writing the
Administrative Agent&#8217;s authority to take the actions contemplated by this <u>Section 9.26</u>. Any representation, warranty or covenant contained in any Credit Document relating to any asset of any Credit Party shall no longer be deemed to be
made once the Lien on such asset is released in accordance herewith.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acknowledgement and Consent of Bail-In of EEA Financial Institutions</b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Solely to the extent any
Agent, Lender or Issuing Lender that is an EEA Financial Institution is a party to this Agreement and notwithstanding anything to the contrary in any Credit Document or in any other agreement, arrangement or understanding among any such parties,
each party hereto acknowledges that any liability of any Lender that is an EEA Financial Institution arising under any Credit Document, to the extent such liability is unsecured, may be subject to the write-down and conversion powers of an EEA
Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by:</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the application of any Write-Down and Conversion Powers by an EEA Resolution Authority to any such
liabilities arising hereunder which may be payable to it by any Lender that is an EEA Financial Institution; and</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the effects of any Bail-in Action on any such liability, including, if applicable:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a reduction in full or in part or
cancellation of any such liability;</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a conversion of all, or a portion of, such
liability into shares or other instruments of ownership in such EEA Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership
will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Credit Document; or</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the variation of the terms of such
liability in connection with the exercise of the write-down and conversion powers of any EEA Resolution Authority.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 9.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain ERISA Matters</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Lender (x) represents and warrants, as of the date such Person became a Lender party hereto, to,
and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent, the Arrangers, and their respective Affiliates, and not, for the
avoidance of doubt, to or for the benefit of the Borrower or any other Credit Party, that at least one of the following is and will be true:</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">102</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such Lender is not using &#8220;plan
assets&#8221; (within the meaning of 29 CFR &#167; 2510.3-101, as modified by Section 3(42) of ERISA) of one or more Benefit Plans in connection with the Loans, the Letters of Credit or the Commitments,</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the transaction exemption set forth in one
or more PTEs, such as PTE 84-14 (a class exemption for certain transactions determined by independent qualified professional asset managers), PTE 95-60 (a class exemption for certain transactions involving insurance company general accounts), PTE
90-1 (a class exemption for certain transactions involving insurance company pooled separate accounts), PTE 91-38 (a class exemption for certain transactions involving bank collective investment funds) or PTE 96-23 (a class exemption for certain
transactions determined by in-house asset managers), is applicable with respect to such Lender&#8217;s entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Agreement,</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) such Lender is an investment fund
managed by a &#8220;Qualified Professional Asset Manager&#8221; (within the meaning of Part VI of PTE 84-14), (B) such Qualified Professional Asset Manager made the investment decision on behalf of such Lender to enter into, participate in,
administer and perform the Loans, the Letters of Credit, the Commitments and this Agreement, (C) the entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Agreement satisfies
the requirements of sub-sections (b) through (g) of Part I of PTE 84-14 and (D) to the best knowledge of such Lender, the requirements of subsection (a) of Part I of PTE 84-14 are satisfied with respect to such Lender&#8217;s entrance into,
participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Agreement, or</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:50.4pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such other representation, warranty and
covenant as may be agreed in writing between the Administrative Agent, in its sole discretion, and such Lender.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, unless sub-clause (i) in the immediately preceding clause (a) is true with respect to a
Lender or such Lender has not provided another representation, warranty and covenant as provided in sub-clause (iv) in the immediately preceding clause (a), such Lender further (x) represents and warrants, as of the date such Person became a Lender
party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent, the Arrangers and their respective Affiliates, and
not, for the avoidance of doubt, to or for the benefit of the Borrower or any other Credit Party, that none of the Administrative Agent, any Arranger or any of their respective Affiliates is a fiduciary with respect to the Collateral or the assets
of such Lender (including in connection with the reservation or exercise of any rights by the Administrative Agent under this Agreement, any Credit Document or any documents related to hereto or thereto).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Administrative Agent, and each Arranger, the syndication agent or other agents listed on the
cover page hereof hereby informs the Lenders that each such Person is not undertaking to provide investment advice, or to give advice in a fiduciary capacity, in connection with the transactions contemplated hereby, and that such Person has a
financial interest in the transactions contemplated hereby in that such Person or an Affiliate thereof (i) may receive interest or other payments with respect to the Loans, the Letters of Credit, the Commitments, this Agreement and any other Credit
Documents, (ii) may recognize a gain if it extended the Loans, the Letters of Credit or the Commitments for an amount less than the amount being paid for an interest in the Loans, the Letters of Credit or the Commitments by such Lender or (iii) may
receive fees or other payments in connection with the transactions contemplated hereby, the Credit Documents or otherwise, including structuring fees, commitment fees, arrangement fees, facility fees, upfront fees, underwriting fees, ticking fees,
agency fees, administrative agent or collateral agent fees, utilization fees, minimum usage fees, letter of credit fees, fronting fees, deal-away or alternate transaction fees, amendment fees, processing fees, term out premiums, banker&#8217;s
acceptance fees, breakage or other early termination fees or fees similar to the foregoing.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">103</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><font
style="color:#0000ff;"><u style="border-bottom:#000000 thin double;"><b>Section 9.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acknowledgement Regarding Any Supported QFCs</b>. To the extent that the Credit Documents provide support, through a guarantee or
otherwise, for Swap Obligations or any other agreement or instrument that is a QFC (such support &#8220;QFC Credit Support&#8221; and each such QFC a &#8220;Supported QFC&#8221;), the parties acknowledge and agree as follows with respect to the
resolution power of the Federal Deposit Insurance Corporation under the Federal Deposit Insurance Act and Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act (together with the regulations promulgated thereunder, the
&#8220;U.S. Special Resolution Regimes&#8221;) in respect of such Supported QFC and QFC Credit Support (with the provisions below applicable notwithstanding that the Credit Documents and any Supported QFC may in fact be stated to be governed by the
laws of the State of New York and/or of the United States or any other state of the United States):</u></font></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;"><font style="color:#0000ff;"><u style="border-bottom:#000000 thin double;">In the event a Covered Entity that is party to a Supported
QFC (each, a &#8220;Covered Party&#8221;) becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer of such Supported QFC and the benefit of such QFC Credit Support (and any interest and obligation in or under such
Supported QFC and such QFC Credit Support, and any rights in property securing such Supported QFC or such QFC Credit Support) from such Covered Party will be effective to the same extent as the transfer would be effective under the U.S. Special
Resolution Regime if the Supported QFC and such QFC Credit Support (and any such interest, obligation and rights in property) were governed by the laws of the United States or a state of the United States. In the event a Covered Party or a BHC Act
Affiliate of a Covered Party becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under the Credit Documents that might otherwise apply to such Supported QFC or any QFC Credit Support that may be exercised against
such Covered Party are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if the Supported QFC and the Credit Documents were governed by the laws of the United States
or a state of the United States. Without limitation of the foregoing, it is understood and agreed that rights and remedies of the parties with respect to a Defaulting Lender shall in no event affect the rights of any Covered Party with respect to a
Supported QFC or any QFC Credit Support.</u></font></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>ARTICLE X<br> <br> GUARANTY</b></p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>The Guaranty</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">In order to induce the Lenders to enter into this Agreement and any Bank Product Provider to enter into any Bank Product and to extend
credit hereunder and thereunder and in recognition of the direct benefits to be received by the Guarantors from the Extensions of Credit hereunder and any Bank Product, each of the Guarantors hereby agrees with the Administrative Agent, the Lenders
and the Bank Product Providers as follows: each Guarantor hereby unconditionally and irrevocably jointly and severally guarantees as primary obligor and not merely as surety the full and prompt payment when due, whether upon maturity, by
acceleration or otherwise, of any and all Credit Party Obligations. If any or all of the indebtedness or other obligations becomes due and payable hereunder or under any Bank Product, each Guarantor unconditionally promises to pay such indebtedness
to the Administrative Agent, the Lenders, the Bank Product Providers, or their respective order, on demand, together with any and all reasonable expenses which may be incurred by the Administrative Agent or the Lenders in collecting any of the
Credit Party Obligations. The Guaranty set forth in this <u>Article X</u> is a guaranty of timely payment and not of collection. The word &#8220;indebtedness&#8221; is used in this <u>Article X</u> in its most comprehensive sense and includes any
and all advances, debts, obligations and liabilities of the Borrower, including specifically all Credit Party Obligations, arising in connection with this Agreement, the other Credit Documents or any Bank Product, in each case, heretofore, now, or
hereafter made, incurred or created, whether voluntarily or involuntarily, absolute or contingent, liquidated or unliquidated, determined or undetermined, whether or not such indebtedness is from time to time reduced, or extinguished and thereafter
increased or incurred, whether the Borrower may be liable individually or jointly with others, whether or not recovery upon such indebtedness may be or hereafter become barred by any statute of limitations, and whether or not such indebtedness may
be or hereafter become otherwise unenforceable.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Notwithstanding any provision to the contrary contained herein or in any other of the Credit Documents, to the extent the obligations
of a Guarantor shall be adjudicated to be invalid or unenforceable for any reason (including, without limitation, because of any applicable state or federal law relating to fraudulent conveyances or transfers) then the obligations of each such
Guarantor hereunder shall be limited to the maximum amount that is permissible under applicable law (whether federal or state and including, without limitation, the Bankruptcy Code).</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">104</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Bankruptcy</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Additionally, each of the Guarantors unconditionally and irrevocably guarantees jointly and severally the payment of any and all
Credit Party Obligations of the Borrower to the Lenders and any Bank Product Provider whether or not due or payable by the Borrower upon the occurrence of any Bankruptcy Event and unconditionally promises to pay such Credit Party Obligations to the
Administrative Agent for the account of the Lenders and to any such Bank Product Provider, or order, on demand, in lawful money of the United States. Each of the Guarantors further agrees that to the extent that the Borrower or a Guarantor shall
make a payment or a transfer of an interest in any property to the Administrative Agent, any Lender or any Bank Product Provider, which payment or transfer or any part thereof is subsequently invalidated, declared to be fraudulent or preferential,
or otherwise is avoided, and/or required to be repaid to the Borrower or a Guarantor, the estate of the Borrower or a Guarantor, a trustee, receiver or any other party under any bankruptcy law, state or federal law, common law or equitable cause,
then to the extent of such avoidance or repayment, the obligation or part thereof intended to be satisfied shall be revived and continued in full force and effect as if said payment had not been made.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Nature of Liability</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The liability of each Guarantor hereunder is exclusive and independent of any security for or other guaranty of the Credit Party
Obligations of the Borrower whether executed by any such Guarantor, any other guarantor or by any other party, and no Guarantor&#8217;s liability hereunder shall be affected or impaired by (a) any direction as to application of payment by the
Borrower or by any other party, or (b) any other continuing or other guaranty, undertaking or maximum liability of a guarantor or of any other party as to the Credit Party Obligations of the Borrower, or (c) any payment on or in reduction of any
such other guaranty or undertaking, or (d) any dissolution, termination or increase, decrease or change in personnel by the Borrower, or (e) any payment made to the Administrative Agent, the Lenders or any Bank Product Provider on the Credit Party
Obligations which the Administrative Agent, such Lenders or such Bank Product Provider repay the Borrower pursuant to court order in any bankruptcy, reorganization, arrangement, moratorium or other debtor relief proceeding, and each of the
Guarantors waives any right to the deferral or modification of its obligations hereunder by reason of any such proceeding.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 10.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Independent Obligation</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The
obligations of each Guarantor hereunder are independent of the obligations of any other Guarantor or the Borrower, and a separate action or actions may be brought and prosecuted against each Guarantor whether or not action is brought against any
other Guarantor or the Borrower and whether or not any other Guarantor or the Borrower is joined in any such action or actions.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
10.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorization</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Each of the Guarantors authorizes the Administrative Agent, each Lender and each Bank Product Provider without notice or demand
(except as shall be required by applicable statute and cannot be waived), and without affecting or impairing its liability hereunder, from time to time to (a) renew, compromise, extend, increase, accelerate or otherwise change the time for payment
of, or otherwise change the terms of the Credit Party Obligations or any part thereof in accordance with this Agreement and any Bank product, as applicable, including any increase or decrease of the rate of interest thereon, (b) take and hold
security from any Guarantor or any other party for the payment of this Guaranty or the Credit Party Obligations and exchange, enforce waive and release any such security, (c) apply such security and direct the order or manner of sale thereof as the
Administrative Agent and the Lenders in their discretion may determine and (d) release or substitute any one or more endorsers, Guarantors, the Borrower or other obligors.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">105</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 10.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reliance</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">It is not
necessary for the Administrative Agent, the Lenders or any Bank Product Provider to inquire into the capacity or powers of the Borrower or the officers, directors, members, partners or agents acting or purporting to act on its behalf, and any Credit
Party Obligations made or created in reliance upon the professed exercise of such powers shall be guaranteed hereunder.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 10.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Waiver</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the Guarantors waives any right (except as shall be required by applicable statute and cannot
be waived) to require the Administrative Agent, any Lender or any Bank Product Provider to (i) proceed against the Borrower, any other guarantor or any other party, (ii) proceed against or exhaust any security held from the Borrower, any other
guarantor or any other party, or (iii) pursue any other remedy in the Administrative Agent&#8217;s, any Lender&#8217;s or any Bank Product Provider&#8217;s power whatsoever. Each of the Guarantors waives any defense based on or arising out of any
defense of the Borrower, any other guarantor or any other party other than payment in full of the Credit Party Obligations (other than contingent indemnification obligations), including, without limitation, any defense based on or arising out of the
disability of the Borrower, any other guarantor or any other party, or the unenforceability of the Credit Party Obligations or any part thereof from any cause, or the cessation from any cause of the liability of the Borrower other than payment in
full of the Credit Party Obligations. The Administrative Agent may, at its election, foreclose on any security held by the Administrative Agent or a Lender by one or more judicial or nonjudicial sales, whether or not every aspect of any such sale is
commercially reasonable (to the extent such sale is permitted by applicable law), or exercise any other right or remedy the Administrative Agent or any Lender may have against the Borrower or any other party, or any security, without affecting or
impairing in any way the liability of any Guarantor hereunder except to the extent the Credit Party Obligations have been paid in full and the Commitments have been terminated. Each of the Guarantors waives any defense arising out of any such
election by the Administrative Agent or any of the Lenders, even though such election operates to impair or extinguish any right of reimbursement or subrogation or other right or remedy of the Guarantors against the Borrower or any other party or
any security.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the Guarantors waives all presentments, demands for performance, protests and notices,
including, without limitation, notices of nonperformance, notice of protest, notices of dishonor, notices of acceptance of this Guaranty, and notices of the existence, creation or incurring of new or additional Credit Party Obligations. Each
Guarantor assumes all responsibility for being and keeping itself informed of the Borrower&#8217;s financial condition and assets, and of all other circumstances bearing upon the risk of nonpayment of the Credit Party Obligations and the nature,
scope and extent of the risks which such Guarantor assumes and incurs hereunder, and agrees that neither the Administrative Agent nor any Lender shall have any duty to advise such Guarantor of information known to it regarding such circumstances or
risks.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the Guarantors hereby agrees it will not exercise any rights of subrogation which it may at
any time otherwise have as a result of this Guaranty (whether contractual, under Section 509 of the U.S. Bankruptcy Code, or otherwise) to the claims of the Lenders or any Bank Product Provider against the Borrower or any other guarantor of the
Credit Party Obligations of the Borrower owing to the Lenders or such Bank Product Provider (collectively, the &#8220;<u>Other Parties</u>&#8221;) and all contractual, statutory or common law rights of reimbursement, contribution or indemnity from
any Other Party which it may at any time otherwise have as a result of this Guaranty until such time as the Credit Party Obligations shall have been paid in full and the Commitments have been terminated. Each of the Guarantors hereby further agrees
not to exercise any right to enforce any other remedy which the Administrative Agent, the Lenders or any Bank Product Provider now have or may hereafter have against any Other Party, any endorser or any other guarantor of all or any part of the
Credit Party Obligations of the Borrower and any benefit of, and any right to participate in, any security or collateral given to or for the benefit of the Lenders and/or the Bank Product Providers to secure payment of the Credit Party Obligations
of the Borrower until such time as the Credit Party Obligations (other than contingent indemnification obligations) shall have been paid in full and the Commitments have been terminated.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">106</div> </div> </div>
<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"> <div class="PGHDR" style="text-align: left; width: 100%"> <div class="hf-row"> <div class="hf-cell TOCLink">&nbsp;</div> </div>
</div> </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 10.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitation on Enforcement</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The Lenders
and the Bank Product Providers agree that this Guaranty may be enforced only by the action of the Administrative Agent acting upon the instructions of the Required Lenders or such Bank Product Provider (only with respect to obligations under the
applicable Bank Product) and that no Lender or Bank Product Provider shall have any right individually to seek to enforce or to enforce this Guaranty, it being understood and agreed that such rights and remedies may be exercised by the
Administrative Agent for the benefit of the Lenders under the terms of this Agreement and for the benefit of any Bank Product Provider under any Bank Product. The Lenders and the Bank Product Providers further agree that this Guaranty may not be
enforced against any director, officer, employee or stockholder of the Guarantors.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 10.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Confirmation of Payment</u></b>.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The
Administrative Agent and the Lenders will, upon request after payment of the Credit Party Obligations which are the subject of this Guaranty and termination of the Commitments relating thereto, confirm to the Borrower, the Guarantors or any other
Person that such indebtedness and obligations have been paid and the Commitments relating thereto terminated, subject to the provisions of Section 10.2.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section
10.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Agreements for Contribution</u></b>.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent that any Guarantor is required, by reason of its obligations hereunder, to pay to the
Lender an amount greater than the amount of the value (as determined in accordance with applicable insolvency laws) actually made available to or for the benefit of such Guarantor on account of any Credit Document, such Guarantor shall have an
enforceable right of contribution against the remaining Guarantors, and the remaining Guarantors shall be jointly and severally liable for repayment of the full amount of such excess payment.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent that any Guarantor would, but for the operation of this Section 10.10 and by reason of
its Obligations hereunder or its obligations to other Guarantors under this Section 10.10, be rendered insolvent for any purpose under applicable insolvency laws, each of the Guarantors hereby agrees to indemnify such Guarantor and commits to make a
contribution to such Guarantor&#8217;s capital in an amount at least equal to the amount necessary to prevent such Guarantor from having been rendered insolvent by reason of the incurrence of any such obligations.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent that any Guarantor would, but for the operation of this Section 10.10, be rendered
insolvent under any applicable insolvency law by reason of its incurring of obligations to any other Guarantor under the foregoing Sections 10.10(a) and (b), such Guarantor shall, in turn, have rights of contribution to the full extent provided in
the foregoing Sections 10.10(a) and (b) against the remaining Guarantors, such that all obligations of all the Guarantors hereunder and under this Section 10.10 shall be allocated in a manner such that no Guarantor shall be rendered insolvent for
any purpose under applicable insolvency law by reason of its incurrence of such obligations.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><b>Section 10.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Keepwell</u></b>. Each Qualified ECP Guarantor hereby jointly and severally
absolutely, unconditionally and irrevocably undertakes to provide such funds or other support as may be needed from time to time by each other Guarantor to honor all of its obligations under this Guaranty in respect of a Swap Obligation (provided,
however, that each Qualified ECP Guarantor shall only be liable under this Section 10.11 for the maximum amount of such liability that can be hereby incurred without rendering its obligations under this Section 10.11 or otherwise under this Guaranty
voidable under applicable law relating to fraudulent conveyance or fraudulent transfer, and not for any greater amount). Except as otherwise provided herein, the obligations of each Qualified ECP Guarantor under this Section 10.11 shall remain in
full force and effect until the termination of all Swap Obligations. Each Qualified ECP Guarantor intends that this Section 10.11 constitute, and this Section 10.11 shall be deemed to constitute, a &#8220;keepwell, support, or other agreement&#8221;
for the benefit of each other Credit Party for all purposes of Section 1a(18)(A)(v)(II) of the Commodity Exchange Act.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">&nbsp;</p> <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%"> <div class="hf-row"> <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">107</div> </div> </div> </div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p> </div> <div class="LAST-PAGE-BREAK"> <div class="PGFTR"> <div class="hf-row"> <div class="hf-cell PGNUM">&nbsp;</div> </div>
</div> </div> </BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>d888266dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Roger J. Medel, M.D., certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of MEDNAX, Inc.;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;7, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Roger J. Medel, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Roger J. Medel, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(Principal Executive Officer)</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>d888266dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Stephen D. Farber, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of MEDNAX, Inc.;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;7, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen D. Farber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Stephen D. Farber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(Principal Financial Officer)</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>d888266dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification Pursuant to 18 U.S.C Section&nbsp;1350 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Adopted by Section&nbsp;906 of the Sarbanes-Oxley Act of 2002) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Quarterly Report of MEDNAX, Inc. on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended
March&nbsp;31, 2020 (the &#147;Report&#148;), each of the undersigned hereby certifies, pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that (i)&nbsp;the Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of
the Securities Exchange Act of 1934 and (ii)&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of MEDNAX, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A signed original of this written statement required by Section&nbsp;906 has been provided to MEDNAX, Inc. and will be retained by MEDNAX,
Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;7, 2020 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Roger J. Medel, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Roger J. Medel, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Principal Executive Officer)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/<B> </B>Stephen D. Farber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Stephen D. Farber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Principal Financial Officer)</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>md-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-May-2020 [10:48:53] {PM}-->
<schema targetNamespace="http://www.mednax.com/20200331" elementFormDefault="qualified" xmlns:md="http://www.mednax.com/20200331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.mednax.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" id="ConsolidatedBalanceSheetsUnaudited">
<link:definition>1002 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" id="ConsolidatedBalanceSheetsUnauditedParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfIncome" id="ConsolidatedStatementsOfIncome">
<link:definition>1004 - Statement - Consolidated Statements of Income</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfEquity" id="ConsolidatedStatementsOfEquity">
<link:definition>1005 - Statement - Consolidated Statements of Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1006 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements" id="BasisOfPresentationAndNewAccountingPronouncements">
<link:definition>1007 - Disclosure - Basis of Presentation and New Accounting Pronouncements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19" id="CoronavirusPandemicCovid19">
<link:definition>1008 - Disclosure - Coronavirus Pandemic ("COVID-19")</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestments" id="CashEquivalentsAndInvestments">
<link:definition>1009 - Disclosure - Cash Equivalents and Investments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1010 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenue" id="AccountsReceivableAndNetRevenue">
<link:definition>1011 - Disclosure - Accounts Receivable and Net Revenue</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/DiscontinuedOperations" id="DiscontinuedOperations">
<link:definition>1012 - Disclosure - Discontinued Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpenses" id="AccountsPayableAndAccruedExpenses">
<link:definition>1013 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentShares" id="CommonAndCommonEquivalentShares">
<link:definition>1014 - Disclosure - Common and Common Equivalent Shares</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans" id="StockIncentivePlansAndStockPurchasePlans">
<link:definition>1015 - Disclosure - Stock Incentive Plans and Stock Purchase Plans</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonStockRepurchasePrograms" id="CommonStockRepurchasePrograms">
<link:definition>1016 - Disclosure - Common Stock Repurchase Programs</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1017 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/SubsequentEvent" id="SubsequentEvent">
<link:definition>1018 - Disclosure - Subsequent Event</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies" id="BasisOfPresentationAndNewAccountingPronouncementsPolicies">
<link:definition>1019 - Disclosure - Basis of Presentation and New Accounting Pronouncements (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables" id="CashEquivalentsAndInvestmentsTables">
<link:definition>1020 - Disclosure - Cash Equivalents and Investments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1021 - Disclosure - Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables" id="AccountsReceivableAndNetRevenueTables">
<link:definition>1022 - Disclosure - Accounts Receivable and Net Revenue (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables" id="AccountsPayableAndAccruedExpensesTables">
<link:definition>1023 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables" id="CommonAndCommonEquivalentSharesTables">
<link:definition>1024 - Disclosure - Common and Common Equivalent Shares (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/SubsequentEventTable" id="SubsequentEventTable">
<link:definition>1025 - Disclosure - Subsequent Event (Table)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" id="BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail">
<link:definition>1026 - Disclosure - Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" id="CoronavirusPandemicCovid19AdditionalInformationDetail">
<link:definition>1027 - Disclosure - Coronavirus Pandemic ("COVID-19") - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" id="CashEquivalentsAndInvestmentsAdditionalInformationDetail">
<link:definition>1028 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" id="CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail">
<link:definition>1029 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" id="FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails">
<link:definition>1030 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" id="FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails">
<link:definition>1031 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" id="AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
<link:definition>1032 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" id="AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
<link:definition>1033 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" id="AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
<link:definition>1034 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail" id="DiscontinuedOperationsAdditionalInformationDetail">
<link:definition>1035 - Disclosure - Discontinued Operations - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" id="AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
<link:definition>1036 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" id="AccountsPayableAndAccruedExpensesAdditionalInformationDetail">
<link:definition>1037 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" id="CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
<link:definition>1038 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" id="StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
<link:definition>1039 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" id="CommonStockRepurchaseProgramsAdditionalInformationDetail">
<link:definition>1040 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail" id="SubsequentEventAdditionalInformationDetail">
<link:definition>1041 - Disclosure - Subsequent Event - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" id="SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail">
<link:definition>1042 - Disclosure - Subsequent Event - Summary of Major Classes of Assets and Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="md-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="md-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="md-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="md-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
<import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
<element name="AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PracticeSalariesAndBenefits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PracticeSalariesAndBenefits" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PracticeSuppliesAndOtherOperatingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PracticeSuppliesAndOtherOperatingExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodSharesStockSwaps" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_StockIssuedDuringPeriodSharesStockSwaps" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodValueStockSwaps" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_StockIssuedDuringPeriodValueStockSwaps" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ExtraordinaryItemsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ExtraordinaryItemsAbstract" substitutionGroup="xbrli:item" />
<element name="CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="AccountsReceivableAndNetRevenueDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_AccountsReceivableAndNetRevenueDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="CommonStockRepurchasesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_CommonStockRepurchasesTextBlock" substitutionGroup="xbrli:item" />
<element name="FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" substitutionGroup="xbrli:item" />
<element name="NorthAmericanPartnersInAnesthesiaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_NorthAmericanPartnersInAnesthesiaMember" substitutionGroup="xbrli:item" />
<element name="BasisOfPresentationAndNewAccountingPronouncementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_BasisOfPresentationAndNewAccountingPronouncementsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="UnnamedCorporateJointVentureOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_UnnamedCorporateJointVentureOneMember" substitutionGroup="xbrli:item" />
<element name="UnnamedCorporateJointVentureTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_UnnamedCorporateJointVentureTwoMember" substitutionGroup="xbrli:item" />
<element name="BasisOfPresentationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_BasisOfPresentationLineItems" substitutionGroup="xbrli:item" />
<element name="PercentageIncreaseDecreaseInSalaryAndWage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PercentageIncreaseDecreaseInSalaryAndWage" substitutionGroup="xbrli:item" />
<element name="ContributionsInAidOfReimbursementOfLostRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_ContributionsInAidOfReimbursementOfLostRevenue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromContributionInAidOfReimbursementOfLostRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfDeferredPaymentOfSocialSecurityTaxes" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" substitutionGroup="xbrli:item" />
<element name="SupplementaryLeverageRatioRequired" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_SupplementaryLeverageRatioRequired" substitutionGroup="xbrli:item" />
<element name="EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" substitutionGroup="xbrli:item" />
<element name="ExtraordinaryItemsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ExtraordinaryItemsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ExtraordinaryItemsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ExtraordinaryItemsDomain" substitutionGroup="xbrli:item" />
<element name="CovidNinenteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CovidNinenteenMember" substitutionGroup="xbrli:item" />
<element name="ForecastForSecondAndThirdQuartersOf2020Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ForecastForSecondAndThirdQuartersOf2020Member" substitutionGroup="xbrli:item" />
<element name="ForecastForFourthQuarterOf2020Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ForecastForFourthQuarterOf2020Member" substitutionGroup="xbrli:item" />
<element name="ForecastForFirstQuarterOf2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ForecastForFirstQuarterOf2021Member" substitutionGroup="xbrli:item" />
<element name="ForecastForSecondQuarterOf2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ForecastForSecondQuarterOf2021Member" substitutionGroup="xbrli:item" />
<element name="CreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CreditAgreementMember" substitutionGroup="xbrli:item" />
<element name="UrbanAreaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_UrbanAreaMember" substitutionGroup="xbrli:item" />
<element name="RuralAreaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_RuralAreaMember" substitutionGroup="xbrli:item" />
<element name="Seniorunsecurdnotes2023Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_Seniorunsecurdnotes2023Member" substitutionGroup="xbrli:item" />
<element name="Seniorunsecurdnotes2027Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_Seniorunsecurdnotes2027Member" substitutionGroup="xbrli:item" />
<element name="CashEquivalentsAndInvestmentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CashEquivalentsAndInvestmentsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CashEquivalentsAndInvestmentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CashEquivalentsAndInvestmentsLineItems" substitutionGroup="xbrli:item" />
<element name="MoneyMarketFundsFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_MoneyMarketFundsFairValueDisclosure" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MutualFundsFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_MutualFundsFairValueDisclosure" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TwoThousandTwentyThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_TwoThousandTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentySevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_TwoThousandTwentySevenMember" substitutionGroup="xbrli:item" />
<element name="HospitalsContractsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_HospitalsContractsMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfFinancingReceivablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ScheduleOfFinancingReceivablesLineItems" substitutionGroup="xbrli:item" />
<element name="PercentageOfNetPatientServiceRevenueByTypeOfPayor" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" substitutionGroup="xbrli:item" />
<element name="ContractedManagedCareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ContractedManagedCareMember" substitutionGroup="xbrli:item" />
<element name="TransactionRelatedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_TransactionRelatedExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="WorkingCapitalTrueUp" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_WorkingCapitalTrueUp" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxAssetsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DeferredTaxAssetsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DeferredTaxAssetsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DeferredTaxAssetsDomain" substitutionGroup="xbrli:item" />
<element name="AccruedContingentConsiderationLiabilityCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_AccruedContingentConsiderationLiabilityCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedPayrollTaxesAndBenefitsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_AccruedPayrollTaxesAndBenefitsCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInAccruedSalariesAndBonuses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_IncreaseDecreaseInAccruedSalariesAndBonuses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AmendedAndRestatedTwoThousandEightPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_AmendedAndRestatedTwoThousandEightPlanMember" substitutionGroup="xbrli:item" />
<element name="NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandFifteenNonQualifiedStockPurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="CommonStockTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CommonStockTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CommonStockLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CommonStockLineItems" substitutionGroup="xbrli:item" />
<element name="MaximumConsiderationReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_MaximumConsiderationReceivable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccountsReceivableRetained" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_AccountsReceivableRetained" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>md-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-May-2020 [10:48:53] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#ConsolidatedStatementsOfIncome" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfIncome" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" roleURI="http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" />
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermLineOfCredit" xlink:label="loc_us-gaap_LongTermLineOfCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LongTermLineOfCredit" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="16" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_IncomeTaxesReceivable" use="optional" order="29" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeNet" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_PracticeSalariesAndBenefits" xlink:label="loc_md_PracticeSalariesAndBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_md_PracticeSalariesAndBenefits" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="loc_md_PracticeSuppliesAndOtherOperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_md_PracticeSuppliesAndOtherOperatingExpenses" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_RestructuringCharges" use="optional" order="12" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" use="optional" order="14" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="18" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" use="optional" order="20" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" use="optional" order="23" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" use="optional" order="26" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit" use="optional" order="30" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" use="optional" order="31" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" use="optional" order="32" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" use="optional" order="34" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" use="optional" order="35" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts" use="optional" order="36" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedSalariesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="loc_md_AccruedPayrollTaxesAndBenefitsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_md_AccruedPayrollTaxesAndBenefitsCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_AccruedContingentConsiderationLiabilityCurrent" xlink:label="loc_md_AccruedContingentConsiderationLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_md_AccruedContingentConsiderationLiabilityCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_InterestPayableCurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities" xlink:label="loc_MD_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_MD_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" use="optional" order="9" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>md-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-May-2020 [10:48:53] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#ConsolidatedStatementsOfEquity" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfEquity" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#SubsequentEventTable" roleURI="http://www.mednax.com/role/SubsequentEventTable" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CoronavirusPandemicCovid19AdditionalInformationDetail" roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CashEquivalentsAndInvestmentsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#DiscontinuedOperationsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsPayableAndAccruedExpensesAdditionalInformationDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CommonStockRepurchaseProgramsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#SubsequentEventAdditionalInformationDetail" roleURI="http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" roleURI="http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CoverPage" roleURI="http://www.mednax.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsReceivableAndNetRevenue" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenue" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsReceivableAndNetRevenueTables" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#ConsolidatedStatementsOfIncome" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfIncome" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsPayableAndAccruedExpenses" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsPayableAndAccruedExpensesTables" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CommonAndCommonEquivalentShares" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentShares" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CommonAndCommonEquivalentSharesTables" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#StockIncentivePlansAndStockPurchasePlans" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CommonStockRepurchasePrograms" roleURI="http://www.mednax.com/role/CommonStockRepurchasePrograms" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CommitmentsAndContingencies" roleURI="http://www.mednax.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#FairValueMeasurements" roleURI="http://www.mednax.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#FairValueMeasurementsTables" roleURI="http://www.mednax.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#BasisOfPresentationAndNewAccountingPronouncementsPolicies" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#BasisOfPresentationAndNewAccountingPronouncements" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CashEquivalentsAndInvestments" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestments" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CashEquivalentsAndInvestmentsTables" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#DiscontinuedOperations" roleURI="http://www.mednax.com/role/DiscontinuedOperations" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CoronavirusPandemicCovid19" roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#SubsequentEvent" roleURI="http://www.mednax.com/role/SubsequentEvent" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_98" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_113" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_NetIncomeLoss_106" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_SharesIssued_105" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_99" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StatementTable_99" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_97" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_99" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_97" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97" xlink:to="loc_us-gaap_EquityComponentDomain_96" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97" xlink:to="loc_us-gaap_EquityComponentDomain_96_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_101" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_CommonStockMember_100" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_RetainedEarningsMember_102" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_104" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_117" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_108" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_110" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_StockIssuedDuringPeriodSharesStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodSharesStockSwaps_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_md_StockIssuedDuringPeriodSharesStockSwaps_115" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_107" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_109" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_StockIssuedDuringPeriodValueStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodValueStockSwaps_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_md_StockIssuedDuringPeriodValueStockSwaps_114" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_119" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_118" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_393245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_393245" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SubsequentEventTable">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689294" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_689290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689294" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_689290" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_689291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_689290" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_689291" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_689292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_689291" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_689292" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_689292_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_689291" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_689292_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember_689293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_689292" xlink:to="loc_md_NorthAmericanPartnersInAnesthesiaMember_689293" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_689295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689294" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_689295" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_BasisOfPresentationLineItems" xlink:label="loc_md_BasisOfPresentationLineItems_393378" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_BasisOfPresentationLineItems_393378" xlink:to="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_393376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_393376" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_393376_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_393376_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="loc_md_UnnamedCorporateJointVentureOneMember_393377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_393376" xlink:to="loc_md_UnnamedCorporateJointVentureOneMember_393377" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="loc_md_UnnamedCorporateJointVentureTwoMember_670768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_393376" xlink:to="loc_md_UnnamedCorporateJointVentureTwoMember_670768" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_393379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_BasisOfPresentationLineItems_393378" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_393379" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_686007" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_686004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_StatementTable_686004" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_686005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_StatementClassOfStockAxis_686005" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_686006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_686005" xlink:to="loc_us-gaap_ClassOfStockDomain_686006" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_686006_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_686005" xlink:to="loc_us-gaap_ClassOfStockDomain_686006_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ExtraordinaryItemsAxis" xlink:label="loc_md_ExtraordinaryItemsAxis_686017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_md_ExtraordinaryItemsAxis_686017" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ExtraordinaryItemsDomain" xlink:label="loc_md_ExtraordinaryItemsDomain_686018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_md_ExtraordinaryItemsAxis_686017" xlink:to="loc_md_ExtraordinaryItemsDomain_686018" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ExtraordinaryItemsDomain" xlink:label="loc_md_ExtraordinaryItemsDomain_686018_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_md_ExtraordinaryItemsAxis_686017" xlink:to="loc_md_ExtraordinaryItemsDomain_686018_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CovidNinenteenMember" xlink:label="loc_md_CovidNinenteenMember_686019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_ExtraordinaryItemsDomain_686018" xlink:to="loc_md_CovidNinenteenMember_686019" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_686021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_TitleOfIndividualAxis_686021" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_686021" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_686021" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_686023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" xlink:to="loc_srt_ExecutiveOfficerMember_686023" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_686024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_StatementScenarioAxis_686024" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_686025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_686024" xlink:to="loc_srt_ScenarioUnspecifiedDomain_686025" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_686025_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_686024" xlink:to="loc_srt_ScenarioUnspecifiedDomain_686025_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ForecastForSecondAndThirdQuartersOf2020Member" xlink:label="loc_md_ForecastForSecondAndThirdQuartersOf2020Member_686026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForSecondAndThirdQuartersOf2020Member_686026" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ForecastForFourthQuarterOf2020Member" xlink:label="loc_md_ForecastForFourthQuarterOf2020Member_686027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForFourthQuarterOf2020Member_686027" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ForecastForFirstQuarterOf2021Member" xlink:label="loc_md_ForecastForFirstQuarterOf2021Member_686028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForFirstQuarterOf2021Member_686028" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ForecastForSecondQuarterOf2021Member" xlink:label="loc_md_ForecastForSecondQuarterOf2021Member_686029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForSecondQuarterOf2021Member_686029" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_686030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_CreditFacilityAxis_686030" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_686031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_686030" xlink:to="loc_us-gaap_CreditFacilityDomain_686031" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_686031_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_686030" xlink:to="loc_us-gaap_CreditFacilityDomain_686031_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CreditAgreementMember" xlink:label="loc_md_CreditAgreementMember_686032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_686031" xlink:to="loc_md_CreditAgreementMember_686032" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_686033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_RangeAxis_686033" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_686034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_686033" xlink:to="loc_srt_RangeMember_686034" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_686034_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_686033" xlink:to="loc_srt_RangeMember_686034_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_686035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_686034" xlink:to="loc_srt_MaximumMember_686035" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_686037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_686034" xlink:to="loc_srt_MinimumMember_686037" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaap_GeographicDistributionAxis_686038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_GeographicDistributionAxis_686038" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaap_GeographicDistributionDomain_686039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GeographicDistributionAxis_686038" xlink:to="loc_us-gaap_GeographicDistributionDomain_686039" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaap_GeographicDistributionDomain_686039_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GeographicDistributionAxis_686038" xlink:to="loc_us-gaap_GeographicDistributionDomain_686039_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_UrbanAreaMember" xlink:label="loc_md_UrbanAreaMember_686040" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicDistributionDomain_686039" xlink:to="loc_md_UrbanAreaMember_686040" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_RuralAreaMember" xlink:label="loc_md_RuralAreaMember_686041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicDistributionDomain_686039" xlink:to="loc_md_RuralAreaMember_686041" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_689758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_DebtInstrumentAxis_689758" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_689758" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689759" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689759_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_689758" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689759_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_Seniorunsecurdnotes2023Member" xlink:label="loc_md_Seniorunsecurdnotes2023Member_689760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689759" xlink:to="loc_md_Seniorunsecurdnotes2023Member_689760" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_Seniorunsecurdnotes2027Member" xlink:label="loc_md_Seniorunsecurdnotes2027Member_689762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689759" xlink:to="loc_md_Seniorunsecurdnotes2027Member_689762" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="loc_md_PercentageIncreaseDecreaseInSalaryAndWage_686008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_PercentageIncreaseDecreaseInSalaryAndWage_686008" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_686012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_686012" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ContributionsInAidOfReimbursementOfLostRevenue_686014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_ContributionsInAidOfReimbursementOfLostRevenue_686014" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_686015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_686015" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xlink:label="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes_686016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes_686016" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_SupplementaryLeverageRatioRequired" xlink:label="loc_md_SupplementaryLeverageRatioRequired_686070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_SupplementaryLeverageRatioRequired_686070" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization_689397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization_689397" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_689754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_689754" use="optional" order="46" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="loc_md_CashEquivalentsAndInvestmentsTable_393444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" xlink:to="loc_md_CashEquivalentsAndInvestmentsTable_393444" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_393445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable_393444" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_393445" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_393445" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_393445" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_393447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" xlink:to="loc_us-gaap_CashEquivalentsMember_393447" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_393448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable_393444" xlink:to="loc_srt_RangeAxis_393448" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_393449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_393448" xlink:to="loc_srt_RangeMember_393449" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_393449_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_393448" xlink:to="loc_srt_RangeMember_393449_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_393453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_393453" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_393416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" xlink:to="loc_us-gaap_InvestmentTypeAxis_393416" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_393417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_393416" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_393417" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_393417_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_393416" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_393417_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_393418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_393418" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_393420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_393420" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_393421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_CertificatesOfDepositMember_393421" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="loc_us-gaap_AllOtherCorporateBondsMember_494118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_AllOtherCorporateBondsMember_494118" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_670778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" xlink:to="loc_us-gaap_AvailableForSaleSecurities_670778" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_670787" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_670784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_670787" xlink:to="loc_us-gaap_StatementTable_670784" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_670785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_StatementClassOfStockAxis_670785" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670785" xlink:to="loc_us-gaap_ClassOfStockDomain_670786" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670786_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670785" xlink:to="loc_us-gaap_ClassOfStockDomain_670786_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_670796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_670796" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_670797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_670797" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_670798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_670798" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_670801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_670801" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670787" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="loc_md_MoneyMarketFundsFairValueDisclosure_670789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_md_MoneyMarketFundsFairValueDisclosure_670789" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_670790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_670790" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_MutualFundsFairValueDisclosure" xlink:label="loc_md_MutualFundsFairValueDisclosure_670791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_md_MutualFundsFairValueDisclosure_670791" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670787" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670792" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:label="loc_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_670793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670792" xlink:to="loc_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_670793" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_670808" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_670805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_670808" xlink:to="loc_us-gaap_StatementTable_670805" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_670806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_670805" xlink:to="loc_us-gaap_StatementClassOfStockAxis_670806" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670806" xlink:to="loc_us-gaap_ClassOfStockDomain_670807" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670807_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670806" xlink:to="loc_us-gaap_ClassOfStockDomain_670807_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_670813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_670805" xlink:to="loc_us-gaap_DebtInstrumentAxis_670813" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_670814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_670813" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_670814" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_670814_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_670813" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_670814_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_TwoThousandTwentyThreeMember" xlink:label="loc_md_TwoThousandTwentyThreeMember_670815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_670814" xlink:to="loc_md_TwoThousandTwentyThreeMember_670815" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_TwoThousandTwentySevenMember" xlink:label="loc_md_TwoThousandTwentySevenMember_670816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_670814" xlink:to="loc_md_TwoThousandTwentySevenMember_670816" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_670809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670808" xlink:to="loc_us-gaap_LiabilitiesAbstract_670809" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_670810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_670809" xlink:to="loc_us-gaap_NotesPayable_670810" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670808" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_670812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_670812" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="loc_md_ScheduleOfFinancingReceivablesLineItems_259" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_ScheduleOfFinancingReceivablesLineItems_259" xlink:to="loc_us-gaap_DisaggregationOfRevenueAbstract_255" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_255" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_260" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_ScheduleOfFinancingReceivablesLineItems_259" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" xlink:to="loc_srt_ProductOrServiceAxis_256" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_256" xlink:to="loc_srt_ProductsAndServicesDomain_257" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_257_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_256" xlink:to="loc_srt_ProductsAndServicesDomain_257_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_261" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_HospitalsContractsMember" xlink:label="loc_md_HospitalsContractsMember_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_md_HospitalsContractsMember_262" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_395272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_395272" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:label="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" xlink:to="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_270" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ContractedManagedCareMember" xlink:label="loc_md_ContractedManagedCareMember_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_md_ContractedManagedCareMember_271" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_GovernmentMember_272" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelfPayMember" xlink:label="loc_us-gaap_SelfPayMember_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_SelfPayMember_274" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="loc_us-gaap_ThirdPartyPayorMember_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_ThirdPartyPayorMember_273" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_468359" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_468356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_StatementTable_468356" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_DeferredTaxAssetsAxis" xlink:label="loc_md_DeferredTaxAssetsAxis_468387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_md_DeferredTaxAssetsAxis_468387" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_DeferredTaxAssetsDomain" xlink:label="loc_md_DeferredTaxAssetsDomain_468388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_md_DeferredTaxAssetsAxis_468387" xlink:to="loc_md_DeferredTaxAssetsDomain_468388" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_DeferredTaxAssetsDomain" xlink:label="loc_md_DeferredTaxAssetsDomain_468388_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_md_DeferredTaxAssetsAxis_468387" xlink:to="loc_md_DeferredTaxAssetsDomain_468388_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_670845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_670845" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_670846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_670845" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_670846" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_670846_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_670845" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_670846_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_670847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_670846" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_670847" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_574667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_574667" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_670827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_670827" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_TransactionRelatedExpenses" xlink:label="loc_md_TransactionRelatedExpenses_684128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_TransactionRelatedExpenses_684128" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_WorkingCapitalTrueUp" xlink:label="loc_md_WorkingCapitalTrueUp_685980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_WorkingCapitalTrueUp_685980" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393221" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_393221" xlink:to="loc_us-gaap_StatementTable_393218" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393218" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393219" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393219" xlink:to="loc_us-gaap_ClassOfStockDomain_393220" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393220_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393219" xlink:to="loc_us-gaap_ClassOfStockDomain_393220_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses_671366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393221" xlink:to="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses_671366" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_595" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_594" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_592" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_AwardTypeAxis_575" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_us-gaap_EmployeeStockOptionMember_603" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_us-gaap_RestrictedStockMember_604" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_PlanNameAxis_576" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_576" xlink:to="loc_us-gaap_PlanNameDomain_577" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_577_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_576" xlink:to="loc_us-gaap_PlanNameDomain_577_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="loc_md_AmendedAndRestatedTwoThousandEightPlanMember_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_AmendedAndRestatedTwoThousandEightPlanMember_585" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_586" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_583" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_584" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_srt_RangeAxis_578" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_578" xlink:to="loc_srt_RangeMember_579" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_579_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_578" xlink:to="loc_srt_RangeMember_579_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_579" xlink:to="loc_srt_MaximumMember_587" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_589" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_588" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_591" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_593" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_393080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_393080" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CommonStockLineItems" xlink:label="loc_md_CommonStockLineItems_636" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_648" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CommonStockTable" xlink:label="loc_md_CommonStockTable_637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_md_CommonStockTable_637" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_AwardTypeAxis_635" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" xlink:to="loc_us-gaap_RestrictedStockMember_650" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_640" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_640" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_641" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_641_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_640" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_641_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_642" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_642" xlink:to="loc_us-gaap_EquityComponentDomain_638" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_638_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_642" xlink:to="loc_us-gaap_EquityComponentDomain_638_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_412583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_412583" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_412584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_412583" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_412584" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_412584_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_412583" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_412584_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_647" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_643" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_554331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_554331" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689344" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_689332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689344" xlink:to="loc_us-gaap_SubsequentEventTable_689332" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_689333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_689332" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_689333" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_689334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_689333" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_689334" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_689334_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_689333" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_689334_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_689335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_689334" xlink:to="loc_us-gaap_SubsequentEventMember_689335" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_689337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_689332" xlink:to="loc_srt_RangeAxis_689337" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_689338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_689337" xlink:to="loc_srt_RangeMember_689338" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_689338_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_689337" xlink:to="loc_srt_RangeMember_689338_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_689339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_689338" xlink:to="loc_srt_MaximumMember_689339" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_689340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_689338" xlink:to="loc_srt_MinimumMember_689340" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_689341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_689332" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_689341" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_689342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_689341" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_689342" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_689342_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_689341" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_689342_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember_689343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_689342" xlink:to="loc_md_NorthAmericanPartnersInAnesthesiaMember_689343" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_689345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689344" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_689345" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_MaximumConsiderationReceivable" xlink:label="loc_md_MaximumConsiderationReceivable_689346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689344" xlink:to="loc_md_MaximumConsiderationReceivable_689346" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_AccountsReceivableRetained" xlink:label="loc_md_AccountsReceivableRetained_689347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689344" xlink:to="loc_md_AccountsReceivableRetained_689347" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_689348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689344" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_689348" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689309" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_689304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689309" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_689304" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_689306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_689304" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_689306" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_689307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_689306" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_689307" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_689307_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_689306" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_689307_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember_689308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_689307" xlink:to="loc_md_NorthAmericanPartnersInAnesthesiaMember_689308" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689309" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_689311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_689311" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_689312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_689312" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_689313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_689313" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_689314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_689314" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_689315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_689315" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_689316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_689316" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_689318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_689318" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_689319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689309" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_689319" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_689320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_689319" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_689320" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities_689323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_689319" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities_689323" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_689325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_689319" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_689325" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_689327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_689319" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_689327" use="optional" order="18" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>md-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-May-2020 [10:48:53] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentQuarterlyReport" xml:lang="en-US">Document Quarterly Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents of continuing operations at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xml:lang="en-US">Debt Securities, Held-to-maturity, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xml:lang="en-US">Short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xml:lang="en-US">Income Taxes Receivable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xml:lang="en-US">Income taxes receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Intangible assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use&#160;assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xml:lang="en-US">Deferred Tax Assets, Net, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xml:lang="en-US">Deferred income tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent" xml:lang="en-US">Deferred income tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and shareholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities Excluding Accrued Income Taxes Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:to="lab_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xml:lang="en-US">Accounts payable and accrued liabilities excluding accrued income taxes current.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xml:lang="en-US">Accrued Income Taxes, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xml:lang="en-US">Income taxes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Finance Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Current portion of finance lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current portion of operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xml:lang="en-US">Long Term Debt and Capital Lease Obligations Excluding Long Term Line of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xml:lang="en-US">Long-term debt and finance lease liabilities, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:to="lab_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xml:lang="en-US">Long term debt and capital lease obligations excluding long term line of credit.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermLineOfCredit" xlink:label="loc_us-gaap_LongTermLineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermLineOfCredit" xml:lang="en-US">Long-term Line of Credit, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermLineOfCredit" xml:lang="en-US">Line of credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xml:lang="en-US">Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xml:lang="en-US">Long-term professional liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:to="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock; $.01 par value; 200,000 shares authorized; 85,150 and 84,248 shares issued and outstanding, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock; $.01 par value; 1,000 shares authorized; none issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained earnings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total shareholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Long-term operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, aggregate shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Net loss:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xml:lang="en-US">Weighted average common shares:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average number of common and common equivalent shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average number of common shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">(Loss) income from continuing operations before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Equity in earnings of unconsolidated affiliates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeNet" xml:lang="en-US">Investment Income, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentIncomeNet" xml:lang="en-US">Investment and other (expense) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total non-operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_PracticeSalariesAndBenefits" xlink:label="loc_md_PracticeSalariesAndBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PracticeSalariesAndBenefits" xml:lang="en-US">Practice Salaries and Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PracticeSalariesAndBenefits" xml:lang="en-US">Practice salaries and benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PracticeSalariesAndBenefits" xlink:to="lab_md_PracticeSalariesAndBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PracticeSalariesAndBenefits" xml:lang="en-US">Practice salaries and benefits.</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="loc_md_PracticeSuppliesAndOtherOperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PracticeSuppliesAndOtherOperatingExpenses" xml:lang="en-US">Practice Supplies And Other Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PracticeSuppliesAndOtherOperatingExpenses" xml:lang="en-US">Practice supplies and other operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PracticeSuppliesAndOtherOperatingExpenses" xlink:to="lab_md_PracticeSuppliesAndOtherOperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PracticeSuppliesAndOtherOperatingExpenses" xml:lang="en-US">The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Transformational and restructuring related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Income from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Net revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">(Loss) income from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Loss from discontinued operations, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Loss from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Loss on classification as held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xlink:label="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xml:lang="en-US">Income Loss from Continuing Operations Per Basic and Diluted Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xml:lang="en-US">Loss (income) from continuing operations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xlink:to="lab_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xml:lang="en-US">It represents Income (Loss) from continuing operations, per basic and diluted share</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xml:lang="en-US">Loss from discontinued operations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xml:lang="en-US">Forfeitures of restricted stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xml:lang="en-US">Issuance of restricted stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_StockIssuedDuringPeriodSharesStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodSharesStockSwaps" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_StockIssuedDuringPeriodSharesStockSwaps" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_StockIssuedDuringPeriodSharesStockSwaps" xml:lang="en-US">Stock swaps, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_StockIssuedDuringPeriodSharesStockSwaps" xlink:to="lab_md_StockIssuedDuringPeriodSharesStockSwaps" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_StockIssuedDuringPeriodSharesStockSwaps" xml:lang="en-US">Stock issued during period shares stock swaps.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xml:lang="en-US">Issuance of restricted stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_StockIssuedDuringPeriodValueStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodValueStockSwaps" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_StockIssuedDuringPeriodValueStockSwaps" xml:lang="en-US">Stock Issued During Period Value Stock Swaps</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_StockIssuedDuringPeriodValueStockSwaps" xml:lang="en-US">Stock swaps</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_StockIssuedDuringPeriodValueStockSwaps" xlink:to="lab_md_StockIssuedDuringPeriodValueStockSwaps" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_StockIssuedDuringPeriodValueStockSwaps" xml:lang="en-US">Stock issued during period value stock swaps.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Stock Repurchased During Period, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Repurchased common stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xml:lang="en-US">Stock Repurchased During Period, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xml:lang="en-US">Repurchased common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Unrealized holding loss on investments, net of tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Including Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net increase in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash (used in) provided by financing activities&#8212;continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xml:lang="en-US">Payments of contingent consideration liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Payments for Repurchase of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Repurchases of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xml:lang="en-US">Payments of Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xml:lang="en-US">Payments for credit facility amendment and financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xml:lang="en-US">Proceeds from Issuance of Senior Long-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xml:lang="en-US">Proceeds from issuance of senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Borrowings on credit agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xml:lang="en-US">Repayments of Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xml:lang="en-US">Payments on credit agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xml:lang="en-US">Payments on finance lease obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash used in financing activities - discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash (used in) provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in investing activities &#8211; continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Acquisition payments, net of cash acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xml:lang="en-US">Payments to Acquire Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xml:lang="en-US">Purchases of investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Other Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds from maturities or sales of investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xml:lang="en-US">Proceeds from Sales of Business, Affiliate and Productive Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xml:lang="en-US">Proceeds from sales of businesses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash used in investing activities - discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net income to net cash from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of premiums, discounts and issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other Noncash Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xml:lang="en-US">Income taxes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xml:lang="en-US">Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xml:lang="en-US">Long-term professional liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:to="lab_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Other long-term assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xml:lang="en-US">Payments of contingent consideration liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash provided by operating activities - discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in operating activities &#8211; continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xml:lang="en-US">Less cash and cash equivalents of discontinued operations at end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and New Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ExtraordinaryItemsAbstract" xlink:label="loc_md_ExtraordinaryItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ExtraordinaryItemsAbstract" xml:lang="en-US">Extraordinary Items [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ExtraordinaryItemsAbstract" xlink:to="lab_md_ExtraordinaryItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ExtraordinaryItemsAbstract" xml:lang="en-US">Extraordinary Items [Abstract]</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:label="loc_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xml:lang="en-US">Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xml:lang="en-US">Coronavirus Pandemic ("COVID-19")</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:to="lab_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xml:lang="en-US">Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xml:lang="en-US">Cash Equivalents and Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TextBlockAbstract" xml:lang="en-US">Text Block [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:label="loc_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xml:lang="en-US">Accounts Receivable And Net Revenue Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xml:lang="en-US">Accounts Receivable and Net Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:to="lab_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xml:lang="en-US">Accounts receivable and net revenue disclosure.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Discontinued Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Common and Common Equivalent Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock Incentive Plans and Stock Purchase Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CommonStockRepurchasesTextBlock" xlink:label="loc_md_CommonStockRepurchasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CommonStockRepurchasesTextBlock" xml:lang="en-US">Common Stock Repurchases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CommonStockRepurchasesTextBlock" xml:lang="en-US">Common Stock Repurchase Programs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CommonStockRepurchasesTextBlock" xlink:to="lab_md_CommonStockRepurchasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CommonStockRepurchasesTextBlock" xml:lang="en-US">Entire disclosure of common stock repurchases.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xml:lang="en-US">Subsequent Event [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xml:lang="en-US">Schedule of Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:label="loc_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xml:lang="en-US">Financial Instruments Measured At Carrying Amount Table Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xml:lang="en-US">Financial Instruments Measured At Carrying Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:to="lab_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xml:lang="en-US">Tabular disclosure of financial instruments measured at carrying amount.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Schedule of Net Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xml:lang="en-US">Schedule of Accounts Receivable, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xml:lang="en-US">Schedule of Percentage of Net Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xml:lang="en-US">Disposal Group Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xml:lang="en-US">Disposal Group Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xml:lang="en-US">Disposal Group Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xml:lang="en-US">Disposal Group Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NorthAmericanPartnersInAnesthesiaMember" xml:lang="en-US">North American Partners In Anesthesia [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_NorthAmericanPartnersInAnesthesiaMember" xml:lang="en-US">North American Partners In Anesthesia [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NorthAmericanPartnersInAnesthesiaMember" xlink:to="lab_md_NorthAmericanPartnersInAnesthesiaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NorthAmericanPartnersInAnesthesiaMember" xml:lang="en-US">North American Partners In Anesthesia [member].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xml:lang="en-US">Summary Of Major Classes of Assets And Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_BasisOfPresentationAndNewAccountingPronouncementsTable" xml:lang="en-US">Basis of Presentation and New Accounting Pronouncements [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="lab_md_BasisOfPresentationAndNewAccountingPronouncementsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="loc_md_UnnamedCorporateJointVentureOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_UnnamedCorporateJointVentureOneMember" xml:lang="en-US">Unnamed Corporate Joint Venture One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_UnnamedCorporateJointVentureOneMember" xlink:to="lab_md_UnnamedCorporateJointVentureOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_UnnamedCorporateJointVentureOneMember" xml:lang="en-US">Unnamed Corporate Joint Venture [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="loc_md_UnnamedCorporateJointVentureTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_UnnamedCorporateJointVentureTwoMember" xml:lang="en-US">Unnamed Corporate Joint Venture Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_UnnamedCorporateJointVentureTwoMember" xlink:to="lab_md_UnnamedCorporateJointVentureTwoMember" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_BasisOfPresentationLineItems" xlink:label="loc_md_BasisOfPresentationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_BasisOfPresentationLineItems" xml:lang="en-US">Basis Of Presentation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_BasisOfPresentationLineItems" xlink:to="lab_md_BasisOfPresentationLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity method ownership percentage in joint venture</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="loc_md_PercentageIncreaseDecreaseInSalaryAndWage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PercentageIncreaseDecreaseInSalaryAndWage" xml:lang="en-US">Percentage Increase Decrease In Salary And Wage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PercentageIncreaseDecreaseInSalaryAndWage" xml:lang="en-US">Decrease In Salary | %</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:to="lab_md_PercentageIncreaseDecreaseInSalaryAndWage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PercentageIncreaseDecreaseInSalaryAndWage" xml:lang="en-US">Percentage Increase Decrease In Salary And Wage.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Credit Facility Borrowing Capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ContributionsInAidOfReimbursementOfLostRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ContributionsInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Contributions In Aid Of Reimbursement of Lost Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ContributionsInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Reimbursement of Lost Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:to="lab_md_ContributionsInAidOfReimbursementOfLostRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ContributionsInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Contributions In Aid Of Reimbursement of Lost Revenue.</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:to="lab_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xlink:label="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xml:lang="en-US">Percentage Of Deferred Payment Of Social Security Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xml:lang="en-US">Deferred Payment Of Social Security Taxes | %</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xlink:to="lab_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xml:lang="en-US">Percentage Of Deferred Payment Of Social Security Taxes.</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_SupplementaryLeverageRatioRequired" xlink:label="loc_md_SupplementaryLeverageRatioRequired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_SupplementaryLeverageRatioRequired" xml:lang="en-US">Supplementary Leverage Ratio Required</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_SupplementaryLeverageRatioRequired" xml:lang="en-US">Leverage ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_SupplementaryLeverageRatioRequired" xlink:to="lab_md_SupplementaryLeverageRatioRequired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_SupplementaryLeverageRatioRequired" xml:lang="en-US">Supplementary Leverage Ratio Required.</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xml:lang="en-US">Estimated Earnings Before Interest Taxes Depreciation And Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xml:lang="en-US">Estimated EBITDA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:to="lab_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xml:lang="en-US">Estimated Earnings Before Interest Taxes Depreciation And Amortization</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt Instrument Interest Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ExtraordinaryItemsAxis" xlink:label="loc_md_ExtraordinaryItemsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ExtraordinaryItemsAxis" xml:lang="en-US">Extraordinary Items [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ExtraordinaryItemsAxis" xlink:to="lab_md_ExtraordinaryItemsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ExtraordinaryItemsAxis" xml:lang="en-US">Extraordinary Items [Axis]</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ExtraordinaryItemsDomain" xlink:label="loc_md_ExtraordinaryItemsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ExtraordinaryItemsDomain" xml:lang="en-US">Extraordinary Items [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ExtraordinaryItemsDomain" xlink:to="lab_md_ExtraordinaryItemsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ExtraordinaryItemsDomain" xml:lang="en-US">Extraordinary Items [Axis]</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CovidNinenteenMember" xlink:label="loc_md_CovidNinenteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CovidNinenteenMember" xml:lang="en-US">Covid Ninenteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CovidNinenteenMember" xml:lang="en-US">COVID-19 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CovidNinenteenMember" xlink:to="lab_md_CovidNinenteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CovidNinenteenMember" xml:lang="en-US">Covid Ninenteen [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ExecutiveOfficerMember" xml:lang="en-US">Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ExecutiveOfficerMember" xml:lang="en-US">Executive Officer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ForecastForSecondAndThirdQuartersOf2020Member" xlink:label="loc_md_ForecastForSecondAndThirdQuartersOf2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ForecastForSecondAndThirdQuartersOf2020Member" xml:lang="en-US">Forecast For Second And Third Quarters Of 2020 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ForecastForSecondAndThirdQuartersOf2020Member" xml:lang="en-US">Forecast For Second And Third Quarters Of 2020 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ForecastForSecondAndThirdQuartersOf2020Member" xlink:to="lab_md_ForecastForSecondAndThirdQuartersOf2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ForecastForSecondAndThirdQuartersOf2020Member" xml:lang="en-US">Forecast For Second And Third Quarters Of 2020 [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ForecastForFourthQuarterOf2020Member" xlink:label="loc_md_ForecastForFourthQuarterOf2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ForecastForFourthQuarterOf2020Member" xml:lang="en-US">Forecast For Fourth Quarter Of 2020 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ForecastForFourthQuarterOf2020Member" xml:lang="en-US">Forecast For Fourth Quarter Of 2020 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ForecastForFourthQuarterOf2020Member" xlink:to="lab_md_ForecastForFourthQuarterOf2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ForecastForFourthQuarterOf2020Member" xml:lang="en-US">Forecast For Fourth Quarter Of 2020 [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ForecastForFirstQuarterOf2021Member" xlink:label="loc_md_ForecastForFirstQuarterOf2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ForecastForFirstQuarterOf2021Member" xml:lang="en-US">Forecast For First Quarter Of 2021 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ForecastForFirstQuarterOf2021Member" xml:lang="en-US">Forecast For First Quarter Of 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ForecastForFirstQuarterOf2021Member" xlink:to="lab_md_ForecastForFirstQuarterOf2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ForecastForFirstQuarterOf2021Member" xml:lang="en-US">Forecast For First Quarter Of 2021 [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ForecastForSecondQuarterOf2021Member" xlink:label="loc_md_ForecastForSecondQuarterOf2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ForecastForSecondQuarterOf2021Member" xml:lang="en-US">Forecast For Second Quarter Of 2021 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ForecastForSecondQuarterOf2021Member" xml:lang="en-US">Forecast For Second Quarter Of 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ForecastForSecondQuarterOf2021Member" xlink:to="lab_md_ForecastForSecondQuarterOf2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ForecastForSecondQuarterOf2021Member" xml:lang="en-US">Forecast For Second Quarter Of 2021 [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CreditAgreementMember" xlink:label="loc_md_CreditAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CreditAgreementMember" xml:lang="en-US">Credit Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CreditAgreementMember" xml:lang="en-US">Credit Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CreditAgreementMember" xlink:to="lab_md_CreditAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CreditAgreementMember" xml:lang="en-US">Credit Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaap_GeographicDistributionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeographicDistributionAxis" xml:lang="en-US">Geographic Distribution [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionAxis" xlink:to="lab_us-gaap_GeographicDistributionAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaap_GeographicDistributionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeographicDistributionDomain" xml:lang="en-US">Geographic Distribution [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionDomain" xlink:to="lab_us-gaap_GeographicDistributionDomain" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_UrbanAreaMember" xlink:label="loc_md_UrbanAreaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_UrbanAreaMember" xml:lang="en-US">Urban Area [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_UrbanAreaMember" xml:lang="en-US">Urban Area [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_UrbanAreaMember" xlink:to="lab_md_UrbanAreaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_UrbanAreaMember" xml:lang="en-US">Urban Area [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_RuralAreaMember" xlink:label="loc_md_RuralAreaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_RuralAreaMember" xml:lang="en-US">Rural Area [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_RuralAreaMember" xml:lang="en-US">Rural Area [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_RuralAreaMember" xlink:to="lab_md_RuralAreaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_RuralAreaMember" xml:lang="en-US">Rural Area [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_Seniorunsecurdnotes2023Member" xlink:label="loc_md_Seniorunsecurdnotes2023Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_Seniorunsecurdnotes2023Member" xml:lang="en-US">SeniorUnsecurdNotes2023 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_Seniorunsecurdnotes2023Member" xml:lang="en-US">Senior Unsecurd Notes 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_Seniorunsecurdnotes2023Member" xlink:to="lab_md_Seniorunsecurdnotes2023Member" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_Seniorunsecurdnotes2027Member" xlink:label="loc_md_Seniorunsecurdnotes2027Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_Seniorunsecurdnotes2027Member" xml:lang="en-US">SeniorUnsecurdNotes2027 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_Seniorunsecurdnotes2027Member" xml:lang="en-US">Senior Unsecurd Notes 2027 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_Seniorunsecurdnotes2027Member" xlink:to="lab_md_Seniorunsecurdnotes2027Member" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="loc_md_CashEquivalentsAndInvestmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CashEquivalentsAndInvestmentsTable" xml:lang="en-US">Cash Equivalents and Investments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable" xlink:to="lab_md_CashEquivalentsAndInvestmentsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashEquivalentsMember" xml:lang="en-US">Cash Equivalents [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="loc_md_CashEquivalentsAndInvestmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CashEquivalentsAndInvestmentsLineItems" xml:lang="en-US">Cash Equivalents And Investments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CashEquivalentsAndInvestmentsLineItems" xlink:to="lab_md_CashEquivalentsAndInvestmentsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xml:lang="en-US">Money Market Funds, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xml:lang="en-US">Cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xml:lang="en-US">Municipal Debt Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xml:lang="en-US">Federal Home Loan Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xml:lang="en-US">Certificates of Deposit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xml:lang="en-US">Certificates of Deposit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="loc_us-gaap_AllOtherCorporateBondsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllOtherCorporateBondsMember" xml:lang="en-US">Other Corporate Bonds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllOtherCorporateBondsMember" xml:lang="en-US">Corporate Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherCorporateBondsMember" xlink:to="lab_us-gaap_AllOtherCorporateBondsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Available-for-sale [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xml:lang="en-US">Available-for-sale Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xml:lang="en-US">Available-for-sale Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="loc_md_MoneyMarketFundsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_MoneyMarketFundsFairValueDisclosure" xml:lang="en-US">Money Market Funds Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_MoneyMarketFundsFairValueDisclosure" xml:lang="en-US">Money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_MoneyMarketFundsFairValueDisclosure" xlink:to="lab_md_MoneyMarketFundsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_MoneyMarketFundsFairValueDisclosure" xml:lang="en-US">Fair value of money market funds.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investments, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_MutualFundsFairValueDisclosure" xlink:label="loc_md_MutualFundsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_MutualFundsFairValueDisclosure" xml:lang="en-US">Mutual Funds Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_MutualFundsFairValueDisclosure" xml:lang="en-US">Mutual Funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_MutualFundsFairValueDisclosure" xlink:to="lab_md_MutualFundsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_MutualFundsFairValueDisclosure" xml:lang="en-US">Mutual funds fair value disclosure.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:label="loc_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xml:lang="en-US">Business Combination Contingent Consideration Liability Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xml:lang="en-US">Contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:to="lab_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xml:lang="en-US">Fair value Of contingent consideration liability.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayable" xml:lang="en-US">Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesPayable" xml:lang="en-US">Notes Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xml:lang="en-US">Notes Payable, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xml:lang="en-US">Notes Payable Fair Value Disclosure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_TwoThousandTwentyThreeMember" xlink:label="loc_md_TwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_TwoThousandTwentyThreeMember" xml:lang="en-US">Two Thousand Twenty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_TwoThousandTwentyThreeMember" xml:lang="en-US">2023 Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_TwoThousandTwentyThreeMember" xlink:to="lab_md_TwoThousandTwentyThreeMember" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_TwoThousandTwentySevenMember" xlink:label="loc_md_TwoThousandTwentySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_TwoThousandTwentySevenMember" xml:lang="en-US">Two Thousand Twenty Seven [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_TwoThousandTwentySevenMember" xml:lang="en-US">2027 Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_TwoThousandTwentySevenMember" xlink:to="lab_md_TwoThousandTwentySevenMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesAbstract" xml:lang="en-US">Receivables [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xml:lang="en-US">Accounts Receivable, Gross, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xml:lang="en-US">Gross accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for Doubtful Accounts Receivable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for contractual adjustments and uncollectibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="loc_us-gaap_HealthCarePatientServiceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xml:lang="en-US">Health Care, Patient Service [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xml:lang="en-US">Net patient service revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCarePatientServiceMember" xlink:to="lab_us-gaap_HealthCarePatientServiceMember" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_HospitalsContractsMember" xlink:label="loc_md_HospitalsContractsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_HospitalsContractsMember" xml:lang="en-US">Hospitals Contracts [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_HospitalsContractsMember" xml:lang="en-US">Hospital contract administrative fees [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_HospitalsContractsMember" xlink:to="lab_md_HospitalsContractsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_HospitalsContractsMember" xml:lang="en-US">Hospitals Contracts [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xml:lang="en-US">Product and Service, Other [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xml:lang="en-US">Other revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="loc_md_ScheduleOfFinancingReceivablesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ScheduleOfFinancingReceivablesLineItems" xml:lang="en-US">Schedule Of Financing Receivables [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ScheduleOfFinancingReceivablesLineItems" xml:lang="en-US">Schedule Of Financing Receivables [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ScheduleOfFinancingReceivablesLineItems" xlink:to="lab_md_ScheduleOfFinancingReceivablesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ScheduleOfFinancingReceivablesLineItems" xml:lang="en-US">Schedule of financing receivables.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xml:lang="en-US">Disaggregation of Revenue [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xml:lang="en-US">Disaggregation of Revenue [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xml:lang="en-US">Health Care Organization Revenue and Expense [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:label="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xml:lang="en-US">Health Care Organization, Receivable and Revenue Disclosures [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xml:lang="en-US">Health Care Organization, Receivable and Revenue Disclosures [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:to="lab_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xml:lang="en-US">Percentage Of Net Patient Service Revenue By Type Of Payor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xml:lang="en-US">Percentage of net patient service revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:to="lab_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xml:lang="en-US">Percentage of net patient service revenue by type payor.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ContractedManagedCareMember" xlink:label="loc_md_ContractedManagedCareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ContractedManagedCareMember" xml:lang="en-US">Contracted Managed Care [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ContractedManagedCareMember" xml:lang="en-US">Contracted Managed Care [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ContractedManagedCareMember" xlink:to="lab_md_ContractedManagedCareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ContractedManagedCareMember" xml:lang="en-US">Contracted Managed Care [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GovernmentMember" xml:lang="en-US">Government [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GovernmentMember" xml:lang="en-US">Government [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentMember" xlink:to="lab_us-gaap_GovernmentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelfPayMember" xlink:label="loc_us-gaap_SelfPayMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SelfPayMember" xml:lang="en-US">Self-Pay [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SelfPayMember" xml:lang="en-US">Private-Pay Patients [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfPayMember" xlink:to="lab_us-gaap_SelfPayMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="loc_us-gaap_ThirdPartyPayorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xml:lang="en-US">Third-Party Payor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xml:lang="en-US">Other Third-Parties [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ThirdPartyPayorMember" xlink:to="lab_us-gaap_ThirdPartyPayorMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xml:lang="en-US">Preliminary and incremental gain loss on sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_TransactionRelatedExpenses" xlink:label="loc_md_TransactionRelatedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_TransactionRelatedExpenses" xml:lang="en-US">Transaction Related Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_TransactionRelatedExpenses" xml:lang="en-US">Transaction related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_TransactionRelatedExpenses" xlink:to="lab_md_TransactionRelatedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_TransactionRelatedExpenses" xml:lang="en-US">Transaction related expenses.</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_WorkingCapitalTrueUp" xlink:label="loc_md_WorkingCapitalTrueUp" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_WorkingCapitalTrueUp" xml:lang="en-US">Working Capital True Up</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_WorkingCapitalTrueUp" xml:lang="en-US">Working capital true up</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_WorkingCapitalTrueUp" xlink:to="lab_md_WorkingCapitalTrueUp" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_WorkingCapitalTrueUp" xml:lang="en-US">Working capital true up.</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_DeferredTaxAssetsAxis" xlink:label="loc_md_DeferredTaxAssetsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DeferredTaxAssetsAxis" xml:lang="en-US">Deferred Tax Assets [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DeferredTaxAssetsAxis" xlink:to="lab_md_DeferredTaxAssetsAxis" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_DeferredTaxAssetsDomain" xlink:label="loc_md_DeferredTaxAssetsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DeferredTaxAssetsDomain" xml:lang="en-US">Deferred Tax Assets [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DeferredTaxAssetsDomain" xlink:to="lab_md_DeferredTaxAssetsDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xml:lang="en-US">Disposal Group Classification [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xml:lang="en-US">Disposal Group Classification [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xml:lang="en-US">Disposal Group Classification [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xml:lang="en-US">Discontinued Operations, Held-for-sale [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses, total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_AccruedContingentConsiderationLiabilityCurrent" xlink:label="loc_md_AccruedContingentConsiderationLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccruedContingentConsiderationLiabilityCurrent" xml:lang="en-US">Accrued Contingent Consideration Liability Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccruedContingentConsiderationLiabilityCurrent" xml:lang="en-US">Accrued contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccruedContingentConsiderationLiabilityCurrent" xlink:to="lab_md_AccruedContingentConsiderationLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccruedContingentConsiderationLiabilityCurrent" xml:lang="en-US">Accrued contingent consideration liability current.</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="loc_md_AccruedPayrollTaxesAndBenefitsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccruedPayrollTaxesAndBenefitsCurrent" xml:lang="en-US">Accrued Payroll Taxes And Benefits Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccruedPayrollTaxesAndBenefitsCurrent" xml:lang="en-US">Accrued payroll taxes and benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:to="lab_md_AccruedPayrollTaxesAndBenefitsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccruedPayrollTaxesAndBenefitsCurrent" xml:lang="en-US">Accrued payroll taxes and benefits current.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued Salaries, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued salaries and bonuses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Interest Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xml:lang="en-US">Malpractice Loss Contingency, Accrual, Undiscounted, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xml:lang="en-US">Accrued professional liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:to="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_IncreaseDecreaseInAccruedSalariesAndBonuses" xml:lang="en-US">Increase Decrease In Accrued Salaries And Bonuses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_IncreaseDecreaseInAccruedSalariesAndBonuses" xml:lang="en-US">Net decrease in accrued salaries and bonuses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:to="lab_md_IncreaseDecreaseInAccruedSalariesAndBonuses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_IncreaseDecreaseInAccruedSalariesAndBonuses" xml:lang="en-US">Increase decrease in accrued salaries and bonuses.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities not included in the diluted net income per common share calculation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xml:lang="en-US">Weighted average number of dilutive common share equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="loc_md_AmendedAndRestatedTwoThousandEightPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AmendedAndRestatedTwoThousandEightPlanMember" xml:lang="en-US">Amended and Restated Two Thousand Eight Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AmendedAndRestatedTwoThousandEightPlanMember" xml:lang="en-US">Amended and Restated 2008 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:to="lab_md_AmendedAndRestatedTwoThousandEightPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AmendedAndRestatedTwoThousandEightPlanMember" xml:lang="en-US">Amended and restated two thousand eight plan.</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:to="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xml:lang="en-US">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xml:lang="en-US">1996 Non-Qualified Employee Stock Purchase Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:to="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xml:lang="en-US">1996 non-qualified employee stock purchase plan.</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">2015 Non-Qualified Stock Purchase Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:to="lab_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common stock, reserved for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Award vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Vesting period of options, maximum years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Shares available for future grants and awards under Stock Incentive Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Percentage of market value of common stock at which employees are permitted to purchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Aggregate number Shares issued under Stock Purchase Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CommonStockTable" xlink:label="loc_md_CommonStockTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CommonStockTable" xml:lang="en-US">Common Stock [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CommonStockTable" xml:lang="en-US">Common Stock [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CommonStockTable" xlink:to="lab_md_CommonStockTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CommonStockTable" xml:lang="en-US">Common Stock [Table]</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CommonStockLineItems" xlink:label="loc_md_CommonStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CommonStockLineItems" xml:lang="en-US">Common Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CommonStockLineItems" xml:lang="en-US">Common Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CommonStockLineItems" xlink:to="lab_md_CommonStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CommonStockLineItems" xml:lang="en-US">Common Stock [Line Items]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Amount withheld to satisfy minimum statutory tax withholding obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Shares Paid for Tax Withholding for Share Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Number of shares withheld to satisfy minimum statutory tax withholding obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xml:lang="en-US">Common stock authorized for repurchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xml:lang="en-US">Company's Common stock repurchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xml:lang="en-US">Share Repurchase Program [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xml:lang="en-US">Share Repurchase Program [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xml:lang="en-US">Share Repurchase Program [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xml:lang="en-US">Share Repurchase Program [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from Divestiture of Businesses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from Divestiture of Businesses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_MaximumConsiderationReceivable" xlink:label="loc_md_MaximumConsiderationReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_MaximumConsiderationReceivable" xml:lang="en-US">Maximum Consideration Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_MaximumConsiderationReceivable" xml:lang="en-US">Maximum consideration receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_MaximumConsiderationReceivable" xlink:to="lab_md_MaximumConsiderationReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_MaximumConsiderationReceivable" xml:lang="en-US">Maximum consideration receivable.</label>
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_AccountsReceivableRetained" xlink:label="loc_md_AccountsReceivableRetained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccountsReceivableRetained" xml:lang="en-US">Accounts Receivable Retained</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccountsReceivableRetained" xml:lang="en-US">Accounts receivable retained</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccountsReceivableRetained" xlink:to="lab_md_AccountsReceivableRetained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccountsReceivableRetained" xml:lang="en-US">Accounts receivable retained.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xml:lang="en-US">Gain (Loss) on Disposition of Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xml:lang="en-US">Gain loss on sale of business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xml:lang="en-US">Prepaid expenses and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xml:lang="en-US">Intangible assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xml:lang="en-US">Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities" xml:lang="en-US">Disposal Group Including Discontinued Operation Accrued Professional Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities" xml:lang="en-US">Accrued professional liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities" xlink:to="lab_md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities" xml:lang="en-US">Disposal group including discontinued operation accrued professional liabilities.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Total Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>md-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-May-2020 [10:48:53] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CoverPage" roleURI="http://www.mednax.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#ConsolidatedStatementsOfIncome" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfIncome" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#ConsolidatedStatementsOfEquity" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfEquity" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#BasisOfPresentationAndNewAccountingPronouncements" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CoronavirusPandemicCovid19" roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CashEquivalentsAndInvestments" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestments" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#FairValueMeasurements" roleURI="http://www.mednax.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsReceivableAndNetRevenue" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenue" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#DiscontinuedOperations" roleURI="http://www.mednax.com/role/DiscontinuedOperations" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsPayableAndAccruedExpenses" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CommonAndCommonEquivalentShares" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentShares" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#StockIncentivePlansAndStockPurchasePlans" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CommonStockRepurchasePrograms" roleURI="http://www.mednax.com/role/CommonStockRepurchasePrograms" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CommitmentsAndContingencies" roleURI="http://www.mednax.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#SubsequentEvent" roleURI="http://www.mednax.com/role/SubsequentEvent" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#BasisOfPresentationAndNewAccountingPronouncementsPolicies" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CashEquivalentsAndInvestmentsTables" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#FairValueMeasurementsTables" roleURI="http://www.mednax.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsReceivableAndNetRevenueTables" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsPayableAndAccruedExpensesTables" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CommonAndCommonEquivalentSharesTables" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#SubsequentEventTable" roleURI="http://www.mednax.com/role/SubsequentEventTable" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CoronavirusPandemicCovid19AdditionalInformationDetail" roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CashEquivalentsAndInvestmentsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#DiscontinuedOperationsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#AccountsPayableAndAccruedExpensesAdditionalInformationDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#CommonStockRepurchaseProgramsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#SubsequentEventAdditionalInformationDetail" roleURI="http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200331.xsd#SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" roleURI="http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_187927" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_494056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentType_494056" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_494062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentQuarterlyReport_494062" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_494063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentTransitionReport_494063" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_500141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_AmendmentFlag_500141" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_494057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentPeriodEndDate_494057" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_500152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentFiscalYearFocus_500152" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_500153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentFiscalPeriodFocus_500153" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_494058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityRegistrantName_494058" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_500154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCentralIndexKey_500154" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_500155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_CurrentFiscalYearEndDate_500155" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_494068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCurrentReportingStatus_494068" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_494069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityInteractiveDataCurrent_494069" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_494079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_494079" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_494064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_Security12bTitle_494064" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_494065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_TradingSymbol_494065" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_494066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_SecurityExchangeName_494066" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_494070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityFileNumber_494070" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_494071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityIncorporationStateCountryCode_494071" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_494072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityTaxIdentificationNumber_494072" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_494073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressAddressLine1_494073" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_494076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressCityOrTown_494076" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_494075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressStateOrProvince_494075" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_494078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressPostalZipCode_494078" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_494077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_CityAreaCode_494077" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_494074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_LocalPhoneNumber_494074" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_494059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityFilerCategory_494059" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_494061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntitySmallBusiness_494061" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_494060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityEmergingGrowthCompany_494060" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_494067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityShellCompany_494067" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_23" xlink:to="loc_us-gaap_AssetsAbstract_24" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_AssetsCurrentAbstract_25" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_38" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_39" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_40" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_684080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_IncomeTaxesReceivable_684080" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_OtherAssetsCurrent_41" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_AssetsCurrent_42" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_31" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_Goodwill_32" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_33" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_393135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_393135" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_505340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_505340" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_34" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_Assets_35" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_23" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_27" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent_51" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_393136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_393136" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_393137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_393137" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_53" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_LiabilitiesCurrent_54" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermLineOfCredit" xlink:label="loc_us-gaap_LongTermLineOfCredit_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_LongTermLineOfCredit_43" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit_44" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_393146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_393146" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_45" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_46" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_47" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_Liabilities_48" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_StockholdersEquityAbstract_28" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_PreferredStockValue_55" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_CommonStockValue_56" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_57" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_StockholdersEquity_59" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_50" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_61" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_62" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_63" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_PreferredStockSharesIssued_64" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_65" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_66" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_CommonStockSharesIssued_67" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_68" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_70" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_77" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_OperatingExpensesAbstract_73" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_PracticeSalariesAndBenefits" xlink:label="loc_md_PracticeSalariesAndBenefits_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_md_PracticeSalariesAndBenefits_89" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="loc_md_PracticeSuppliesAndOtherOperatingExpenses_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_md_PracticeSuppliesAndOtherOperatingExpenses_90" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_91" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_92" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_393211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_RestructuringCharges_393211" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_500469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_OperatingExpenses_500469" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_OperatingIncomeLoss_78" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_InvestmentIncomeNet_79" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_InterestExpense_80" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_82" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_84" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_84" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_395226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_395226" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_395229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_395229" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_395230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_NetIncomeLoss_395230" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xlink:label="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_395235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_395235" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_395236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_395235" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_395236" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_395237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_395235" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_395237" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_395238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_395238" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_395239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_395238" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_395239" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_395240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_395238" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_395240" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_EarningsPerShareAbstract_71" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_71" xlink:to="loc_us-gaap_EarningsPerShareBasic_74" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_71" xlink:to="loc_us-gaap_EarningsPerShareDiluted_75" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_72" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_72" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_76" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_88" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_72" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_88" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_95" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_95" xlink:to="loc_us-gaap_StatementTable_99" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_99" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_97" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97" xlink:to="loc_us-gaap_EquityComponentDomain_96" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_CommonStockMember_100" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_101" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_RetainedEarningsMember_102" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_99" xlink:to="loc_us-gaap_StatementLineItems_98" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_104" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_SharesIssued_105" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_NetIncomeLoss_106" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_393245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_393245" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_107" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_108" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_109" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_110" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_113" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_StockIssuedDuringPeriodValueStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodValueStockSwaps_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_md_StockIssuedDuringPeriodValueStockSwaps_114" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_StockIssuedDuringPeriodSharesStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodSharesStockSwaps_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_md_StockIssuedDuringPeriodSharesStockSwaps_115" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_117" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_118" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_119" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_121" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_SharesIssued_122" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_124" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_ProfitLoss_166" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_409658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_409658" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_132" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_133" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_ShareBasedCompensation_134" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_135" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_136" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_140" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_141" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_142" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_143" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_144" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_145" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_146" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_147" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_500479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_500479" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_395242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_395242" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_395244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_395244" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_159" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_160" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_161" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_162" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_163" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_165" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_395245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_395245" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_395246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_395246" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_148" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_149" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_150" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_151" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_152" use="optional" order="36" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_153" use="optional" order="37" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_155" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_157" use="optional" order="39" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_158" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_395250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_395250" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_395251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_395251" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_168" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations_169" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_409842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_409842" use="optional" order="45" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_170" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_393388" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_393389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_393388" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_393389" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CoronavirusPandemicCovid19">
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ExtraordinaryItemsAbstract" xlink:label="loc_md_ExtraordinaryItemsAbstract_685995" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:label="loc_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_685996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ExtraordinaryItemsAbstract_685995" xlink:to="loc_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_685996" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestments">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393394" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_393395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393394" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_393395" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_393301" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_393302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_393301" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_393302" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenue">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_727" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:label="loc_md_AccountsReceivableAndNetRevenueDisclosureTextBlock_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_727" xlink:to="loc_md_AccountsReceivableAndNetRevenueDisclosureTextBlock_728" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/DiscontinuedOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_395107" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_395108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_395107" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_395108" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpenses">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_751" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_751" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_752" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonAndCommonEquivalentShares">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_781" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_781" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_782" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_787" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_787" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_788" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonStockRepurchasePrograms">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_794" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CommonStockRepurchasesTextBlock" xlink:label="loc_md_CommonStockRepurchasesTextBlock_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_794" xlink:to="loc_md_CommonStockRepurchasesTextBlock_795" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_800" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_800" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_801" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SubsequentEvent">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_689297" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_689300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_689297" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_689300" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_393384" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_393386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_393384" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_393386" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393404" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_393406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393404" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_393406" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_393304" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_393310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_393304" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_393310" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:label="loc_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_393311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_393304" xlink:to="loc_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_393311" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_730" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_730" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_731" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_730" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_732" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_730" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_733" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_754" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_754" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_755" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_784" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_784" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_785" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SubsequentEventTable">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_494095" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_689290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_494095" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_689290" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_689291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_689290" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_689291" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_689292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_689291" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_689292" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember_689293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_689292" xlink:to="loc_md_NorthAmericanPartnersInAnesthesiaMember_689293" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_689290" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689294" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_689295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689294" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_689295" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_393368" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_393368" xlink:to="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_393376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_393376" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="loc_md_UnnamedCorporateJointVentureOneMember_393377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_393376" xlink:to="loc_md_UnnamedCorporateJointVentureOneMember_393377" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="loc_md_UnnamedCorporateJointVentureTwoMember_670768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_393376" xlink:to="loc_md_UnnamedCorporateJointVentureTwoMember_670768" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_BasisOfPresentationLineItems" xlink:label="loc_md_BasisOfPresentationLineItems_393378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" xlink:to="loc_md_BasisOfPresentationLineItems_393378" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_393379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_BasisOfPresentationLineItems_393378" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_393379" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ExtraordinaryItemsAbstract" xlink:label="loc_md_ExtraordinaryItemsAbstract_686001" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_686004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ExtraordinaryItemsAbstract_686001" xlink:to="loc_us-gaap_StatementTable_686004" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_686005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_StatementClassOfStockAxis_686005" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_686006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_686005" xlink:to="loc_us-gaap_ClassOfStockDomain_686006" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ExtraordinaryItemsAxis" xlink:label="loc_md_ExtraordinaryItemsAxis_686017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_md_ExtraordinaryItemsAxis_686017" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ExtraordinaryItemsDomain" xlink:label="loc_md_ExtraordinaryItemsDomain_686018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ExtraordinaryItemsAxis_686017" xlink:to="loc_md_ExtraordinaryItemsDomain_686018" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CovidNinenteenMember" xlink:label="loc_md_CovidNinenteenMember_686019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ExtraordinaryItemsDomain_686018" xlink:to="loc_md_CovidNinenteenMember_686019" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_686021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_TitleOfIndividualAxis_686021" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_686021" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_686023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" xlink:to="loc_srt_ExecutiveOfficerMember_686023" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_686024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_StatementScenarioAxis_686024" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_686025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_686024" xlink:to="loc_srt_ScenarioUnspecifiedDomain_686025" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ForecastForSecondAndThirdQuartersOf2020Member" xlink:label="loc_md_ForecastForSecondAndThirdQuartersOf2020Member_686026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForSecondAndThirdQuartersOf2020Member_686026" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ForecastForFourthQuarterOf2020Member" xlink:label="loc_md_ForecastForFourthQuarterOf2020Member_686027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForFourthQuarterOf2020Member_686027" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ForecastForFirstQuarterOf2021Member" xlink:label="loc_md_ForecastForFirstQuarterOf2021Member_686028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForFirstQuarterOf2021Member_686028" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ForecastForSecondQuarterOf2021Member" xlink:label="loc_md_ForecastForSecondQuarterOf2021Member_686029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForSecondQuarterOf2021Member_686029" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_686030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_CreditFacilityAxis_686030" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_686031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_686030" xlink:to="loc_us-gaap_CreditFacilityDomain_686031" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CreditAgreementMember" xlink:label="loc_md_CreditAgreementMember_686032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_686031" xlink:to="loc_md_CreditAgreementMember_686032" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_686033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_RangeAxis_686033" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_686034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_686033" xlink:to="loc_srt_RangeMember_686034" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_686035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_686034" xlink:to="loc_srt_MaximumMember_686035" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_686037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_686034" xlink:to="loc_srt_MinimumMember_686037" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaap_GeographicDistributionAxis_686038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_GeographicDistributionAxis_686038" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaap_GeographicDistributionDomain_686039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionAxis_686038" xlink:to="loc_us-gaap_GeographicDistributionDomain_686039" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_UrbanAreaMember" xlink:label="loc_md_UrbanAreaMember_686040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionDomain_686039" xlink:to="loc_md_UrbanAreaMember_686040" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_RuralAreaMember" xlink:label="loc_md_RuralAreaMember_686041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionDomain_686039" xlink:to="loc_md_RuralAreaMember_686041" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_689758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_DebtInstrumentAxis_689758" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_689758" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689759" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_Seniorunsecurdnotes2023Member" xlink:label="loc_md_Seniorunsecurdnotes2023Member_689760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689759" xlink:to="loc_md_Seniorunsecurdnotes2023Member_689760" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_Seniorunsecurdnotes2027Member" xlink:label="loc_md_Seniorunsecurdnotes2027Member_689762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689759" xlink:to="loc_md_Seniorunsecurdnotes2027Member_689762" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_686007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_StatementLineItems_686007" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="loc_md_PercentageIncreaseDecreaseInSalaryAndWage_686008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_PercentageIncreaseDecreaseInSalaryAndWage_686008" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization_689397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization_689397" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_SupplementaryLeverageRatioRequired" xlink:label="loc_md_SupplementaryLeverageRatioRequired_686070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_SupplementaryLeverageRatioRequired_686070" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_686012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_686012" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ContributionsInAidOfReimbursementOfLostRevenue_686014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_ContributionsInAidOfReimbursementOfLostRevenue_686014" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_686015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_686015" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xlink:label="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes_686016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes_686016" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_689754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_689754" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393443" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="loc_md_CashEquivalentsAndInvestmentsTable_393444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393443" xlink:to="loc_md_CashEquivalentsAndInvestmentsTable_393444" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_393445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable_393444" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_393445" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_393445" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_393447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" xlink:to="loc_us-gaap_CashEquivalentsMember_393447" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_393448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable_393444" xlink:to="loc_srt_RangeAxis_393448" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_393449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_393448" xlink:to="loc_srt_RangeMember_393449" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable_393444" xlink:to="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_393453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_393453" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393412" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393412" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_393416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" xlink:to="loc_us-gaap_InvestmentTypeAxis_393416" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_393417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_393416" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_393417" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="loc_us-gaap_AllOtherCorporateBondsMember_494118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_AllOtherCorporateBondsMember_494118" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_393418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_393418" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_393420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_393420" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_393421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_CertificatesOfDepositMember_393421" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_670778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" xlink:to="loc_us-gaap_AvailableForSaleSecurities_670778" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_670782" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_670784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_670782" xlink:to="loc_us-gaap_StatementTable_670784" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_670785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_StatementClassOfStockAxis_670785" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670785" xlink:to="loc_us-gaap_ClassOfStockDomain_670786" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_670796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_670796" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_670797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_670797" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_670798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_670798" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_670801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_670801" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_670787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_StatementLineItems_670787" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670787" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="loc_md_MoneyMarketFundsFairValueDisclosure_670789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_md_MoneyMarketFundsFairValueDisclosure_670789" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_670790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_670790" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_MutualFundsFairValueDisclosure" xlink:label="loc_md_MutualFundsFairValueDisclosure_670791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_md_MutualFundsFairValueDisclosure_670791" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670787" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670792" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:label="loc_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_670793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670792" xlink:to="loc_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_670793" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_670803" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_670805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_670803" xlink:to="loc_us-gaap_StatementTable_670805" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_670806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670805" xlink:to="loc_us-gaap_StatementClassOfStockAxis_670806" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670806" xlink:to="loc_us-gaap_ClassOfStockDomain_670807" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_670813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670805" xlink:to="loc_us-gaap_DebtInstrumentAxis_670813" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_670814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_670813" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_670814" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_TwoThousandTwentyThreeMember" xlink:label="loc_md_TwoThousandTwentyThreeMember_670815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_670814" xlink:to="loc_md_TwoThousandTwentyThreeMember_670815" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_TwoThousandTwentySevenMember" xlink:label="loc_md_TwoThousandTwentySevenMember_670816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_670814" xlink:to="loc_md_TwoThousandTwentySevenMember_670816" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_670808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670805" xlink:to="loc_us-gaap_StatementLineItems_670808" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_670809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670808" xlink:to="loc_us-gaap_LiabilitiesAbstract_670809" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_670810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_670809" xlink:to="loc_us-gaap_NotesPayable_670810" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670808" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_670812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_670812" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_249" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_249" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_250" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_249" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_251" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_249" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_252" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract_254" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract_254" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" xlink:to="loc_srt_ProductOrServiceAxis_256" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_256" xlink:to="loc_srt_ProductsAndServicesDomain_257" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_261" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_HospitalsContractsMember" xlink:label="loc_md_HospitalsContractsMember_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_md_HospitalsContractsMember_262" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_395272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_395272" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="loc_md_ScheduleOfFinancingReceivablesLineItems_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" xlink:to="loc_md_ScheduleOfFinancingReceivablesLineItems_259" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ScheduleOfFinancingReceivablesLineItems_259" xlink:to="loc_us-gaap_DisaggregationOfRevenueAbstract_255" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_255" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_260" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract_265" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract_265" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_ContractedManagedCareMember" xlink:label="loc_md_ContractedManagedCareMember_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_md_ContractedManagedCareMember_271" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_GovernmentMember_272" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="loc_us-gaap_ThirdPartyPayorMember_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_ThirdPartyPayorMember_273" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelfPayMember" xlink:label="loc_us-gaap_SelfPayMember_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_SelfPayMember_274" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:label="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" xlink:to="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" xlink:to="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_270" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_395169" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_468356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_395169" xlink:to="loc_us-gaap_StatementTable_468356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_DeferredTaxAssetsAxis" xlink:label="loc_md_DeferredTaxAssetsAxis_468387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_md_DeferredTaxAssetsAxis_468387" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_DeferredTaxAssetsDomain" xlink:label="loc_md_DeferredTaxAssetsDomain_468388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DeferredTaxAssetsAxis_468387" xlink:to="loc_md_DeferredTaxAssetsDomain_468388" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_670845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_670845" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_670846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_670845" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_670846" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_670847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_670846" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_670847" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_468359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_StatementLineItems_468359" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_574667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_574667" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_670827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_670827" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_TransactionRelatedExpenses" xlink:label="loc_md_TransactionRelatedExpenses_684128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_TransactionRelatedExpenses_684128" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_WorkingCapitalTrueUp" xlink:label="loc_md_WorkingCapitalTrueUp_685980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_WorkingCapitalTrueUp_685980" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_364" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_AccountsPayableCurrent_365" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_AccruedSalariesCurrent_366" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="loc_md_AccruedPayrollTaxesAndBenefitsCurrent_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_md_AccruedPayrollTaxesAndBenefitsCurrent_367" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_368" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_AccruedContingentConsiderationLiabilityCurrent" xlink:label="loc_md_AccruedContingentConsiderationLiabilityCurrent_369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_md_AccruedContingentConsiderationLiabilityCurrent_369" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_InterestPayableCurrent_370" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_371" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_372" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_393216" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_393216" xlink:to="loc_us-gaap_StatementTable_393218" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393218" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393219" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393219" xlink:to="loc_us-gaap_ClassOfStockDomain_393220" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393218" xlink:to="loc_us-gaap_StatementLineItems_393221" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses_671366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393221" xlink:to="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses_671366" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_568" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_568" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_569" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_568" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_570" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_568" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_571" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_568" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_574" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_574" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_PlanNameAxis_576" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_576" xlink:to="loc_us-gaap_PlanNameDomain_577" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_583" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_584" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="loc_md_AmendedAndRestatedTwoThousandEightPlanMember_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_AmendedAndRestatedTwoThousandEightPlanMember_585" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_586" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_AwardTypeAxis_575" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_us-gaap_EmployeeStockOptionMember_603" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_us-gaap_RestrictedStockMember_604" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_srt_RangeAxis_578" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_578" xlink:to="loc_srt_RangeMember_579" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_579" xlink:to="loc_srt_MaximumMember_587" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_588" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_589" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_591" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_592" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_593" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_594" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_595" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_393080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_393080" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_634" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CommonStockTable" xlink:label="loc_md_CommonStockTable_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_634" xlink:to="loc_md_CommonStockTable_637" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_640" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_640" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_641" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_AwardTypeAxis_635" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" xlink:to="loc_us-gaap_RestrictedStockMember_650" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_642" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_642" xlink:to="loc_us-gaap_EquityComponentDomain_638" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_412583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_412583" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_412584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_412583" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_412584" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_CommonStockLineItems" xlink:label="loc_md_CommonStockLineItems_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_md_CommonStockLineItems_636" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_643" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_554331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_554331" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_647" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_648" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_689331" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_689332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_689331" xlink:to="loc_us-gaap_SubsequentEventTable_689332" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_689333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_689332" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_689333" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_689334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_689333" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_689334" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_689335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_689334" xlink:to="loc_us-gaap_SubsequentEventMember_689335" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_689337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_689332" xlink:to="loc_srt_RangeAxis_689337" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_689338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_689337" xlink:to="loc_srt_RangeMember_689338" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_689339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_689338" xlink:to="loc_srt_MaximumMember_689339" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_689340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_689338" xlink:to="loc_srt_MinimumMember_689340" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_689341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_689332" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_689341" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_689342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_689341" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_689342" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember_689343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_689342" xlink:to="loc_md_NorthAmericanPartnersInAnesthesiaMember_689343" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_689332" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689344" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_689345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689344" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_689345" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_MaximumConsiderationReceivable" xlink:label="loc_md_MaximumConsiderationReceivable_689346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689344" xlink:to="loc_md_MaximumConsiderationReceivable_689346" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_AccountsReceivableRetained" xlink:label="loc_md_AccountsReceivableRetained_689347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689344" xlink:to="loc_md_AccountsReceivableRetained_689347" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_689348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689344" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_689348" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_689303" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_689304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_689303" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_689304" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_689306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_689304" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_689306" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_689307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_689306" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_689307" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember_689308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_689307" xlink:to="loc_md_NorthAmericanPartnersInAnesthesiaMember_689308" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_689304" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689309" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689309" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_689311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_689311" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_689312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_689312" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_689313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_689313" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_689314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_689314" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_689315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_689315" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_689316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_689316" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_689318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_689310" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_689318" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_689319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_689309" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_689319" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_689320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_689319" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_689320" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200331.xsd#md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities_689323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_689319" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities_689323" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_689325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_689319" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_689325" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_689327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_689319" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_689327" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796510624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Coronavirus Pandemic ("COVID-19") - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Mar. 25, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Apr. 01, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2023Member', window );">Senior Unsecurd Notes 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt Instrument Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2027Member', window );">Senior Unsecurd Notes 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt Instrument Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member', window );">Forecast For Second And Third Quarters Of 2020 [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Estimated EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member', window );">Forecast For Second And Third Quarters Of 2020 [Member] | Credit Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5.00:1:00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member', window );">Forecast For Second And Third Quarters Of 2020 [Member] | Credit Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4.50:1:00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForFourthQuarterOf2020Member', window );">Forecast For Fourth Quarter Of 2020 [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4.75:1:00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForFirstQuarterOf2021Member', window );">Forecast For First Quarter Of 2021 [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForSecondQuarterOf2021Member', window );">Forecast For Second Quarter Of 2021 [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit Facility Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember', window );">COVID-19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ContributionsInAidOfReimbursementOfLostRevenue', window );">Reimbursement of Lost Revenue</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue', window );">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes', window );">Deferred Payment Of Social Security Taxes | %</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember', window );">COVID-19 [Member] | Urban Area [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ContributionsInAidOfReimbursementOfLostRevenue', window );">Reimbursement of Lost Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember', window );">COVID-19 [Member] | Rural Area [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ContributionsInAidOfReimbursementOfLostRevenue', window );">Reimbursement of Lost Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember', window );">COVID-19 [Member] | Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageIncreaseDecreaseInSalaryAndWage', window );">Decrease In Salary | %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ContributionsInAidOfReimbursementOfLostRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contributions In Aid Of Reimbursement of Lost Revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ContributionsInAidOfReimbursementOfLostRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Earnings Before Interest Taxes Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PercentageIncreaseDecreaseInSalaryAndWage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Increase Decrease In Salary And Wage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PercentageIncreaseDecreaseInSalaryAndWage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Deferred Payment Of Social Security Taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PercentageOfDeferredPaymentOfSocialSecurityTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_SupplementaryLeverageRatioRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplementary Leverage Ratio Required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_SupplementaryLeverageRatioRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForFourthQuarterOf2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForFourthQuarterOf2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForFirstQuarterOf2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForFirstQuarterOf2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForSecondQuarterOf2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForSecondQuarterOf2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ExtraordinaryItemsAxis=md_CovidNinenteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=md_UrbanAreaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=md_UrbanAreaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=md_RuralAreaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=md_RuralAreaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6627886160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses consist of the following (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 10%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 10%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,&#160;2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,&#160;2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47,519 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39,610 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued salaries and bonuses </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">108,079 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">268,619 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll taxes and benefits </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47,791 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">67,268 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional liabilities </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48,149 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44,869 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued contingent consideration </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,288 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2,696 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27,422 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32,910 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43,115 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">55,894 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">323,363 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">511,866 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6645962224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and New Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Basis of Presentation and New Accounting Pronouncements</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">1. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Basis of Presentation and New Accounting Pronouncements:</div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;">The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of MEDNAX, Inc. and its consolidated subsidiaries (collectively, &#8220;MDX&#8221;) together with the accounts of MDX&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#8220;affiliated professional contractors&#8221;). Certain subsidiaries of MDX have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The terms &#8220;MEDNAX&#8221; and the &#8220;Company&#8221; refer collectively to MEDNAX, Inc., its subsidiaries and the affiliated professional contractors.</div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is a party to a joint venture in which it owns a 37.5% economic interest and a second joint venture in which it owns a 49.0% economic interest. The Company accounts for these joint ventures under the equity method of accounting because the Company exercises significant influence over, but does not control, these entities. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;">The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#8217;s most recent Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> (the &#8220;Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K&#8221;). </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2019, the Company divested its management services organization, which operated as MedData, to allow the Company to focus on its core physician services business. The operating results of MedData were reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the three months ended March&#160;31, 2019. See note 6 for more information. </div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New Accounting Pronouncements </div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div> loss limitations. The guidance becomes effective for the Company on January&#160;1, 2021, including interim periods therein, with early adoption permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company does not believe the adoption of this new guidance will have a material impact on its Consolidated Financial Statements and related disclosures. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787339616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">85,150,000<span></span>
</td>
<td class="nump">84,248,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">85,150,000<span></span>
</td>
<td class="nump">84,248,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6671301600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event - Summary of Major Classes of Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=md_NorthAmericanPartnersInAnesthesiaMember', window );">North American Partners In Anesthesia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">147,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">14,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="nump">545,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets, net</a></td>
<td class="nump">60,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total Assets</a></td>
<td class="nump">768,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">54,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities', window );">Accrued professional liabilities</a></td>
<td class="nump">20,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">5,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total Liabilities</a></td>
<td class="nump">$ 80,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation accrued professional liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=md_NorthAmericanPartnersInAnesthesiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=md_NorthAmericanPartnersInAnesthesiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6645577728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Gross accounts receivable</a></td>
<td class="nump">$ 1,840,118<span></span>
</td>
<td class="nump">$ 1,943,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for contractual adjustments and uncollectibles</a></td>
<td class="num">(1,363,127)<span></span>
</td>
<td class="num">(1,444,795)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 476,991<span></span>
</td>
<td class="nump">$ 498,869<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6773517136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 47,519<span></span>
</td>
<td class="nump">$ 39,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued salaries and bonuses</a></td>
<td class="nump">108,079<span></span>
</td>
<td class="nump">268,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccruedPayrollTaxesAndBenefitsCurrent', window );">Accrued payroll taxes and benefits</a></td>
<td class="nump">47,791<span></span>
</td>
<td class="nump">67,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent', window );">Accrued professional liabilities</a></td>
<td class="nump">48,149<span></span>
</td>
<td class="nump">44,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccruedContingentConsiderationLiabilityCurrent', window );">Accrued contingent consideration</a></td>
<td class="nump">1,288<span></span>
</td>
<td class="nump">2,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">27,422<span></span>
</td>
<td class="nump">32,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">43,115<span></span>
</td>
<td class="nump">55,894<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses, total</a></td>
<td class="nump">$ 323,363<span></span>
</td>
<td class="nump">$ 511,866<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccruedContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued contingent consideration liability current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccruedContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccruedPayrollTaxesAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll taxes and benefits current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccruedPayrollTaxesAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6642450096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Incentive Plans and Stock Purchase Plans</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></div>. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Stock Incentive Plans and Stock Purchase Plans:</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Amended and Restated 2008 Incentive Compensation Plan (the &#8220;Amended and Restated 2008 Incentive Plan&#8221;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;">Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within 10 years from the date of grant and generally become exercisable on a pro rata basis over a three-year period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of three years upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the three months ended March&#160;31, 2020, the Company granted 894,718 shares of restricted stock to its employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors under the Amended and Restated 2008 Incentive Plan. At March&#160;31, 2020, the Company had 6.6 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million </div>shares available for future grants and awards under <div style="letter-spacing: 0px; top: 0px;;display:inline;">the</div> Amended and Restated 2008 Incentive Plan.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;">Under the Company&#8217;s 1996 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</div> Employee Stock Purchase Plan, as amended (the &#8220;ESPP&#8221;), employees are permitted to purchase the Company&#8217;s common stock at 85% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#8217;s 2015 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</div> Stock Purchase Plan (the &#8220;SPP&#8221;), certain eligible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> service providers are permitted to purchase the Company&#8217;s common stock at 90% of market value on January 1st, April 1st, July 1st and October 1st of each year.</div> <div style="margin-top: 1em; margin-bottom: 0em;"/> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0px; margin-left: 4%;">Each of the ESPP and the SPP provide for the issuance of an aggregate of 2.6&#160;million shares of the Company&#8217;s common stock less the number of shares of common stock purchased under the other plan. The Company recognizes stock-based compensation expense for the discount received by participating employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> service providers. During the three months ended March&#160;31, 2020, approximately 78,300 shares in aggregate were issued under the ESPP and SPP. At March&#160;31, 2020, the Company had approximately 1.0&#160;million shares in aggregate reserved for issuance under the ESPP and SPP.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended March&#160;31, 2020 and 2019, the Company recognized stock-based compensation expense of $7.8&#160;million and $11.0&#160;million, respectively. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6628546384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccountsReceivableAndNetRevenueDisclosureTextBlock', window );">Accounts Receivable and Net Revenue</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Accounts Receivable and Net Revenue:</div></td></tr></table><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net consists of the following (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 7%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 7%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,&#160;2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,&#160;2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross accounts receivable </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,840,118 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,943,664 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for contractual adjustments and uncollectibles </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(1,363,127</div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(1,444,795</div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">476,991 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">498,869 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient service revenue is recognized at the time services are provided by the Company&#8217;s affiliated physicians. The Company&#8217;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#8217;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) and third-party insurance payors. Payments for services rendered to the Company&#8217;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#8220;DSO&#8221;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within&#160;30&#160;to&#160;60&#160;days of billing. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s net revenue by category (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style=" font-size: 0pt; ">
<td style="width:76%;">&#160;</td>
<td style="width:4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width:4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months&#160;Ended </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net patient service revenue </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;734,387</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;749,585</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hospital contract administrative fees </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">104,595</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">94,721</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenue </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6,936 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6,877 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">845,918</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">851,183</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The approximate percentage of net patient service revenue by type of payor was as follows: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style=" font-size: 0pt; ">
<td style="width:82%;">&#160;</td>
<td style="width:7%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width:7%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months&#160;Ended </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contracted managed care </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">68</div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">%</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">69</div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other third-parties </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 82%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Private-pay</div> patients</div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">100</div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">%</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">100</div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">%</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccountsReceivableAndNetRevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable and net revenue disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccountsReceivableAndNetRevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6648931392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and New Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New Accounting Pronouncements </div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div> loss limitations. The guidance becomes effective for the Company on January&#160;1, 2021, including interim periods therein, with early adoption permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company does not believe the adoption of this new guidance will have a material impact on its Consolidated Financial Statements and related disclosures. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>94</ContextCount>
  <ElementCount>293</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedStatementsOfIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedStatementsOfEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - Basis of Presentation and New Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements</Role>
      <ShortName>Basis of Presentation and New Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Coronavirus Pandemic ("COVID-19")</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CoronavirusPandemicCovid19</Role>
      <ShortName>Coronavirus Pandemic ("COVID-19")</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CashEquivalentsAndInvestments</Role>
      <ShortName>Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Accounts Receivable and Net Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenue</Role>
      <ShortName>Accounts Receivable and Net Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Common and Common Equivalent Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonAndCommonEquivalentShares</Role>
      <ShortName>Common and Common Equivalent Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Stock Incentive Plans and Stock Purchase Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Common Stock Repurchase Programs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonStockRepurchasePrograms</Role>
      <ShortName>Common Stock Repurchase Programs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Basis of Presentation and New Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies</Role>
      <ShortName>Basis of Presentation and New Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables</Role>
      <ShortName>Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/CashEquivalentsAndInvestments</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/FairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Accounts Receivable and Net Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables</Role>
      <ShortName>Accounts Receivable and Net Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/AccountsReceivableAndNetRevenue</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/AccountsPayableAndAccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Common and Common Equivalent Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables</Role>
      <ShortName>Common and Common Equivalent Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/CommonAndCommonEquivalentShares</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Subsequent Event (Table)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/SubsequentEventTable</Role>
      <ShortName>Subsequent Event (Table)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/SubsequentEvent</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Coronavirus Pandemic ("COVID-19") - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail</Role>
      <ShortName>Coronavirus Pandemic ("COVID-19") - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mednax.com/role/CoronavirusPandemicCovid19</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail</Role>
      <ShortName>Cash Equivalents and Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail</Role>
      <ShortName>Cash Equivalents and Investments - Schedule of Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Discontinued Operations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail</Role>
      <ShortName>Discontinued Operations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail</Role>
      <ShortName>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail</Role>
      <ShortName>Common Stock Repurchase Programs - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Subsequent Event - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail</Role>
      <ShortName>Subsequent Event - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d888266d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Subsequent Event - Summary of Major Classes of Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail</Role>
      <ShortName>Subsequent Event - Summary of Major Classes of Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="d888266d10q.htm">d888266d10q.htm</File>
    <File>d888266dex101.htm</File>
    <File>d888266dex311.htm</File>
    <File>d888266dex312.htm</File>
    <File>d888266dex321.htm</File>
    <File>md-20200331.xsd</File>
    <File>md-20200331_cal.xml</File>
    <File>md-20200331_def.xml</File>
    <File>md-20200331_lab.xml</File>
    <File>md-20200331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6778167184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 845,918<span></span>
</td>
<td class="nump">$ 851,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember', window );">Net patient service revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">734,387<span></span>
</td>
<td class="nump">749,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=md_HospitalsContractsMember', window );">Hospital contract administrative fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">104,595<span></span>
</td>
<td class="nump">94,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 6,936<span></span>
</td>
<td class="nump">$ 6,877<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=md_HospitalsContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=md_HospitalsContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6646008320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_IncreaseDecreaseInAccruedSalariesAndBonuses', window );">Net decrease in accrued salaries and bonuses</a></td>
<td class="nump">$ 160.5<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncreaseDecreaseInAccruedSalariesAndBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued salaries and bonuses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncreaseDecreaseInAccruedSalariesAndBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>d888266d10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:md="http://www.mednax.com/20200331"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="md-20200331.xsd" xlink:type="simple"/>
    <context id="P01_01_2020To03_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn08_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="PAsOn05_01_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2020-05-01</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">md:UnnamedCorporateJointVentureOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_UnnamedCorporateJointVentureTwoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">md:UnnamedCorporateJointVentureTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_HospitalsContractsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_TwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:Seniorunsecurdnotes2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_Seniorunsecurdnotes2027MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:Seniorunsecurdnotes2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019_HospitalsContractsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-25</instant>
        </period>
    </context>
    <context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForSecondQuarterOf2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-25</instant>
        </period>
    </context>
    <context id="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2020-03-27</endDate>
        </period>
    </context>
    <context id="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="PAsOn04_01_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_RuralAreaMemberusgaapGeographicDistributionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">md:RuralAreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-01</instant>
        </period>
    </context>
    <context id="PAsOn04_01_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_UrbanAreaMemberusgaapGeographicDistributionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">md:UrbanAreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-01</instant>
        </period>
    </context>
    <context id="PAsOn04_01_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-01</instant>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForFourthQuarterOf2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForFirstQuarterOf2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-06</instant>
        </period>
    </context>
    <context id="PAsOn05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-06</instant>
        </period>
    </context>
    <context id="PAsOn05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-06</instant>
        </period>
    </context>
    <context id="P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-06</startDate>
            <endDate>2020-05-06</endDate>
        </period>
    </context>
    <context id="P05_06_2020To05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-06</startDate>
            <endDate>2020-05-06</endDate>
        </period>
    </context>
    <context id="P05_06_2020To05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-06</startDate>
            <endDate>2020-05-06</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2020To03_31_2020">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2020"
      decimals="INF"
      id="hidden12788133"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2020"
      decimals="INF"
      id="hidden12788135"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2020To03_31_2020">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2020To03_31_2020">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="P01_01_2020To03_31_2020">0000893949</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="P01_01_2020To03_31_2020">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="P01_01_2020To03_31_2020">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="P01_01_2020To03_31_2020">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="P01_01_2020To03_31_2020">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="P01_01_2020To03_31_2020">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="P01_01_2020To03_31_2020">001-12111</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P01_01_2020To03_31_2020">MEDNAX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2020To03_31_2020">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2020To03_31_2020">26-3667538</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2020To03_31_2020">1301 Concord Terrace</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2020To03_31_2020">Sunrise</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2020To03_31_2020">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2020To03_31_2020">33323</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2020To03_31_2020">954</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2020To03_31_2020">384-0175</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="P01_01_2020To03_31_2020">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2020To03_31_2020">MD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2020To03_31_2020">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="P01_01_2020To03_31_2020">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P01_01_2020To03_31_2020">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P01_01_2020To03_31_2020">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2020To03_31_2020">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2020To03_31_2020">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="P01_01_2020To03_31_2020">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn05_01_2020"
      decimals="INF"
      unitRef="Unit_shares">85409248</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">312155000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">112767000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">85041000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">74510000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">476991000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">498869000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">19409000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">21919000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">26449000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">20851000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">23442000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">940896000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">731507000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">100227000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">94492000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2710292000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2710292000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">263308000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">274407000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">79810000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">82824000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">132783000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
    <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">162385000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">92346000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">89994000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4319662000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4145901000</us-gaap:Assets>
    <md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">323363000</md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent>
    <md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">511866000</md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">697000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">130000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">22340000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">23317000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">6505000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">346400000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">541818000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">368500000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermLineOfCredit>
    <md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1733469000</md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit>
    <md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1730295000</md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">62238000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">67005000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">238347000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">226892000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent>
    <us-gaap:DeferredTaxLiabilitiesNoncurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">61975000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">57995000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">21337000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">22900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2832266000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2646905000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn03_31_2020"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2019"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2020"
      decimals="INF"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2020"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2020"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2020"
      decimals="INF"
      unitRef="Unit_shares">85150000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2020"
      decimals="INF"
      unitRef="Unit_shares">85150000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">84248000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">84248000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">852000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">842000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">995257000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">987942000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">491287000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">510212000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1487396000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1498996000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4319662000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4145901000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">845918000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">851183000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <md:PracticeSalariesAndBenefits
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">652721000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">621539000</md:PracticeSalariesAndBenefits>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">25264000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">25791000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">105235000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">101821000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">18673000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">20033000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">30907000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3544000</us-gaap:RestructuringCharges>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">832800000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">772728000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">13118000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">78455000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-679000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1647000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">27608000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">30723000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1345000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1236000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-26942000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-27840000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-13824000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">50615000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2286000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">8962000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-16110000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">41653000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-2602000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-284525000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-18712000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-242872000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P01_01_2020To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.20</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P01_01_2019To03_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.48</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P01_01_2020To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.20</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P01_01_2019To03_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.48</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P01_01_2020To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P01_01_2019To03_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-3.31</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P01_01_2020To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P01_01_2019To03_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-3.29</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2019To03_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2019To03_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_shares">82799000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_shares">86073000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_shares">82799000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_shares">86545000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">84248000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">842000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">987942000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">510212000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1498996000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-18712000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-18712000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_12788507"
      unitRef="Unit_USD">-213000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      id="Fact_12788440"
      unitRef="Unit_USD">-213000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">78000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1831000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1832000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">968000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-19000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8035000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8035000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">125000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2541000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2542000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">85150000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">852000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">995257000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">491287000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1487396000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">87820000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">878000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">992647000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2094359000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">3087884000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-242872000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-242872000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_12788508"
      unitRef="Unit_USD">-194000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      id="Fact_12788442"
      unitRef="Unit_USD">-194000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">140000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3541000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3542000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">978000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-6000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <md:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-20000</md:StockIssuedDuringPeriodSharesStockSwaps>
    <md:StockIssuedDuringPeriodValueStockSwaps
      contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-666000</md:StockIssuedDuringPeriodValueStockSwaps>
    <md:StockIssuedDuringPeriodValueStockSwaps
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-666000</md:StockIssuedDuringPeriodValueStockSwaps>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">11100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">11100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">2525000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">28740000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">50217000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">78982000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">86387000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">864000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">977872000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1801076000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2779812000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-18712000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-242872000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-2602000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-284525000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">18673000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">20033000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1458000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1520000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8035000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">10989000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">33582000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-5108000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1883000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-2767000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-25904000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">15915000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-5101000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-4790000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-11189000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-9580000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-198452000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-132559000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-32883000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">14373000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">102000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">42000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">6969000</us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve>
    <us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-496000</us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-7912000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-11993000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-146431000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-60408000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3591000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-146431000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-56817000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">75000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4250000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">21042000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">9860000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4800000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">13713000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">5821000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4750000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-20220000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-5271000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-3420000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-20220000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-8691000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">515000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">518500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">146500000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">866000000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">500000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">8380000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1248000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1308000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">42000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1832000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2876000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2542000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">78982000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">366039000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">66664000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">366039000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">66664000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">199388000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1156000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">112767000</us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">56745000</us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="PAsOn03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">11425000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">312155000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">46476000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="P01_01_2020To03_31_2020">
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1. &lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of Presentation and New Accounting Pronouncements:&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of MEDNAX, Inc. and its consolidated subsidiaries (collectively, &#x201c;MDX&#x201d;) together with the accounts of MDX&#x2019;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#x201c;affiliated professional contractors&#x201d;). Certain subsidiaries of MDX have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The terms &#x201c;MEDNAX&#x201d; and the &#x201c;Company&#x201d; refer collectively to MEDNAX, Inc., its subsidiaries and the affiliated professional contractors.&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is a party to a joint venture in which it owns a 37.5% economic interest and a second joint venture in which it owns a 49.0% economic interest. The Company accounts for these joint ventures under the equity method of accounting because the Company exercises significant influence over, but does not control, these entities. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#x2019;s most recent Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; (the &#x201c;Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2019, the Company divested its management services organization, which operated as MedData, to allow the Company to focus on its core physician services business. The operating results of MedData were reported as discontinued operations in the Company&#x2019;s Consolidated Statements of Income for the three months ended March&#160;31, 2019. See note 6 for more information. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;New Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;step-up&lt;/div&gt; in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-to-date&lt;/div&gt; loss limitations. The guidance becomes effective for the Company on January&#160;1, 2021, including interim periods therein, with early adoption permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company does not believe the adoption of this new guidance will have a material impact on its Consolidated Financial Statements and related disclosures. &lt;/div&gt;&lt;/div&gt; </us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn03_31_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="3"
      unitRef="Unit_pure">0.375</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn03_31_2020_UnnamedCorporateJointVentureTwoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="3"
      unitRef="Unit_pure">0.490</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2020To03_31_2020">&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;New Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;step-up&lt;/div&gt; in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-to-date&lt;/div&gt; loss limitations. The guidance becomes effective for the Company on January&#160;1, 2021, including interim periods therein, with early adoption permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company does not believe the adoption of this new guidance will have a material impact on its Consolidated Financial Statements and related disclosures. &lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock contextRef="P01_01_2020To03_31_2020">
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Coronavirus Pandemic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;COVID-19&#x201d;): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; and related &#x201c;stay at home&#x201d; and social distancing measures implemented across the country has significantly impacted demand for medical services provided by the Company&#x2019;s affiliated clinicians. Beginning in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-March&lt;/div&gt; 2020, the Company experienced a significant decline in the number of elective surgeries at the facilities where&#160;the Company&#x2019;s affiliated clinicians provided anesthesia services. See Note 12 - Subsequent Events for information regarding the divestment of the Company&#x2019;s anesthesia medical group on May 6, 2020. Much of this decline has been due to the closure of operating suites or facilities following federal advisories to cancel &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-urgent&lt;/div&gt; procedures and the prohibition of such procedures by several states. Within the Company&#x2019;s radiology service line, orders for radiological studies have declined by a meaningful amount from historically normal levels, with much of this reduction focused in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-urgent&lt;/div&gt; studies. The Company&#x2019;s affiliated office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, have seen a significant elevation of appointment cancellations compared to historical normal levels. At this time, the Company has not experienced, nor does it currently anticipate, any significant impact to neonatal intensive care unit (NICU) patient volumes as a result of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has implemented a number of actions to preserve financial flexibility and partially mitigate the significant anticipated impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19.&lt;/div&gt; These steps included a suspension of most activities related to the Company&#x2019;s transformational and restructuring programs, limiting these expenditures to those that &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;provide&lt;/div&gt;&#160;essential support for the Company&#x2019;s response to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19.&lt;/div&gt; In addition, (i)&#160;the Company temporarily reduced executive and key management base salaries, including 50% reductions in salaries for its named executive officers through at least June&#160;30, 2020; (ii) the Board of Directors agreed to forego their annual cash retainer and cash meeting payments, until further notice; (iii)&#160;the Company enacted a combination of salary reductions and furloughs for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-clinical&lt;/div&gt; employees; and (iv)&#160;the Company enacted significant operational and practice-specific expense reduction plans across its clinical operations. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In response to the anticipated impact of COVID-19 on the Company&#x2019;s results of operations, on &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;25, 2020, the Company amended and restated its Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $139.2&#160;million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by the Company from 4.50:1:00 to 5.00:1:00 for the second and third quarters of 2020 and 4.75:1:00 for the fourth quarter of 2020, before returning to &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.50:1:00&lt;/div&gt; for the first quarter of 2021 and beyond, (iii)&#160;require that the Company maintains minimum availability under the Credit Agreement of $300.0&#160;million through the third quarter of 2021, (iv) provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $300.0&#160;million, plus a reserve for certain payables, and (v)&#160;temporarily restrict the Company&#x2019;s ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;exceptions. At March 31, 2020, the Company believes it was in compliance, in all material respects, with the financial covenants and other restrictions applicable to the Company under its Credit Agreement, its 5.25% senior unsecured notes due 2023 and its 6.25% senior unsecured notes due 2027. The Company believes it will be in compliance with these covenants for the next twelve months.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CARES Act &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES Act&#x201d;) into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $100&#160;billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19.&lt;/div&gt; The Department of Health and Human Services (&#x201c;HHS&#x201d;) is administering this program and began disbursing funds from the initial $30&#160;billion in early April 2020, of which the Company&#x2019;s affiliated physician practices received an aggregate of $12.2&#160;million based on their respective share of Medicare fee for service reimbursements in 2019. The remaining $70&#160;billion in aid is intended to focus on providers in areas particularly impacted by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19,&lt;/div&gt; rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act the Company and its affiliated physician practices will qualify for and receive. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due December&#160;31, 2021 and the remaining 50% due December&#160;31, 2022. The Company intends to utilize this deferral option throughout 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company currently expects that the COVID-19 situation will materially impact its financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from COVID-19, the Company is unable to predict the ultimate impact on its business, financial condition, results of operations and cash flows. The Company, however, believes it will be able to generate sufficient liquidity to satisfy its obligations for the next twelve months.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0px;"/&gt;</md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock>
    <md:PercentageIncreaseDecreaseInSalaryAndWage
      contextRef="P01_01_2020To03_31_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</md:PercentageIncreaseDecreaseInSalaryAndWage>
    <md:EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">139200000</md:EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis">4.50:1:00</md:SupplementaryLeverageRatioRequired>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis">5.00:1:00</md:SupplementaryLeverageRatioRequired>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis">4.75:1:00</md:SupplementaryLeverageRatioRequired>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis">2020</md:SupplementaryLeverageRatioRequired>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">300000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">300000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P01_01_2020To03_31_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0525</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P01_01_2020To03_31_2020_Seniorunsecurdnotes2027MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0625</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <md:ContributionsInAidOfReimbursementOfLostRevenue
      contextRef="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis"
      decimals="-6"
      unitRef="Unit_USD">100000000</md:ContributionsInAidOfReimbursementOfLostRevenue>
    <md:ContributionsInAidOfReimbursementOfLostRevenue
      contextRef="PAsOn04_01_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_UrbanAreaMemberusgaapGeographicDistributionAxis"
      decimals="-6"
      unitRef="Unit_USD">30000000</md:ContributionsInAidOfReimbursementOfLostRevenue>
    <md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue
      contextRef="PAsOn04_01_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis"
      decimals="-5"
      unitRef="Unit_USD">12200000</md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue>
    <md:ContributionsInAidOfReimbursementOfLostRevenue
      contextRef="PAsOn04_01_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_RuralAreaMemberusgaapGeographicDistributionAxis"
      decimals="-6"
      unitRef="Unit_USD">70000000</md:ContributionsInAidOfReimbursementOfLostRevenue>
    <md:PercentageOfDeferredPaymentOfSocialSecurityTaxes
      contextRef="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</md:PercentageOfDeferredPaymentOfSocialSecurityTaxes>
    <md:PercentageOfDeferredPaymentOfSocialSecurityTaxes
      contextRef="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</md:PercentageOfDeferredPaymentOfSocialSecurityTaxes>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="P01_01_2020To03_31_2020">
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash Equivalents and Investments:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&#160;31, 2020 and December&#160;31, 2019, the Company&#x2019;s cash equivalents consisted entirely of money market funds totaling $6.4&#160;million and $16.8&#160;million, respectively. Investments consisted of corporate securities, municipal debt securities, federal home loan securities and certificates of deposit. All investments are classified as current. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;margin-left:4%;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:6pt"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held at March&#160;31, 2020 and December&#160;31, 2019 are summarized as follows (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31,&#160;2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31,&#160;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate securities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;46,883 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;32,962&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Municipal debt securities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;23,327 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,066&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal home loan securities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,052 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certificates of deposit &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,779 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,469&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;85,041 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;74,510&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt; </us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="PAsOn03_31_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-5"
      unitRef="Unit_USD">6400000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="PAsOn12_31_2019_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-5"
      unitRef="Unit_USD">16800000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="P01_01_2020To03_31_2020">&lt;div style="font-family:Times New Roman;margin-left:4%;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:6pt"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held at March&#160;31, 2020 and December&#160;31, 2019 are summarized as follows (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31,&#160;2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31,&#160;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate securities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;46,883 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;32,962&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Municipal debt securities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;23,327 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,066&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal home loan securities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,052 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certificates of deposit &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,779 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,469&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;85,041 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;74,510&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn03_31_2020_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">46883000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">32962000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn03_31_2020_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">23327000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">29066000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn03_31_2020_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">8052000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">8013000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn03_31_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6779000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">4469000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">85041000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">74510000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2020To03_31_2020">
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor;width: 100%;text-align: left;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;font-weight: normal;margin-top: 18pt;margin-bottom: 0pt;border-collapse: collapse;border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4. &lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements:&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.&#160;Each fair value measurement is reported in one of three levels: &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 8%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1 &#x2013; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 8%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2 &#x2013; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 8%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3 &#x2013; inputs are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are accounted for at fair value on a recurring basis at March&#160;31, 2020 and December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair&#160;Value&lt;br/&gt;Category &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31,&#160;2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31,&#160;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,357 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,775&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term investments &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;85,041 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;74,510&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mutual Funds &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,640 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,264&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,288 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,696&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are not carried at fair value at March&#160;31, 2020 and December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 92%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31, 2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, 2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carrying&lt;br/&gt;Amount &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carrying&lt;br/&gt;Amount &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023 Notes &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;750,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;611,250&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;750,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;766,875&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027 Notes &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,000,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;801,200&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,000,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,025,600&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the Company&#x2019;s line of credit approximates fair value. If the line of credit was measured at fair value, it would be &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;categorized as Level&#160;2 in the fair value hierarchy. &lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="P01_01_2020To03_31_2020">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are accounted for at fair value on a recurring basis at March&#160;31, 2020 and December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair&#160;Value&lt;br/&gt;Category &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31,&#160;2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31,&#160;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,357 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,775&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term investments &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;85,041 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;74,510&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mutual Funds &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,640 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,264&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,288 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,696&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <md:MoneyMarketFundsFairValueDisclosure
      contextRef="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">6357000</md:MoneyMarketFundsFairValueDisclosure>
    <md:MoneyMarketFundsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">16775000</md:MoneyMarketFundsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">85041000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">74510000</us-gaap:InvestmentsFairValueDisclosure>
    <md:MutualFundsFairValueDisclosure
      contextRef="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">11640000</md:MutualFundsFairValueDisclosure>
    <md:MutualFundsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">14264000</md:MutualFundsFairValueDisclosure>
    <md:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure
      contextRef="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1288000</md:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <md:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">2696000</md:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock contextRef="P01_01_2020To03_31_2020">&lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are not carried at fair value at March&#160;31, 2020 and December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 92%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31, 2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, 2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carrying&lt;br/&gt;Amount &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carrying&lt;br/&gt;Amount &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023 Notes &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;750,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;611,250&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;750,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;766,875&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027 Notes &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,000,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;801,200&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,000,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,025,600&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock>
    <us-gaap:NotesPayable
      contextRef="PAsOn03_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">750000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn03_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">611250000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">750000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">766875000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="PAsOn03_31_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn03_31_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">801200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1025600000</us-gaap:NotesPayableFairValueDisclosure>
    <md:AccountsReceivableAndNetRevenueDisclosureTextBlock contextRef="P01_01_2020To03_31_2020">
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;. &lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts Receivable and Net Revenue:&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31,&#160;2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31,&#160;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross accounts receivable &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,840,118 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,943,664 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance for contractual adjustments and uncollectibles &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,363,127&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,444,795&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;476,991 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;498,869 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patient service revenue is recognized at the time services are provided by the Company&#x2019;s affiliated physicians. The Company&#x2019;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#x2019;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#x201c;GHC Programs&#x201d;) and third-party insurance payors. Payments for services rendered to the Company&#x2019;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#x201c;DSO&#x201d;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within&#160;30&#160;to&#160;60&#160;days of billing. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Some of the Company&#x2019;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&#x2019;s net revenue by category (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"&gt;
&lt;tr style=" font-size: 0pt; "&gt;
&lt;td style="width:76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Three&#160;Months&#160;Ended &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net patient service revenue &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;734,387&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;749,585&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hospital contract administrative fees &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;104,595&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;94,721&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other revenue &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,936 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,877 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;845,918&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;851,183&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The approximate percentage of net patient service revenue by type of payor was as follows: &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"&gt;
&lt;tr style=" font-size: 0pt; "&gt;
&lt;td style="width:82%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width:7%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width:7%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Three&#160;Months&#160;Ended &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contracted managed care &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;68&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;69&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Government &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other third-parties &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 82%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Private-pay&lt;/div&gt; patients&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 82%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 82%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt; </md:AccountsReceivableAndNetRevenueDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="P01_01_2020To03_31_2020">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31,&#160;2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31,&#160;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross accounts receivable &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,840,118 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,943,664 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance for contractual adjustments and uncollectibles &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,363,127&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,444,795&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;476,991 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;498,869 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1840118000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1943664000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1363127000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1444795000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">476991000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">498869000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="P01_01_2020To03_31_2020">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&#x2019;s net revenue by category (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"&gt;
&lt;tr style=" font-size: 0pt; "&gt;
&lt;td style="width:76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width:4%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Three&#160;Months&#160;Ended &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net patient service revenue &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;734,387&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;749,585&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hospital contract administrative fees &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;104,595&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;94,721&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other revenue &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,936 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,877 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;845,918&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;851,183&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To03_31_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">734387000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To03_31_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">749585000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To03_31_2020_HospitalsContractsMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">104595000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To03_31_2019_HospitalsContractsMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">94721000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To03_31_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">6936000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To03_31_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">6877000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">845918000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">851183000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="P01_01_2020To03_31_2020">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The approximate percentage of net patient service revenue by type of payor was as follows: &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"&gt;
&lt;tr style=" font-size: 0pt; "&gt;
&lt;td style="width:82%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width:7%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width:7%;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Three&#160;Months&#160;Ended &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contracted managed care &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;68&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;69&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Government &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other third-parties &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; width: 82%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Private-pay&lt;/div&gt; patients&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 82%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;%&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 82%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To03_31_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.68</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To03_31_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.69</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To03_31_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To03_31_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.24</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To03_31_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To03_31_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To03_31_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.02</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To03_31_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.02</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To03_31_2020"
      decimals="2"
      unitRef="Unit_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To03_31_2019"
      decimals="2"
      unitRef="Unit_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="P01_01_2020To03_31_2020">
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;. &lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Discontinued Operations:&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;10, 2019, the Company entered into a securities purchase agreement with an affiliate of Frazier Healthcare Partners to divest its management services organization, which operated as MedData, and the transaction closed on October&#160;31, 2019. The operating results of the management services service line were reported as discontinued operations in the Company&#x2019;s Consolidated Statements of Income for the three months ended March&#160;31, 2019. Loss from discontinued operations, net of income taxes, as reported in the Company&#x2019;s Consolidated Statements of Income for the three months ended March&#160;31, 2019&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; was $284.5&#160;million&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; which included a loss on classification as held for sale of $321.2&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left;text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 0pt;margin-bottom: 0px;margin-left: 4%;"&gt;During the three months ended March&#160;31, 2020, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company recorded an incremental loss on the sale of MedData &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;of $3.6&#160;million, primarily related to the finalization of certain transaction related expenses of $5.1&#160;million and a working capital &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;true-up&lt;/div&gt; of $0.2&#160;million, partially offset by the completion of its preliminary valuation for the contingent economic consideration&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; which decreased the loss on sale by $1.7&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0px;"/&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To03_31_2019"
      decimals="-5"
      unitRef="Unit_USD">-284500000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To03_31_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">321200000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To03_31_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">3600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <md:TransactionRelatedExpenses
      contextRef="P01_01_2020To03_31_2020"
      decimals="-5"
      unitRef="Unit_USD">5100000</md:TransactionRelatedExpenses>
    <md:WorkingCapitalTrueUp
      contextRef="P01_01_2020To03_31_2020"
      decimals="-5"
      unitRef="Unit_USD">200000</md:WorkingCapitalTrueUp>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P01_01_2020To03_31_2020"
      decimals="-5"
      unitRef="Unit_USD">1700000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="P01_01_2020To03_31_2020">
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7. &lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts Payable and Accrued Expenses:&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued expenses consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31,&#160;2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31,&#160;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;47,519 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;39,610 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued salaries and bonuses &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;108,079 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;268,619 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued payroll taxes and benefits &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;47,791 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;67,268 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued professional liabilities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;48,149 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;44,869 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued contingent consideration &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,288 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,696 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued interest &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;27,422 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;32,910 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other accrued expenses &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;43,115 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;55,894 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;323,363 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;511,866 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The net decrease in accrued salaries and bonuses of $160.5&#160;million, from December&#160;31, 2019 to March&#160;31, 2020, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#x2019;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the three months ended March&#160;31, 2020. A majority of the Company&#x2019;s payments for performance-based incentive compensation is paid annually during the first quarter. &lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="P01_01_2020To03_31_2020">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued expenses consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31,&#160;2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31,&#160;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;47,519 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;39,610 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued salaries and bonuses &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;108,079 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;268,619 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued payroll taxes and benefits &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;47,791 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;67,268 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued professional liabilities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;48,149 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;44,869 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued contingent consideration &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,288 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,696 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued interest &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;27,422 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;32,910 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other accrued expenses &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;43,115 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;55,894 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;323,363 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;511,866 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">47519000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">39610000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">108079000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">268619000</us-gaap:AccruedSalariesCurrent>
    <md:AccruedPayrollTaxesAndBenefitsCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">47791000</md:AccruedPayrollTaxesAndBenefitsCurrent>
    <md:AccruedPayrollTaxesAndBenefitsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">67268000</md:AccruedPayrollTaxesAndBenefitsCurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">48149000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">44869000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent>
    <md:AccruedContingentConsiderationLiabilityCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1288000</md:AccruedContingentConsiderationLiabilityCurrent>
    <md:AccruedContingentConsiderationLiabilityCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2696000</md:AccruedContingentConsiderationLiabilityCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">27422000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">32910000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">43115000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">55894000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">323363000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">511866000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <md:IncreaseDecreaseInAccruedSalariesAndBonuses
      contextRef="P01_01_2019To03_31_2019"
      decimals="-5"
      unitRef="Unit_USD">160500000</md:IncreaseDecreaseInAccruedSalariesAndBonuses>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2020To03_31_2020">
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common and Common Equivalent Shares:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock, deferred stock and stock options and is calculated using the treasury stock method. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculation of shares used in the basic and diluted net income per common share calculation for the three months ended March&#160;31, 2020 and 2019 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Three&#160;Months&#160;Ended &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of common shares outstanding &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;82,799 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;86,073 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of dilutive common share equivalents &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; width: 6%; height: 17px; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;472 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of common and common&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;equivalent shares outstanding&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;(a)&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;82,799 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;86,545 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.13in; line-height: normal; text-indent: -0.13in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Antidilutive securities not included in the diluted&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;net income per common share&lt;br/&gt; calculation &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;849 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;504 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0px;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 8%; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(a) &lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to a loss from continuing operations for the three months ended March&#160;31, 2020, no incremental shares are included because the effect would be antidilutive.&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="P01_01_2020To03_31_2020">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculation of shares used in the basic and diluted net income per common share calculation for the three months ended March&#160;31, 2020 and 2019 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Three&#160;Months&#160;Ended &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of common shares outstanding &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;82,799 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;86,073 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of dilutive common share equivalents &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; width: 6%; height: 17px; padding: 0pt 5pt 0pt 0pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;472 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of common and common&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;equivalent shares outstanding&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;(a)&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;82,799 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;86,545 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.13in; line-height: normal; text-indent: -0.13in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Antidilutive securities not included in the diluted&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;net income per common share&lt;br/&gt; calculation &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;849 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;504 &lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0px;"/&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; table-layout: fixed;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 8%; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(a) &lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to a loss from continuing operations for the three months ended March&#160;31, 2020, no incremental shares are included because the effect would be antidilutive.&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_shares">82799000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_shares">86073000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_shares">472000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      id="Fact_12788386"
      unitRef="Unit_shares">82799000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      id="Fact_12788387"
      unitRef="Unit_shares">86545000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_shares">849000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_shares">504000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2020To03_31_2020">
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock Incentive Plans and Stock Purchase Plans:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s Amended and Restated 2008 Incentive Compensation Plan (the &#x201c;Amended and Restated 2008 Incentive Plan&#x201d;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within 10 years from the date of grant and generally become exercisable on a pro rata basis over a three-year period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of three years upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the three months ended March&#160;31, 2020, the Company granted 894,718 shares of restricted stock to its employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; directors under the Amended and Restated 2008 Incentive Plan. At March&#160;31, 2020, the Company had 6.6 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million &lt;/div&gt;shares available for future grants and awards under &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&lt;/div&gt; Amended and Restated 2008 Incentive Plan.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;Under the Company&#x2019;s 1996 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Qualified&lt;/div&gt; Employee Stock Purchase Plan, as amended (the &#x201c;ESPP&#x201d;), employees are permitted to purchase the Company&#x2019;s common stock at 85% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#x2019;s 2015 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Qualified&lt;/div&gt; Stock Purchase Plan (the &#x201c;SPP&#x201d;), certain eligible &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; service providers are permitted to purchase the Company&#x2019;s common stock at 90% of market value on January 1st, April 1st, July 1st and October 1st of each year.&lt;/div&gt; &lt;div style="margin-top: 1em; margin-bottom: 0em;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0px; margin-left: 4%;"&gt;Each of the ESPP and the SPP provide for the issuance of an aggregate of 2.6&#160;million shares of the Company&#x2019;s common stock less the number of shares of common stock purchased under the other plan. The Company recognizes stock-based compensation expense for the discount received by participating employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; service providers. During the three months ended March&#160;31, 2020, approximately 78,300 shares in aggregate were issued under the ESPP and SPP. At March&#160;31, 2020, the Company had approximately 1.0&#160;million shares in aggregate reserved for issuance under the ESPP and SPP.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the three months ended March&#160;31, 2020 and 2019, the Company recognized stock-based compensation expense of $7.8&#160;million and $11.0&#160;million, respectively. &lt;/div&gt;&lt;/div&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2020To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2020To03_31_2020_RestrictedStockMemberusgaapAwardTypeAxis">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2020To03_31_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">894718</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn03_31_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_shares">6600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P01_01_2020To03_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P01_01_2020To03_31_2020_TwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">2600000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2020To03_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">78300</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">1000000.0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To03_31_2020"
      decimals="-5"
      unitRef="Unit_USD">7800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To03_31_2019"
      decimals="-5"
      unitRef="Unit_USD">11000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <md:CommonStockRepurchasesTextBlock contextRef="P01_01_2020To03_31_2020">
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common Stock Repurchase Programs:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;In July 2013, the Company&#x2019;s Board of Directors authorized the repurchase of shares of the Company&#x2019;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#x2019;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;time-to-time&lt;/div&gt; based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#x2019;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#x2019;s acquisition program. No shares were purchased under this program during the three months ended March&#160;31, 2020.&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $500.0&#160;million of the Company&#x2019;s common stock in addition to its existing share repurchase program, of which $107.2&#160;million remained available&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for repurchase as of December&#160;31, 2019. Under this share repurchase program, during the three months ended March&#160;31, 2020, &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the Company withheld &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;125,100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;its&lt;/div&gt; common stock to satisfy minimum statutory withholding obligations of $&lt;/div&gt;2.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in connection with the vesting of restricted stock.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </md:CommonStockRepurchasesTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="PAsOn08_31_2018"
      decimals="-5"
      unitRef="Unit_USD">500000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="PAsOn12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">107200000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="P01_01_2020To03_31_2020_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">125100</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="P01_01_2020To03_31_2020_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">2500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2020To03_31_2020">
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;. &lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commitments and Contingencies:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of March&#160;31, 2020 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company&#x2019;s affiliated physicians. The Company&#x2019;s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company&#x2019;s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations, cash flows and the trading price of its securities. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company&#x2019;s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations, cash flows and the trading price of its securities. &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2020To03_31_2020">
&lt;table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Subsequent Event:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May&#160;6, 2020, the Company entered into a securities purchase agreement with an affiliate of North American Partners in Anesthesia (&#x201c;NAPA&#x201d;) to divest of the Company&#x2019;s anesthesiology medical group, and the transaction closed on May&#160;6, 2020. Pursuant to the terms and conditions of the agreement, at the closing of the transaction, the Company received a cash payment&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of $&lt;/div&gt;50.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, subject to certain customary adjustments, as well as a contingent economic interest in NAPA with a value ranging from $0 to $250 million based upon the multiple of invested capital returned to NAPA&#x2019;s owners upon exit of the investment. The Company will begin to receive a payment on its economic interest at an exit multiple of 2.0, with such payment reaching&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;250&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million at an exit multiple of 5.0. In addition, the Company retained the accounts receivable of the anesthesiology medical group, which net of various other working capital items, approximated&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;110.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million at March 31, 2020. Upon completion of a valuation to determine the final net proceeds, the Company anticipates recording a loss on disposal in the range of approximately &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;500.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to $&lt;/div&gt;600.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table represents the major classes of assets and liabilities of the anesthesiology medical group that are included in the accompanying Consolidated Balance Sheets as of March&#160;31, 2020 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 68%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;19&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;147,717&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid expenses and other assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,519&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;900&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;545,272&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60,034&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$768,461&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;54,311&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued professional liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;20,627&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,174&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$80,112&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">50000000.0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <md:MaximumConsiderationReceivable
      contextRef="PAsOn05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">0</md:MaximumConsiderationReceivable>
    <md:MaximumConsiderationReceivable
      contextRef="PAsOn05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">250000000</md:MaximumConsiderationReceivable>
    <md:MaximumConsiderationReceivable
      contextRef="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">250000000</md:MaximumConsiderationReceivable>
    <md:AccountsReceivableRetained
      contextRef="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">110000000.0</md:AccountsReceivableRetained>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="P05_06_2020To05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">500000000.0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="P05_06_2020To05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">600000000.0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="P01_01_2020To03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">&lt;div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table represents the major classes of assets and liabilities of the anesthesiology medical group that are included in the accompanying Consolidated Balance Sheets as of March&#160;31, 2020 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 68%; font-size: 10pt; border-collapse: separate; border-spacing: 0;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;19&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;147,717&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid expenses and other assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,519&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;900&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;545,272&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60,034&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$768,461&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;54,311&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued professional liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;20,627&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="padding: 0px; vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-align: left; text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,174&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$80,112&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&#160;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">19000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">147717000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets
      contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">14519000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1
      contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">545272000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">60034000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">768461000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities
      contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">54311000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities>
    <md:DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities
      contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">20627000</md:DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities
      contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">5174000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"
      decimals="-3"
      unitRef="Unit_USD">80112000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_12788386"
          xlink:label="Fact_12788386"
          xlink:type="locator"/>
        <link:footnote id="FN_48780" xlink:label="FN_48780" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Due to a loss from continuing operations for the three months ended March 31, 2020, no incremental shares are included because the effect would be antidilutive.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_12788386"
          xlink:to="FN_48780"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_12788387"
          xlink:label="Fact_12788387"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_12788387"
          xlink:to="FN_48780"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_12788440"
          xlink:label="Fact_12788440"
          xlink:type="locator"/>
        <link:footnote id="FN_49229" xlink:label="FN_49229" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Presented within retained earnings on the consolidated balance sheet as the balance is immaterial. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_12788440"
          xlink:to="FN_49229"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_12788442"
          xlink:label="Fact_12788442"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_12788442"
          xlink:to="FN_49229"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_12788507"
          xlink:label="Fact_12788507"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_12788507"
          xlink:to="FN_49229"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_12788508"
          xlink:label="Fact_12788508"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_12788508"
          xlink:to="FN_49229"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6641907456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract', window );"><strong>Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12. </div></div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subsequent Event:</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;6, 2020, the Company entered into a securities purchase agreement with an affiliate of North American Partners in Anesthesia (&#8220;NAPA&#8221;) to divest of the Company&#8217;s anesthesiology medical group, and the transaction closed on May&#160;6, 2020. Pursuant to the terms and conditions of the agreement, at the closing of the transaction, the Company received a cash payment<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of $</div>50.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, subject to certain customary adjustments, as well as a contingent economic interest in NAPA with a value ranging from $0 to $250 million based upon the multiple of invested capital returned to NAPA&#8217;s owners upon exit of the investment. The Company will begin to receive a payment on its economic interest at an exit multiple of 2.0, with such payment reaching&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div>250<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million at an exit multiple of 5.0. In addition, the Company retained the accounts receivable of the anesthesiology medical group, which net of various other working capital items, approximated<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div>110.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million at March 31, 2020. Upon completion of a valuation to determine the final net proceeds, the Company anticipates recording a loss on disposal in the range of approximately </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div>500.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to $</div>600.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents the major classes of assets and liabilities of the anesthesiology medical group that are included in the accompanying Consolidated Balance Sheets as of March&#160;31, 2020 (in thousands): </div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 68%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 87%; padding: 0px;">&#160;</td>
<td style="width: 5%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,<br/> 2020 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets </div></div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">147,717</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other assets </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14,519</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">900</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">545,272</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60,034</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$768,461</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities </div></div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">54,311</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional liabilities </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20,627</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5,174</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$80,112</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6630943200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Common and Common Equivalent Shares</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div>. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Common and Common Equivalent Shares:</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock, deferred stock and stock options and is calculated using the treasury stock method. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of shares used in the basic and diluted net income per common share calculation for the three months ended March&#160;31, 2020 and 2019 is as follows (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months&#160;Ended </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common shares outstanding </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82,799 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">86,073 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of dilutive common share equivalents </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; font-size: 10pt; width: 6%; height: 17px; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">472 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common and common<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>equivalent shares outstanding<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;(a)</div> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82,799 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">86,545 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.13in; line-height: normal; text-indent: -0.13in;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Antidilutive securities not included in the diluted<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>net income per common share<br/> calculation </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">849 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">504 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="margin-top: 6pt; margin-bottom: 0px;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(a) </div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Due to a loss from continuing operations for the three months ended March&#160;31, 2020, no incremental shares are included because the effect would be antidilutive.</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6630943200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor;width: 100%;text-align: left;font-family: &quot;Times New Roman&quot;;font-size: 10pt;font-weight: normal;margin-top: 18pt;margin-bottom: 0pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">4. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Fair Value Measurements:</div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px; background: none;"/><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.&#160;Each fair value measurement is reported in one of three levels: </div></div><div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 8%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 &#8211; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. </div></div><div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 8%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 &#8211; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </div></div><div style="text-align: left; text-indent: 0%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 8%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 &#8211; inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at March&#160;31, 2020 and December&#160;31, 2019 (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 60%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 9%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 9%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 9%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair&#160;Value<br/>Category </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,&#160;2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,&#160;2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets: </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6,357 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16,775</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">85,041 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">74,510</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mutual Funds </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11,640 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14,264</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities: </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,288 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2,696</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at March&#160;31, 2020 and December&#160;31, 2019 (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 92%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 62%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, 2020 </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2019 </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying<br/>Amount </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Value </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying<br/>Amount </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Value </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities: </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 Notes </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">750,000</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">611,250</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">750,000</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">766,875</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027 Notes </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,000,000</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">801,200</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,000,000</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,025,600</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the Company&#8217;s line of credit approximates fair value. If the line of credit was measured at fair value, it would be </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">categorized as Level&#160;2 in the fair value hierarchy. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6788174256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember', window );">Unnamed Corporate Joint Venture One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method ownership percentage in joint venture</a></td>
<td class="nump">37.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureTwoMember', window );">Unnamed Corporate Joint Venture Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method ownership percentage in joint venture</a></td>
<td class="nump">49.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6655089520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable, Net</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net consists of the following (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 7%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 7%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,&#160;2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,&#160;2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross accounts receivable </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,840,118 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,943,664 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for contractual adjustments and uncollectibles </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(1,363,127</div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(1,444,795</div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">)</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">476,991 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">498,869 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Net Revenue</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s net revenue by category (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style=" font-size: 0pt; ">
<td style="width:76%;">&#160;</td>
<td style="width:4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width:4%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months&#160;Ended </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net patient service revenue </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;734,387</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;749,585</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hospital contract administrative fees </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">104,595</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">94,721</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenue </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6,936 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6,877 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 76%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">845,918</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">851,183</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Percentage of Net Revenue</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The approximate percentage of net patient service revenue by type of payor was as follows: </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style=" font-size: 0pt; ">
<td style="width:82%;">&#160;</td>
<td style="width:7%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width:7%;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months&#160;Ended </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contracted managed care </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">68</div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">%</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">69</div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">%</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other third-parties </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; width: 82%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Private-pay</div> patients</div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 82%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">100</div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">%</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">100</div></div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; white-space: nowrap;">%</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796572864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (18,712)<span></span>
</td>
<td class="num">$ (242,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="nump">2,602<span></span>
</td>
<td class="nump">284,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">18,673<span></span>
</td>
<td class="nump">20,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of premiums, discounts and issuance costs</a></td>
<td class="nump">1,458<span></span>
</td>
<td class="nump">1,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">8,035<span></span>
</td>
<td class="nump">10,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">33,582<span></span>
</td>
<td class="num">(5,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(1,883)<span></span>
</td>
<td class="nump">2,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">25,904<span></span>
</td>
<td class="num">(15,915)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,101<span></span>
</td>
<td class="nump">4,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">11,189<span></span>
</td>
<td class="nump">9,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(198,452)<span></span>
</td>
<td class="num">(132,559)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(32,883)<span></span>
</td>
<td class="nump">14,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Payments of contingent consideration liabilities</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve', window );">Long-term professional liabilities</a></td>
<td class="nump">6,969<span></span>
</td>
<td class="num">(496)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(7,912)<span></span>
</td>
<td class="num">(11,993)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities &#8211; continuing operations</a></td>
<td class="num">(146,431)<span></span>
</td>
<td class="num">(60,408)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by operating activities - discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,591<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(146,431)<span></span>
</td>
<td class="num">(56,817)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition payments, net of cash acquired</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(4,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(21,042)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities or sales of investments</a></td>
<td class="nump">9,860<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(13,713)<span></span>
</td>
<td class="num">(5,821)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Proceeds from sales of businesses</a></td>
<td class="nump">4,750<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities &#8211; continuing operations</a></td>
<td class="num">(20,220)<span></span>
</td>
<td class="num">(5,271)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash used in investing activities - discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,420)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(20,220)<span></span>
</td>
<td class="num">(8,691)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on credit agreement</a></td>
<td class="nump">515,000<span></span>
</td>
<td class="nump">518,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Payments on credit agreement</a></td>
<td class="num">(146,500)<span></span>
</td>
<td class="num">(866,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from issuance of senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments for credit facility amendment and financing costs</a></td>
<td class="num">(500)<span></span>
</td>
<td class="num">(8,380)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments of contingent consideration liabilities</a></td>
<td class="num">(1,248)<span></span>
</td>
<td class="num">(1,308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payments on finance lease obligations</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">1,832<span></span>
</td>
<td class="nump">2,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(2,542)<span></span>
</td>
<td class="num">(78,982)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash (used in) provided by financing activities&#8212;continuing operations</a></td>
<td class="nump">366,039<span></span>
</td>
<td class="nump">66,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash used in financing activities - discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="nump">366,039<span></span>
</td>
<td class="nump">66,664<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">199,388<span></span>
</td>
<td class="nump">1,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">112,767<span></span>
</td>
<td class="nump">56,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Less cash and cash equivalents of discontinued operations at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,425)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents of continuing operations at end of period</a></td>
<td class="nump">$ 312,155<span></span>
</td>
<td class="nump">$ 46,476<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the entity and the disposal group, cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799750704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 312,155<span></span>
</td>
<td class="nump">$ 112,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">85,041<span></span>
</td>
<td class="nump">74,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">476,991<span></span>
</td>
<td class="nump">498,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">19,409<span></span>
</td>
<td class="nump">21,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="nump">26,449<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">20,851<span></span>
</td>
<td class="nump">23,442<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">940,896<span></span>
</td>
<td class="nump">731,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">100,227<span></span>
</td>
<td class="nump">94,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,710,292<span></span>
</td>
<td class="nump">2,710,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">263,308<span></span>
</td>
<td class="nump">274,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use&#160;assets</a></td>
<td class="nump">79,810<span></span>
</td>
<td class="nump">82,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred income tax assets</a></td>
<td class="nump">132,783<span></span>
</td>
<td class="nump">162,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">92,346<span></span>
</td>
<td class="nump">89,994<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,319,662<span></span>
</td>
<td class="nump">4,145,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">323,363<span></span>
</td>
<td class="nump">511,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">697<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">22,340<span></span>
</td>
<td class="nump">23,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,505<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">346,400<span></span>
</td>
<td class="nump">541,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Line of credit</a></td>
<td class="nump">368,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit', window );">Long-term debt and finance lease liabilities, net</a></td>
<td class="nump">1,733,469<span></span>
</td>
<td class="nump">1,730,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">62,238<span></span>
</td>
<td class="nump">67,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent', window );">Long-term professional liabilities</a></td>
<td class="nump">238,347<span></span>
</td>
<td class="nump">226,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred income tax liabilities</a></td>
<td class="nump">61,975<span></span>
</td>
<td class="nump">57,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">21,337<span></span>
</td>
<td class="nump">22,900<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,832,266<span></span>
</td>
<td class="nump">2,646,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $.01 par value; 1,000 shares authorized; none issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $.01 par value; 200,000 shares authorized; 85,150 and 84,248 shares issued and outstanding, respectively</a></td>
<td class="nump">852<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">995,257<span></span>
</td>
<td class="nump">987,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">491,287<span></span>
</td>
<td class="nump">510,212<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">1,487,396<span></span>
</td>
<td class="nump">1,498,996<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 4,319,662<span></span>
</td>
<td class="nump">$ 4,145,901<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts payable and accrued liabilities excluding accrued income taxes current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt and capital lease obligations excluding long term line of credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31958-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6641907456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Repurchase Programs<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CommonStockRepurchasesTextBlock', window );">Common Stock Repurchase Programs</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div></div>. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Common Stock Repurchase Programs:</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;">In July 2013, the Company&#8217;s Board of Directors authorized the repurchase of shares of the Company&#8217;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#8217;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">time-to-time</div> based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#8217;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#8217;s acquisition program. No shares were purchased under this program during the three months ended March&#160;31, 2020.</div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $500.0&#160;million of the Company&#8217;s common stock in addition to its existing share repurchase program, of which $107.2&#160;million remained available&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for repurchase as of December&#160;31, 2019. Under this share repurchase program, during the three months ended March&#160;31, 2020, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company withheld </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div>125,100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of <div style="letter-spacing: 0px; top: 0px;;display:inline;">its</div> common stock to satisfy minimum statutory withholding obligations of $</div>2.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in connection with the vesting of restricted stock.</div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions. </div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CommonStockRepurchasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of common stock repurchases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CommonStockRepurchasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6641878272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div>. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Discontinued Operations:</div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;10, 2019, the Company entered into a securities purchase agreement with an affiliate of Frazier Healthcare Partners to divest its management services organization, which operated as MedData, and the transaction closed on October&#160;31, 2019. The operating results of the management services service line were reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the three months ended March&#160;31, 2019. Loss from discontinued operations, net of income taxes, as reported in the Company&#8217;s Consolidated Statements of Income for the three months ended March&#160;31, 2019<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> was $284.5&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> which included a loss on classification as held for sale of $321.2&#160;million. </div></div></div><div style="text-align: left;text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 0pt;margin-bottom: 0px;margin-left: 4%;">During the three months ended March&#160;31, 2020, <div style="letter-spacing: 0px; top: 0px;;display:inline;">the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company recorded an incremental loss on the sale of MedData </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">of $3.6&#160;million, primarily related to the finalization of certain transaction related expenses of $5.1&#160;million and a working capital <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">true-up</div> of $0.2&#160;million, partially offset by the completion of its preliminary valuation for the contingent economic consideration<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> which decreased the loss on sale by $1.7&#160;million. </div></div><div style="margin-top: 18pt; margin-bottom: 0px;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>36
<FILENAME>0001193125-20-136311-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-20-136311-xbrl.zip
M4$L#!!0    ( $2#IU"V_])*N L! !8A$0 /    9#@X.#(V-F0Q,'$N:'1M
M[+UI<]M(LB[\_4;<_U"AF3[7CH!D MPMVS=H+=TZUY8TDCRGY_WB* )%$6,0
M8!< +?/KWZP"0((D2''#RIR8EB4LA5J>S'HR*ROKT_]]&5GDB7'7=.S/1^I)
M[8@P6W<,TW[\?.1[@^/.$?F_7_[W__HT].!!>-AV/XZ,ST=#SQM__/#A^?GY
M9,0,F[Z<Z,[H@U;3:K5Z73T*G[1,^]?,LR]];ITX_/&#>.Z#N-VG+HL>%W<-
M<_)"_.'6A^#FY-&%HI_K\EFUV^U^D'<GC[IFTH-0J/KAS^_?[O4A&]%CTW8]
M:NLS=3%7U'W^>8/-5=QE^LFC\_0!;L ;:O>XIAY/>\9TG8:FME=]('AB6OZ8
M,YUZS%CZ3O<#Y3IW+/9A^G#TNN[XML=?DZL8WA35;,]64_<Y!SPL>R^\F] ^
M]J(/DU\2=Q)>L*FIN\EOR%L)E7--/?D%N"$>5^<>]\9\R?-P1[S0F7W!=X\?
M*1U/WAE0MR_[.KR1T(H7:\6(_ODMADK?XRL&$NY.JLV]Q1K Q210O2PK4A6
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MG1! =Z(9/&-V$(J!N$V']1\_>G</%W??_D7N+FYO[A[([8^[^Q^]ZP?R<$.
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MU"' IMT3Y&1*T9&Z_>RZ,#6OF%T1:3LCC5-IBI2"(I>XG^]?1U =%&(4XA3
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MU&9=(=&/]Z=''Y+&,MY9]1--3O8S%3YIM1/J'%X^G9GEY,0SH_(=_>C+@Y
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M:]54()M$$FP62+!)DM"-\F]M258W/IQV7Q7=E^)<JMAF$J82=?P29DS=]M2
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MV'=9",B ?*(W$WT4%9P6)@+U3<C3G:CRS>"'&\P,F7#,=E?I5.%T!/1OHNY
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MD:S-:_>%3S^;AC>$D?[ME$1CK+;$(,3P?$C*/M$7M2.A.X]!=3H)7#/O9O!
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MQ=TLI<G%BM*)TIF[=*[V+^XBG2VEUEYT_)=&.BMBG"-;.N0E6=3(A=#(\0W
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MM'O&O_TP[>>#LR1D1'JW^_.A*'?L+]]T38_=,_YDZBSPA-\QW7FT92DRC*6
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MH[=M':[>0JI>")E'\49*@[A&7*^)ZUWVHLU(PY[*0=<N"E=EA LG#<0UXKH
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M5574,F^Q0$%%02V&H*;,I[I*LW.H? J94FY+?F/Z*M?[9!Y"7>?B@(.)^^K
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M;\QU5[C4@(LMVTX G(W!*\C64.]GHO=!DX\=EUJ_@U(9K];OR5-$@M+/9MM
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MR&^ W(!J)B(B6)G125 EH7X#8AYCD1-&Y\0<H!%##.17R*9+OC/CG'I4D83
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M[,C:D?6ND/68?N7(>I_*YI_:#&IV,=7:^Z&Y5E3KJY7>GXYD#@UV%0V<E_]
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MH;F:-;Y["N%)PBB4][00G.YX7F22SG5O$:(B[7Y?1NH\T76Y05W7W.O0NM=
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MXW-$S6S8KC?LCV38"0,<2UHU 6G1]YKK[BX[:Z[F70(B_Y6D83;2,R;&-ZP
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M >WN^0U=E;2KDG9!EY44?@V#$;7LHHF .#]66!GO^\"@=SD&XRJF=PCE5UX
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MDB&-C_P8QJ!UAT&$B,\:-_WFJY!YE-%/"GUZ1B[PXJ&:\^<-'6U5WN.X")X
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MXXKI# $\H;/.^*U*M:>$LFX(K\]H'I/AMLBZ"\9J!ATN-'>*-L+V:(J3W\Q
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MA&>V##ML59!T'N91#.KG3 V#,;H*R]HF7L#:U;^1?P-PW8$_M'530$'8CA&
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M]&JI0M?5BVZ.35F$BIU-^=0V95 7MF_F&-1&I5.MP<=Y P&U.B+*XWIP,K>
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MR8%4DW(FGZQ%<5,:,&<9-X! EXD_E1@)1A4DQ&2*'VP?$H42,S).V9\1 3K
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M&EK:5:9# >0\92\O-LK&IC#*YZ[P#,H[F)7WI+!%9F4^Y]?0,;7+),YGQJ&
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M:'1M['W[<]K(EO#O5/$_=,WNG<^N(AX_XKPW53*6;68P> $GD]W:'X1HC&Y
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M4; I"-$14"_\$HAAE]M$L=^C !E]1LXUG[<%4?^?\*PZ7L%?<+FP*'@4Q@@
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M(I'6N39ELA&?_-RL P^NP4],CK14S(YO 79FQ392)87IG-CHZA9O4&V',-R
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M@=:^:+3)=%."ZD%0R59")6:M!*XKL]7J?FM^,<JVXJN";*:77JDVEGGV94Q
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M#^.Y#B-%W'Z>L!WEZ*@VS3[<T'E5]WQLQXK6N*9U%\QR7 3P&'ZI,1^+8XN
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M+8+;#L;EV?Y2EQZS#K*<2&5BHM'[W1L]JW]!SOXV U9%XBU*LT(FC40TUM!
M1@'91;7L(>&7]/YSX13T9*'CF>>D5>U,&!Q21=8 _<^Z%_4V2!QD+XC(B)1V
M5;XYCI=P*W2,F1E(P].6BG$/BYY5XII<#INS&H$X29%(5?:,_$0@*CGJ2Q"F
MU$>5[Q"G0J0K1%4KPAJO>7?59JG<NJQ+IYQZHJ893EXC-XPK;>&PF:FPCHJ2
MHV-M"8$^>"S?B1+KN[4D1-9-N8]U@WWB[HG3.="@22Z!2-N:M',JCS7% =2T
M\$ ,M '9#]X$73*.3Q@D=>#'PCF/;D3AJA"KK.F!#2$&_0&/=B;B?/6 TE0
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M6AI(-D>1.H3*GJK_WEUL?%514"D$3X<]Q-G825X/HEBU(M:BR3PB$T9V/4U
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MPR\N1[,XS".Q>Z:FH%*D2UHUZTM0AZ(/L#L'68"IQ?'RPNZ=D.+4Y*I210J
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MMOAZ^\;V/O;%>.3ZVW,3=2_O \;O>'BKIT>^/#V[5^.F#E7MD3L+<DK\NHT
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M\(?_#/C#;RH H9ND[(\^\MV$=@*H$U73"N!.+28O$^YJZSQ='DFHA!N^O^&
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M;0K!6J'J_2S@R*\=!XG[-6Y\#OK7*\A4J1PWQR#<>=)S.U(YJSKU/J;B!%8
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M)LJ><YXU)C6 IW(>,4]+"F[4@V;J"2#OW\+>:R?JTWTR$O_O.Z)26_S_V"J
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M--R&G&+@',.>J4;/.T$3IDRMD%W!)GCVS3M1H"=3#!@VPIP">< TE))0XXC
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M-?D [H6?NKNLTD.<=$;8D]S+#L[NG8Y'KR,NWHY1@K&4B6H+?QZI88B]!P'
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MICB+/+\)=,,!%8JT0_RD0"2S,4VB381%HG<L8"4!!'@(\U04, -';YM_+"J
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M"VQGA+U";BD.9N&,F:^L\FM*H[ "F"#;/<FD3!YG^U#<@!,5C')OB@3VW9,
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M1(=]T@-DT78WG;ZWW1P]^_:PT8B,C>RPHA(6@X,>@Q)@W&^5=)&ES ^0(47
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M! .U&OGNYU:EF>#WM@5<6RV/'T#.>IYCBE%.RB!,F7JY*H/-O]N"N[%IOK=
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M:.T69U/FJZ/'^>U>C_-=X9R4>2'GM&')_L-[GY^CL/5# <5WS57DDQ_*Y;+
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M$YMP#&0>,PZ3X.!BWLB4YQ^Z#1CT;V!%>W2E[R[I?Y&V _51]K@'F/6G9P>
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MW+1\=./#)<5ICA=3S&_1\K,^>OSVX,R*Z_99X'(/A.7I]I=N,C:Y9,(2:UO
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M@I*U!QS8@_"B=M;"F4^ O6#R"MG>M)I64/_]YBB6#M'/?IJ<-S4 ^&C+G"]
MJ[G@!OF'$@3=!Q+ZO;,S!1218U>?:*3!?C)YC$ 1>)G?4.(6PXJADW-(N?+Y
M*3 :9CYI+1@?^/<:=+\ M8(NG]]<!]P3^2S!KU1B_@J44*^*5;V1XB#*/(IH
M!7SN,E^0=0?=%5.SGJ&O2.2 0F^=]RVE1[\/O]Q/,ZPEW9>_H$<_+[Z#='R
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MGS4&7LQZWC0WYB_\:UIN;MW6\X\).^Z]T?&(;;H!#'$L3_PDM*;,2_N)$B%
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MT!EQ"1(>(//*;LJ\;-ST 49V7I@<*(D(!E_4KBT:G=S9+:UUV:Z*G+H^0&,
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MLXP\"9,500G9/<!P$#S!>/1"_"WW#+"/KUD_:,<%SX^_/W[KWNC)DY/CTU$
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M-QA ZC46@PWC/8<M#9-SDZ/F_=&I0AF8.L,U.[81=,)98 9%>IDCY!MV)."
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MFZ2^_,?82-6Y?[?10YN93R9^<.6+.!%KV^>U>[K'S4F32-"(*V)*E%'#03>
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M&$.@((WTS<Z0\D>$\\E"*%UDGF,Q]) _>I@Z**>8YQMN>->?5#$\S/9," )
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M^?0=_8)/Z"C^^ 64O]SGR+7:X'J:3+=7$@*6^3^HE.!S;F>*KDI>5\?)4P%
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M;YXOLV*:>AH"6@T28AUE:P2IP9,2T#I(3:D]X(Q:+>EIIZ8"2^>?^?02W]:
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MMOTJ'VD8:0/'A66;5D?A]O:K**_!.1 $4%CNR%R')6S.T&=F)-)U+FZS 4'
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M:+)CKY &137U!%K3S[YG*0FWX-0O R1"!$+((!$Y&# .0-J3J<B#!0Q]3IF
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M4':&VCUAO-2\NZ*%@3/*+)M!NSU,=K7E357>*G9C-BNJ=H!F.RZI46JZ6U1
M4$P-C"O&OFJ47')/-@8-O,>AAJ$@,IC?<<\0@1Q;V4UJUU86W\VV"MN[JK;7
M@4&YL:*C5K.(\Y_0#1YJ0*?")=9$<2:1*,T%7YC'I'(3EU<G0H91S.^ZBBX%
MK4O(DKBJ=6G#682D8'(JH8:[8BZA2/:Y)S/[]+EDW0@\MX%T%*8#_DMGKIU=
M2X.'0M\RTS*KW9J.K_T]K;31&/GY-RPTR<,+W7<15PXU33U;MFXV+X>+?;M#
M]*L-E$A0 T,@9-M\.IY;[ FL.I*'I_D9-L[D:,?,$DPYX#:O 2?Y7YK.+J,-
MX$])Z<Y%NZ2* 0F=XE;D(C3\B)0)K'T/0.P>$C^@:2"4]Z D6"R(' /S.EYW
M(GP2SSH%90U&]:"Y$-I9LH-3;+2OB9@(Z?+M$L0\/;3U+6PC,2_JG,/CVF@-
MFSY"0TV66\Q_CF3 \,MI<06# BY@=V30!PN)F%2ZV:VG907_F30=M25?HRH)
M5KBK3O4YU!%P]L]-LSL:N@:B.L.Y5!BJ9T._1K)-,?]:,<0+#9Q*(C4:O:J
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M^C;\7F99SMZ5'LR696)"=<FG:PO.WR\+ZDCZ$>73'@V;_>,M,??D)D$4'/0
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M#Q9#T.\Y[/T].VX,PY&TE!D8P8BMAW9*E2X">PT'[I/FIFRU0+P&>7:/@G?
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M7XKC0KF>'-NLH$T9O"6C. 1&IO@5!R\-6!N8IM]\%*[Q<-+> 1.9(U:YE/4
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M%VQ"T3NTU*8A*PQMG>ZNG@K"1J'Q A/#MS '5W>JS.C$ 8B"H]S/+]VE-3A
M7="'3KK<Q234+Y-<ER\8HU "DQ887YUH"7+N)[R IV&F F2=\+L 2(,F# I)
MKN-A;2\:?5QB5AW6#LX(3WDC!!!BPM==ESX77147NA&"6_!$PHE&\&^$2?N;
M>3DWZO],TXK<R]_,4T##V)H9-6]N#.7A-1>U6\'N%0!+ :!O*J8YF'+CS3U3
M@\P6Q-22&1[U+/5>RB_IS$!U>_YT_#+N>U,AZ_<N '5QNH?<WY.7,"L#L41Y
M 9^\SI+@<XM^L,P^@&N8+(A.<H;\:!,=/__"(CCI-\I[1C\NK]T9KG_$32?^
M*_W*Q3<?]2=29I[(EXO0E@PVS\C5%^[.K!-/OX&O7RVOLF4'%H-^-\>7@VH9
MS-1&XVZ1_%F&-2V+^9/BMB!ZG;G[!C;^V(0GCU'H1_AG9DPR#UBZ\!RT5)S3
M=%4M@1@,TFT^ZD/J$) @!B^ O@/<%Q]AR/KJRZ*=$\N\M$_(TL#_=I4S_X7V
MA(!"XT7CQO#PKOVNZS0J[#W?%?8>5V'O06A<X-O9_A[?EUX*OI/9#/Z\E!'1
M&Y<-QF\MPYPE1 OSL@>$^>9^G1=GVKH$S3@?EM> X',GQO]Y_9(Z+++S/DML
MNH>)7:B.KI%K*JX(.L&8XI .&SA+/]P6UT&O;!#9%!;I9K3_%/4,(\T.")I'
M=]9$L/L#CY*?2]*^ZHY2-M=]3K/'P0QX^1_LX^K3AWI4/02_A+%(^D=PI"ML
MZYH".(K-7I=3/,E>E<@= 0A'+OR\;%HW%++VOF-W^//'$W*DSJO%O,Q.3^4.
MKYKI],GK%FH\/T/OTX>%&R^\><P<2^N-F]86TMD+7DIPM8-%<T%$>R8F0VHK
M?%'NC5\MYZ1GN3 L'OB\/)\_'7XXS#ZXF0 'UD#7W+J#W:1"0VY!RXQ)G!B\
M"AQG_XU2!C]NLQN7[CW8<E+<Q#*\BL43#6\.GB?R*DX6V,BQD-#0_7 !,4E=
M>@K/>7&KB9 /"^XQ!#OR2]-^E%9,_OM/=057PH]%*[^3K_8^!\0X %L#(_+W
M!S_A_T#K^=4S8ST_B^T\)><=E;.!5J4A*O83YPNBXAHW6ZNDC%\7^WMH>,",
MY-Y\R 64\007-_&V=+8!J!!Z?--EE*W>++EW\F=D/P:V290V4B,7;QU9ZQK*
MD+:1$A%6M1>Z(6!K_UX#%\]U(W&6!@#[*B\ ?5$J'AY>4U*A_4N.*!U(3<MV
MFA7*1HT<$"JP']Q!CE!:YKIP^HC;//B6-[+V103-5_0F(.C$W;WI=/BY#I@<
M<SO;2./7FZQ1YLZ*GI')K(WIVY 5MN,P&UCRGDPT^^Z'EV#^]_=\E@"[I,./
M?JY%+8H\9U91(VF;";\/'S-P?;#R=UI0ZRTFF//$^["M $84@7@/G5_67V10
MS0OTB8-ONI_K)G.. ,2EQE?B)H;H&2>Z]O0"Z;77GZ_AI9><LOLM'D3JK%X]
M/[,RZ-Q%G(L  Z]!9XY=#IWT<S;-U+M)G.8220IDKF2M"+Z,>%F]:HE,HNEP
MI5[N"B369#WC9B9/A>XA/>"1Q>B58C9<.8?;<?1RK(O!Q?'9^>G+-R?9?_UM
MW+KGA?_Y_J?CL^.WY[] A/#@V.&'9>$\>GIXM+;W #+C3!]YM\T\G-#3WS+,
MQ?UE*20+DK$/A(D'<L3?02#C A7H"H3_0M 9X6;ZGT,#V7":>'^/4W^A',,B
M_!$C$DPV6RLWK=H2@P!TKZ276KE%V,*JPKQ1TCV!>RL-R,O4".)AAV3[YJ)6
MN]!H<0\7*7F&J=<"ZXBI6>Q,%/M7NK?>5.ZYK%7-  FQ8OW0?[DC8,&_[YQ1
M;O%3F@'HJ#Q=74'E!+V?II7FB,R%H"P!X&+:DB6/L>4342YN)J\72D-Y>UG6
MI-@I;/!(0WA50,H:JC'C.TJMSI6^*$AT"W4VS#LP4@[06#J'B?FBD9M87@:L
MZ[$[+5"%2].TED)=_",W1!H^]W G5"0'WKN?^WC282HJI@L#C6_V*OV0D+)G
MHR61KU@.HFP>UH-Q!Z.RQK2\0D6-,$U@9U7)A)3<J L[VU'<O/4[)UG&Y?*)
M(5P4L"I31-!+B8A+@Y=H+7"LTD7T-,> M7+C_"\PT)1:4K(VN+XS@C#SO/ID
MR4(=@<<"M#QPFULW01(/VG<BV2=PC9@[9N#>A-NY:KH%HG_;\A(LAYN.#NFA
MR#HAX65'5" RW<7TAC6_X;9='DJ=N0]9SH$>RY0I_8#[.6/*NU6[(U?F@F1-
M*JR[P]T&]$V:U":P<G$Y5^'!RP16_=L<<XE>5!?@EKE?3E F0F]\ZNW#C7.E
MZX4;\/R.LHGF%[EJ(K-X+ZPM'/6\^N]E-<6$#^Y$_W-NP<V\F>5G?]>FQ872
MVZ*P#NAP +<>MBO\%[O=X>L(>(!!+*ONDDGV%_JX^WON25OB(,)'H<?. V6,
M0!S,[35X^7,T797;WTM\N>[+8K%)+!F^W?5&S_)[=V1C^\_"=VBLS#$9P&Q<
MR/[&^-<%#4N*+GP(P?UQ:V<,:Z,#M_$1X;(N 0TP*>%IM]'+>MNG[/'9T1YO
MC^?68H&/F+%GD(DWUH\+)$2(2MF<812L 91Q^J\EPCXTCG8[T3T1[R'S\E3'
MAXX1 QG*<;6&@6B.J+"E!PB9!#"'M% NI?2YBX$#TK!96RRGRWE)9&,WY1W)
M'<+)PQFC#K'1=?R<JCY&&;+07UJ:,!4WX%5EZ"*OBE^Q/,T8@X#:L2,R.O8/
M CW,[$ VBCQ,(]EB?S(,SI&<]NWR>C&!N'A:/CB<:=?_V2L3?[$K$S^N,O%#
M<QP</3U\MC;/X#?V5A,;'$]]K#080Z\+9$W(FHYI*5O)"L-!,#D<B/1@O *?
M,]HYPTF.R$&"R+)I-;#D"$HOK:S\K'//*&.Y/!\ )S<2SFP49 X^F-2YDP&<
MPIVI9U&;5*QBD.&\23X]$17W8D^@TREN9\NYBY?J\FX@;7V27@,":Q=B/"P+
MI_$. ? Z=FN@$^UCB4R*JCA=!*6Z"#'(+AG5PU:&ZH;I+1$DF=FAL-H,P$I3
MX/T*+'P0W+/JJ(OIOY<E+FUVP22L<:99-2>L;P3+K2W=1=T/%:I&!-Q)$#4#
MHKTDF4TH=(?Z%= \ "!*?N2!224OI0SJ$(,?A7E>=FZ?YI*&B\#Q5+WUF9:Q
M7_RHA)7R#0GKV.#:PE#,/<0"=QEZF#EVH]716I%:JP'U8\\&O9(\\AQIZ]I7
M4@N&E>1+M'5,_4=GG(C!F#B"G.^ZI#P"YLC0;29L"U5!0&[>#0GF6Y;%94%I
M"U3>A)#YH<^'1Y"^?[[V6'T+.456@RH2>LQ;%E]"DBM@5TUDBI?2MEN",@LF
MKR@X\?WZ0M6': ! ##=&NR](O5V&*D/[>ZM.5#DDF3/=9QZ6=I"Y,1 7.G+W
M?_QI8SJ$O,=_61LV_2PDHCVJ17*"YLJ9/4Z#0$\8]II@*0%+_R0%%/*-RI85
M6)$U@*E! H)\/#*_9PMA-:5U6O.@ 0+X&3@6#5ESPZEI9CVK6JB@X:8>#PUT
M,N(CZ4Y4J"CKX,D>18O*-$WZ-='V"/] <I0FM9.*>1[@I2E+ABDS/.!:HJQW
MTW2)RJ$5:C9UD,*<QZX4W:$,QTS]W1MFV5>>W2)2/;S&Z6P?OI/I).@40I.^
M%YY'X8ZY7K;=LB"A">>?(:TF[MXZ.B_AA&W:BZ)FF'W0 ) #QP>(7E9N&>F"
M@^P=GH+SJIP9>(CI"9+DO?'+5-F2\4/:T@>N!V<\ G7/AF1Y;5[&[\BQ)I L
M.Z@?RS;:\#"R_&+M$7AJ#+=?F8\ERGPP29!4(C!U$ )Z*#K[$GE$;UV_MW8W
M-$48(EH:&#%OTOG#N?@QHJ\74CKM^#04;==HJ%%HR5=UY[=>AK^'1GG-(%/9
M_ V>#6X'H;:7>3"2%^8)MW&U13[K>N%7Y@;]G_X^W3)+-Q#Z;R#-DP>2/GI>
M#>1F.-?NUGI%D1]E*/;W#EAE'6 -/I+CJ'C<*U.(SL^DJ"E2H]-P.N(B&=^'
MO$OVWLB]Q#+L(NF5YHE2H_LON*(NE"\IWN6$3\XPF=PX3(JC\#UI1)9,SA,B
M:^&:LT;;%*$ E ]_.B'RF/ =4YF+E&KD,%+H6JK)A268LL5N@D![A] [AS2Z
MEK,0FK^AD3CO!PEG,/'C[GC9S-W+]M$,S#=<.C!WL?\LB3&31\2'^=ZXNBMG
M"%?EKS2QH&]*20!<,9D1!O?65 :8DQ..Z-G@#_@UACGA&=5R[LFMYIIQY\7<
M-PX3L'H@\1>+QU.S;-4:/A(\K[1PCM\ 9UY%I5I,5+&4*<Z?H0ITEW6;&2O6
M?F_GO8210>>XOS_\^;$K=T7EKA>[<M>NW!4%)1O)M*/6VC:'(:>B&KV_5Y?0
M>@Z8#CE6?F-> E&ZZ*@((K=4M@M,7RLY?6QP\> @(3T H^%I@I;YJ@3][8Y(
MY6H9 9%]%.K/7"];5))@0;?)@K08.B;-\]U%0A71/QA)QDU18)1<8FD^K8PQ
M46@Y#<AE*#U SZ8>FQ%W5:]J&]WI<(^NT7ES>_1G<$7:Q[)#'S'/?C]$Z67!
M?E,D@<@Y#B5@5_$7?WOI$0.):B0)-<T4Q&F+9+J]E\9&II?X4@B&O"R6E'_P
MKNIE.9]ZA'WB9OM[J^_6".T*YD!+\P'L2[H3=I=5<IAVHK0RL&K"]$/77+ H
M%ET#L(+!.K59"9 "!1#PF+"?E!=A#"[$A9(WE\_UTN^;O0C^-[:P27"B^DMK
MHK8#\UV/I,7\UU5M<K;^*Z-\'6QMPT?'2,3%%J:(\6G+D,\P T<,+GBOB%5#
M0:H=R[7QL"8NE^ #<H^@%!,>L*EWL[^WR<LAB'HR5G-Q&"H1PSE;,J(=*1K*
MR;R!8=6)S;<&MJ\L>^,P;D,$:$6)?.>WZX\06?;1QR5"CPNE!_#!+ 2B50?$
M8%=7<("S1KLV'1PD5!KY2Z&$=@BQ'#'^FGT"8Q6H^U3-P\IG]^830EP4(4[9
MQJ'U9R<[3^9]]O=,XH?>SBT7=WKJEZFL-!\G?1SOX/+&AT#P ,(XQ")H_ZDA
MN/(?E3)<.;V/@>L;-8;8RMI<N_:T,<3WND"7: 83><'D'WHQ4CDGM!/-:@C!
M-\>PNVA;5E=C=V0H-4FW'+>-!W:D5TLB"[G9>L!W;=?#-GJ>:SE;UZPMMTZ9
MN)3QZY2@)?XW0Z&,)%YN)7"#,B5T@9QLS1'%'X01.),67%"2PC.Y=/!I=UY=
M-C5@$LPO#2E8G!3,[;CD@<M?@2H1[X8ACZ]Y+]N6><WK$L%,A<(C5QP3,)D6
MSEYT0!'3<5<7RZ4SU1L@$HA4U8WK8UE><R:ZG,^8F1'.Z_ 04R?(\QLJ_)#"
M.Z0-I6=M9M1[1[B&JITLK[H%(?3'98&/IS&=,QL?Y1W8K.J:)"I\H$:<CWO3
MW<29 \ZM+LP5X-I2C0_Q)'Y^"(*_;#N;?;?JN\C.6E8+:=-)VJ\Z/$",CCW:
MR"7SD4QOX'R*AM+(K-,J +:BFI4.O5(]?B><2C R^(1;:5W6L9L.6)>P%==-
M,;*1H-=BW0?/1F!/"EI)%5%1% NR\5A(\443>NG0CNBV'9!(]&H$V@]"/3V3
MQ;*8,\!')7=>//U&H;% ,!&U@(2%&N7&G\R+RI=I-LH9K3_1+NQ"7:QJV^P[
MOK=&>7PSO,N!US69,P,F]V;^;?GW=SB@]T0Y 3D*I>R1CLI@2BFH;MH[ZA%4
M@*A_N8%?D-.WJ_'26V,,@;@\1*_;C^$N7@_9)RV'I8NXYC0E^%UFOAF<9&-;
M?@?/CO='B+1&%FQJR(_W"'7R"Y8UBL;7X: V7J7.)-)C-.R<:SMAX*9'[X?"
M1ZDYK5C5!:D4:R1X[X4N^4U+0QXP*A$H/Q '":.S)N!)!?KB>C6SN 'C_T6
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M1HQ6QFK'S7KM^(:6MLN"RLDKFF!KGV@;6E9_T/G8:34&G=XUN_F]?_M[XWK
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M?7 CDC,<#K^/,T.I=37Y-&RWKHQ.OUTNM2:#R=!H&U]JIXVCD]:Q?L3VXW0
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M',VL%G@@,V.VS-U3X>=2X?T;I,)D#3:__M)X_^%<IEA/\U$Z5@/'$?BH\#0
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MDITP(B$YD!1?$W]"Q(;J+O<Q9:V&KLJ"U->Q]BNET1O"SQRLFXIE,8"KCF;
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M&0?S.1V=S"*_)-;AJ>506S&$W%H[/DT:!W:+ _+2F5.4"8\[M&$^2.L(7CF
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MS5$$]%#Q;F:)6$C0$J"W]"[1"S?T ;4]*9L.+@<I6NRN@][AH&3%7;K#83J
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MU524-0%ZJN1X5Q8ER&HN,6T?07'0<ZS-ZK+#YJ*,HZO\B."99?M+8</SRVX
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M9^5UG=/][Q1[R\Q;G"?QU2)9B$HO5R6<:,+.VF9PXQ,\='D1,[_E<M+@B29
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M(H M+'LEA$WTEN+@YNVL0O3T5. G8@K#R@ 9NLXP# :NLPI P^;;3RY&75-
M&G0CM8TQP^ZQ.<M^;,/PNV<#D!F$^S%> *%^TV[*N^#]B P2],?RVR%?H@D$
M_E9:'-M KE<"U! 4@!JT!@6:H,Y51JR+;!F G;XX+"-Z!S(!+I!F4"ZD99(;
M_LQG,^$LEH[E<E@O#1&"69%%M-ZSGN473B,LQDD1V\43G,78+CGL@ 5K(8,+
M#Q,1L&5H0WB=581SR&^M@+ &^/7','ALX ^U"N'E1M@\M;4K<J>E\/[HI4IJ
M35F8IJDA&=@G: :Z7?UXI+;/_<&E/EBOHQD+O.A)/ +&('<7,4U.1Q-;+YE
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M!=7![']9 4XY35JA+0SS&4K:M: -Q'B,29XFVV&$(9J.3B.=Y81J,<9\4VN
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M)LE86;KW^R2F><A3U!29F9^G5$W@F@0=L"C*#'20 ELY0&%CLU0.<. +7#G
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M[EQ\[SQ8:V=8!I+QJ)G4CZ33WW$^]=,;!\0X 6Y$C%;56KD@MBG<\*K<K0
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M 6"2V@:O7H<QN[#[/$$H=SOI\_<EP=G%Y=$E@+6Z09.5':JLPU <'P"'K;9
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M#-^V"2HSZ.L6=8DV;>QM@'?/.=>*LABC_.T;H7(#=N>[,5Q?2ZIX07U_LH>
M2SL(1=_")!RS5\6)]FJ ID)P= Y\ZN[*QM:&TH@.U)7G9YRO'CXR.H<VBP9@
MWB _#.MQ[8$3\&6"230(23[GYKJ18&EY*@W@2W9^6-:  [WHXVF7@&*V)S-2
MO%:.H@>^:>>'6@FH/7#OJ613V;DO8F1620!TGF$_#5,B.G/&WJII[R(.4&>B
MQ) ;("H0RLS8UI4C-^^<FZ&##]@AZ(/-+4.PIAQZ["ADPN&9>@H4/<[*)#W9
M511A@>8^&:5DRC^%\0(J.IA$]!>S- OC+R0M9C:Q\(XML4/#PS. 4/FZ^6I.
MSBZ.H<.BZLI8L=[+ 4*EL)',O[?E%[Z$[R+;GL*OIBK*,74L9^]"S%NSHQX!
M5.89&U:4#BQU88$+R%=E%+:9FPT4/4\A4YT]>*(<\5@O8\.03T9?DU]D.^G6
M(WKR\><*J.>99M0HS2EG3'6%C.!72BL>G;5@ V._']&2VQ._H3BB9BG%;PX]
MM6Q!R MX(;9G5:D53EC[_;A6T\PI?)Z%#HQSF?HU&/K]1-::WC^DN52/OU#]
M_YIFV6.R*&Z[!MBW&)R>GYR!GVBK:;98#&J W8,(N?MDF$X1P\?"O.3SX /*
M'T?ZT#B79O@L>M0W7:F%$#2-CRQ!&@F3+!P*AU_,+C*7D4&*K;>Z?'!V<7)X
MU)7T6282[:#X2MGC,<K]]Y3\@9/Q3<@O8[R0 GV?R:F2E:3(3B\O@/W-+B1I
M0;2606>'8:5E9IBK)**?4'A+)=P.]%<6A7$GE]W)%OT)8QO7L:96<'P&<#U[
M0[KVN1/6*]#. _L^C)*5+V,Z.'L0P5D.E><P#@E&=EER)!6H/("]'/7I5<(!
MC;F4K&UE7RE2VFY,S2:.]AHE:(1S#76V52EJ8"/3D40W8'MP+?I;&,^8,/"0
M&];+ET^&\U)<WY.(&=ITPD*1>2S7:8[*$MB(K3G2ZX/MVO7J4N=-[][83 B6
M;5 Y +NO:L\,3@CW($+SGJHOI2BWMM?D%8)CZ+";FL-<!V</HC+Y7?-2M2OY
M-\TTZRM2^0"'UM>DVP;6'D1N*O>X3CK@T J5'' DOI_]FAFC+Y\T8/([I>>C
M0]%U+;A#+H^/EJ]-]"!JCO>WR[9S*4_#D> ZF'\^\K9Z=8O+I%O'O N:#)PJ
MH?RU'WEC4CCJRFF DB,YMQHX_8[0:QJ,P:70E;<3G$;I-@:HT#N)4^(^&1(4
M9N@6B;_ODPW7*G/+I4FA/#IU:" X.S\$=SAK:-GR1=3!YLD7 ?/>P4TZG5(V
MDDC\</=G@=_"F-UPF5#A5@[O;L)X6,1EJAWQR^\9BNZ3ZS##0Q[.'Q<Y8AEE
M1$#! !%>#,:*O0M)@I-QMNB%A0FKJA*<+AVI.P3P.\+C"97G%=6+<(P>"A:F
MMY#\8Y%G>9BP%$5<_!I43NU0J,!FD9X$^;Q; Z(G:[AN/(2W""?QF'@8B]$K
M$%_E.<&O1<YSYJ7\,XJ<'[WP-RT)"9.Q>(1<'_?4L/'@%-HS64>9?.'>@SPP
MBG%53O1;P\M]$E*U1"4(;/=YG(;T(-MZT6&7+L\DQQ$#B=_0,QH6A+ON[MY9
M#CT4B1Q[TUF1E[;#EFBGS#6F<X;Z:)]*&]A-6D>E/$+WM .!L5+YYIC.S+1%
M*HE!+'+$\D\'!1E.Z$PL/NR.&W5UQ9S:SI0DE&1A)43S)LWRC)/T6EE&;.\L
MUV^817A#)C)<K9S5OE>7S^OY]NKZ(R21?7K#AM\1G$('EOJ@6.&B\"ND/8BK
M8_,&>WS:X$RN%J,"AG9I^*51KBO;D/? IEV ,GJ9UPM2_- 1=UMLZ%FK]KMK
MN08?<()RA!+^]_P9OS^DR=^*,,8CC**[Z2Q.YPAMK>ZZ9(1-6J1C #C+F8RS
M+==D<XA="X][^9&^3-(B"UFZ_Q''5H'DQ'^MIJA4@'.@61'? !MHF)PL('+*
M[7Z>B"EC;OFH NZ.;9]-1+NT0&4 ?97!AE]W2*#A<=[F<PK8XPRPVSY0'J"O
M4;2W9C03RCX$\7'[F'Z+85.P5HY2 )TT9A>[ @GF/;@L7E]@*WDDD?7FHHVO
MHZ0!>S@EJJ'P0K0&'_1:NJ>3Z^JT_,BA&#/:*.L$9P? >YOVN);KED$4OF["
MP[[]E.4$L]ST'*11.Z3EJ3B -S^[U@R-&%J[@%]?*ZR>U'UBHM(\E+S\/9V-
MH3-:M&F<2+ J*.W\*\D<AG)(;Y2@4('B=2025U!2[:F"%,BKO5:D? O?\;28
M:FE9*T.5%/")ZBVY;U,CZ:V"G%X]:6*<6U13RU>;&.7&C5-!0P<T[V*/Z$M0
M"HWLU37?VK)8#V.\>@MQS.3^.25?:%U=A$!;7TE)@38B/"F69[6UDIM"F7MU
MJ;FVA/@??Z<&.$[& T1P&AVVH<"2KZ'"A[[IU4VE5<I*H:B]\N"NHF/T4GG=
ME,K=^PR+Q!-")B8M]?$=P>DE]-VU]E74GZ 4^MD_?W,=D2Q/70@>BN@P%J+.
MSV/$0S5M**SQ2RDQT'9M-S784G(*E>Z5W[J"K;2#BGR2$OP/I)M$-;6H:( /
M--I5*B-T1;A=KWS5(G([RPH4W19D:6H(P,H3:/U-X5HM4I%V_22DV1351"P*
M3>M5(&]E.)59=@7V)THV>4,1W8U]+O*"(":D,!GJ8LF=VZ)B[/IIBJ^YRD4@
M"KWJ5<3P5<P;+V]P;4FXS."CBQ*Q:H *##I\I%4-<I&"0FUZE0&TMC39%?Q\
M?I]D.2FX&Y9G3GN9A(DXS<ZX3RF[M]R@[J ++)W" ?2=F8YZ6>J*4C$$&F4,
MV5DZ";Y./*'9<O.3CDDX[=+M/$&+35*(M8+!V;'3[3E)K&Q%0JH;;9)2](N!
M[Y_(!+$^5I3=WH-;8GQP;VFT*0&9LE)P=@(T72I)TLQ[&@A[<"-,#M$NA%-1
MC<JF"^XP#6\N;%<Q[4%J]GK!W6?'0-:YXX"5]!KTVM<_P[,7D8EGQ\#GD!+5
MJ&GLUH:_!VG;/07?GG9]NU2;8[E.:<2P!\G>ERD&A97,1)HF3(BV*6IE]>B*
M"W3^X6HDFE'LP:6P#7#&141:GHH1.H3*3):<90V>?;@ 5KQFZ,^"R>6-_F%A
M'RIJ!">'1V )!5P'K@&"I]M44/F'M]&9+3]5'2$3Z#,> U_6+&]@\G4IRD=Z
MXHK^?M7$9"M*4FT'NI=M.?2T_>[@-:1Z!_[;GH=E:(/(2:>-_K1K@:Y5G9AE
M-SC4G,[;8NK@U25/:O"$V+R#D_$*^:I,7<VP:30X/3VADTS/]<4):0?O6M7S
M^V2#$+, @Y?P_7><3R9IS-*GT@_D>UB37\>Q.3HD@4Y>ZJA-;8#[</EKD0BQ
M3)/XDC;7F+I-4J$"[?-J:$TSD*U=TMI%7MEUT[A#!]0;/;-)#*NJ$IQ=7*[6
M/L -F"F!JZ2XZ#MT&+!)L';[KC4\^W F[LUEPH4"'9VK8\O-?;* LP^'XUY]
M*%PP'?6A+$AS]:$L,.W!R?@&2./1EK2\$ AT**N1+BN:-Q!U[R#=<Y(8#A0X
MSLQA'I9WOGMGS"WD?>%@@788<K$KJ-GH;_?.>EO*_\(!0^?FV1#^-D7R/G?O
ML-:.))R82:J6X8"A C$=2)+V>0_.7&]Q-DNS,/Y"TF+&GT'%(SP4!.@W$H::
M0DC0(9CN&PI;6'N0Y5(#U;C!,-85@@+V&MB2Z:P*&QB[='C[D))\<C5%A'8U
M&80D3ZB*W2=7"<KR"<IPJ,W@;5=9  ?V%MC3LW7\ZPIS'PZ%Q8NPR]"CZS!F
M=T2?)PCE[('[I=MU]?!1=CU?DS&5$'OT#"=C5B9-<IP4*'J<(9$?)-/%"@#T
M0K#7,5>'Q0H$(:)]..X>D'2(4)2Q)_EN\1O+JI3SY[NNBXP"SN2/:3O4%M("
M=JM :(?BR,I!8K 'X9)5LMQUW5"\."J1/Z$APF_J"X'Z.@(K\(L4\-IA+R?8
MXV[9RSC#(0O?R%9]?6+GCHDT>8ZVO, ([,7KA"Y8R&@?,HQ^H9"^IEGVF#R'
M<64*U"PXJBI"+L 1ZO"Z8RVFUG)Z[C[VX;F83D,R?QQ]"_\S)7Q+@[+'T17]
M*V>/[7[%X2N.^?O#8 _JKAC6$UQ5F8J6V#VNZ^E+N(XL']_8J[V6*9!C1ST0
M$@;>8[6@,% [LW6A[D& 2OLB,[BI=],!0=G>&__KZ@DU2-8$O@<!/D[@K2[/
MUVQ1"'7OMRUK^F/A^J\AP,Z]]KRK0X$#X(U+4^(:'14<*+<CO8KA_VN>%!P
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M1J%S[L<CFUL9Z>6%3PP$>Q_]W_X_4$L! A0#%     @ 1(.G4+;_TDJX"P$
M%B$1  \              ( !     &0X.#@R-C9D,3!Q+FAT;5!+ 0(4 Q0
M   ( $2#IU"4PG!!A%H" )ZA$  1              "  >4+ 0!D.#@X,C8V
M9&5X,3 Q+FAT;5!+ 0(4 Q0    ( $2#IU"MAFUR$P@  'HN   1
M      "  9AF P!D.#@X,C8V9&5X,S$Q+FAT;5!+ 0(4 Q0    ( $2#IU#C
M9?=7$ @  &LN   1              "  =IN P!D.#@X,C8V9&5X,S$R+FAT
M;5!+ 0(4 Q0    ( $2#IU B8.C7100  .</   1              "  1EW
M P!D.#@X,C8V9&5X,S(Q+FAT;5!+ 0(4 Q0    ( $2#IU#P/GEP#0\  )>1
M   /              "  8U[ P!M9"TR,#(P,#,S,2YX<V102P$"% ,4
M" !$@Z=0$K\I[WD.  "%T0  $P              @ ''B@, ;60M,C R,# S
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( $2#IU!P,P]LG"(  /+] 0 3
M      "  7&9 P!M9"TR,#(P,#,S,5]D968N>&UL4$L! A0#%     @ 1(.G
M4+T\PL0350  N]P$ !,              ( !/KP# &UD+3(P,C P,S,Q7VQA
M8BYX;6Q02P$"% ,4    " !$@Z=0B1\[4J<[  !.K@, $P
M@ &"$00 ;60M,C R,# S,S%?<')E+GAM;%!+!08     "@ * 'H"  !:300
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800216192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, aggregate shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Vesting period of options, maximum years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember', window );">1996 Non-Qualified Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock at which employees are permitted to purchase</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">2015 Non-Qualified Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock at which employees are permitted to purchase</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember', window );">Amended and Restated 2008 Plan [Member] | Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants and awards under Stock Incentive Plans</a></td>
<td class="nump">6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember', window );">Amended and Restated 2008 Plan [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">894,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, aggregate shares authorized</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Aggregate number Shares issued under Stock Purchase Plans</a></td>
<td class="nump">78,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for issuance</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6734246480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_TwoThousandTwentyThreeMember', window );">2023 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable Fair Value Disclosure</a></td>
<td class="nump">611,250<span></span>
</td>
<td class="nump">766,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_TwoThousandTwentySevenMember', window );">2027 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable Fair Value Disclosure</a></td>
<td class="nump">$ 801,200<span></span>
</td>
<td class="nump">$ 1,025,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_TwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_TwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_TwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_TwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775584576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Preliminary and incremental gain loss on sale</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss on classification as held for sale</a></td>
<td class="num">(2,602)<span></span>
</td>
<td class="num">$ (284,525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_TransactionRelatedExpenses', window );">Transaction related expenses</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_WorkingCapitalTrueUp', window );">Working capital true up</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss on classification as held for sale</a></td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 321,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_TransactionRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction related expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_TransactionRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_WorkingCapitalTrueUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital true up.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_WorkingCapitalTrueUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800264016">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 845,918<span></span>
</td>
<td class="nump">$ 851,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PracticeSalariesAndBenefits', window );">Practice salaries and benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">652,721<span></span>
</td>
<td class="nump">621,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PracticeSuppliesAndOtherOperatingExpenses', window );">Practice supplies and other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,264<span></span>
</td>
<td class="nump">25,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">105,235<span></span>
</td>
<td class="nump">101,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,673<span></span>
</td>
<td class="nump">20,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Transformational and restructuring related expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30,907<span></span>
</td>
<td class="nump">3,544<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">832,800<span></span>
</td>
<td class="nump">772,728<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,118<span></span>
</td>
<td class="nump">78,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment and other (expense) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(679)<span></span>
</td>
<td class="nump">1,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(27,608)<span></span>
</td>
<td class="num">(30,723)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,345<span></span>
</td>
<td class="nump">1,236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(26,942)<span></span>
</td>
<td class="num">(27,840)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income from continuing operations before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,824)<span></span>
</td>
<td class="nump">50,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,286)<span></span>
</td>
<td class="num">(8,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">(Loss) income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,110)<span></span>
</td>
<td class="nump">41,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,602)<span></span>
</td>
<td class="num">(284,525)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (18,712)<span></span>
</td>
<td class="num">$ (242,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract', window );"><strong>Loss (income) from continuing operations:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.20)<span></span>
</td>
<td class="nump">0.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract', window );"><strong>Loss from discontinued operations:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.03)<span></span>
</td>
<td class="num">(3.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.03)<span></span>
</td>
<td class="num">(3.29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.23)<span></span>
</td>
<td class="num">(2.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (2.81)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average common shares:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82,799<span></span>
</td>
<td class="nump">86,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">82,799<span></span>
</td>
<td class="nump">86,545<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Due to a loss from continuing operations for the three months ended March 31, 2020, no incremental shares are included because the effect would be antidilutive.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents Income (Loss) from continuing operations, per basic and diluted share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSalariesAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Practice salaries and benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSalariesAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSuppliesAndOtherOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSuppliesAndOtherOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868656-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868656-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1278-109256<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6642443952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Coronavirus Pandemic ("COVID-19")<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ExtraordinaryItemsAbstract', window );"><strong>Extraordinary Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock', window );">Coronavirus Pandemic ("COVID-19")</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2. </div></div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Coronavirus Pandemic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;COVID-19&#8221;): </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px; background: none;"/><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and related &#8220;stay at home&#8221; and social distancing measures implemented across the country has significantly impacted demand for medical services provided by the Company&#8217;s affiliated clinicians. Beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020, the Company experienced a significant decline in the number of elective surgeries at the facilities where&#160;the Company&#8217;s affiliated clinicians provided anesthesia services. See Note 12 - Subsequent Events for information regarding the divestment of the Company&#8217;s anesthesia medical group on May 6, 2020. Much of this decline has been due to the closure of operating suites or facilities following federal advisories to cancel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> procedures and the prohibition of such procedures by several states. Within the Company&#8217;s radiology service line, orders for radiological studies have declined by a meaningful amount from historically normal levels, with much of this reduction focused in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> studies. The Company&#8217;s affiliated office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, have seen a significant elevation of appointment cancellations compared to historical normal levels. At this time, the Company has not experienced, nor does it currently anticipate, any significant impact to neonatal intensive care unit (NICU) patient volumes as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19. </div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has implemented a number of actions to preserve financial flexibility and partially mitigate the significant anticipated impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> These steps included a suspension of most activities related to the Company&#8217;s transformational and restructuring programs, limiting these expenditures to those that <div style="letter-spacing: 0px; top: 0px;;display:inline;">provide</div>&#160;essential support for the Company&#8217;s response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> In addition, (i)&#160;the Company temporarily reduced executive and key management base salaries, including 50% reductions in salaries for its named executive officers through at least June&#160;30, 2020; (ii) the Board of Directors agreed to forego their annual cash retainer and cash meeting payments, until further notice; (iii)&#160;the Company enacted a combination of salary reductions and furloughs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> employees; and (iv)&#160;the Company enacted significant operational and practice-specific expense reduction plans across its clinical operations. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In response to the anticipated impact of COVID-19 on the Company&#8217;s results of operations, on </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;25, 2020, the Company amended and restated its Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $139.2&#160;million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the </div></div></div><div style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by the Company from 4.50:1:00 to 5.00:1:00 for the second and third quarters of 2020 and 4.75:1:00 for the fourth quarter of 2020, before returning to <div style="letter-spacing: 0px; top: 0px;;display:inline;">4.50:1:00</div> for the first quarter of 2021 and beyond, (iii)&#160;require that the Company maintains minimum availability under the Credit Agreement of $300.0&#160;million through the third quarter of 2021, (iv) provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $300.0&#160;million, plus a reserve for certain payables, and (v)&#160;temporarily restrict the Company&#8217;s ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">exceptions. At March 31, 2020, the Company believes it was in compliance, in all material respects, with the financial covenants and other restrictions applicable to the Company under its Credit Agreement, its 5.25% senior unsecured notes due 2023 and its 6.25% senior unsecured notes due 2027. The Company believes it will be in compliance with these covenants for the next twelve months.</div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-style: normal; font-weight: normal; margin-top: 18pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CARES Act </div></div></div></div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $100&#160;billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The Department of Health and Human Services (&#8220;HHS&#8221;) is administering this program and began disbursing funds from the initial $30&#160;billion in early April 2020, of which the Company&#8217;s affiliated physician practices received an aggregate of $12.2&#160;million based on their respective share of Medicare fee for service reimbursements in 2019. The remaining $70&#160;billion in aid is intended to focus on providers in areas particularly impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act the Company and its affiliated physician practices will qualify for and receive. </div></div><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due December&#160;31, 2021 and the remaining 50% due December&#160;31, 2022. The Company intends to utilize this deferral option throughout 2020. </div></div></div><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company currently expects that the COVID-19 situation will materially impact its financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from COVID-19, the Company is unable to predict the ultimate impact on its business, financial condition, results of operations and cash flows. The Company, however, believes it will be able to generate sufficient liquidity to satisfy its obligations for the next twelve months.</div></div></div><div style="margin-top: 18pt; margin-bottom: 0px;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ExtraordinaryItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extraordinary Items [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ExtraordinaryItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6644091264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of shares used in the basic and diluted net income per common share calculation for the three months ended March&#160;31, 2020 and 2019 is as follows (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months&#160;Ended </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, </div></div></div> </td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 0in;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 </div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common shares outstanding </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82,799 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">86,073 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of dilutive common share equivalents </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; font-size: 10pt; width: 6%; height: 17px; padding: 0pt 5pt 0pt 0pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">472 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 1px solid rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common and common<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>equivalent shares outstanding<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;(a)</div> </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82,799 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">86,545 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.13in; line-height: normal; text-indent: -0.13in;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Antidilutive securities not included in the diluted<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>net income per common share<br/> calculation </div></div> </td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">849 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">504 </div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; border-bottom: 3px double rgb(0, 0, 0); padding-bottom: 0in;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="margin-top: 6pt; margin-bottom: 0px;"/>
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; table-layout: fixed;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(a) </div></td>
<td style="text-align: left; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Due to a loss from continuing operations for the three months ended March&#160;31, 2020, no incremental shares are included because the effect would be antidilutive.</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6641907456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;margin-left:4%;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:6pt"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held at March&#160;31, 2020 and December&#160;31, 2019 are summarized as follows (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 11%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 11%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,&#160;2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,&#160;2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate securities </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46,883 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32,962</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Municipal debt securities </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23,327 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29,066</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal home loan securities </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8,052 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8,013</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of deposit </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6,779 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4,469</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">85,041 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">74,510</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6644191904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CashEquivalentsAndInvestmentsLineItems', window );"><strong>Cash Equivalents And Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="nump">$ 16.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CashEquivalentsAndInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CashEquivalentsAndInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6720148080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event - Additional information (Detail) - Subsequent Event [Member] - North American Partners In Anesthesia [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>May 06, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from Divestiture of Businesses</a></td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MaximumConsiderationReceivable', window );">Maximum consideration receivable</a></td>
<td class="nump">250.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccountsReceivableRetained', window );">Accounts receivable retained</a></td>
<td class="nump">110.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MaximumConsiderationReceivable', window );">Maximum consideration receivable</a></td>
<td class="nump">250.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain loss on sale of business</a></td>
<td class="nump">600.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MaximumConsiderationReceivable', window );">Maximum consideration receivable</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain loss on sale of business</a></td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccountsReceivableRetained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable retained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccountsReceivableRetained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MaximumConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum consideration receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MaximumConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>48
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d888266d10q.htm": {
   "axisCustom": 1,
   "axisStandard": 19,
   "contextCount": 94,
   "dts": {
    "calculationLink": {
     "local": [
      "md-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "md-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "d888266d10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "md-20200331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "md-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "md-20200331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 378,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 4,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 9
   },
   "keyCustom": 28,
   "keyStandard": 265,
   "memberCustom": 21,
   "memberStandard": 24,
   "nsprefix": "md",
   "nsuri": "http://www.mednax.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "role": "http://www.mednax.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Fair Value Measurements",
     "role": "http://www.mednax.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Accounts Receivable and Net Revenue",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenue",
     "shortName": "Accounts Receivable and Net Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Discontinued Operations",
     "role": "http://www.mednax.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Accounts Payable and Accrued Expenses",
     "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Common and Common Equivalent Shares",
     "role": "http://www.mednax.com/role/CommonAndCommonEquivalentShares",
     "shortName": "Common and Common Equivalent Shares",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Stock Incentive Plans and Stock Purchase Plans",
     "role": "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CommonStockRepurchasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Common Stock Repurchase Programs",
     "role": "http://www.mednax.com/role/CommonStockRepurchasePrograms",
     "shortName": "Common Stock Repurchase Programs",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CommonStockRepurchasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Commitments and Contingencies",
     "role": "http://www.mednax.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Subsequent Event",
     "role": "http://www.mednax.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Basis of Presentation and New Accounting Pronouncements (Policies)",
     "role": "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies",
     "shortName": "Basis of Presentation and New Accounting Pronouncements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited",
     "shortName": "Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Cash Equivalents and Investments (Tables)",
     "role": "http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables",
     "shortName": "Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.mednax.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Accounts Receivable and Net Revenue (Tables)",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables",
     "shortName": "Accounts Receivable and Net Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Common and Common Equivalent Shares (Tables)",
     "role": "http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables",
     "shortName": "Common and Common Equivalent Shares (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Subsequent Event (Table)",
     "role": "http://www.mednax.com/role/SubsequentEventTable",
     "shortName": "Subsequent Event (Table)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail",
     "shortName": "Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Coronavirus Pandemic (\"COVID-19\") - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
     "shortName": "Coronavirus Pandemic (\"COVID-19\") - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
     "shortName": "Cash Equivalents and Investments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)",
     "role": "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail",
     "shortName": "Cash Equivalents and Investments - Schedule of Investments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "md:MoneyMarketFundsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)",
     "role": "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of fair value on a recurring basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "md:MoneyMarketFundsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)",
     "role": "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails",
     "shortName": "Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Discontinued Operations - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
     "shortName": "Discontinued Operations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)",
     "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail",
     "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2019To03_31_2019",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "md:IncreaseDecreaseInAccruedSalariesAndBonuses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
     "shortName": "Accounts Payable and Accrued Expenses - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2019To03_31_2019",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "md:IncreaseDecreaseInAccruedSalariesAndBonuses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)",
     "role": "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
     "shortName": "Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2019To03_31_2019",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Consolidated Statements of Income",
     "role": "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": "-3",
      "lang": null,
      "name": "md:PracticeSalariesAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn08_31_2018",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
     "shortName": "Common Stock Repurchase Programs - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn08_31_2018",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Subsequent Event - Additional information (Detail)",
     "role": "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail",
     "shortName": "Subsequent Event - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Subsequent Event - Summary of Major Classes of Assets and Liabilities (Detail)",
     "role": "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail",
     "shortName": "Subsequent Event - Summary of Major Classes of Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn03_31_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated Statements of Equity",
     "role": "http://www.mednax.com/role/ConsolidatedStatementsOfEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1007 - Disclosure - Basis of Presentation and New Accounting Pronouncements",
     "role": "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements",
     "shortName": "Basis of Presentation and New Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Coronavirus Pandemic (\"COVID-19\")",
     "role": "http://www.mednax.com/role/CoronavirusPandemicCovid19",
     "shortName": "Coronavirus Pandemic (\"COVID-19\")",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Cash Equivalents and Investments",
     "role": "http://www.mednax.com/role/CashEquivalentsAndInvestments",
     "shortName": "Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d888266d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 46,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounts payable and accrued liabilities excluding accrued income taxes current.",
        "label": "Accounts Payable and Accrued Liabilities Excluding Accrued Income Taxes Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_AccountsReceivableAndNetRevenueDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounts receivable and net revenue disclosure.",
        "label": "Accounts Receivable And Net Revenue Disclosure [Text Block]",
        "terseLabel": "Accounts Receivable and Net Revenue"
       }
      }
     },
     "localname": "AccountsReceivableAndNetRevenueDisclosureTextBlock",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_AccountsReceivableRetained": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounts receivable retained.",
        "label": "Accounts Receivable Retained",
        "terseLabel": "Accounts receivable retained"
       }
      }
     },
     "localname": "AccountsReceivableRetained",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_AccruedContingentConsiderationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued contingent consideration liability current.",
        "label": "Accrued Contingent Consideration Liability Current",
        "terseLabel": "Accrued contingent consideration"
       }
      }
     },
     "localname": "AccruedContingentConsiderationLiabilityCurrent",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_AccruedPayrollTaxesAndBenefitsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued payroll taxes and benefits current.",
        "label": "Accrued Payroll Taxes And Benefits Current",
        "terseLabel": "Accrued payroll taxes and benefits"
       }
      }
     },
     "localname": "AccruedPayrollTaxesAndBenefitsCurrent",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_AmendedAndRestatedTwoThousandEightPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended and restated two thousand eight plan.",
        "label": "Amended and Restated Two Thousand Eight Plan [Member]",
        "terseLabel": "Amended and Restated 2008 Plan [Member]"
       }
      }
     },
     "localname": "AmendedAndRestatedTwoThousandEightPlanMember",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_BasisOfPresentationAndNewAccountingPronouncementsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Basis of Presentation and New Accounting Pronouncements [Table]"
       }
      }
     },
     "localname": "BasisOfPresentationAndNewAccountingPronouncementsTable",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_BasisOfPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Basis Of Presentation [Line Items]"
       }
      }
     },
     "localname": "BasisOfPresentationLineItems",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value Of contingent consideration liability.",
        "label": "Business Combination Contingent Consideration Liability Fair Value Disclosure",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_CashEquivalentsAndInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Equivalents And Investments [Line Items]"
       }
      }
     },
     "localname": "CashEquivalentsAndInvestmentsLineItems",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_CashEquivalentsAndInvestmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Equivalents and Investments [Table]"
       }
      }
     },
     "localname": "CashEquivalentsAndInvestmentsTable",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_CommonStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock [Line Items]",
        "label": "Common Stock [Line Items]",
        "terseLabel": "Common Stock [Line Items]"
       }
      }
     },
     "localname": "CommonStockLineItems",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_CommonStockRepurchasesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entire disclosure of common stock repurchases.",
        "label": "Common Stock Repurchases [Text Block]",
        "terseLabel": "Common Stock Repurchase Programs"
       }
      }
     },
     "localname": "CommonStockRepurchasesTextBlock",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchasePrograms"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_CommonStockTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock [Table]",
        "label": "Common Stock [Table]",
        "terseLabel": "Common Stock [Table]"
       }
      }
     },
     "localname": "CommonStockTable",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_ContractedManagedCareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracted Managed Care [Member]",
        "label": "Contracted Managed Care [Member]",
        "terseLabel": "Contracted Managed Care [Member]"
       }
      }
     },
     "localname": "ContractedManagedCareMember",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ContributionsInAidOfReimbursementOfLostRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contributions In Aid Of Reimbursement of Lost Revenue.",
        "label": "Contributions In Aid Of Reimbursement of Lost Revenue",
        "terseLabel": "Reimbursement of Lost Revenue"
       }
      }
     },
     "localname": "ContributionsInAidOfReimbursementOfLostRevenue",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]",
        "label": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]",
        "terseLabel": "Coronavirus Pandemic (\"COVID-19\")"
       }
      }
     },
     "localname": "CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_CovidNinenteenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Covid Ninenteen [Member]",
        "label": "Covid Ninenteen [Member]",
        "terseLabel": "COVID-19 [Member]"
       }
      }
     },
     "localname": "CovidNinenteenMember",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement [Member]"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_DeferredTaxAssetsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Assets [Axis]"
       }
      }
     },
     "localname": "DeferredTaxAssetsAxis",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_DeferredTaxAssetsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Assets [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetsDomain",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal group including discontinued operation accrued professional liabilities.",
        "label": "Disposal Group Including Discontinued Operation Accrued Professional Liabilities",
        "terseLabel": "Accrued professional liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedProfessionalLiabilities",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated Earnings Before Interest Taxes Depreciation And Amortization",
        "label": "Estimated Earnings Before Interest Taxes Depreciation And Amortization",
        "terseLabel": "Estimated EBITDA"
       }
      }
     },
     "localname": "EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_ExtraordinaryItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extraordinary Items [Abstract]",
        "label": "Extraordinary Items [Abstract]"
       }
      }
     },
     "localname": "ExtraordinaryItemsAbstract",
     "nsuri": "http://www.mednax.com/20200331",
     "xbrltype": "stringItemType"
    },
    "md_ExtraordinaryItemsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extraordinary Items [Axis]",
        "label": "Extraordinary Items [Axis]"
       }
      }
     },
     "localname": "ExtraordinaryItemsAxis",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_ExtraordinaryItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extraordinary Items [Axis]",
        "label": "Extraordinary Items [Domain]"
       }
      }
     },
     "localname": "ExtraordinaryItemsDomain",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at carrying amount.",
        "label": "Financial Instruments Measured At Carrying Amount Table Text Block",
        "verboseLabel": "Financial Instruments Measured At Carrying Amount"
       }
      }
     },
     "localname": "FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_ForecastForFirstQuarterOf2021Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forecast For First Quarter Of 2021 [Member]",
        "label": "Forecast For First Quarter Of 2021 [Member]",
        "terseLabel": "Forecast For First Quarter Of 2021 [Member]"
       }
      }
     },
     "localname": "ForecastForFirstQuarterOf2021Member",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ForecastForFourthQuarterOf2020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forecast For Fourth Quarter Of 2020 [Member]",
        "label": "Forecast For Fourth Quarter Of 2020 [Member]",
        "terseLabel": "Forecast For Fourth Quarter Of 2020 [Member]"
       }
      }
     },
     "localname": "ForecastForFourthQuarterOf2020Member",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ForecastForSecondAndThirdQuartersOf2020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forecast For Second And Third Quarters Of 2020 [Member]",
        "label": "Forecast For Second And Third Quarters Of 2020 [Member]",
        "terseLabel": "Forecast For Second And Third Quarters Of 2020 [Member]"
       }
      }
     },
     "localname": "ForecastForSecondAndThirdQuartersOf2020Member",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ForecastForSecondQuarterOf2021Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forecast For Second Quarter Of 2021 [Member]",
        "label": "Forecast For Second Quarter Of 2021 [Member]",
        "terseLabel": "Forecast For Second Quarter Of 2021 [Member]"
       }
      }
     },
     "localname": "ForecastForSecondQuarterOf2021Member",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_HospitalsContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospitals Contracts [Member]",
        "label": "Hospitals Contracts [Member]",
        "terseLabel": "Hospital contract administrative fees [Member]"
       }
      }
     },
     "localname": "HospitalsContractsMember",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "It represents Income (Loss) from continuing operations, per basic and diluted share",
        "label": "Income Loss from Continuing Operations Per Basic and Diluted Share [Abstract]",
        "terseLabel": "Loss (income) from continuing operations:"
       }
      }
     },
     "localname": "IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "md_IncreaseDecreaseInAccruedSalariesAndBonuses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase decrease in accrued salaries and bonuses.",
        "label": "Increase Decrease In Accrued Salaries And Bonuses",
        "verboseLabel": "Net decrease in accrued salaries and bonuses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedSalariesAndBonuses",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term debt and capital lease obligations excluding long term line of credit.",
        "label": "Long Term Debt and Capital Lease Obligations Excluding Long Term Line of Credit",
        "verboseLabel": "Long-term debt and finance lease liabilities, net"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_MaximumConsiderationReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum consideration receivable.",
        "label": "Maximum Consideration Receivable",
        "terseLabel": "Maximum consideration receivable"
       }
      }
     },
     "localname": "MaximumConsiderationReceivable",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_MoneyMarketFundsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of money market funds.",
        "label": "Money Market Funds Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsFairValueDisclosure",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_MutualFundsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mutual funds fair value disclosure.",
        "label": "Mutual Funds Fair Value Disclosure",
        "terseLabel": "Mutual Funds"
       }
      }
     },
     "localname": "MutualFundsFairValueDisclosure",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "1996 non-qualified employee stock purchase plan.",
        "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member]",
        "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_NorthAmericanPartnersInAnesthesiaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "North American Partners In Anesthesia [member].",
        "label": "North American Partners In Anesthesia [Member]",
        "terseLabel": "North American Partners In Anesthesia [Member]"
       }
      }
     },
     "localname": "NorthAmericanPartnersInAnesthesiaMember",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail",
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail",
      "http://www.mednax.com/role/SubsequentEventTable"
     ],
     "xbrltype": "domainItemType"
    },
    "md_PercentageIncreaseDecreaseInSalaryAndWage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage Increase Decrease In Salary And Wage.",
        "label": "Percentage Increase Decrease In Salary And Wage",
        "terseLabel": "Decrease In Salary | %"
       }
      }
     },
     "localname": "PercentageIncreaseDecreaseInSalaryAndWage",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "md_PercentageOfDeferredPaymentOfSocialSecurityTaxes": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage Of Deferred Payment Of Social Security Taxes.",
        "label": "Percentage Of Deferred Payment Of Social Security Taxes",
        "terseLabel": "Deferred Payment Of Social Security Taxes | %"
       }
      }
     },
     "localname": "PercentageOfDeferredPaymentOfSocialSecurityTaxes",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "md_PercentageOfNetPatientServiceRevenueByTypeOfPayor": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of net patient service revenue by type payor.",
        "label": "Percentage Of Net Patient Service Revenue By Type Of Payor",
        "terseLabel": "Percentage of net patient service revenue"
       }
      }
     },
     "localname": "PercentageOfNetPatientServiceRevenueByTypeOfPayor",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "md_PracticeSalariesAndBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Practice salaries and benefits.",
        "label": "Practice Salaries and Benefits",
        "terseLabel": "Practice salaries and benefits"
       }
      }
     },
     "localname": "PracticeSalariesAndBenefits",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_PracticeSuppliesAndOtherOperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.",
        "label": "Practice Supplies And Other Operating Expenses",
        "terseLabel": "Practice supplies and other operating expenses"
       }
      }
     },
     "localname": "PracticeSuppliesAndOtherOperatingExpenses",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.",
        "label": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue",
        "terseLabel": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue"
       }
      }
     },
     "localname": "ProceedsFromContributionInAidOfReimbursementOfLostRevenue",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_RuralAreaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rural Area [Member]",
        "label": "Rural Area [Member]",
        "terseLabel": "Rural Area [Member]"
       }
      }
     },
     "localname": "RuralAreaMember",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ScheduleOfFinancingReceivablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of financing receivables.",
        "label": "Schedule Of Financing Receivables [Line Items]",
        "terseLabel": "Schedule Of Financing Receivables [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfFinancingReceivablesLineItems",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_Seniorunsecurdnotes2023Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SeniorUnsecurdNotes2023 [Member]",
        "terseLabel": "Senior Unsecurd Notes 2023 [Member]"
       }
      }
     },
     "localname": "Seniorunsecurdnotes2023Member",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_Seniorunsecurdnotes2027Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SeniorUnsecurdNotes2027 [Member]",
        "terseLabel": "Senior Unsecurd Notes 2027 [Member]"
       }
      }
     },
     "localname": "Seniorunsecurdnotes2027Member",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_StockIssuedDuringPeriodSharesStockSwaps": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock issued during period shares stock swaps.",
        "label": "Stock Issued During Period, Shares, Stock Swaps",
        "terseLabel": "Stock swaps, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwaps",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "md_StockIssuedDuringPeriodValueStockSwaps": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock issued during period value stock swaps.",
        "label": "Stock Issued During Period Value Stock Swaps",
        "terseLabel": "Stock swaps"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockSwaps",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_SupplementaryLeverageRatioRequired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplementary Leverage Ratio Required.",
        "label": "Supplementary Leverage Ratio Required",
        "terseLabel": "Leverage ratio"
       }
      }
     },
     "localname": "SupplementaryLeverageRatioRequired",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_TransactionRelatedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction related expenses.",
        "label": "Transaction Related Expenses",
        "verboseLabel": "Transaction related expenses"
       }
      }
     },
     "localname": "TransactionRelatedExpenses",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "label": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "terseLabel": "2015 Non-Qualified Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandFifteenNonQualifiedStockPurchasePlanMember",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_TwoThousandTwentySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Two Thousand Twenty Seven [Member]",
        "terseLabel": "2027 Notes [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentySevenMember",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "md_TwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Two Thousand Twenty Three [Member]",
        "terseLabel": "2023 Notes [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyThreeMember",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "md_UnnamedCorporateJointVentureOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unnamed Corporate Joint Venture [Member]",
        "label": "Unnamed Corporate Joint Venture One [Member]"
       }
      }
     },
     "localname": "UnnamedCorporateJointVentureOneMember",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_UnnamedCorporateJointVentureTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Unnamed Corporate Joint Venture Two [Member]"
       }
      }
     },
     "localname": "UnnamedCorporateJointVentureTwoMember",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_UrbanAreaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Urban Area [Member]",
        "label": "Urban Area [Member]",
        "terseLabel": "Urban Area [Member]"
       }
      }
     },
     "localname": "UrbanAreaMember",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_WorkingCapitalTrueUp": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Working capital true up.",
        "label": "Working Capital True Up",
        "terseLabel": "Working capital true up"
       }
      }
     },
     "localname": "WorkingCapitalTrueUp",
     "nsuri": "http://www.mednax.com/20200331",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r132",
      "r168",
      "r170",
      "r265",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r161",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r133",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Accounts payable and accrued expenses, total"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r134",
      "r135"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Gross, Current",
        "terseLabel": "Gross accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r25",
      "r42",
      "r134",
      "r135",
      "r169"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 26.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail",
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r37",
      "r235",
      "r252"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r30",
      "r31",
      "r57"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued salaries and bonuses"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r174",
      "r176",
      "r188",
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherCorporateBondsMember": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments in corporate fixed maturity debt securities classified as other.",
        "label": "Other Corporate Bonds [Member]",
        "verboseLabel": "Corporate Securities [Member]"
       }
      }
     },
     "localname": "AllOtherCorporateBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r176",
      "r185",
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r48",
      "r136",
      "r143"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Allowance for Doubtful Accounts Receivable, Current",
        "negatedLabel": "Allowance for contractual adjustments and uncollectibles"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r101",
      "r220"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of premiums, discounts and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Antidilutive securities not included in the diluted net income per common share calculation"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r130",
      "r233",
      "r251"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r27",
      "r29",
      "r68"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 23.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r18",
      "r152"
     ],
     "calculation": {
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r178",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r24",
      "r49",
      "r103"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 24.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents of continuing operations at end of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For the entity and the disposal group, cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents.",
        "label": "Cash and Cash Equivalents, at Carrying Value, Including Discontinued Operations",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r98",
      "r217"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "terseLabel": "Net cash used in financing activities - discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r15",
      "r98"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Net cash used in investing activities - discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r15",
      "r98"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "definitionGuidance": "Net cash provided by operating activities - discontinued operations",
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "verboseLabel": "Certificates of Deposit [Member]"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r62",
      "r160",
      "r240",
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r159",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, aggregate shares authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r41",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock; $.01 par value; 200,000 shares authorized; 85,150 and 84,248 shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r234",
      "r236",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r59",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Debt Instrument Interest Rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "verboseLabel": "Schedule of Investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r101",
      "r104",
      "r195",
      "r196"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent": {
     "auth_ref": [
      "r191",
      "r192",
      "r194"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 22.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.",
        "label": "Deferred Tax Assets, Net, Noncurrent",
        "terseLabel": "Deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNoncurrent": {
     "auth_ref": [
      "r191",
      "r192",
      "r193"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.",
        "label": "Deferred Tax Liabilities, Net, Noncurrent",
        "terseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r101",
      "r127"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 11.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]",
        "terseLabel": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Net Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock Incentive Plans and Stock Purchase Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsHeldforsaleMember": {
     "auth_ref": [
      "r2",
      "r3",
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations, Held-for-sale [Member]"
       }
      }
     },
     "localname": "DiscontinuedOperationsHeldforsaleMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r152"
     ],
     "calculation": {
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r152"
     ],
     "calculation": {
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]",
        "verboseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r152"
     ],
     "calculation": {
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "negatedPeriodEndLabel": "Less cash and cash equivalents of discontinued operations at end of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r152"
     ],
     "calculation": {
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r152"
     ],
     "calculation": {
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r152"
     ],
     "calculation": {
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r152"
     ],
     "calculation": {
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r152"
     ],
     "calculation": {
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r101",
      "r149",
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "terseLabel": "Preliminary and incremental gain loss on sale"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r23",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail",
      "http://www.mednax.com/role/SubsequentEventTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net loss:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r79",
      "r107",
      "r111",
      "r114",
      "r115",
      "r116",
      "r119",
      "r246",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic, Other Disclosures [Abstract]",
        "terseLabel": "Weighted average common shares:"
       }
      }
     },
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r79",
      "r107",
      "r111",
      "r114",
      "r115",
      "r116",
      "r119",
      "r246",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Common and Common Equivalent Shares"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentShares"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method ownership percentage in joint venture"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r210",
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Disclosures"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r210",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r210",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r210",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Measurements, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 19.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r101",
      "r203"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "terseLabel": "Gain loss on sale of business"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeographicDistributionAxis": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.",
        "label": "Geographic Distribution [Axis]"
       }
      }
     },
     "localname": "GeographicDistributionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeographicDistributionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities.",
        "label": "Geographic Distribution [Domain]"
       }
      }
     },
     "localname": "GeographicDistributionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r146",
      "r147"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization that is the governing authority of a community.",
        "label": "Government [Member]",
        "terseLabel": "Government [Member]"
       }
      }
     },
     "localname": "GovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Health Care Organization, Receivable and Revenue Disclosures [Line Items]",
        "terseLabel": "Health Care Organization, Receivable and Revenue Disclosures [Line Items]"
       }
      }
     },
     "localname": "HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Health Care Organization Revenue and Expense [Abstract]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueAndExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Axis]",
        "terseLabel": "Health Care Organization, Revenue Sources [Axis]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Domain]",
        "terseLabel": "Health Care Organization, Revenue Sources [Domain]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCarePatientServiceMember": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility.",
        "label": "Health Care, Patient Service [Member]",
        "terseLabel": "Net patient service revenue [Member]"
       }
      }
     },
     "localname": "HealthCarePatientServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 25.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Debt Securities, Held-to-maturity, Current",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r75",
      "r107",
      "r231",
      "r243",
      "r264"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "(Loss) income from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 13.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "(Loss) income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r73",
      "r79",
      "r111",
      "r114",
      "r115",
      "r241",
      "r244",
      "r246",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r73",
      "r79",
      "r111",
      "r114",
      "r115",
      "r116",
      "r246",
      "r260",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract]",
        "terseLabel": "Loss from discontinued operations:"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r19",
      "r79",
      "r261"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      },
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 14.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "negatedLabel": "Loss from discontinued operations",
        "terseLabel": "Loss on classification as held for sale",
        "verboseLabel": "Loss from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r77",
      "r79",
      "r113",
      "r114",
      "r115",
      "r246",
      "r261",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r76",
      "r101",
      "r128",
      "r141",
      "r242",
      "r259"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "verboseLabel": "Equity in earnings of unconsolidated affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail",
      "http://www.mednax.com/role/SubsequentEventTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail",
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail",
      "http://www.mednax.com/role/SubsequentEventTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r17",
      "r20",
      "r21",
      "r22",
      "r153",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail",
      "http://www.mednax.com/role/SubsequentEventTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r129",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r65",
      "r239",
      "r258"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 29.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "verboseLabel": "Income taxes receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve",
        "terseLabel": "Long-term professional liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r112",
      "r118"
     ],
     "calculation": {
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Weighted average number of dilutive common share equivalents"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r74",
      "r126",
      "r218",
      "r220",
      "r247"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r31",
      "r32",
      "r57"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r81",
      "r83",
      "r84"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "verboseLabel": "Investment and other (expense) income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r140",
      "r232",
      "r248",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r47",
      "r237",
      "r255"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r18",
      "r152"
     ],
     "calculation": {
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventSummaryOfMajorClassesOfAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "verboseLabel": "Credit Facility Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r60",
      "r163",
      "r164"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit, Noncurrent",
        "terseLabel": "Line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).",
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Current",
        "terseLabel": "Accrued professional liabilities"
       }
      }
     },
     "localname": "MalpracticeLossContingencyAccrualUndiscountedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).",
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent",
        "terseLabel": "Long-term professional liabilities"
       }
      }
     },
     "localname": "MalpracticeLossContingencyAccrualUndiscountedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net cash (used in) provided by financing activities\u2014continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash used in investing activities \u2013 continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r98",
      "r99",
      "r102"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r98",
      "r99",
      "r102"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash used in operating activities \u2013 continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r71",
      "r72",
      "r78",
      "r102",
      "r118",
      "r245",
      "r262"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "definitionGuidance": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total non-operating expenses"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r38",
      "r236",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Notes Payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "verboseLabel": "Notes Payable Fair Value Disclosure"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 21.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use\u00a0assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r106",
      "r108",
      "r125",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation and New Accounting Pronouncements"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r57"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 28.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 20.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r69",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized holding loss on investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payments of contingent consideration liabilities"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Operating Activities",
        "negatedLabel": "Payments of contingent consideration liabilities"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 34.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 36.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payments for credit facility amendment and financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "terseLabel": "Amount withheld to satisfy minimum statutory tax withholding obligations"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition payments, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Payments to Acquire Other Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r178",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock; $.01 par value; 1,000 shares authorized; none issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r26",
      "r28",
      "r145"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 27.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from Divestiture of Businesses"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 33.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 35.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).",
        "label": "Proceeds from Issuance of Senior Long-term Debt",
        "terseLabel": "Proceeds from issuance of senior notes"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r91",
      "r105"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Borrowings on credit agreement"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "verboseLabel": "Proceeds from maturities or sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Proceeds from Sales of Business, Affiliate and Productive Assets",
        "verboseLabel": "Proceeds from sales of businesses"
       }
      }
     },
     "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "verboseLabel": "Other revenue [Member]"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r71",
      "r72",
      "r97",
      "r130",
      "r131",
      "r200",
      "r201",
      "r202",
      "r205",
      "r206"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "definitionGuidance": "Net income (loss)",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r34",
      "r35",
      "r150",
      "r256"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r93",
      "r105"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedLabel": "Payments on credit agreement"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 32.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).",
        "label": "Repayments of Long-term Capital Lease Obligations",
        "negatedLabel": "Payments on finance lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r101",
      "r156",
      "r157",
      "r158"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 12.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "verboseLabel": "Transformational and restructuring related expenses"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r44",
      "r166",
      "r254"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r167",
      "r168"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Net revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable, Net"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "verboseLabel": "Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r17",
      "r20",
      "r21",
      "r22",
      "r153",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Summary Of Major Classes of Assets And Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventTable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r209",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of the major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table]",
        "terseLabel": "Schedule of Revenue Sources, Health Care Organization [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r178",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r215",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Percentage of Net Revenue"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SelfPayMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Patients who pay out of pocket for a health-related service in absence of insurance to cover the medical or surgical procedure performed.",
        "label": "Self-Pay [Member]",
        "terseLabel": "Private-Pay Patients [Member]"
       }
      }
     },
     "localname": "SelfPayMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants and awards under Stock Incentive Plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r175",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Vesting period of options, maximum years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percentage of market value of common stock at which employees are permitted to purchase"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Shares Paid for Tax Withholding for Share Based Compensation",
        "terseLabel": "Number of shares withheld to satisfy minimum statutory tax withholding obligations"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r64",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r40",
      "r41",
      "r165",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Aggregate number Shares issued under Stock Purchase Plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r40",
      "r41",
      "r165",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "terseLabel": "Forfeitures of restricted stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r40",
      "r41",
      "r165",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Gross",
        "terseLabel": "Issuance of restricted stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r40",
      "r41",
      "r166",
      "r177",
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Gross",
        "terseLabel": "Issuance of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Common stock authorized for repurchase"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Company's Common stock repurchased"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r40",
      "r41",
      "r165",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchased common stock, shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r40",
      "r41",
      "r165",
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchased common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r41",
      "r45",
      "r46",
      "r137"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r198",
      "r199",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/SubsequentEventAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ThirdPartyPayorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization other than the patient (first party) or health care provider (second party) involved in the financing of personal health services.",
        "label": "Third-Party Payor [Member]",
        "terseLabel": "Other Third-Parties [Member]"
       }
      }
     },
     "localname": "ThirdPartyPayorMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r171",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "verboseLabel": "Federal Home Loan Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "auth_ref": [
      "r171",
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "verboseLabel": "Municipal Debt Securities [Member]"
       }
      }
     },
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r110",
      "r116"
     ],
     "calculation": {
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted",
        "totalLabel": "Weighted average number of common and common equivalent shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r109",
      "r116"
     ],
     "calculation": {
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic",
        "verboseLabel": "Weighted average number of common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1278-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=SL6283291-111563"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955255&loc=SL82921835-210448"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31958-109318"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355146-122828"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r273": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r274": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r275": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r276": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r277": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r278": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(ee)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6648531152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Cash Equivalents and Investments</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3. </div></div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash Equivalents and Investments:</div></div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px; background: none;"/><div style="clear: both; max-height: 0px; background: none;"/><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2020 and December&#160;31, 2019, the Company&#8217;s cash equivalents consisted entirely of money market funds totaling $6.4&#160;million and $16.8&#160;million, respectively. Investments consisted of corporate securities, municipal debt securities, federal home loan securities and certificates of deposit. All investments are classified as current. </div></div><div style="font-family:Times New Roman;margin-left:4%;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:6pt"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held at March&#160;31, 2020 and December&#160;31, 2019 are summarized as follows (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 11%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 11%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,&#160;2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,&#160;2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate securities </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46,883 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32,962</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Municipal debt securities </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23,327 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29,066</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal home loan securities </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8,052 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8,013</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of deposit </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6,779 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4,469</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">85,041 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">74,510</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801278192">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,087,884<span></span>
</td>
<td class="nump">$ 878<span></span>
</td>
<td class="nump">$ 992,647<span></span>
</td>
<td class="nump">$ 2,094,359<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(242,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(242,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding loss on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,542<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_StockIssuedDuringPeriodValueStockSwaps', window );">Stock swaps</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_StockIssuedDuringPeriodSharesStockSwaps', window );">Stock swaps, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(78,982)<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
<td class="num">(28,740)<span></span>
</td>
<td class="num">(50,217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,779,812<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
<td class="nump">977,872<span></span>
</td>
<td class="nump">1,801,076<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,498,996<span></span>
</td>
<td class="nump">$ 842<span></span>
</td>
<td class="nump">987,942<span></span>
</td>
<td class="nump">510,212<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18,712)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,712)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding loss on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(213)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(213)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,832<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,542)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(2,541)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,487,396<span></span>
</td>
<td class="nump">$ 852<span></span>
</td>
<td class="nump">$ 995,257<span></span>
</td>
<td class="nump">$ 491,287<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Presented within retained earnings on the consolidated balance sheet as the balance is immaterial.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_StockIssuedDuringPeriodSharesStockSwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_StockIssuedDuringPeriodSharesStockSwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_StockIssuedDuringPeriodValueStockSwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value stock swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_StockIssuedDuringPeriodValueStockSwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796621344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MEDNAX, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000893949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,409,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-3667538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1301 Concord Terrace<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Sunrise<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781139824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Schedule of Investments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 85,041<span></span>
</td>
<td class="nump">$ 74,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember', window );">Corporate Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">46,883<span></span>
</td>
<td class="nump">32,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">23,327<span></span>
</td>
<td class="nump">29,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Federal Home Loan Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">8,052<span></span>
</td>
<td class="nump">8,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 6,779<span></span>
</td>
<td class="nump">$ 4,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6645628048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Table)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=md_NorthAmericanPartnersInAnesthesiaMember', window );">North American Partners In Anesthesia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Summary Of Major Classes of Assets And Liabilities</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents the major classes of assets and liabilities of the anesthesiology medical group that are included in the accompanying Consolidated Balance Sheets as of March&#160;31, 2020 (in thousands): </div></div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 68%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 87%; padding: 0px;">&#160;</td>
<td style="width: 5%; padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td>
<td style="padding: 0px;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,<br/> 2020 </div></div></div></div> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets </div></div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">147,717</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other assets </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14,519</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">900</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">545,272</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60,034</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$768,461</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities </div></div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">54,311</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional liabilities </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20,627</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"> <div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities </div></div></div> </td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5,174</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; font-size: 10pt;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$80,112</div></div></div> </td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=md_NorthAmericanPartnersInAnesthesiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=md_NorthAmericanPartnersInAnesthesiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6642044592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at March&#160;31, 2020 and December&#160;31, 2019 (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 84%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 60%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 9%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 9%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 9%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair&#160;Value<br/>Category </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,&#160;2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,&#160;2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets: </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6,357 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16,775</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">85,041 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">74,510</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mutual Funds </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11,640 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14,264</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities: </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,288 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2,696</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock', window );">Financial Instruments Measured At Carrying Amount</a></td>
<td class="text"><div style="text-align: left; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at March&#160;31, 2020 and December&#160;31, 2019 (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 92%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 62%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 2%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, 2020 </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2019 </div></div></div></td>
<td style="padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying<br/>Amount </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Value </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying<br/>Amount </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Value </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities: </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 Notes </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">750,000</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">611,250</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">750,000</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">766,875</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027 Notes </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,000,000</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">801,200</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,000,000</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,025,600</div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at carrying amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781069472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Repurchase Programs - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Common stock authorized for repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Company's Common stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Number of shares withheld to satisfy minimum statutory tax withholding obligations</a></td>
<td class="nump">125,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Amount withheld to satisfy minimum statutory tax withholding obligations</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CommonStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CommonStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>56
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_O"["H?.^;W_Q\8705/#K[LP7U!+ P04    " !$@Z=0F5R<(Q &  "<)P
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M^MNYO6^':6YX,/HT3JK)-"YO_@!02P,$%     @ 1(.G4!/M]/"6!   218
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M,Q(:W5KJ%?F)V:6LN76@0EZ ^IHZ4RI !G56,EXA'ZYA0. L5#>6?=9=W]U
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MKG[LAZ\^?6]/!U"GB[XY3H=KR_,)W\U_4$L#!!0    ( $2#IU 2>F8&M0$
M -(#   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL?5/;;MP@$/T5Q <$
M+[M)DY5M*9LH2J5$6J5J^LS:8QL%C -XG?Y]!^RX5F/U!9CAG#,7AG0P]LTU
M )Y\:-6ZC#;>=WO&7-& %N["=-#B366L%AY-6S/761!E)&G%>))<,2UD2_,T
M^HXV3TWOE6SA:(GKM1;V]P&4&3*ZH9^.%UDW/CA8GG:BAA_@?W9'BQ:;54JI
MH772M,1"E=';S?ZP"_@(>)4PN,69A$I.QKP%XWN9T20D! H*'Q0$;F>X Z6"
M$*;Q/FG2.60@+L^?Z@^Q=JSE)!S<&?5+EK[)Z#4E)52B5_[%#(\PU7-)R53\
M$YQ!(3QD@C$*HUQ<2=$[;_2D@JEH\3'NLHW[,-Y<7DVT=0*?"'PF7,<X; P4
M,[\77N2I-0.Q8^\[$9YXL^?8FR(X8ROB'2;OT'O.-S<W*3L'H0ES&#%\B9D1
M#-7G$'PMQ(%_H?-U^G8UPVVD;Y?T)%D7V*T*[*+ [K\E?L7PY-\BV:*G&FP=
MI\F1PO1MG.2%=Q[86Q[?Y"]\G/9G86O9.G(R'E\V]K\RQ@.FDES@"#7XP69#
M0>7#\1N>[3AFH^%--_T@-G_C_ ]02P,$%     @ 1(.G4'H(Q'.T 0  T@,
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MLYG';#8<#LL/8NLW+G\!4$L#!!0    ( $2#IU#K<,*IM0$  -(#   8
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL?5/;;MP@$/T5Q <$F]U-HI5M*9LH
M:J566J5J^\S:XXL"C MXG?Y] 3NNVUI] 6:8<^;,,&0CFE?; CCRIJ2V.6V=
MZX^,V;(%)>P-]J#]38U&">=-TS#;&Q!5!"G)>)+<,B4Z38LL^LZFR'!PLM-P
M-L0.2@GS\P02QYRF]-WQTC6M"PY69+UHX NXK_W9>(LM+%6G0-L.-3%0Y_0A
M/9[V(3X&?.M@M*LS"95<$%^#\;'*:1($@832!0;AMRL\@I2!R,OX,7/2)64
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MPZ["0X0?_E'X?I\@VR7((D&V)4B35R7NQ;PNDFUZJL&T<9HLJ7#LXR1OO.O
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MT(>73?UO$#T$*;N;,$)=^&"+H:#Q\?@VG.TT9I/AL9]_$%N^<?D+4$L#!!0
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MX\/Q Y[M/&:SX<VP_""V?N/R+U!+ P04    " !$@Z=0.NKE7L0!   W!
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MDM-G6.I),5J*_PI7X!;N,K$:I>3:?U$Y:B/%PF)3$>QU7KO>K]-\DJ1+6#B
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M<*ZG2S$95@WS?6?+HU.^ U!+ P04    " !$@Z=0$C9;_-8"  !R#   &0
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M5FVOFR 8_2O&'W 1\/7&FNQV6;9D2YJ[;/M,6UK-17% Z]V_'Z U5NGBOE3
M\QS/.?4!\XZ+-UE2JKSWFC5RXY=*M<\ R$-):R*?>$L;?>?$14V4GHHSD*V@
MY&B+:@90$,2@)E7C%[E=VXDBYQ?%JH;NA"<O=4W$GQ?*>+?QH7];>*W.I3(+
MH,A;<J;?J?K1[H2>@9'E6-6TD15O/$%/&_\#?-["R!18Q,^*=G(R]HR5/>=O
M9O+EN/$#HX@R>E"&@NC+E6XI8X9)Z_@]D/KC,TWA='QC_V3-:S-[(NF6LU_5
M494;/_6](SV1"U.OO/M,!T.1[PWNO](K91INE.AG'#B3]M<[7*3B]<"BI=3D
MO;]6C;UV _^MS%V A@(T%L#PGP5X*,"S M KLU8_$D6*7/#.$_V_U1+S4L!G
MK,,\F$6;G;VGW4J]>BUP$.?@:H@&S$N/01,,ND=LEX@H'2% "QA5(*<*9.OQ
MG8K$38"=!-@2A'<$Z<Q&CXDMIK&8- I".+.R1"5A! .WF- I)G2(R=P$D9,@
M6A]'["2(5\318Z*)T3!.4SR+8XG"*(N16TSB%),LQ3S*,W42I.OCR)P$V8HX
MLH51A#%*9G$X4%D0QVXQ,'"W7. (!#Z@>-"U<'TDT-UR$*T(90!-_:9!M.A^
M%PKB!W+<#0P='0P?O&;0W78P_(]0W(T'HS6A1(LM(DZ2;![*$A6&\7P; )-]
MVAR<WX@X5XWT]ESI+=]NS"?.%=6,P9-F+/59/4X8/2DS3/18] =6/U&\'0YC
M,'X1%'\!4$L#!!0    ( $2#IU!3]AE(+0(  ,,&   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,P+GAM;(V5;Z^;(!3&OXKQ UP$%6UCFZQ=EBW9DN8NVU[3
M]K2:B^* UKMO/T!K6J7+WL@?G_/P.T>!HA/R394 .GBO>:-68:EUNT1('4JH
MF7H1+33FS4G(FFDSE&>D6@GLZ()JCD@4452SJ@G7A9O;R74A+II7#>QDH"YU
MS>2?#7#1K4(<WB9>JW.I[01:%RT[PW?0/]J=-",TNARK&AI5B2:0<%J%'_!R
MBUV 4_RLH%-W_<"FLA?BS0Z^'%=A9(F PT%;"V::*VR!<^MD.'X/IN&XI@V\
M[]_</[GD33)[IF K^*_JJ,M5F(?!$4[LPO6KZ#[#D% :!D/V7^$*W,@MB5GC
M(+ARS^!P45K4@XM!J=E[WU:-:[O!_Q;F#R!# !D#</+/@'@(B"<!J"=SJ7YD
MFJT+*;I ]E^K9?:GP,O8%/-@)UWMW#N3K3*SUW6,XP)=K=&@V?0:<J<ACXKM
M7)'FHP09@)&">"F(BT\>*!*_0>PUB)U!_&"0^@T2KT'B(:"3.O0:ZC2-T] X
MS2:EF(LPS;(G+*F7)?6P3);9])KT?AE,DV@"XU$EA#ZI+/7"4 _,DV^;>0VR
M__\TN=<@GQ%0/*E&/LLS3Z-DHMK.55F2XLC/LO"R+#S56/@-<.3?<-&\'N0)
M WZR9_&<@DQ+,H@>?D22Y].-.U<1NJ 3''1WFMCC_1N3YZI1P5YH<S"YX^,D
MA ;C&+V8^I;F1AD''$[:=C/3E_VQV@^T:(<K XWWUOHO4$L#!!0    ( $2#
MIU#Z<YWV'@(  -(&   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;(U5
MVXZ;,!3\%<0'K"^$2R*"U$U5M5(K15NU?7:2DX#68&H[8?OWM0U!A+C=\( O
MS PSQV#GG9"OJ@30P5O-&[4.2ZW;%4)J7T+-U)-HH3%/CD+63)NA/"'52F '
M1ZHYHA@GJ&95$Q:YF]O*(A=GS:L&MC)0Y[IF\L\S<-&M0Q)>)UZJ4ZGM!"KR
MEIW@.^@?[5::$1I5#E4-C:I$$T@XKL,/9+4ACN 0/ROHU*0?V"@[(5[MX,MA
M'6+K"#CLM95@IKG !CBW2L;'[T$T'-]IB=/^5?V3"V_"[)B"C>"_JH,NUV$6
M!@<XLC/7+Z+[#$.@. R&]%_A MS K1/SCKW@RMV#_5EI40\JQDK-WOJV:ES;
M#?I7FI] !P(="63Q7T(T$*(9 ?7.7-2/3+,BEZ(+9+]:+;,?!5E%IIA[.^EJ
MYYZ9M,K,7HJ(TAQ=K-" >>XQ=(*9(3;WB#@;(<@8&%U0KPOJ^(L;%Y%?(/(*
M1$X@NA' ?H&%5V#A<;"8U:'') [3.$P:8W/-BO$N[,9.[+43/YXG\0HDGCSQ
M+$^/B2=&$T)H/,]S#TN3)$MCOYW4:R?UV$G\ IE7('N\($NOP/*!!5[>)248
M>U;X?=R-(8+]OQY^/!/YQ]]+'ECF 33](#-,Z%TJ#XY@&B=WL=!D<[&[_3<F
M3U6C@IW09I]RN\E1" U&%#^9*I7F@!D''([:=E/3E_TNVP^T:(<3!(W'6/$7
M4$L#!!0    ( $2#IU#O+"\0\0$  /D$   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;'U4P8Z;,!3\%>1[UX -@8@@;;*J6JF5HJVV/3OP$M :3&TG
M;/^^MB$H(;07[/>8&<]@XZP7\EU5 -K[:'BK-JC2NEMCK(H*&J:>1 >M>7,4
MLF':E/*$52>!E8[4<!SZ?HP;5K<HSUQO+_-,G#6O6]A+3YV;ALD_6^"BWZ
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M:X*OF^^5Z58_$4&RE-'.8OW7:HGZ4Z %EF;F*JB]T^]DMUQ&SQG&*'7.BFC
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M-XYHOU9-S9^"/(=:S,P8K7;VG:Y6:NLI#<,X\4Z&J,.L6DQP@2$]PM/L?8@
M"[$*;MR#ZP#K6P3Q8SQ$B%816H+PJHHI3A"A!)$EB*X(9@,9,,Q\4,ECS%4B
M$S21R2U!Y.,$,4H0CY=BBA),1TB!8"(RD +#!'@B,S21&4(0X@1SE& ^7@KB
MX]WACQ # T710 T4-+F3S)U6)0C%G38A:"LN2? !2?!6(^$821!0-!U*\AAT
MG0S>M@3IMVAVAP)O.#+Y@"1XRY%XC"0(*!H>'_\!M<EX%V=[">)@QZ!T,GZL
ME#E%+ZS]J%T&9C8,["LS@NW,>*=IY_=W*@Y%)9TM5WKRV/FPYUR!SM%_TH+E
M^LK0;QCLE5E.]5JT<[/=*%YW=P*OOYBD_P!02P,$%     @ 1(.G4.<KRFXE
M @  )P8  !D   !X;"]W;W)K<VAE971S+W-H965T,S4N>&ULC55;;YLP%/XK
MB/<6,)>@B" UF:9-VJ2HT[IGAYP$5!LSVPG=OY\OA%)PIKU@^W#.=S'VH>@9
M?Q4U@/3>*&G%QJ^E[-9!(*H:*!:/K(-6O3DQ3K%42WX.1,<!'TT1)0$*PRR@
MN&G]LC"Q/2\+=I&D:6'//7&A%/,_6R"LW_B1?PL\-^=:ZD!0%AT^PP^0/[L]
M5ZM@1#DV%%K1L-;C<-KX3]%ZE^M\D_#20"\F<T\[.3#VJA=?CQL_U(* 0"4U
M E;#%79 B 92,GX/F/Y(J0NG\QOZ9^-=>3E@ 3M&?C5'66_\W/>.<,(7(I]9
M_P4&/ZGO#>:_P16(2M=*%$?%B#!/K[H(R>B HJ10_&;'IC5C/^#?RMP%:"A
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M>69,4N4S?E+YU:J)+I.6GJ4>YFK,ITXR320;YBX9+:UZ^P]02P,$%     @
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MKNQ<=?=JMS"RZ=\,,CQ<^7]02P,$%     @ 1(.G4(8'YP.' @  #@D  !D
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MV=N:H,4RN5FB'K/I,'B$P7\BMCX"4#Y@$I/!D 8.IH$=03I. U"8( T2I(Z
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MW?"VQ]^@39@@&1ZB8@.R)&O:-WA&47K65( ["0[%PEB0TPCU8P2B< MZ$L_
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MJ%Q&S7-FO1X\'"T0.)HJSW[MGM^*@Z8";H&232^%GG^I3 D SL,8'NI0Y"=
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M$FXV\J^Y3X?]A5Y9UY,!<T!5.4:;AKXV6Y"WV I?I\Q6MHD F4# O;@!R&@
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M  3B88-ZCR7481T#EB,?M$%'RV]UM)&OX1TY$RZFHD!H!E@>38?ZWQ<ST%*
M?.AHD$.I.HD>SH<P&/Y;_0)_C:;>#/ZBF)8"0%B"N4YS,116KXK257E.JGCO
M<$4?NF*R]+,P9@Q$&P98CIQ7RX7183"IUYI4'-0AEX=N966#N%9W9X*2&["
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M+^=IF2VE,8^LGH7XMU8?P_J9TZ>1?%7H8(IU"H?V])@!LS!:K6"O"46Y>?'
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M@-K794#RDSI7BL:M\HR!,! ))VO<(:ZA:S2$X'^@''CCA.2:K]0<E/NNV6+
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M:2=U)^TT2T2.M]MH'HMYW9W%TK*-T69A]LFZDHKH->N IWE>?/>_4$L#!!0
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M_%9$D"4"6?Y'R)F'\!<8HA9D(IF*("L$LNH-\O2FY1'D/@*YWQODF)I5!'F
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M[Q?3BU:(L2L[EY\5#1^\_#T>/AJ^^P%02P,$%     @ 1(.G4.4A,.2P 0
M QH  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\79P4["0!#&\5<A
M?0"7F5D1#7CRXE5]@:8LE%#:IKM&?7MK+Y8$^GD@GY>2!C+S/S2_;,KJ)51Y
MVC=U+/=MG'T>JSJNLS*E]L&Y6)3AF,>;I@UU_\VVZ8YYZF^[G6OSXI#O@M/Y
M?.&Z\8SL<36>.7O>K+/N>2/9["WO=B&M,_=9N8^F.\0RA!3=\"$W_8+^)U]M
M^,OZ9KO=%^&I*=Z/H4YG*GX79.Y\D$X'*3W(IH.,'N2G@SP]Z'8ZZ)8>M)@.
M6M"#[J:#[NA!R^F@)3WH?CKHGAXD<R#CG)^$L.9K+8!KX7LM &SABRV ;.&;
M+0!MX:LM@&WANRT ;N'++8!NX=LM &_AZZU ;^7KK4!O_8>S-CIL\_56H+?R
M]5:@M_+U5J"W\O56H+?R]5:@M_+U5J"W\O56H+?R]3:@M_'U-J"W\?4VH+?]
MP[L2]+*$K[<!O8VOMP&]C:^W ;V-K[<!O8VOMP&]C:^W ;V-K[<'>GN^WA[H
M[?EZ>Z"WY^OM1WK',N_"YC5U^WH7KUUR,OQBS0CNF+ZJ</V,8>K%_2.E4[\E
MN.%Z]2=EF/H3X4[^\WG\!E!+ P04    " !$@Z=0,)0TP:\!  ! &@  $P
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M#5!+ 0(4 Q0    ( $2#IU ?(\\#P    !,"   +              "  0
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $2#IU GZ(<.@@   +$    0
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M965T,RYX;6Q02P$"% ,4    " !$@Z=0Y?WC<EX$  !7%   &
M    @ &-$P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
M1(.G4(!6"*>6!    Q8  !@              ( !(1@  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( $2#IU"@=IZC:04  .T;   8
M          "  >T<  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " !$@Z=0$GIF!K4!  #2 P  &               @ &,(@  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 1(.G4'H(Q'.T 0  T@,
M !@              ( !=R0  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( $2#IU#K<,*IM0$  -(#   8              "  6$F  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !$@Z=0BV^7J[8!
M  #2 P  &0              @ %,*   >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( $2#IU WBUL0M $  -(#   9              "
M 3DJ  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 1(.G
M4 DRB6*U 0  T@,  !D              ( !)"P  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " !$@Z=0N'%0[+4!  #2 P  &0
M        @ $0+@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( $2#IU"D!63[LP$  -(#   9              "  ?PO  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ 1(.G4'@>S9^U 0  T@,
M !D              ( !YC$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " !$@Z=01HOY,[0!  #2 P  &0              @ '2,P
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( $2#IU Y#61/
MM $  -(#   9              "  ;TU  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ 1(.G4/5LQN*R 0  T@,  !D
M ( !J#<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !$
M@Z=0M^JE7[<!  #2 P  &0              @ &1.0  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( $2#IU!Y=7LBM@$  -(#   9
M          "  7\[  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#
M%     @ 1(.G4#KJY5[$ 0  -P0  !D              ( !;#T  'AL+W=O
M<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !$@Z=0F\47 =0!  "<
M!   &0              @ %G/P  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM
M;%!+ 0(4 Q0    ( $2#IU &?M*7M@$  -(#   9              "  7)!
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ 1(.G4+E0
MUN*S 0  T@,  !D              ( !7T,  'AL+W=O<FMS:&5E=',O<VAE
M970R-"YX;6Q02P$"% ,4    " !$@Z=0T^)88KP!   3!   &0
M    @ %)10  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M $2#IU#2JL4 O0$  ( $   9              "  3Q'  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ 1(.G4!(V6_S6 @  <@P  !D
M             ( !,$D  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " !$@Z=0K8O7:[H!   2!   &0              @ $]3   >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( $2#IU"7X[_Q4 (
M !T(   9              "  2Y.  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ 1(.G4%/V&4@M @  PP8  !D              ( !
MM5   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " !$@Z=0
M^G.=]AX"  #2!@  &0              @ $94P  >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( $2#IU#O+"\0\0$  /D$   9
M      "  6Y5  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ 1(.G4&\/^\1= @  I <  !D              ( !EE<  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !$@Z=0#,PTS5P"  "D"
M&0              @ $J6@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( $2#IU#G*\IN)0(  "<&   9              "  ;U<  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ 1(.G4+'-M59B
M @  M@<  !D              ( !&5\  'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " !$@Z=04%3/V+(!  "5 P  &0
M@ &R80  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( $2#
MIU [C.211 (  .D&   9              "  9MC  !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ 1(.G4%Q:#D3_ @  I@P  !D
M         ( !%F8  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
M    " !$@Z=0)U8/PB,"   Q!@  &0              @ %,:0  >&PO=V]R
M:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( $2#IU"W]710$0(  ,0&
M   9              "  :9K  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL
M4$L! A0#%     @ 1(.G4(8'YP.' @  #@D  !D              ( ![FT
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M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !$@Z=0,)0TP:\!  ! &@  $P
M            @ $PHP  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     ,P S
+ -<-   0I0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6612473680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11</div>. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Commitments and Contingencies:</div></td> </tr> </table> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of March&#160;31, 2020 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company&#8217;s affiliated physicians. The Company&#8217;s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company&#8217;s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. </div></div> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company&#8217;s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6628546384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top; white-space: nowrap;"><div style="font-weight:bold;display:inline;">7. </div></td>
<td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Accounts Payable and Accrued Expenses:</div></td></tr></table><div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses consist of the following (in thousands): </div></div>
<table border="0" cellpadding="0" cellspacing="0" style="margin: 12pt auto 0px; width: 76%; font-size: 10pt; border-collapse: separate; border-spacing: 0;">
<tr style="font-size: 0px;">
<td style="width: 66%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 10%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="width: 10%; font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/>
<td style="font-family: &quot;Times New Roman&quot;; padding: 0px;"/></tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 8pt; padding-bottom: 0.5pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"/></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,&#160;2020 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); font-size: 8pt;;width:;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,&#160;2019 </div></div></div></td>
<td style="padding-right: 2pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; padding-bottom: 0.5pt;;width:;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47,519 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39,610 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued salaries and bonuses </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">108,079 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">268,619 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll taxes and benefits </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47,791 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">67,268 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional liabilities </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48,149 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44,869 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued contingent consideration </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,288 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2,696 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27,422 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32,910 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses </div></div></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43,115 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">55,894 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 0.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="padding: 0px; vertical-align: top; font-size: 10pt; width: 66%;"><div style="text-align: left; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"/></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">323,363 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">511,866 </div></div></td>
<td style="padding-right: 2pt; margin-top: 0pt; margin-bottom: 0pt; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 0pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 3px double rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="padding-right: 2pt; vertical-align: bottom; padding-bottom: 1.5px; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <div style="text-align: left; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0px; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The net decrease in accrued salaries and bonuses of $160.5&#160;million, from December&#160;31, 2019 to March&#160;31, 2020, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#8217;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the three months ended March&#160;31, 2020. A majority of the Company&#8217;s payments for performance-based incentive compensation is paid annually during the first quarter. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6741684976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of fair value on a recurring basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 6,357<span></span>
</td>
<td class="nump">$ 16,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MutualFundsFairValueDisclosure', window );">Mutual Funds</a></td>
<td class="nump">11,640<span></span>
</td>
<td class="nump">14,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">85,041<span></span>
</td>
<td class="nump">74,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="nump">$ 1,288<span></span>
</td>
<td class="nump">$ 2,696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value Of contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MoneyMarketFundsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of money market funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MoneyMarketFundsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MutualFundsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mutual funds fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MutualFundsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6722116352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember', window );">Contracted Managed Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember', window );">Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember', window );">Other Third-Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember', window );">Private-Pay Patients [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net patient service revenue by type payor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PercentageOfNetPatientServiceRevenueByTypeOfPayor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6631651408">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82,799<span></span>
</td>
<td class="nump">86,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average number of dilutive common share equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common and common equivalent shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">82,799<span></span>
</td>
<td class="nump">86,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in the diluted net income per common share calculation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">849<span></span>
</td>
<td class="nump">504<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Due to a loss from continuing operations for the three months ended March 31, 2020, no incremental shares are included because the effect would be antidilutive.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
